Abstracts  by unknown
© 2013 The Authors
HPB 2013, 15 (Suppl. 1), 1–87 HPB © 2013 Americas Hepato-Pancreato-Biliary Association
ROCK-STAR AND OTHER SHOCKINGLY 
UNCOMMON CAUSES OF 
PANCREATITIS?
A. Abdo and S. C. Cunningham
1Saint Agnes Hospital, Baltimore, MD, USA
Acute pancreatitis is a frequent disease with approximately 
300,000 cases occurring in the USA annually, 10–20% of 
which are severe, with mortality as high as 30%. Common 
etiologies are well recognized (stones and alcohol account-
ing for ∼80%) with a wide variety of other causes, including 
trauma, tumors, triglycerides, toxins, medications, divisum, 
infections, genetics, vasculitides, ischemia and pregnancy. 
We have observed associations in two patients with none of 
the above known etiologies. Patient A is 46-year-old man 
who on two occasions consumed Rockstar™ energy drink, 
both times followed by acute pancreatitis requiring hospital-
ization. Patient B is a healthy 54-year-old female, also with 
none of the above etiologies, who during a 10-hour road trip 
wore a transcutaneous electrical nerve stimulation (TENS) 
device for mild chronic back pain. Shortly after arrival she 
developed severe acute pancreatitis with massive necrosis, 
from which she failed to thrive. She therefore required necro-
sectomy, and is back to her healthy baseline status as of 
10-month follow-up. Rockstar™ ingredients include: water, 
sugar, caffeine, ginseng, Ginkgo biloba, milk thistle extract, 
and guarana seed. While 4 pancreatitis cases were listed in 
FDA reports of patients taking Gingko biloba, little evidence 
exists associating these in combination. TENS devices use 
electric current to stimulate nerves for therapeutic purposes. 
Typical uses range from low- to high-frequency pulses per 
second (1–100 Hz), with frequencies of 1–10 Hz often used 
for pain suppression. Energy drinks such as Rockstar™ and 
TENS devices may, we speculate, be predisposing factors in 
the development of acute pancreatitis.
CHARACTERIZATION OF PANCREATIC 
ADENOCARCINOMA OF PRIMARY AND 
PERITONEAL METASTASIS A PILOT 
STUDY USING BIOMARKERS FOR 
METASTASIS (EMT)
A. Abrams1, T. Jie1, E. Ong1, R. Heimark1, 
A. Bhattacharyya2 and C. Patel2
1University Of Arizona Department Of Surgery, Tucson, 
AZ, USA; 2University Of Arizona Department Pathology, 
Tucson, AZ, USA
Purpose: The purpose of this study is to evaluate the molec-
ular markers of peritoneal metastasis and to compare that to 
primary tumors. A patient cohort was selected where autopsy 
tissue specimens were taken from both peritoneal metastasis 
and primary tumors.
Methods: Tissues were sectioned and evaluated by H & E 
and Immunohistochemistry. Markers used included Ck-19, 
E-Cadherin, Zeb1, and Snail2. The cohort population con-
sisted of 9 patients diagnosed with moderately differentiated 
pancreatic adenocarcinoma. This population consisted of 
males and females with an average age of 61 at the time of 
diagnosis. Survival varied from one to six months with a 
mean of 3 months. These patients all presented with signs 
and symptoms of abdominal carcinomatosis at the time of 
diagnosis.
Summary of results: All peritoneal metastases and primary 
tumors were Ck-19 positive. Two subgroups were described 
in the peritoneal metastasis. The first group had MUC1 
expression and lacked EMT markers Zeb1 and Snail2. The 
second group lacked MUC1 expression and stained for Zeb1 
and Snail2 markers associated with metastasis. 9/9 of these 
patients had metastasis whose features based on H and were 
consistent with moderately differentiated Pancreatic adeno-
carcinoma. In addition to Ck-19, a pancreatic ductal marker, 
all primary tumors stained for MUC1.
CLASSIFICATION OF THE ANATOMICAL 
VARIATION OF THE RIGHT POSTERIOR 
SECTORAL BILE DUCT
H. M. Alghamdi1,2
1University Of Dammam, Alkhobar, Eastern Province, 
Saudi Arabia; 2King Fahad Hospital Of The University, 
Alkhobar, Eastern Province, Saudi Arabia
It is well recognized that most hilar bile ducts anatomical 
variations stem from different right posterior sectoral bile 
duct (RPSBD) origin. The aim of the study is to evaluating 
the usefulness and frequency of the Hjortsjo sign at ERCP 
and how helpful it is to delineate the RPSBD pattern in Saudi 
patients. Prospective study involves recruiting all Saudi 
patients undergoing indicated ERCP from 1st of March 2010 
to 30th of May 2012, without a history of liver resection or 
biliary instrumentation. Cholohgiogram will be reviewed 
with the same radiologist. Around 223 ERCPs done during 
the study period. Only 126 were eligible to be included in 
the study. The pattern of RPSBD origin found to be as 
follow: •Type 1: 29% (positive Hjortsjosign) •Type I: 30% 
(negative Hjortsjosign •Type II: 25% (positive Hjortsjosign) 
•Type II: 10% (negative Hjortsjosign) •Type III: 3% •Type 
IV: 7% (positive Hjortsjosign) •Type V: 1% In this study the 
Hjortsjosign was positive in only 61% of the cases. The 
profile of the RPSBD in Saudi were found to be around 59% 
of the typical type I which is different than the international 
data. We concluded that HjortsjoCrook sign is not commonly 
found in our community and transplant surgeon should antic-
ipate larger unfavorable bile duct anomalies and 
difficulties.
INCIDENCE AND OUTCOMES OF 
HEPATOBLASTOMAS IN CHILDREN
B. J. Allan, E. A. Perez, H. L. Neville and J. E. Sola
University Of Miami, Miami, FL, USA
Background: We sought to define current incidence trends 
and outcomes for children with hepatoblastoma (HB) and 
factors predictive of survival.
Methods: The Surveillance, Epidemiology, and End Results 
database was queried from 1973 to 2009 for all patients with 
HB younger than 20 years of age.
Results: A total of 606 patients were identified. The overall 
age-adjusted incidence in children was 1.3 cases per million 
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in 2009, with an annual percentage change (APC) of 2.18 
(95% CI: 1.10–3.27, p < 0.05) over the study period. The 
majority of tumors were seen in Caucasian (81%) and chil-
dren < 5 y (92%). Overall 5, 10 and 20 year survival were 
63%, 61% and 59%, respectively. Survival at 10 years was 
significantly improved for patients with resectable disease 
undergoing tumor resection compared to those that did not 
(86% vs. 39%, p < 0.0001). Multivariate analysis showed 
tumor resection (HR 0.23 95% CI: 0.17–0.31; p < 0.0001), 
Hispanic ethnicity (HR 0.61 95% CI: 0.43–0.89, p = 0.01), 
local disease at presentation (HR 0.43 95% CI: 0.29–0.63, p 
< 0.0001) and age less than 5 y (HR 0.63 95% CI: 0.41–0.95, 
p < 0.03) to be independent prognostic factors of survival.
Conclusion: The incidence of hepatoblastoma in children 
has increased over time. HBs are almost exclusively seen in 
children < 5 y, however, if HBs present after the age of 5 y 
the prognosis is most unfavorable. Tumor extirpation mark-
edly improves survival for local disease.
NON-INVASIVE PREOPERATIVE 
QUANTIFICATION OF HEPATIC 
STEATOSIS USING A NOVEL MRI 
TECHNIQUE: 100% ACCURACY 
CONFIRMED WITH PATHOLOGIC 
ASSESSMENT
T. A. Aloia, G. Zimmitti, J. Ma, P. Hou, A. Rashid,  
S. A. Curley, J. Vauthey and H. Choi
UT MD Anderson Cancer Center, Houston, TX, USA
Background: The epidemic of obesity has significantly 
increased the incidence and severity of hepatic steatosis in 
liver surgery patients, potentially impacting postoperative 
liver regeneration. Development of a non-invasive means to 
accurately quantify hepatic steatosis would facilitate selec-
tion of candidates for liver resection and transplant 
donation.
Methods: An IRB-approved protocol enrolled 16 patients 
with liver tumors requiring hepatic resection for a preopera-
tive research MRI protocol that included pre-contrast gradi-
ent-echo fast in-phase/out-of-phase and water-only/fat-only 
2-point Dixon sequences obtained at 3 different flip angles 
(FA): 85o, 20o and 12o. MRI estimation of steatosis was 
quantified (%FF) and compared to intraoperative and patho-
logical findings using standard statistical tests.
Results: Patient clinicopathologic features included 10 
male : 6 female non-diabetic patients with median age of 44 
(29–64 yrs) and median BMI of 25.8 (19–39 kg/m2). Tumor 
histology included 11 patients with colorectal liver mets (all 
treated with preoperative systemic therapy) and 5 patients 
with other metastatic lesions. The best correlation between 
MRI-calculated values and pathological findings occurred 
when using the 12oFA (r = 0.94). For patients with greater 
than 30% steatosis the mean %FF was 23% (SD ± 5.1%), 
compared to a mean %FF of only 1.8% (SD ± 3.2%) (p = 
0.0001) in patients with less than 30% steatosis. Using scaled 
values for the MR-calculated %FF all patients with > 30% 
steatosis could be identified preoperatively.
Conclusions: This novel MR technique identified liver 
surgery patients with clinically-relevant steatosis with 100% 
accuracy. After validation on a larger patient population, 
these findings could have significant impact on the clinical 
management of liver resection patients and liver transplant 
donors.
MAKING HEPATIC 
TRISECTIONECTOMIES FOR HILAR 
CHOLANGIOCARCINOMA SAFER BY 
RETAINING SUB-SEGMENT 4A
A. A. Alseidi, F. G. Rocha, S. Damle and W. S. Helton
Virginia Mason Medical Center, Seattle, WA, USA
Right hepatic trisectionectomy for hilar cholangiocarcinoma 
presents unique challenges not encountered in other major 
formal hepatic resections. These include potential damage to 
the remaining hepatic outflow through the left hepatic vein 
(LHV) given its variable and intimate relationship with the 
middle hepatic vein (MHV) which is usually sacrificed with 
right trisectionectomy. Other risks include a marginal future 
liver remnant and torsion of the liver remnant once compen-
satory hypertrophy occurs. Sub-segment 4A can often be 
retained when performing right trisectionectomy for hilar 
cholangiocarcinoma as it typically is not required for onco-
logic clearance. By dividing the MHV in the mid-hepatic 
plane, between Sub-segment 4A and segment 8, the possibil-
ity of injury to the LHV is avoided. Preservation of sub-
segment 4A, when it’s biliary drainage empties into the 
umbilical portion of the left hepatic duct, increases the 
remnant liver volume. Lastly, the 2- 4A segmental unit 
affords improved stability and may decrease risk of torsion 
of the hepatic remnant. This anatomic approach should be 
considered when feasible.
ALPPS: TIPS AND TRICKS
F. Alvarez, V. Ardiles, R. Sanchez Claria, J. Pekolj  
and E. De Santibanes
HPB Surgery And Liver Transplant Unit. Hospital Italiano 
De Buenos Aires, Buenos Aires, Argentina
Background: Associating liver partition and portal vein 
ligation (PVL) for staged hepatectomy (ALPPS) has recently 
been described as a revolutionary strategy to induce a rapid 
and large future liver remnant (FLR) volume increase. We 
aim to describe our ALPPS surgical technique, adding 
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surgical tips and tricks learned after our initial experience 
with this new 2-stage approach that contribute facilitating 
this complex procedure.
Technique: The indications for this technique are patients 
with marginally resectable or primarily non-resectable liver 
tumors of any origin due to an insufficient FLR. During the 
1st-stage, after a complete lymphadenectomy of the hepatic 
pedicle and tumor resection (clean-up) of the FLR, liver 
partition and PVL of the diseased hemi-liver (DH) are per-
formed. At the end of the procedure, the DH is either wrapped 
in a hermetic plastic bag or a plastic film is lay between both 
cut surfaces. The vasculobiliary structures are encircled with 
a black silk (Figure). Once volumetric studies demonstrate a 
sufficient FLR, usually after 7 days, the patient undergoes 
the 2nd-stage with right hepatectomy, right trisectionectomy 
or left trisectionectomy using vascular staplers. Before con-
cluding both surgical steps, we routinely perform a trans-
cystic hydraulic test and cholangiography to avoid biliary 
fistulas.
Conclusions: The presented technique was feasible and safe 
in the hands of experienced hepatobiliary surgeons, offering 
the possibility of cure to patients previously declared 
unresectable.
INCIDENCE OF COAGULOPATHY 
DURING HEPATECTOMIES AND THE 
EFFECT OF EPIDURAL USE ON 
POSTOPERATIVE COMPLICATIONS
A. Amini, A. E. Patanwala, E. S. Glazer, G. H. Skrepnek, 
T. Jie, R. W. Gruessner and E. S. Ong
University Of Arizona, Tucson, AZ, USA
Epidural analgesia has been shown to improve postoperative 
pain in patients after major abdominal surgery. However, 
epidural use is often avoided in patients undergoing hepate-
ctomy because they are at risk for the development of coagu-
lopathy which could result in postoperative complications. 
The purpose of this study was to evaluate the incidence of 
coagulopathy in patients undergoing hepatectomy and to 
determine the effect of epidural use on postoperative com-
plications. The Nationwide Inpatient Sample (2006 to 2010) 
was used to identify patients who received a hepatectomy. 
Incidence of coagulopathy and postoperative complications 
were compared between the epidural and non-epidural 
groups. Multivariate logistic regression was used to evaluate 
the effect of epidural use on postoperative complications. A 
total of 16,015 patients underwent hepatectomy. Of these, 
4% received epidural analgesia and 96% did not. The inci-
dence of coagulopathy was 7.9% in the epidural group and 
9.2% in the non-epidural group (p = 0.69). Total composite 
complications including death were 43.4% in the epidural 
group and 43.6% in the non-epidural group (p = 0.98). In the 
multivariate analysis, after adjusting for coagulopathy and 
other confounders, epidural use was not associated with 
complications (odds ratio 0.84, 95% CI 0.56 to 1.26, p = 
0.39). Epidural use was infrequently utilized during hepate-
ctomies from 2006 to 2010. Incidence of coagulopathy was 
low in hepatectomies and not associated with epidural use. 
Furthermore, epidural use was not predictive of increased 
complications after adjusting for coagulopathy. Prospective 
randomized trials comparing the safety of epidural analgesia 
and their effects on postoperative complications remain to be 
performed.
HEPATIC ADENOMATOSIS PRESENTING 
WITH HEMORRHAGIC SHOCK:  
A CASE REPORT AND REVIEW OF  
THE LITERATURE
B. M. Amundsen, J. A. Greene and L. Bijelic
MedStar Washington Hospital Center, Washington,  
DC, USA
Here we present the evaluation and management of hemor-
rhagic shock due to hepatic adenomatosis. A 19-year old 
woman with history of heart transplant for cardiomyopathy 
presented to our institution with acute onset of fever and 
abdominal pain. Her physical exam and vital signs were 
consistent with stage II shock and acute abdomen. CT 
showed multiple liver lesions with intraperitoneal fluid. She 
underwent surgical exploration that revealed hemorrhagic 
lesions throughout the liver with ruptured left lobe mass and 
intraperitoneal hemorrhage. Hemorrhage control was 
obtained with liver sutures and partial resection of the rup-
tured mass. The pathology confirmed liver adenomas. 
Hepatic adenomatosis is strongly correlated with women 
taking oral contraception and individuals with glycogen 
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storage diseases. Adenomatosis has been defined by the pres-
ence of more than ten adenomas, the absence of exogenous 
steroid hormone administration, the absence of association 
with glycogen storage disease, with prevalence in both men 
and women. Approximately 100 cases have been described 
in the literature to date, with few describing more than three 
cases. Symptoms due to bleeding or necrosis of the tumor 
are frequent but hemorrhagic shock is rare. Surgery is indi-
cated for the resection of symptomatic lesions and progres-
sive symptomatic disease has been treated by liver 
transplantation. The etiology of hepatic adenomatosis 
remains unclear but association with germline mutations of 
HNF1A and diabetes has recently been described. The pres-
ence of liver adenomatosis in a patient with congenital heart 
disease has not previously been described and the possibility 
of an underlying genetic abnormality could be investigated.
IS TOTAL PANCREATECTOMY FOR 
DUCTAL ADENOCARCINOMA OF THE 
HEAD OF THE PANCREAS JUSTIFIED 
BASED ON THE RISK OF TUMOR 
MULTICENTRICITY?
A. Andreou1, T. Denecke2, M. Bahra1, F. Klein1, 
P. Warnick1, P. Neuhaus1 and M. Glanemann1
1Department Of General, Visceral And Transplantation 
Surgery, Charite-Universitatsmedizin Berlin, Germany; 
2Klinik Fur Strahlenheilkunde, Charite-Universitatsmedizin 
Berlin, Germany
Introduction: The risk for multicentricity of ductal adeno-
carcinoma of the pancreas raises the question if resection of 
the head of the pancreas is sufficient for the treatment of 
patients with pancreatic head carcinoma. Therefore, we eval-
uated the incidence of multicentricity of pancreatic adeno-
carcinoma in patients who underwent resection of the head 
of the pancreas with curative intent.
Methods: Pylorus-preserving pancreatoduodenectomy or 
Kausch-Whipple procedure was performed in 858 patients in 
our institution from 2004 to 2011. Patients who underwent 
re-operation with remnant pancreatectomy due to Bassi C 
complication (insufficiency of the pancreatic anastomosis or 
acute bleeding) within 30 days after the initial operation were 
included in the study. The pancreatic remnant was histologi-
cally examined in patients with ductal adenocarcinoma to 
evaluate the proportion of patients with multicentric tumor.
Results: Thirty-three patients had a Bassi C complication 
after resection of the head of the pancreas, requiring resec-
tion of the pancreatic remnant. Eleven of these suffered from 
ductal adenocarcinoma. Histological examination of the pan-
creatic remnant revealed multicentric carcinoma in 1 out of 
these 11 patients (9%). Preoperative computed tomography 
failed to identify tumor multicentricity in this patient.
Conclusions: The incidence of multicentric carcinoma in 
our study was high, reaching 9%; however the number of 
patients included was low. Therefore, total pancreatectomy 
cannot be considered as standard of care for the treatment of 
ductal adenocarcinoma of the pancreatic head. Considering 
however the risk for multicentric presentation of the tumor, 
frequent postoperative surveillance with cross-sectional 
imaging is recommended after resection of the head of the 
pancreas.
ASSOCIATING LIVER PARTITION AND 
PORTAL VEIN LIGATION FOR STAGE 
HEPATECTOMY (ALPPS). A MODERN 
APPROACH FOR AVOIDING 
POSTOPERATIVE LIVER FAILURE
V. Ardiles, S. Sala, F. Alvarez, J. Pekolj and  
E. De Santibanes
HPB And Liver Transplantation Unit. Hospital Italiano De 
Buenos Aires, Buenos Aires, Argentina
Background: Major hepatectomies are many times required 
to achieve R0 resections in locally advanced primary or 
secondary liver malignancies. Postoperative liver failure 
(PLF) is the most severe complication after this procedure 
and is associated with an insufficient future liver remnant 
(FLR). Associating liver partition and portal vein ligation 
(ALPPS) has recently been described as a revolutionary 
strategy to induce a rapid and large FLR volume increase.
Methods: we present the case of a 49 yo male with multiple 
CRLM who underwent neoadjuvant chemoteraphy. FLR 
volume was 402 ml and FRL/total liver volume 21%. ALPPS 
was performed. During the first step, clean-up of FLR, liver 
partition and right portal vein ligation were performed. After 
a volumetric CT or MRI has demonstrated a sufficient FLR, 
the completion surgery was carried out at day 7. In the 
second step the patient undergoes a completion surgery with 
right trisectionectomy. Postoperative course was uneventful 
unless elevation of total bilirrubin until day 20. He was 
discharge at day 17. After 7 month follow up is disease free.
Conclusions: The presented technique was feasible and safe 
in the hands of experienced hepatobiliary surgeons with sat-
isfactory short-term results. It induces rapid liver hypertro-
phy and at the same time offers the possibility of cure to 
patients previously declared unresectable.
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THE EVALUATION AND 
STRATIFICATION OF PERIOPERATIVE 
RISK FACTORS FOR DELAYED GASTRIC 
EMPTYING AFTER 
PANCREATICODUODENECTOMY IN 
ORDER TO IDENTIFY SELECTION 
CRITERIA FOR PROPHYLACTIC 
SURGICAL ENTERAL ACCESS
M. B. Bailey, D. Davenport, P. C. McGrath and  
S. McKenzie
University Of Kentucky, Lexington, KY, USA
Introduction: Delayed Gastric Emptying (DGE) remains a 
common and formidable complication after pancreaticoduo-
denectomy (PD). Placement of prophylactic enteral access 
(PEA) is associated with morbidity and cost, and may be 
unnecessary in the majority of patients. The purpose of this 
study was to identify perioperative risk factors for DGE in 
order to select patients for PEA during PD.
Methods: A retrospective analysis of all PDs performed by 
a single surgeon from 2005–2010 was performed. Patients 
were grouped by occurrence or not of DGE as defined by 
International Study Group of Pancreatic Surgery (ISGPS) 
guidelines. Preoperative and perioperative factors were com-
pared in the two groups using chi-square analyses and mul-
tivariable logistic regression.
Results: Of 64 consecutive patients, DGE occurred in 51% 
(n = 33). DGE persisted beyond 14 days in 11% (n = 7) of 
patients, and indefinitely in 13% (n = 8). DGE occurred in 
all patients who had a history of cardiac revascularization 
(HCR) or who developed a postoperative deep organ space 
infection (p = 0.007 and < 0.001, respectively). Pancreatic 
fistula (PF) (24.2% vs. 3.2%, p = 0.017) and operative dura-
tion > 6 hours (OD > 6H) (84.4% vs. 50%, p = 0.008) were 
also associated with DGE; all patients who experienced both 
had DGE. PF (HR 12.4, CI 1.16–133.0, p = 0.037) and OD 
> 6H (HR 7.42, CI 1.18–31.0, p = 0.006) were independent 
predictors of DGE.
Conclusion: Based on our analysis, HCR, deep organ space 
infection, PF, and OD > 6H are strong predictors of DGE. 
We recommend considering HCR, OD > 6H, and known risk 
factors for pancreatic fistula as selection criteria for PEA in 
patients undergoing PD.
DOES REGIONAL VARIATION IMPACT 
DECISION MAKING IN THE 
MANAGEMENT AND PALLIATION OF 
PANCREATIC HEAD 
ADENOCARCINOMA?
C. G. Ball1, V. Hurdle1, J. Ouellet1, E. Dixon1, 
T. J. Howard2 and K. D. Lillemoe3
1University Of Calgary, Calgary, Alberta, Canada; 
2Indiana University, Indianapolis, IN, USA; 3Harvard 
University, Boston, MA, USA
Background: Management and palliation of pancreatic 
head adenocarcinoma is challenging. End-of-life decision-
making is a variable process involving multiple factors.
Methods: A qualitative, physician-based, 40-question inter-
national survey characterized the impact of medical, reli-
gious, and system factors on care.
Results: The 160 clinician respondents from United States, 
Canada, Europe, and other regions were typically fellowship 
trained (75%) with 15 years (mean) in a University affiliated 
(91%), HPB/GI oncology (75%) practice. Most (89%) 
believed resection is potentially curative, and described it as 
‘curative with a high risk of recurrence’ to patients (91%). 
Most patients are discussed preoperatively by multidiscipli-
nary teams (93%) and medical assessment clinics (64%), but 
rarely critical care (78%). Neoadjuvant therapy is often con-
sidered (55%) and portal vein resection is acceptable (90%). 
Intra-operative surgical palliation includes double bypass 
(43%) and no intervention (49%) for locally advanced non-
resectable tumors (vs. 14% and 82% respectively for patients 
with hepatic metastases). Celiac splanchnicectomy is 
common (64%). Postoperative ICU admission is frequent 
(59%). Severe postoperative complications are often treated 
with aggressive CPR, intubation, and critical care (94%), 
with no defined time-points for futility (72%). Admitting 
surgeons guide most end-of-life decisions (89%). Formal 
medical futility laws are rarely available (27%). Ethics con-
sultation services are accessible (94%), but rarely employed 
(16%), and often unhelpful (47%). Insurance status does not 
alter treatment (96%) or palliation (95%) in non-universal 
care regions. Clinician experience and regional culture 
impacts treatment (p < 0.05).
Conclusions: Despite remarkable overall agreement, geo-
graphic differences are evident in the treatment and palliation 
of pancreatic head adenocarcinoma.
HEPATIC OUTFLOW MODULATION TO 
TARGET LIVER REGENERATION
S. Balzan1,2,3, V. G. Gava1,3, M. A. Magalhaes2,3, 
M. L. Dotto1,2 and S. Balzan1,2,3
1University Of Santa Cruz Do Sul – UNISC, Santa Cruz 
Do Sul, RS, Brazil; 2Ana Nery Hospital/Institute Of 
Oncology Saint Gallen, Santa Cruz Do Sul, RS, Brazil; 
3Moinhos De Vento Hospital, Porto Alegre, RS, Brazil
Background: Stimulation of hepatic hypertrophy is useful 
to accomplish hepatic resections when the future liver 
remnant is short. Although inflow occlusion, especially 
through portal flow, has been extensively studied, the role of 
outflow modulation has not yet being described.
Methods: Description of outflow modulation during hepa-
tectomy for bilobar metastatic disease. An illustrative case 
of short future liver remnant (FLR), segments I and IV, 
managed with a two stage procedure. The first one consisted 
of a right hepatectomy and modulation of the left hepatic 
vein outflow thorough reduction of its diameter. A macro-
scopic congested area in segments II-III could be observed 
by the end of the procedure.
Results: After one month, CT scan revealed an increase of 
156% in the volume of segment IV (from 137 to 351 cm3), 
100% in the volume of segment I (from 20 to 40 cm3), and 
only 24% in the volume of segments II-III (from 205 to 
253 cm3). Left lateral resection was performed with unevent-
ful postoperative course.
Conclusion: Modulation of the liver outflow allows main-
tenance of function in the segments to be resected while 
avoiding their hypertrophy. This process prevents liver 
failure and optimizes regeneration of hepatic territories to be 
preserved.
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HETEROGENEITY OF PANCREATIC 
CANCER ASSOCIATED FIBROBLASTS
H. L. Beal1, Q. Dai1, J. E. Shea1, C. L. Scaife1,2, 
M. A. Firpo1,2 and S. J. Mulvihill1,2
1Department Of Surgery, Salt Lake City, UT, USA; 
2Huntsman Cancer Institute, Salt Lake City, UT, USA
Recent attention has focused on the contribution of stromal 
cells to the progression of pancreatic ductal adenocarcinoma 
(PDAC). We derived 30 pancreas cancer associated fibrob-
last (PCAF) primary cultures from PDAC tumors by out-
growth. All 30 PCAF cultures exhibited consistent 
mesenchymal morphology, stained positive for alpha-smooth 
muscle actin, and were negative for cytokeratin 19 by immu-
nohistochemical staining, as expected for activated fibrob-
lasts. To assess the affect of PCAF cells on PDAC cell 
growth, red fluorescent protein (RFP) tagged MIA PaCa-2 or 
AsPC-1 cells were grown in contacting co-culture experi-
ments with six different PCAF lines. PDAC cell growth was 
measured by changes in RFP signal over three days. The 
presence of PCAF cells resulted in 1.5 to 3.5 fold increased 
growth of the PDAC cell lines relative to PDAC cells grown 
in the absence of PCAFs. To assess the affect of secreted 
factors from PDAC cells on PCAF growth, PCAF cells were 
grown in conditioned media from MIA PaCa-2 cells col-
lected under serum-free conditions. PCAF cell growth was 
monitored by resorufin reduction assays. The presence of 
serum-free conditioned media from MIA PaCa-2 cells had 
no effect on PCAF4 cells, but produced significantly 
increased growth on PCAF17 cells to an extent similar to 
addition of 10% fetal bovine serum (Figure 1). These results 
indicate that stromal fibroblasts arising in the context of 
PDAC are phenotypically heterogeneous, perhaps reflecting 
the heterogeneous nature of PDAC tumors, and may not 
present a uniform target for intervention.
MEDIAL OPEN TRANSVERSUS 
ABDOMINIS PLANE (MOTAP) 
CATHETER ANALGESIA: A SIMPLE, 
SAFE, EFFECTIVE TECHNIQUE 
FOLLOWING OPEN LIVER RESECTION
R. Behman, P. McHardy, J. Sawyer, J. Lam-McCulloch,  
C. Law, N. Coburn, S. Hanna and P. Karanicolas
Sunnybrook Health Sciences Centre, University Of Toronto, 
Toronto, ON, Canada
Background: Effective pain management after open liver 
resection is critical for patient well-being and to minimize 
complications including atelectasis, pneumonia, and car-
diovascular events. Ultrasound-guided placement of Trans-
versus Abdominis Plane (TAP) catheters has recently 
emerged as an effective alternative to epidural catheteriza-
tion. We describe a novel technique of surgeon-placed 
Medial Open Transversus Abdominis Plane (MOTAP) 
catheter insertion.
Methods: 10 patients undergoing liver resection through a 
subcostal incision received MOTAP catheters. A standard 
procedure was used for placement in all patients: following 
liver resection, a Tuohy needle was introduced from inferio-
medial to superiolateral into the space between the right 
transversus abdominis muscle and the internal oblique 
muscle. A peripheral nerve catheter was passed down the 
needle to lie in the TAP. The catheter was passed through the 
skin superior to the incision. Patients received a combination 
of ropivacaine infusion through the catheter and oral 
analgesics.
Results: Nine of the patients had an effective sensory nerve 
block around the incision and reported excellent pain control. 
In one patient the nerve block was not effective and he was 
treated with intravenous analgesics. There were no complica-
tions related to the MOTAP catheters.
Conclusion: MOTAP catheters are a simple, safe, and effec-
tive alternative to intravenous or epidural analgesia that 
eliminates many of the risks associated with these forms of 
analgesia.
HEMOSTATIC EFFICACY OF LATEST 
GENERATION FIBRIN SEALANT AFTER 
HEPATIC RESECTION; A RANDOMIZED 
CONTROLLED CLINICAL STUDY
H. Bektas1, S. Nadalin2, J. Schmidt3, I. Szabo4, 
B. Ploder4 and M. Sharkhawy4
1Medizinische Hochschule Hannover, Klinik F. Allgemein-, 
Viszeral- U. Transplantationschirurgie, Hannover, 
Niedersachsen Germany; 2Eberhard Karls Univ. Tuebingen, 
Klinik F. Allgemein-, Viszeral- U. Transplantationschirurg., 
Tuebingen, Baden-Wuerttemberg Germany; 3Hirslanden 
Clinics Zurich, Zurich, Switzerland; 4Baxter Innovations 
GmbH, Vienna, Austria
The objective of this randomized, controlled, multicenter 
study was to evaluate the hemostatic efficacy of latest gen-
eration fibrin sealant (FS) containing synthetic aprotinin as 
fibrinolysis inhibitor as supportive treatment to improve 
hemostasis in adult patients (≥18 years) undergoing partial 
hepatectomy involving resection of at least one anatomical 
liver segment. Subjects were randomized (1:1) to receive 
either FS or manual compression with a surgical gauze swab 
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(MC) to control oozing from the cut liver surface persisting 
after primary hemostasis of major vessels had been achieved 
using sutures, ligations, clips, vascular staplers, point elec-
trocautery or focal radiofrequency ablation. The primary 
endpoint, hemostasis at 4 minutes from the start of treatment 
application, was achieved in 82.9% (29/35) of FS-treated 
subjects compared to 37.1% (13/35) of subjects receiving 
MC (p < 0.001 in the likelihood ratio chi-squared test with 
a 5% two-sided significance level). In addition, significantly 
more FS-treated subjects achieved hemostasis at 6 (91.4% 
vs. 57.1%; p < 0.001), 8 (91.4% vs. 71.4%; p = 0.028), and 
10 minutes (94.3% vs. 74.3%; p = 0.017). The number of 
intra and postoperative re-bleedings was small in both 
groups. Transfusion requirements and 48-hour drainage 
volumes were similar between FS and MC. (For categorical 
outcomes see Table 1.) This randomized, controlled, multi-
center study demonstrated that FS is safe and its efficacy 
superior to MC for hemostasis in subjects undergoing hepatic 
resection. The use of synthetic aprotinin further improves the 
safety margin of FS by eliminating the risk of transmission 
of bovine spongiform encephalopathy and other bovine 
pathogens.
BLUNT HEPATIC TRAUMA IN THE AGE 
OF ANGIOEMBOLIZATION: A SINGLE 
CENTRE EXPERIENCE
K. Bertens, K. N. Vogt, K. P. Croome, D. Gray and  
R. Hernandez-Alejandro
Western University Canada, London, ON Canada
Non-operative management (NOM) of blunt hepatic injury 
(BHI) is increasingly common. Although literature demon-
strates decreasing mortality, liver-related morbidity remains 
high. This study was undertaken to explore morbidity and 
mortality of BHI during the era of angioembolization (AE) 
and to evaluate the role of routine post-injury imaging. A 
retrospective cohort of patients with BHI treated at our Lead 
Trauma Hospital between 1999–2011 was identified. Logis-
tic regression was undertaken to identify factors associated 
with need for operative management (OM) and mortality. A 
total of 396 patients were identified. Mean ISS was 33 
(± 14). Sixty-two (18%) patients had severe liver injuries 
(AAST Grade 4≤). OM occurred in 109 (27%) patients. 
Logistic regression revealed high ISS (OR 1.07; 95% CI 
1.05–1.10); and lower systolic blood pressure on arrival (OR 
0.98; 95% CI 0.97–0.99) as associations with need for OM. 
Eight hepatic AE occurred; 4 to treat pseudoaneurysms iden-
tified on routine, repeat CT imaging. The overall mortality 
was 17%, with increasing age (OR 1.05; 95% CI 1.03–1.07), 
increasing ISS (OR 1.11; 95% CI 1.08–1.14) and require-
ment of OM (OR 2.89; 95% CI 1.47–5.69) associated with 
death. Liver-related morbidities occurred with similar fre-
quency in the OM (23%) and AE (29%) groups (p = 0.32). 
Only 3% of those treated non-operatively experienced mor-
bidity. BHI can be successfully managed non-operatively 
with low morbidity. Although patients with BHI are routinely 
assessed for pseudoaneurysms at some centers, our data sug-
gests that this may not be justified in patients with less severe 
BHI.
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A COMPARISON OF 
PANCREATICODUODENECTOMY TO 
TOTAL PANCREATECTOMY FOR 
PANCREATIC NEOPLASIA – A NATIONAL 
SURGICAL QUALITY IMPROVEMENT 
PROJECT ANALYSIS
N. H. Bhayani, J. L. Miller, E. Kimchi, G. Ortenzi,  
K. F. Staveley-O’Carroll and N. J. Gusani
Section Of Surgical Oncology, Department Of Surgery, 
Penn State Hershey Cancer Institute, Hershey, PA, USA
Background: Pancreaticoduodenectomy (PD) is the most 
common surgery for pancreatic head neoplasms. Periopera-
tive morbidity for this procedure remains high, with the 
Achilles’ heel of PD considered the pancreatic anastomosis. 
Conventional wisdom suggests that eliminating this anasto-
mosis by performing a total pancreatectomy (TP) should 
reduce perioperative morbidity.
Methods: The National Surgical Quality Improvement 
Project database from 2005–2010 was queried for non- 
emergent, PD or TP for all pancreatic tumors. Periopera-
tive morbidity and mortality was compared between the 
groups.
Results: Of 5195 patients, 5032 (97%) underwent PD 
while 163 (3%) underwent TP. Preoperative diabetes and 
post-operative diagnosis of benign neoplasm was more 
common in the TP group (p < 0.003). Intraoperatively, the 
TP group more commonly underwent vascular repairs and 
required blood transfusion (p < 0.02). There was a strong 
trend towards increased 30-day mortality after TP (6% v. 
3%, p = 0.06). This likely arose from higher rates of postop-
erative bleeding requiring transfusion (12% v. 7%, p = 0.03) 
and sepsis (15% v. 10%, p = 0.04). On multivariable logistic 
regression TP resulted in a 59% increased odds of post-
operative sepsis (p = 0.04), controlling for differences in 
age, tobacco use, diabetes, malignant diagnosis and 
transfusion.
Conclusions: In resections for pancreatic neoplasms, TP 
avoids the pancreatic-enteric anastomosis of a PD. While this 
procedure is often believed to confer decreased perioperative 
morbidity, our data demonstrate higher rates of sepsis and 
bleeding requiring transfusion. The TP group also showed a 
strong trend towards increased mortality.
IS IT WORTH THE RISK: THE 
MORBIDITY OF TOTAL 
PANCREATECTOMY WITH AUTO-ISLET 
CELL TRANSPLANTATION COMPARED 
TO TOTAL PANCREATECTOMY ALONE
N. H. Bhayani, E. T. Kimchi, K. F. Staveley-O’Carroll and 
N. J. Gusani
Section Of Surgical Oncology, Department Of Surgery, 
Penn State Hershey Cancer Institute, Hershey, PA, USA
Background: After total pancreatectomy (TP), auto-islet 
cell transplantation (AIT) ameliorates diabetes. However by 
10 years, nearly all patients become insulin-dependent. The 
perioperative risk of AIT after TP has only been described in 
small series; comparative studies are non-existent. We 
hypothesized that auto-islet transplantation adds morbidity 
to total pancreatectomy for chronic pancreatitis.
Methods: The National Surgical Quality Improvement 
Project database from 2005–2010 was queried for total pan-
createctomy procedures performed for pancreatitis. Patients 
who underwent TP were compared to those that had TP+AIT.
Results: Of 179 patients, 56 (31%) underwent TP while 123 
(69%) had TP+AIT. Patients having AIT were younger (39 
v. 49 years), with higher preoperative albumin, and lower 
prevalence of diabetes, hypertension, and coronary artery 
disease (p < 0.003). Median operative time was ∼ 4 hours 
longer for the AIT group (p < 0.0001). More TP+AIT patients 
experienced perioperative morbidity (57% v. 32%), prima-
rily pneumonia (14% v. 2%) and bleeding requiring red cell 
transfusion (23% v. 5%), (p < 0.01). Patients having TP+AIT 
were more likely to experience morbidity (OR 3.8, p = 0.004) 
than those having TP alone after controlling for other factors. 
AIT and American Society of Anesthesiology (ASA) class 
were the only significant predictors of morbidity in our 
model. Mortality was uncommon < 5% and similar between 
groups.
Conclusions: Patients receiving AIT after TP for pancreati-
tis were younger and healthier than those undergoing TP 
alone. Despite this, they experienced more pneumonia, 
bleeding, and overall morbidity. Given the limited long-term 
benefits of AIT, patients should be counseled regarding the 
incremental perioperative risks over TP.
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EVOLUTION OF ROBOTIC SURGICAL 
TECHNIQUE: THE LEARNING CURVE 
OF ROBOTIC ASSISTED 
PANCREATICODUODENECTOMY
B. A. Boone1, M. Daouadi1, M. Zenati1, A. Moser2, 
D. L. Bartlett1, H. J. Zeh1 and A. Zureikat1
1University Of Pittsburgh Department Of Surgery, 
Pittsburgh, PA, USA; 2Beth Israel Deaconness Medical 
Center Department Of Surgery, Boston, MA, USA
Introduction: A growing body of literature supports the 
safety and efficacy of major robotic pancreatic resections. 
One limitation to more widespread application of robotic 
surgery is the investment required to acquire the necessary 
skills to utilize the robot. There is no data establishing the 
experience required to overcome this ‘learning curve’ for 
robotic assisted pancreaticoduodenectomy (RAPD).
Methods: We evaluated metrics of perioperative safety and 
efficiency in our prospectively maintained database of 
robotic assisted pancreatic surgery patients. Patients were 
divided temporally into two groups for evaluation of our 
early and late experience. Student t-test and Fisher exact test 
were utilized to compare the two groups.
Results: 113 patients underwent RAPD over 46 months; 42 
during the initial 23 month experience, followed by 71 in the 
ensuing experience. There was a significant decrease in 
operative time (586 vs. 521 min, p < 0.001) and decreased 
rate of conversion to open (19% vs. 4%, p < 0.05) in the late 
experience group (Table 1). There was a 121 minute decrease 
in operative time between the total average and the last 13 
patients in the cohort, who had a median operative time of 
420 minutes (Figure 1). A trend toward decreased EBL (400 
vs. 250, p = 0.09) and a lower rate of pancreatic leak (24% 
vs. 14%, p = 0.19) was identified in the late experience 
group.
Conclusion: Our experience of over 100 RAPDs suggests 
that operative time and conversion rate decrease significantly 
following 40 cases. With extensive experience operative 
times and outcomes become equivalent to most large open 
series.
COMPUTED TOMOGRAPHY 
PREDICTORS OF 
CHEMOEMBOLIZATION-INDUCED 
HEPATOCELLULAR CARCINOMA 
TUMOR NECROSIS
M. K. Bryant, D. P. Dorn, J. Zarzour, J. K. Smith,  
D. T. Redden, S. Saddekni, A. Kamel, S. H. Gray,  
D. E. Eckhoff and D. A. DuBay
University Of Alabama At Birmingham, Birmingham, AL, 
USA
Background: Imaging features associated with a favorable 
response to Transarterial chemoembolization (TACE) are 
poorly defined for patients with hepatocellular carcinoma 
(HCC). Hypothesis: We hypothesize that the following HCC 
tumor radiographic characteristics will be associated with a 
> 90% or complete tumor necrosis: single tumors, smaller 
tumor size, peripheral tumor location, arterial-phase tumor 
enhancement and portal venous-phase tumor washout.
Methods: All first TACE interventions for HCC performed 
at a single institution from 2008–2011 were retrospectively 
reviewed. Only patients with a pre-TACE CT scan and a 
post-TACE CT scan within 75 days of the intervention were 
included (n = 115). HCC tumor response to TACE was quan-
tified via the mRECIST criteria. Univariate and multivariable 
analyses were constructed to examine the association 
between response variables.
Results: The index HCC tumors experienced a > 90% or 
complete tumor necrosis in 58/115 (50%) of patients follow-
ing the first TACE intervention. On univariate analysis, 
smaller tumor size, peripheral tumor location and arterial 
enhancement were associated with a > 90% or complete 
tumor necrosis whereas only smaller tumor size and periph-
eral location were significant on multivariable analysis 
(Table 1). Neither arterial enhancement or portal venous 
washout were associated with a > 90% or complete tumor 
necrosis in subgroup analyses of centrally located HCC 
tumors < 5 cm (p = ns) or peripherally located HCC tumors 
< 5 cm (p = ns).
Conclusions: Peripherally located smaller HCC tumors are 
most likely to experience a > 90% or complete tumor necro-
sis following TACE. Surprisingly, pre-TACE arterial-phase 
tumor enhancement and portal venous-phase tumor washout 
were not predictive of TACE-induced tumor necrosis.
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INITIAL EXPERIENCE WITH ROBOTIC 
LIVER RESECTIONS
S. G. Carpenter, E. P. Castle, P. E. Andrews,  
N. N. Katariya and D. C. Mulligan
Mayo Clinic Arizona, Phoenix, AZ, USA
Introduction: Few centers have large volume experience 
with robotic liver resection. This study contains video 
and reviews our initial experience with robotic right hepate-
ctomy and right posterior sectorectomy and will review 
helpful beginner techniques from robotic hepatobiliary 
experiences.
Methods: The records of three consecutive patients under-
going robotic hepatic resections were reviewed, and patient 
and operative characteristics were recorded. These proce-
dures were undertaken from November 2011 to February 
2012.
Results: Patient A underwent robotic right hepatectomy for 
a 9 cm right lobe fibronodular hyperplasia enlarging in size 
post-pregnancy. Operative time was 495 minutes with esti-
mated blood loss (EBL) of 2600 mL. The patient received 2 
units of packed red blood cells (PRBC) intraoperatively, but 
none post-operatively. Patient B underwent a robotic right 
posterior sectorectomy for hepatocellular carcinoma outside 
Milan criteria. Operative time was 316 minutes with EBL of 
1300 mL. This patient had a number of preoperative comor-
bidities and did require transfusion of 2U PRBC post-oper-
atively but did not require blood products intraoperatively. 
Finally, Patient C underwent a robotic left lateral segmentec-
tomy for a 10 cm septated biliary cystadenoma. Operative 
time was 177 minutes with EBL of 50 mL. There was no 
transfusion requirement.
Conclusion: Our initial experience indicates that robotic 
hepatic resection confers excellent surgical field visualiza-
tion with improved post-operative pain control over standard 
open resection.
CONTEMPORARY DIFFERENCES IN 
POSTOPERATIVE OUTCOMES 
FOLLOWING LAPAROSCOPIC VERSUS 
OPEN DISTAL PANCREATECTOMY FOR 
PANCREATIC ADENOCARCINOMA
E. P. Ceppa, R. M. McCurdy, J. A. Parikh, E. M. Kilbane, 
C. M. Schmidt, N. J. Zyromski, H. A. Pitt, A. Nakeeb and 
M. G. House
Indiana University School Of Medicine, Indianapolis, IN, 
USA
Purpose: The aim of this study was to compare short- and 
long-term postoperative outcomes of patients with pancreatic 
adenocarcinoma after laparoscopic and open distal pancrea-
tectomy (DP).
Methods: Consecutive cases of DP (n = 343) were reviewed 
at a single high-volume institution between 2005 and 2012. 
All cases were monitored with complete 30-day outcomes 
through the American College of Surgeons-National Surgical 
Quality Improvement Program. Electronic medical records 
were used for 90-day outcomes and survival. Two-way sta-
tistical analyses were performed between the operation 
categories.
Results: Forty patients underwent a DP for pancreatic ade-
nocarcinoma; twenty patients each were found in the laparo-
scopic and open groups. No differences existed in 
demographic or intraoperative variables including duct size, 
gland texture, and stump closure. Postoperative outcomes for 
the groups of patients are summarized in the table. Signifi-
cant differences (*, p < 0.05) between the groups are indi-
cated. Open DP was associated with greater tumor size (4.3 
+ 0.4 cm* vs. 2.9 + 0.3 cm), lymph node sampling (18 + 2* 
vs. 13 + 2), and presence of lymph node metastasis (80%* 
vs. 25%). Median and three year survival for laparoscopic 
DP were 12 months and 36% respectively; no significant 
differences in survival were observed for open DP.
Conclusions: We report one of the largest series of laparo-
scopic DP for pancreatic adenocarcinoma. Laparoscopic DP 
is a safe technique for the treatment of early stage pancreatic 
adenocarcinoma. Understanding comparative outcomes 
between laparoscopic and open DP for adenocarcinoma will 
require randomized prospective clinical trials focusing on the 
management of stage II pancreatic adenocarcinoma.
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RANKINGS VS. REALITY FOR 
PANCREATIC CANCER SURGERY: A 
REAL WORLD COMPARISON
Z. Chau1, J. K. West4, Z. Zhou3, T. P. McDade1, 
J. K. Smith1, S. C. Ng2, T. S. Kent2, M. P. Callery2, 
A. J. Moser2 and J. F. Tseng2
1University Of Massachusetts Medical School, Worcester, 
MA, USA; 2Beth Israel Deaconess Medical Center – 
Harvard Medical School, Boston, MA, USA; 3Northwestern 
University Robert H. Lurie Cancer Center, Chicago, IL, 
USA; 4Massachusetts Department Of Public Health, 
Boston, MA, USA
Background: As more patients turn to multimedia con-
sumer-directed sources to gather information on health care, 
we are increasingly confronted with rating systems for hos-
pitals. However, the correlation between publicized ratings 
and actual outcomes after pancreatectomy is unknown.
Methods: The Massachusetts Division of Health Care 
Finance and Policy Hospital Inpatient Discharge Database 
was queried to identify pancreatic resections performed for 
cancer 2005–2009; hospitals performing < 10 cases/5 years 
were excluded. Primary outcomes included mortality, com-
plications, median length of stay (LOS) and a composite 
outcomes score (COS) including the above. Ranks were 
determined and compared to: 1) volume of pancreatic cancer 
resections and 2) ratings identified from consumer-directed 
Massachusetts hospital ratings e.g., US News and World 
Reports (USNWR) Consumer Reports (CR), Healthgrades 
(HG) and Hospital Compare (HC). An inter-rater reliability 
analysis was performed with correlation coefficients calcu-
lated between outcomes and ratings and between rating 
systems.
Results: 11 hospitals meeting volume criteria comprising 
804 pancreatectomies were identified. Volume rankings were 
most highly correlated with outcomes (mortality, complica-
tions, LOS and COS). Spearman and Kendall rank correla-
tion coefficients followed a similar trend (table). HG and HC 
ratings were less correlated with outcomes and CR ratings 
were inversely correlated. Of all the ratings systems evalu-
ated, the USNWR were most highly associated with volume 
measures.
Conclusion: The plethora of publically available hospital 
ratings systems demonstrates significant heterogeneity. Sur-
gical volume remains a good but not perfect indicator of 
surgical outcomes following pancreatectomy. Further sys-
tematic investigation into what measures truly predict quality 
outcomes in pancreatic cancer surgery will benefit both 
patient and provider.
ZBP-89 FACILITATES DEATH OF 
HEPATOCELLULAR CARCINOMA 
CELLS VIA MULTIPLE CHANNELS
G. G. Chen, C. Ye, C. Z. Zhang and P. B. Lai
The Chinese University Of Hong Kong, Shatin, NT,  
Hong Kong
ZBP-89, a transcription factor, is able to regulate gene 
expression via binding to GC-rich sequences of the gene 
promoter region. This study was to explore the role of 
ZBP-89 in treatment of hepatocellular carcinoma (HCC) 
which is frequently resistant to chemo- and radio-therapies. 
HCC cell lines and HCC mouse models were used to study 
how ZBP-89 induced the death of HCC cells. Tumor cell 
death was determined by MTT assay and TUNEL method. 
The potential binding to the promoter was analyzed by gel 
shift assay. HCC mouse models were established to confirm 
in vitro results. Our results showed that ZBP-89 induced 
apoptosis in HCC cells, enhanced HCC cells to other anti-
HCC treatments, and inhibited the growth of tumor cells both 
in vitro and in vivo. Mechanically, ZBP-89 could function 
as a suppressor of HCC via multiple channels. 1) binds to 
the promoter region of pro-apoptotic Bak to increase its 
expression; 2). interacts with some p53 mutants to re-install 
the normal function of p53; 3). participates in gene methyla-
tion by inhibiting DNA methyltransferase 1 (DNMT1) and 
histone deacetylases 3 (HDAC3); 4). interacts with other 
transcriptional factors such as SP-1 to promote the expres-
sion of pro-apoptotic molecules or/and to suppress the 
expression of anti-apoptotic molecules. Collectively, our 
data demonstrate that ZBP-89 is able to facilitate the death 
of HCC cells via several mechanisms, leading to the inhibi-
tion of HCC growth in vitro and in vivo.
FACTORS AFFECTING LIKELIHOOD OF 
SURGICAL REFERRAL FOR HEPATIC 
MALIGNANCIES
A. P. Chidi1, D. A. Geller1, C. L. Bryce2 and A. Tsung1
1University Of Pittsburgh School Of Medicine, Pittsburgh, 
PA, USA; 2University Of Pittsburgh Graduate School Of 
Public Health, Pittsburgh, PA, USA
Introduction: Proximity to cancer centers has been associ-
ated with different cancer treatment options, while geo-
graphic location, travel time and demographic characteristics 
have been implicated in other cancer disparities. This study 
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explored factors affecting the likelihood of referral for surgi-
cal intervention in patients diagnosed with hepatocellular 
carcinoma (HCC) or cholangiocarcinoma (CC) who had no 
contraindications.
Methods: Initial treatment recommendation, staging, and 
demographic information were abstracted from the Pennsyl-
vania Cancer Registry for patients diagnosed between 2006 
and 2011. Hospital procedure volume was obtained from the 
Pennsylvania Health Care Cost Containment Council and 
travel time from patient ZIP code to the nearest high volume 
cancer center was calculated in ArcGIS (Redlands, CA). 
Logistic regression analyses were performed in Stata 12 
(College Station, TX).
Results: Of 4,359 patients for whom surgery was not con-
traindicated, surgical intervention was recommended for 
1,772 (41%). In multivariate regression, presence of multiple 
cancers, female gender, Asian race, and cholangiocarcinoma 
were associated with significantly higher rates of surgical 
referral (p < 0.05). Older age, black race, regional or distant 
extension, and public insurance or no insurance coverage 
decreased this likelihood (p < 0.05). Distance to a high 
volume center was associated with an increased likelihood 
of surgery recommendation.
Conclusion: In addition to tumor characteristics, referral 
patterns for surgical interventions are affected by both clini-
cal and non-clinical factors, such as diagnosis, staging and 
patient demographics. Future work will investigate relation-
ships between these factors and ultimate treatment.
DOES NEOADJUVANT RADIATION 
THERAPY FOR PANCREATIC CANCER 
INCREASE POST-OPERATIVE 
COMPLICATIONS AFTER 
PANCREATICODUODENECTOMY? 
ANALYSIS OF AMERICAN COLLEGE OF 
SURGEONS NATIONAL SURGICAL 
QUALITY IMPROVEMENT PROGRAM 
(ACS NSQIP)
S. W. Cho, W. C. Johnston, M. A. Cassera, P. H. Newell, 
C. W. Hammill, R. F. Wolf and P. D. Hansen
Providence Portland Medical Center, Portland, OR, USA
Introduction: Neoadjuvant radiation therapy (XRT) is a 
frequent component of multimodality treatment of pancreatic 
cancer. We investigated whether neoadjuvant XRT affects 
complication rates following pancreaticoduodenenctomy.
Method: ACS NSQIP (2005–2010) was queried to identify 
patients undergoing pancreaticoduodenectomy for pancreatic 
cancer. Two groups were identified, those receiving neoad-
juvant XRT and those who did not (control). Outcomes were 
compared.
Results: The query identified 4416 patients (XRT n = 200 
vs. control n = 4216). The XRT group was more likely to 
have weight loss (33.0% vs. 23.1%; p = 0.001), neoadjuvant 
chemotherapy (28.5% vs. 1.6%; p < 0.001), younger age 
(62.9 vs. 65.9; p < 0.001), lower BMI (25.8 vs. 26.7; p = 
0.033), less hypertension (44.5% vs. 55.8%; p = 0.002) and 
lower bilirubin (0.8 vs. 2.8; p < 0.001). The XRT group had 
longer operative times (438 vs. 382 min; p < 0.001), more 
vascular reconstructions (20.5% vs. 8.4%; p < 0.001) but 
shorter hospital stay (11.7 vs. 13.4 days; p = 0.033). Intraop-
erative blood transfusion was similar (41.7% vs. 35.4%; p = 
0.158) but the XRT group required more post-operative 
blood transfusions (13.0% vs. 7.4%; p = 0.003). Overall 
mortality (3.0% vs. 2.7%; p = 0.818) and morbidity (40.5 vs. 
37.6%; p = 404) rates were similar, including abdominal 
abscess (6.5% vs. 8.8%; p = 0.268), sepsis (8.0% vs. 9.9%; 
p = 0.374), septic shock (5.5% vs. 4.2%; p = 0.373) and 
reoperation (4.5% vs. 7.3%; p = 0.133). On logistic regres-
sion analysis, mortality rates were influenced by age > 70 
(p < 0.001; Odds Ratio = 2.46), intraoperative blood transfu-
sion (p = 0.001, OR = 2.05), dyspnea (p = 0.047; OR = 1.77), 
impaired functional status (p = 0.042; OR = 2.11), ascites 
(p = 0.005; OR = 4.94), preoperative sepsis (p = 0.023; OR 
= 2.40), and hyponatremia (p = 0.017, OR = 1.85).
Conclusion: Neoadjuvant radiation therapy for pancreatic 
cancer does not increase complication rates following 
Whipple procedure.
DOES TYPE OF COLORECTAL 
PROCEDURE IMPACT COMPLICATION 
RATES FOLLOWING COMBINED LIVER 
AND COLORECTAL RESECTIONS FOR 
METASTATIC COLORECTAL CANCER? 
ANALYSIS OF AMERICAN COLLEGE OF 
SURGEONS NATIONAL SURGICAL 
QUALITY IMPROVEMENT PROGRAM 
(ACS NSQIP)
S. W. Cho, W. C. Johnston, M. A. Cassera, P. H. Newell, 
C. W. Hammill, M. Whiteford, R. F. Wolf and  
P. D. Hansen
Providence Portland Medical Center, Portland, OR, USA
Introduction: Simulataneous hepatectomy and colorectal 
resections are increasingly performed for metastatic colorec-
tal cancer (CRC). We hypothesized that low anterior resec-
tion (LAR) or abdominoperineal resection (APR) may 
increase postoperative complications more than colectomy 
when combined with hepatectomy.
Methods: The ACS NSQIP database (2005–2010) was 
queried for outcomes of patients undergoing combined hepa-
tectomy and colorectal resection for CRC.
Results: Of 345 patients undergoing partial (n = 265), 
right/left (n = 52) and extended (n = 28) hepatectomies, 209 
patients also had colectomy and 136 had LAR or APR. 
Types of hepatectomies performed were similar between 
the two groups (p = 0.874). They differed (p < 0.05) in 
terms of gender (female = 50.7 vs. 33.8%), COPD (6.2 vs. 
1.5%), hypertension (50.2 vs. 37.5%), steroid use (3.3% vs. 
0.0%), preoperative radiation use (3.8 vs. 38.2%), mean age 
(62.5 vs. 56.1 yrs), albumin (3.7 vs. 3.9 mg/dl), hematocrit 
(36.1 vs. 37.8%), and operative time (254 vs. 340 minutes). 
Outcomes were comparable including mortality (1.0% vs. 
0.0%; p = 0.53) and morbidity rates (38.8% vs. 39.0%; p = 
0.968). Abdominal abscess (11.0 vs. 10.3%), sepsis (8.6 vs. 
6.6%), septic shock (3.8 vs. 4.4%), postoperative bleeding 
(9.1 vs. 7.4%) and reoperation (6.2 vs. 5.9%) occurred sim-
ilarly. Analyzing subgroup of the patients undergoing major 
right/left or extended hepatectomy (n = 80), colorectal pro-
cedure type did not affect morbidity (44.0% colectomy (n = 
50) vs. 33.3% LAR/APR (n = 30); p = 0.346). Logistic 
regression analysis showed hypoalbuminemia (<3.0 vs. 
≥3.0 mg/dl; p = 0.035; Odds Ratio 6.17), anemia (hemat-
ocrit < 30 vs. ≥30%; p = 0.038; OR 2.91) and prolonged 
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operative time (>6 hours; p = 0.001; OR 3.36) increased 
morbidity.
Conclusion: In selected patients, hepatectomy can be 
combined with colectomy or LAR/APR with similar 
outcomes.
HIGH RATES OF PATHOLOGIC 
COMPLETE OR NEAR COMPLETE 
RESPONSE FOLLOWING NEOADJUVANT 
CHEMOTHERAPY AND STEREOTACTIC 
BODY RADIATION THERAPY FOR 
BORDERLINE RESECTABLE 
PANCREATIC CANCER
M. Chuong1, E. Mellon1, S. Hoffe1, R. Shridhar1, P. Hodul1, 
G. Springett1, C. Harris1, S. Vignesh1, J. Klapman1, 
M. Hamilton1, T. Valone1, N. Roehnelt1, H. Widell1, 
T. Hutchinson1, M. Malafa1, R. Karl1, N. Figura2 and 
B. Centeno1
1H. Lee Moffitt Cancer Center & Research Institute, 
Tampa, FL, USA; 2University Of South Florida College Of 
Medicine, Tampa, FL, USA
Purpose: While the clinical response from induction chem-
otherapy followed by stereotactic body radiation therapy 
(SBRT) has been reported for borderline resectable pancre-
atic cancer (BRPC) patients, response from a histopathologic 
standpoint has not been described.
Methods: This single-institution retrospective review eval-
uated BRPC patients who completed induction gemcitabine-
based chemotherapy followed by 5-fraction SBRT. All 
patients were restaged and underwent resection. A patholo-
gist (B.C.) specializing in pancreatic cancer reviewed each 
surgical specimen and assigned two Tumor Regression 
Grade (TRG) scores, one from the College of American 
Pathologists (CAP) and one from the MD Anderson Cancer 
Center (MDACC). Overall survival (OS) and progression 
free survival (PFS) were correlated to TRG score using the 
Kaplan-Meier method.
Results: This study evaluated 35 resected BRPC patients 
with a median follow up of 13.8 months (range, 6.1–24.8). 
All received induction gemcitabine-based chemotherapy, 
most commonly GTX (gemcitabine, docetaxel, capecitabine) 
(82%), followed by 5-fraction SBRT with a median 35 Gy 
(range, 30–40). TRG scores according to the CAP were as 
follows, from best to worst response: 0 (n = 3), 1 (n = 13), 
2 (n = 15), and 3 (n = 4). TRG scores according to MDACC 
were as follows, from best to worst response: IV (n = 3), 
III(M) (n = 6), IIB (n = 11), IIA (n = 10), and I (n = 5). Any 
neoadjuvant treatment effect according to MDACC scoring 
(IIA-IV vs. I) was associated with improved OS and PFS 
(both p = 0.019).
Conclusion: This study demonstrated a significant patho-
logic response with a gemcitabine based neoadjuvant 
regimen containing SBRT and suggests a survival benefit 
based on response as measured by the MDACC scoring 
system.
HEALTH-RELATED QUALITY OF LIFE 
FOR PATIENTS WITH PANCREATIC 
CANCER: A POPULATION-BASED STUDY
C. J. Clark1, V. Zaydfudim2, S. Harmsen3 and 
K. M. Reid-Lombardo2
1Department Of General Surgery, Winston-Salem, NC, 
USA; 2Division Of Gastroenterologic And General Surgery, 
Rochester, MN, USA; 3Division Of Biomedical Statistics 
And Informatics, Rochester, MN, USA
Background: Current understanding of health-related 
quality of life (HRQOL) for patients with pancreatic cancer 
is limited. The aim of this study was to evaluate HRQOL for 
patients diagnosed with pancreatic cancer (PC) using a 
nationwide survey.
Methods: The 1998–2007 Surveillance, Epidemiology and 
End Results-Medicare Health Outcomes Survey (SEER-
MHOS) database was queried for patients with PC and 
patients with no history of cancer. SF-36 data from the first 
survey after diagnosis of PC was compared with survey 
results from no cancer controls. Comparisons were also 
made between PC patients treated with and without 
pancreatectomy.
Results: 74 patients with pancreatic cancer were matched to 
146 patients with no history of cancer. Socioeconomic 
factors, demographics, and comorbidities were similar 
between PC patients and no cancer controls (all p > 0.05). 
Median physical component score (PCS) was significantly 
lower among PC patients compared to no cancer controls 
(33.3 vs. 40.6, p = 0.001). Median mental component score 
(MCS) was similar between PC patients and patients without 
cancer (52.1 vs. 54.9, p = 0.182). For PC patients, median 
PCS was similar between patients treated with and without 
pancreatectomy (35.5 vs. 31.9, p = 0.282). Median MCS was 
significantly lower in unresected patients (48.0 vs. 55.4, p = 
0.039). after adjusting for clinical characteristics, tumor 
stage, and time of survey from diagnosis, there was no sig-
nificant association between pancreatectomy and PCS (p = 
0.652) or MCS (p = 0.344).
Conclusion: Patients with pancreatic cancer reported worse 
overall physical health than patients without cancer; however, 
HRQOL was similar between patients with PC treated with 
or without pancreatectomy.
DOCTOR, WHY DIDN’T THAT GALL 
BLADDER COME OUT?
M. Colaco1,2, A. S. Gillet1, E. Hagopian1,2, J. M. Davis1,2 
and J. J. Vernick1,2
1Jersey Shore University Medical Center – Department Of 
Surgery, Neptune, NJ, USA; 2Robert Wood Johnson 
Medical School, New Brunswick, NJ, USA
Background: Significant subpopulations of our patients 
have met inappropriate delays from the time of the diagnosis 
of symptomatic cholelithiasis to surgery. The purpose of this 
study is to describe this cohort of patients with the complica-
tions associated with their delays.
Methods: Cases were drawn from our practice of three 
general surgeons between 2004 and 2011. Delays were con-
sidered to have occurred if the patients were discharged with 
symptoms of acute cholecystitis without having had surgery 
or if significant complications of cholelithiasis (biliary 
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pancreatitis, cholangitis, and choledocholithiasis) were not 
treated in a timely fashion.
Results: Of a total of 417 cholecystectomies, 355 done 
laparoscopically (LAP), 34 converted from LAP to open 
(CLO) and 28 were planned open (OC) cases. Significant 
delays from the time of diagnosis to surgery were identified 
in 28 (6.7%) of the patients (mean 158.3: range 7 to 1460 
days). Complications from the delay resulted in recurrent 
cholecystitis (6), choledocholithiasis (7), recurrent gall stone 
pancreatitis (9) with pseudocyst (3), cholangitis with liver 
abscess (1), and incomplete cholecystectomy (5) resulting in 
reoperation. Insurance issues accounted for 7 (46.7%) of the 
patient delays in the LAP and CLO groups. In the remaining 
21 patients the reason for delay is unclear. In 3 patients an 
endoscopically placed stent appeared to serve as the defini-
tive treatment for the cholelithiasis.
Conclusions: A cohort of patients with significant delays in 
surgical intervention is identified. In many cases a cavalier 
approach to cholecystitis was taken by both patient and 
physician.
THE USE OF SYSTEMIC 
ANTICOAGULATION IS SAFE IN 
PATIENTS UNDERGOING CURATIVE 
RESECTION OF PANCREATIC DUCTAL 
ADENOCARCINOMA
A. B. Cooper1, R. M. Thomas1, D. S. Kwon2, M. H. Katz1, 
P. W. Pisters1, J. Vauthey1, J. E. Lee1 and J. B. Fleming1
1University Of Texas MD Anderson Cancer Center, 
Houston, TX, USA; 2Henry Ford West Bloomfield Hospital, 
West Bloomfield, MI, USA
Background: Venous resection during pancreaticoduo-
denectomy (PD) for pancreatic ductal adenocarcinoma 
(PDAC) may enable curative surgical extirpation. Debate 
exists on the use of systemic anticoagulation during the vas-
cular reconstruction for fear of resultant post-operative 
bleeding. We hypothesized that such an approach does not 
increase surgical site bleeding and can be utilized safely.
Methods: A retrospective review of a prospectively-main-
tained pancreatic tumor database identified all patients with 
PDAC (n = 124) who underwent PD with systemic intra-
operative anticoagulation (IOAC) between January 2000 and 
September 2011. This group was matched to patients who 
underwent PD without anticoagulation based on use of neo-
adjuvant therapy and operative date ( ± 3 years). Multivariate 
conditional logistic regression modeling was used to compare 
rates of reoperation for bleeding, intra-operative transfusion, 
and early postoperative hemoglobin drop ≥2 grams, control-
ling for patient and tumor parameters.
Results: Patients who underwent PD with IOAC (n = 118) 
received a median of 3000 units intravenous heparin. Opera-
tive length (534 vs. 455 min, p < 0.001), blood loss (1157 
vs. 812 ml, p < 0.001), and intra-operative blood transfused 
(2.2 vs. 1.2 units, p = 0.005) were increased in patients 
undergoing PD with IOAC vs. controls, respectively. When 
accounting for other factors with multivariate analysis, there 
was no statistical difference between groups in regards to 
post-operative transfusion requirement, reoperation for 
bleeding, and early hemoglobin drop.
Conclusions: Systemic anticoagulation with heparin during 
pancreaticoduodenectomy does not increase the incidence of 
post-surgical bleeding. These data suggest the risk of surgical 
site bleeding should not deter the use of anticoagulation 
when necessary for vascular resection during pancreaticodu-
odenectomy for PDAC.
MICROWAVE ABLATION HAS LOWER 
LOCAL RECURRENCE RATES THAN 
RADIOFREQUENCY ABLATION AFTER 
TREATMENT OF COLORECTAL LIVER 
METASTASIS. A MATCHED COHORT 
ANALYSIS
C. Correa-Gallego, Y. Fong, M. Gonen, M. I. D’Angelica, 
P. J. Allen, R. P. DeMatteo, W. R. Jarnagin and  
T. P. Kingham
Memorial Sloan-Kettering Cancer Center, New York, NY, 
USA
Background: Microwave (MWA) and radiofrequency abla-
tion (RFA) are the most commonly used techniques for ablat-
ing colorectal-liver metastases (CLM). The technical and 
oncologic differences between these modalities are unknown.
Methods: We conducted a matched-cohort analysis of 
patients undergoing open MWA or RFA for CLM at a terti-
ary-care center between 2008 and 2011; the primary end-
point was ablation-site recurrence. Tumors were matched by 
size, clinical-risk score, and arterial-intrahepatic or systemic 
chemotherapy use. Outcomes were compared using condi-
tional logistic regression and stratified Log-rank test.
Results: We matched 254 tumors (127 per group) from 134 
patients. MWA and RFA groups were comparable by age 
(median: 53 yrs for both), gender (50% male in both), 
median number of tumors treated (2 vs 3; P = 0.6), proximity 
to major vessels (40% vs 60%; P = 0.9) and postoperative 
complication rates (18% vs 16%; P = 1.0). Patients in the 
MWA group had lower ablation-site recurrence rates (6% vs 
21%; OR 0.2 [95% CI: 0.1–0.5]; P = 0.001). Median follow-
up, however, was significantly shorter (19 [11–29] vs 39 
[23–46] months; P < 0.001) in the MWA group. Kaplan-
Meier estimates of ablation-site recurrence at 2-years were 
significantly lower for the lesions treated with MWA (7% vs. 
18%, P: 0.01). The stratified log-rank test found a similar 
significant difference in local recurrence rates (P: 0.01; 
graph).
Conclusion: Ablation-site recurrences of CLM were lower 
with MWA compared to RFA in this matched cohort analysis. 
Longer follow up time in the MWA may increase the recur-
rence rate; however, actuarial local failure estimations dem-
onstrated better local control with MWA.
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LUNG AND LIVER RESECTION FOR 
COLORECTAL METASTASES: A 
SURVIVAL ANALYSIS
S. Coughlin, K. P. Croome, R. A. Malthaner and  
R. Hernandez-Alejandro
Western University Canada, London, ON, Canada
Metastasectomy for colorectal liver and lung metastases has 
been used to improve patient survival. We compared patients 
who underwent liver and lung resections for colorectal 
metastases to those with only liver metastases to determine 
if these patients had significantly worse survival. We identi-
fied all patients at our centre between 2002–2011 that under-
went liver resection for colorectal liver metastases. We then 
identified a subset of these patients that also underwent lung 
resection for metastases. Survival was compared in patients 
with lung and liver resection to those with only liver resec-
tion using a cox-proportional hazard model adjusting for age, 
number of liver metastases, and presence of an R0 liver 
resection. 175 patients underwent liver resection for color-
ectal metastases. Of these, 17 also had lung metastases and 
underwent lung resection. The mean survival (from liver 
resection) for the liver resection only group was 63.0 months 
(95% CI 55.8 to 70.1) and 51.3 months (95% CI 36.6, 65.9) 
for lung+liver resection group. There was no significant dif-
ference in survival between the two groups (HR 0.689 
(favors liver resection only) 95% CI 0.229, 2.078 p = 0.509). 
We did not identify a significant difference in survival in 
patients undergoing metastasectomy for lung and liver 
lesions compared to those only requiring liver resection. 
Although this suggests that patients requiring lung resection 
in addition to liver resection for colorectal metastases do 
comparably to those undergoing only liver resection, the 
confidence interval for the hazard ratio was quite wide and 
would include clinically significant survival differences.
TWO STAGED HEPATECTOMY FOR 
‘UNRESECTABLE’ COLORECTAL LIVER 
METASTASES: THE USE OF THE ALPPS 
PROCEDURE TO INDUCE RAPID 
HYPERTROPHY IN SCENARIOS WHERE 
TRADITIONAL RESECTION 
STRATEGIES WERE DEEMED TO BE 
SUBOPTIMAL
K. P. Croome, L. VanHouwelingen and  
R. Hernandez-Alejandro
Western University Canada, London, ON, Canada
Purpose: There have been recent publications in Europe 
and South America using Associating Liver Partition and 
Portal vein Ligation for Staged hepatectomy (ALPPS) that 
have demonstrated rapid hypertrophy in the future liver 
remnant. The present case series describes the use of this 
technique in 3 different scenarios with bilobar metastatic 
CRLM where traditional resection strategies were deemed to 
be suboptimal.
Methods: The 2-stage Surgical Hepatectomy was per-
formed with an interval of 7 days between the two opera-
tions. The first stage included right portal vein ligation, 
in-situ splitting between the segment 4 and the left lateral 
segment (LLS) and wedge resection(s) of metastases of the 
left lateral segment. During the second stage a completion 
right extended hepatectomy of the deportalized liver was 
performed.
Results: The second patient had inadequate hypertrophy 
following successful Portal Vein embolization (PVE). The 
third patient had the liver resection performed prior to resec-
tion of the primary rectal cancer (reversal approach). The 
mean LLS hypertrophy was 78.6%. With a mean follow-up 
of 4 months all patients have been discharged, have normal 
CEA levels with no evidence of recurrence in imaging and 
two have restarted on chemotherapy. All the pathologic spec-
imens confirmed R0 resections. One patient had prolonged 
cholestasis that has subsequently resolved.
Conclusions: This present strategy could decrease time of 
disease progression while off chemotherapy and induce sig-
nificantly more hypertrophy than traditional approaches such 
as portal vein embolization. This strategy may be used in 
specific scenarios were traditional resection strategies are 
deemed suboptimal.
PORTAL VEIN THROMBOSIS – HOW 
MUCH IS TOO MUCH WHEN IT COMES 
TO COST-EFFECTIVE LIVER 
TRANSPLANTATION?
L. Dageford and D. E. Moore
Vanderbilt University Medical Center, Nashville, TN, USA
Introduction: Portal vein thrombosis is no longer an abso-
lute contraindication to liver transplantation. However, 
extensive PVT is associated with decreased survival and 
increased cost of transplantation. The aim of this study was 
to evaluate the cost-effectiveness of liver transplantation 
with extensive PVT.
Methods: A Markov-based decision analytic model was 
created to simulate outcomes for liver transplantation with 
stage 1 and 2 PVT versus stage 3 and 4 PVT. Baseline values 
and ranges were determined from the Scientific Registry of 
Transplant Recipients (SRTR) database and literature review. 
Sensitivity analyses were conducted to test model strength 
and parameter variability.
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Results: Liver transplantation with stage 1 and 2 PVT pro-
vided similar outcomes as liver transplantation without PVT 
– 5.2 Quality Adjusted Life Years (QALYs) at $67,000/
QALY versus 5.4 Quality Adjusted Life Years (QALYs) at 
$65,000/QALY; whereas, liver transplantation with stage 3 
and 4 PVT resulted 3.0 QALYs at a cost of $110,000/QALY.
Conclusion: Stage 3 and 4 PVT is not an absolute contrain-
dication to liver transplantation but it is not a cost-effective 
use of the limited supply of grafts available.
MANAGEMENT OF CELIAC ARTERY 
STENOSIS IN 
PANCREATICODUODENECTOMY
S. Damle1, A. A. Alseidi1, T. R. Biehl1, W. S. Helton1, 
R. Moonka1, E. J. Raker2, D. Neuzil2, D. S. Pierce2, 
L. H. Quiroga1 and F. G. Rocha1
1HPB Service, Department Of Surgery, Virginia Mason 
Medical Center, Seattle, WA, USA; 2Vascular Surgery 
Service, Department Of Surgery, Virginia Mason Medical 
Center, Seattle, WA, USA
Purpose: Celiac artery stenosis (CAS) is usually of little 
clinical significance due to the robust collateral blood supply 
provided to the foregut by the superior mesenteric artery 
(SMA) via the gastroduodenal artery). However, in patients 
with CAS undergoing pancreaticoduodenectomy (PD) this 
route is interrupted potentially compromising perfusion to 
the liver and bile duct and resulting in ischemic complica-
tions. Little is known about the incidence and consequence 
of celiac artery intervention in this patient population.
Methods: Records of patients who underwent PD at our 
institution between 2002–2012 were reviewed and those who 
had a concurrent celiac artery intervention were identified 
under an IRB-approved protocol. Patient demographic, pre-
operative imaging, operative reports, pathology, and clinic 
notes were reviewed and their outcomes assessed.
Results: Of 581 patients that underwent PD during this time 
period, 3 (0.5%) required intervention for CAS. The Inter-
ventions included SMA to PHA bypass, median arcuate liga-
ment release, and median arcuate ligament release with 
celiac artery patch angioplasty. Operative time averaged 581 
minutes with an average blood loss of 400 ml and average 
length of stay of 9.3 days. The patient undergoing vascular 
bypass required endovascular stenting of the celiac trunk for 
thrombosis of his bypass and resultant hepatic abscess. The 
patient undergoing the celiac artery patch angioplasty 
required a percutaneous drain for a type B pancreatic fistula. 
All three patients had benign disease on final pathology and 
patent celiac arteries on follow-up imaging.
Conclusions: Although rare, pancreatic surgeons should be 
prepared to repair CAS during PD to prevent ischemic com-
plications and minimize morbidity.
SYMPTOMATIC WALLED-OFF 
PANCREATIC NECROSIS (WOPN): IS 
THERE STILL A ROLE FOR THE 
SURGEON?
S. Damle1, A. Alseidi1, S. I. Gan2, R. Kozarek2, A. Ross2, 
S. Irani2, R. Crane3, M. Fotoohi3, E. Hauptmann3, 
M. Gluck2, W. S. Helton1 and F. G. Rocha1
1HPB Service, Department Of Surgery, Seattle, WA, USA; 
2Gastroenterology Service, Department Of Medicine, 
Seattle, WA, USA; 3Interventional Radiology Service, 
Department Of Radiology, Seattle, WA, USA
Introduction: The management of pancreatic necrosis has 
shifted from open debridement to non-operative and mini-
mally-invasive surgical approaches. Dual modality drainage 
(DMD) by endoscopic and percutaneous routes has been 
shown to decrease morbidity and length of stay when 
compared to standard percutaneous drainage (SPD) alone. 
However, the long-term consequences of these strategies and 
need for surgical intervention have not been examined.
Methods: All patients who presented or were transferred to 
our institution from 2006–2012 with symptomatic WOPN 
without a previous drainage procedure were identified from 
an IRB-approved database. Outcomes were evaluated after 
percutaneous, endoscopic and combined modality therapy 
and those who required surgical intervention were 
analyzed.
Results: Of 149 patients with symptomatic WOPN, 97 had 
DMD while 52 had SPD. Seven (5%) patients, 4 from DMD 
and 3 from the SPD groups eventually required surgical 
intervention for relapsing pain (4), persistent pancreatic 
fistula (2) (both in the SPD group), and gastric outlet obstruc-
tion (1). These included 3 distal pancreatectomies, 2 pancre-
atic debridements, 2 cystgastrostomies (both in the SPD 
group), and 1 gastrojejunostomy with a mean time to opera-
tion of 15 months (range 1–48 months). All but one patient 
had infected necrosis documented by initial fine needle aspi-
rate. Overall mortality in the entire cohort was 3% with no 
operative deaths. There were 7 perioperative complications 
in 3 surgical patients.
Conclusions: Surgical intervention is rarely needed for 
initial management of WOPN but is still important and 
useful for the few patients who fail both endoscopic and 
percutaneous therapy.
LIVER RESECTION AFTER 
DOWNSTAGING CHEMOTHERAPY IN 
PATIENTS WITH INITIALLY 
UNRESECTABLE COLORECTAL LIVER 
METASTASES
N. A. Devaud1, Z. S. Kanji1, N. Dhani2, R. Grant1, 
H. Shoushtari 1, P. Serrano1, S. Nanji1, P. D. Greig1, 
I. D. McGilvray1, C. A. Moulton1, A. Wei1, S. Cleary1 
and S. Gallinger1
1Toronto General Hospital, University Health Network 
(UHN), Toronto, ON, Canada; 2Princess Margaret 
Hospital, University Health Network (UHN), Toronto, ON, 
Canada
Introduction: Liver resection for colorectal metastases 
(CLM) is considered the only curative therapy, however less 
than 25% of patients have anatomically resectable disease. 
 Abstracts 17
© 2013 The Authors
HPB 2013, 15 (Suppl. 1), 1–87 HPB © 2013 Americas Hepato-Pancreato-Biliary Association
Among unresectable patients, some become resection candi-
dates after tumor downstaging following chemotherapy.
Methods: From January 2002–July 2012, 754 liver resec-
tions for CLM have been performed at Toronto General 
Hospital, in Ontario-Canada. 31 patients with median age of 
59 years (22–77) were operated after downstaging chemo-
therapy for initially unresectable disease. Regimens included 
bevacizumab in 51.6%. Criteria for resectability was based 
on intent to preserve two contiguous anatomic segments. 
Surgical and oncologic outcomes were followed prospec-
tively with median follow up of 19 months (1–102). Periop-
erative results, progression free and overall survival were 
analyzed retrospectively.
Results: 87% of patients (n = 27) had synchronous CLM. 
Primary tumor sites were colon = 22 (71%) and rectum = 9 
(29%). Bilobar CLM was present in 97% (n = 30), with 
median number = 6 (2–15) and median size of 4.3 cm 
(1–12.8) before downstaging. A curative intent resection was 
accomplished in 28/31 (90.3%) including 5 patients who had 
concomitant ablation. 3 failed staged surgery because of 
tumor progression. Postoperative morbidity was 15/31 
(48.4%), with no perioperative mortality. Among curative 
intent resections, disease recurrence rate was 23/28 (82%) 
with median progression free survival (PFS) of 8 months 
(1–99). PFS at 2, 3 and 5 years was 18.7, 15 and 10% 
respectively.
Conclusion: Liver resection following downstaging of ini-
tially unresectable CLM can be done with acceptable mor-
bidity and low mortality, however tumor recurrence is 
frequent. Novel genetic or other biomarkers are needed for 
improved patient selection.
ANALYSIS OF PRE-OPERATIVE RISK 
FACTORS PREDICTIVE OF 
REOPERATIONS WITHIN 30 DAYS IN 
PATIENTS UNDERGOING HEPATIC 
RESECTIONS FOR MALIGNANCY
M. Dhir1, L. M. Smith2, G. W. Dittrick3 and C. Are1
1University Of Nebraska Medical Center, Omaha, NE, 
USA; 2University Of Nebraska Medical Center, Omaha, 
NE, USA; 3Nebraska Methodist Hospital, Omaha, NE, USA
Introduction: Major postoperative complications are 
known to be associated with increased risk of reoperations 
whereas preoperative factors associated with reoperations 
have not been well studied. The aim of the current study was 
to identify preoperative risk factors associated with increased 
risk of reoperations within 30 days in patients undergoing 
hepatic resections for malignancy.
Methods: Patients undergoing hepatic resections (primary 
CPT codes 47100, 47120, 47122, 47125 and 47130) for 
malignancy including primary or secondary malignancies 
(ICD-9 155.0, 155.1 and 197.7) were extracted from 2005–
2010 National Surgical Quality Improvement Program Data-
base. Logistic regression analysis was used to test several 
preoperative variables.
Results: A total of 4812 patients who underwent hepatic 
resections for malignancy were included in the study. On 
univariate logistic regression analysis, male gender, depend-
ent functional status, transfer from an acute care or chronic 
care facility, ascites, history of angina, preoperative open 
wound or wound infection, ASA, abnormal preoperative 
albumin, bilirubin, alkaline phosphatase, SGOT, WBC and 
prothrombin time were found to be significantly (p < 0.05) 
associated with increased risk of reoperations within 30 days. 
In the multivariate stepwise logistic regression model, male 
gender, history of angina, dependent functional status, preop-
erative open wound or wound infection and increasing alka-
line phosphatase were found to be statistically significant 
(p < 0.05) with area under ROC of 60%.
Conclusions: Awareness of the preoperative factors associ-
ated with increased risk of reoperations may play a role in 
the pre-operative counseling, optimization of perioperative 
care and surgical decision making in these patients.
RADIOGRAPHIC CHANGES 
ASSOCIATED WITH SURGICAL 
RESECTION FOLLOWING 
NEOADJUVANT RADIATION THERAPY 
FOR LOCALLY ADVANCED PANCREATIC 
ADENOCARCINOMA
A. S. Dholakia, A. Hacker-Prietz, A. Wild, S. Raman,  
D. Laheru, L. Zheng, D. Le, T. Pawlik, M. Makary,  
A. De Jesus-Acosta, C. Wolfgang and J. Herman
Johns Hopkins University School Of Medicine, Baltimore, 
MD, USA
Methods: Retrospective chart review identified 54 patients 
diagnosed with locally advanced (LA) pancreatic cancer by 
a multidisciplinary tumor board from 12/2007–12/2011. Pre- 
and post-neoadjuvant RT CT scans were centrally reviewed 
by a blinded radiologist.
Results: Of 54 patients, 8 underwent resection following 
neoadjuvant RT, 46 remained unresectable. Between the two 
groups, age, gender, mean RT dose, and proportion of pan-
creatic head tumors was not significantly different. Median 
OS was 24.0 vs. 16.7 months in resected compared to unre-
sected patients (p = 0.11). Lack of SMV/PV encasement and 
ascites following neoadjuvant RT were favorable factors 
associated with resection. Notably, celiac artery involve-
ment/encasement, SMA involvement/encasement, question-
able and overt metastases, and percentage change in tumor 
volume were not significant predictors of resectability status. 
Of patients offered resection, 100% had negative margins, 
37.5% had positive nodes, and 37.5% demonstrated patho-
logic complete response at surgery.
Conclusions: From our study, radiographic features alone 
do not appear to be reliable for predicting resection in LA 
pancreatic cancer. Given the improved outcomes in patients 
successfully proceeding to curative surgery, further studies 
are needed to elucidate novel biomarkers or functional 
imaging indicators that predict successful resection follow-
ing neoadjuvant therapy.
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IMPACT OF SARCOPENIA ON 
OUTCOMES FOLLOWING INTRA-
ARTERIAL THERAPY OF HEPATIC 
MALIGNANCIES
R. Dodson, A. Firoozmand, O. Hyder, V. Tahcer,  
D. Cosgrove, N. Bhagat, I. Kamel, J. Geschwind and  
T. M. Pawlik
Johns Hopkins Hospital, Baltimore, MD, USA
Background: Patient performance status (PS) may be asso-
ciated with outcome following intra-arterial therapy (IAT) 
for hepatic malignancies but often is subjective. Sarcopenia 
– measurement of muscle wasting – may be a more objective 
means to assess PS and therefore risk of mortality following 
IAT.
Methods: Total psoas area (TPA) was measured on pre-
operative cross-sectional imaging in 216 patients undergoing 
IAT of hepatic malignancies between 2002–2012. Sarcope-
nia was defined as TPA in the lowest sex-specific quartile. 
The impact of sarcopenia on survival was assessed relative 
to other clinicopathological factors.
Results: Median patient age was 60 years and most patients 
(64%) were male. Indications for IAT included: HCC (51%), 
ICC (13%), CRLM (7%), other metastatic disease (30%). 
Mean TPA among men (594.5 mm2/m2) was greater than 
women (448.5 mm2/m2). IAT involved conventional chem-
oembolization (54%), drug-eluting beads (40%), or yit-
trium-90 (6%). The median number of IAT treatments was 2 
(range, 1 to 9). Median tumor size was 6.4 cm and most 
patients had multiple lesions (74%). 90-day mortality was 
9.3% and 3-year survival was 39%. Tumor-specific factors 
such as tumor size (HR = 1.12), multiplicity (HR = 2.12) and 
a higher Child’s score (HR = 1.20) were associated with risk 
of death (all P < 0.05). After controlling for these factors, 
sarcopenia remained independently associated with an 
increased risk of death (lowest vs. highest quartile TPA, HR 
= 2.16; P = 0.02). Patients with sarcopenia had a 3-year 
survival of 28% vs. 44% for patients without sarcopenia 
(Figure).
Conclusions: Sarcopenia was an independent predictor of 
mortality following IAT, with sarcopenic patients having a 
2-fold increased risk of death. Sarcopenia is an objective 
measure of patient frailty that can help inform clinical deci-
sion-making regarding IAT for hepatic malignancies.
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CHEMOEMBOLIZATION OUTCOMES 
FOR HEPATOCELLULAR CARCINOMA 
IN CIRRHOTIC PATIENTS WITH 
COMPROMISED LIVER FUNCTION
D. P. Dorn, M. K. Bryant, J. G. Zarzour, J. K. Smith,  
D. T. Redden, S. Saddekni, A. Kamel, S. H. Gray,  
D. E. Eckhoff and D. A. DuBay
University Of Alabama At Birmingham, Birmingham, AL, 
USA
Background: TACE is currently recommended as treatment 
for Hepatocellular Carcinoma (HCC) in patients with normal 
underlying liver function. The efficacy of TACE for cirrhotic 
patients with compromised liver function is not known.
Hypothesis: We hypothesize that post-TACE survival and 
TACE-induced HCC tumor necrosis will be superior in 
patients with normal liver function compared to patients with 
compromised liver function.
Methods: All ‘first’ TACE interventions for HCC performed 
at a single institution from 2008–2011 were retrospectively 
reviewed (n = 190). Liver function was quantified via the 
Child’s score. Log-Rank tests used to measure survival fol-
lowing TACE. HCC tumor response to TACE was quantified 
via the mRECIST criteria. Death was verified via the Social 
Security Death Index.
Results: There were 100 Child’s A and 90 Child’s B/C cir-
rhotic patients undergoing a first TACE procedure available 
for analysis. As expected, the lab-MELD score was signifi-
cantly higher in the Child’s B/C cohort. Although the number 
of tumors was similar between groups, the Child’s A cohort 
had larger tumors and a greater total tumor diameter (Table 
1). The 6, 12, 24 and 36 month survival estimates were 
significantly higher in Child’s A (90%, 78%, 47% and 28%) 
compared to Child’s B/C (79%, 52%, 37% and 30%) follow-
ing the first TACE episode (p = 0.03, log rank test).
Conclusions: Contrary to our hypothesis, TACE appears to 
be equally efficacious in cirrhotic patients regardless of their 
Child’s classification based upon equivalent mRECIST 
measures of tumor necrosis. However, inferior survival fol-
lowing TACE was observed in the Child’s B/C cohort.
PREDICTORS OF LENGTH OF ICU STAY 
AND MORTALITY AFTER LIVER 
TRANSPLANT
S. Dumitra, P. Chaudhury, J. S. Barkun, S. Alabbad,  
G. Zogopoulos, P. P. Metrakos, S. Paraskevas,  
M. Hassanain and J. I. Tchervenkov
McGill University Health Center – Multiorgan 
Transplantation Program, Montreal, QC, Canada
Aim: Intensive Care Unit (ICU) care is required for all liver 
transplant (LT) recipients, however its length and outcome 
vary widely. In the new area of judicious resources alloca-
tion, predicting the lICU length of stay (LOS) is 
paramount.
Methods: Patients having undergone LT at our institution 
from 1996 to 2012 were reviewed (n = 645). Recipient demo-
graphics, donor risk index (DRI), Model for End-stage Liver 
Disease (MELD) score, operative characteristics, complica-
tions within 90 days, the number of transplants, the ICU LOS 
(including step-down) and ICU mortality were all collected. 
Statistical analysis was performed using a multivariate 
regression to determine predictors of the length of ICU stay 
and a COX multivariate analysis was performed to determine 
predictors of ICU mortality.
Results: The median ICU LOS was 5 ( ± 13.5) days, the 
mean MELD score was 22.7 ( ± 10.8) and the mean DRI was 
1.55 ( ± 0.33). In the multivariate regression, only the natural 
MELD (coef 0.26 95% CI (0.17–0.34), p = 0.000), pre-LT 
dialysis (coef 4.52, 95% CI (0.97–8.08), p = 0.013) and re-
transplantation (coef 3.05, 95% CI (0.39–5.70), p = 0.013) 
were significant predictors of length of stay while cold 
ischemia, warm ischemia, cause of cirrhosis, recipient age, 
DRI, intraoperative transfusions (PRBC, FFP, platelets) as 
well as postoperative complications (acute renal failure and 
sepsis) were not. When looking at predictors of ICU mortal-
ity, only cold-ischemia (HR 1.06, 95% CI (1.01–1.11), p = 
0.014), diagnosis of HCC (HR 2.25, 95% CI (1.28–3.96), 
p = 0.005) and pre-transplantation dialysis (HR 1.94, 95% 
CI (1.16–3.24), p = 0.012) were significant.
Conclusion: Pre-transplant dialysis is a significant predictor 
of both ICU LOS and mortality, suggesting that a specific 
pathway with particular attention to key details (antibiotics, 
antifungal) might be necessary for these patients. Re-trans-
plantation and the natural MELD were also predictors of 
LOS while cold-ischemia predicted mortality.
EVALUATION OF RESISTANCE AS A 
MEASURE OF SUCCESSFUL TUMOR 
ABLATION DURING IRREVERSIBLE 
ELECTROPORATION
E. M. Dunki-Jacobs, P. Philips, C. R. Scoggins,  
G. G. Callender, K. M. McMasters and R. C. Martin
University Of Louisville, Louisville, KY, USA
Introduction: Intra-operative evaluation of successful 
tumor ablation using irreversible electroporation (IRE) is 
difficult secondary to lack of visual confirmation. The IRE 
generator provides feedback by reporting current, which can 
used to calculate changes in tumor tissue resistance. The 
purpose of the study was to determine if resistance can be 
used to predict successful tumor ablation during IRE for 
hepatic lesions.
20 Abstracts
© 2013 The Authors
HPB © 2013 Americas Hepato-Pancreato-Biliary Association HPB 2013, 15 (Suppl. 1), 1–87
Methods: All patients undergoing hepatic IRE from January 
2010 to December 2012 were evaluated using a prospective 
database. Intra-operative information including change in 
tumor resistance during ablation, and slope of the resistance 
curve were used the evaluate effectiveness of tumor ablation 
in terms of local recurrence (LR) and disease free survival 
(DFS).
Results: Twelve patients underwent hepatic lesion ablation. 
Median follow-up was 10 months. LR was seen in 2 patients. 
Change in tumor tissue resistance and the slope of the resist-
ance curve were both significant in predicting LR (p = 0.039 
and p = 0.040 respectively, Table 1). The median disease free 
survival was 2.5 months in patients who recurred compared 
to 5.6 months in patients who did not recur (p = 0.480). 
Neither mean change in tumor tissue resistance nor the slope 
of the resistance curve significantly predicted DFS (p = 0.291 
and p = 0.283, respectively).
Conclusion: Mean change in tumor tissue resistance and the 
slope of the resistance curve could be used intra-operatively 
to assess successful tumor ablation during IRE. Larger 
sample size and longer follow-up are needed to determine if 
these parameters can be used to predict DFS.
PORTAL VEIN THROMBOSIS 
SECONDARY TO 
HEPATOPANCREATICOBILIARY 
MALIGNANCY: AN ASSESSMENT OF 
INCIDENCE, RISK FACTORS, AND 
CLINICAL MANAGEMENT
E. M. Dunki-Jacobs, E. E. Priddy, P. Philips, M. E. Egger, 
C. R. Scoggins, G. G. Callender, K. M. McMasters and  
R. C. Martin
University Of Louisville, Louisville, KY, USA
Introduction: Portal vein thrombosis (PVT) has not been 
well described in the setting of hepato-pancreatico-biliary 
(HPB) malignancy. The aim of this study is to assess the 
incidence and risk factors of PVT secondary to HPB 
malignancy and to evaluate the effectiveness of systemic 
anticoagulation.
Methods: All patients with a diagnosis of an HBP neoplasm 
from January 2009 and December 2011 were evaluated using 
a prospective database. Patients with a coexisting diagnosis 
of PVT were matched in a 1 : 1 ratio with controls from the 
same database. Data collected included tumor location (pan-
creas vs hepatic), stage, methods of clinical management, 
timing of PVT and clinical management.
Results: 1072 patients with HPB malignancies (630 pan-
creas and 442 intrahepatic) were evaluated. Tumor location 
and cancer stage were the only predictors of PVT (p = 0.049 
and p = 0.042, respectively). Surgical resection, RFA abla-
tion, chemoradiation therapy, and hepatic arterial therapy 
(HAT) did not potentiate PVT (Table 1). Eleven of 41 patients 
(27%) were treated with anticoagulation for the management 
of their PVT. Portal vein recanalization was not achieved in 
any patient and thrombus progression was seen in 64% of 
patients despite therapeutic anticoagulation.
Conclusion: Hepatic malignancies are more likely to 
present with PVT whereas pancreatic malignancies are more 
likely to develop PVT as a sign of progression to stage IV 
disease. The mechanism of PVT secondary to HPB malig-
nancy appears to be different than PVT of benign conditions 
and is not amendable to systemic anticoagulation.
PROGNOSTIC SIGNIFICANCE OF PET 
TAC IN NEUROENDOCRINE TUMOR OF 
THE PANCREAS
H. Duran, E. Vicente, Y. Quijano, B. Ielpo, E. Diaz,  
I. Fabra, R. Puga, C. Oliva, R. Caruso, V. Ferri, J. Plaza,  
L. Garcia, J. Rodriguez and S. Olivares
Sanchinarro University Hospital, Madrid, Spain
Introduction: The application of FDG-PET on neuroendo-
crine tumor of pancreas (NETP) has still to be rule out. Ki-67 
proliferation index is a well-known prognostic factor and the 
WHO 2010 classification of NET is based on grading them 
according to it.
Methods: The aim is to assess the efficacy of the PET as 
prognostic factor of NET. From March 2009 to March 2011 
we reviewed retrospectively 78 patients that underwent pan-
creas surgery. NETP were 21 (26.9%). NETP classification 
was: 8 neuroendocrine tumor (38%); 9 well differentiated 
tumors (42%); 4 poor differentiated tumors (19%). Mean 
tumoral size: neuroendocrine tumor: 1.56 cm; neuroendo-
crine carcinoma: 5.05 (p < 0.05). The prognostic validation 
of PET is based upon a bivariant study: positive/negative 
PET with Ki-67 index and tumoral size.
Results: PET scan results were: 12 positive (mean SUV of 
6.34) and 9 negative. The octreotide scan of these 9 negative 
PET patients was positive in all. Patients with positive PET 
scan has a Ki-67 mean index of 22% and a mean tumoral 
size of 4.5 cm; patients with negative PET tomography and 
Octreotide positive scan has a Ki-67 mean index of 11.6% 
and a mean tumoral size of 3.5 cm (p < 0.05).
Conclusion: This study reveals that a positive PET tomog-
raphy is related with a worse prognosis (higher size and 
Ki-67) than a positive octreotide scan. Further study is 
needed to confirm this result.
 Abstracts 21
© 2013 The Authors
HPB 2013, 15 (Suppl. 1), 1–87 HPB © 2013 Americas Hepato-Pancreato-Biliary Association
STUDY OF TUMOR REGRESSION RATE 
IN RESECTED PANCREAS 
ADENOCARCINOMA AFTER 
NEOADYUVANT TREATMENT WITH 
GEMCITABINA AND NAB PLACLITAXEL. 
PREDICTIVE VALUE OF 
ELASTOGRAPHY
H. Duran, E. Vicente, Y. Quijano, B. Ielpo, E. Diaz,  
I. Fabra, R. Puga, C. Oliva, R. Caruso, V. Ferri, J. Plaza, 
C. Corbacho, A. Cubillo, C. Rubio, V. Grando and  
S. Olivares
Sanchinarro University Hospital, Madrid, Spain
Introduction: Neoadjuvant chemo-radiotherapy has not 
increased yet the overall patient survival rate after surgery 
for adenocarcinoma; furthermore, radiotherapy has still to be 
proven to improve pancreas resecability. Poor results of neo-
adjuvant treatment could be due to the fact that the tissular 
area around pancreas cancer reduces adsorption of the anti 
tumoral drug. It has been proved that, on advanced pancreas 
cancer, overall survival increase using gemcitabine in com-
bination with nab-placlitaxe, reducing the pancreas cancer 
stroma, assessed with elastography. Aim of this study is to 
find the relation between tumor regression rate (TTR) (Ryan 
escale) with the tumor tissue elastography before and after 
the neo adjuvant treatment.
Patients and methods: We included prospectively 15 
patients with resectable pancreatic cancer that underwent 
neoadyuvant treatment with gemcitabine and nab-placlitaxel. 
Six of them were excluded as they developed metastasic 
disease prior to surgery. Elastography was performed before 
and after neoadyuvant treatment; pathology showed the TTR.
Results: The pathology report showed one complete TRR 
and 7 near complete TRR (well and moderately differentia-
tion) and only one without TRR (poorly differentiation). 
Stadistical significance difference was find between the spec-
imen with no TRR and those with higher TRR (showing a 
decline with elastography before and after surgery of 6% and 
71% respectively) (p = 0.003).
Conclusions: Combination of Gemcitabine and nab-placli-
taxel showed efficacy on TRR. It can be easy monitored by 
elastography.
FLUOROSCOPY ASSISTED 
LAPAROSCOPIC CHOLECYSTECTOMY 
IN A PATIENT WITH A HEARTMATE® II 
LEFT VENTRICULAR ASSIST DEVICE
D. L. Eck, E. V. Belli, S. L. Koonce, H. J. Asbun and  
J. A. Stauffer
Mayo Clinic, Jacksonville, FL, USA
Introduction: With an expanding population of patients 
requiring ventricular assist devices, it is inevitable that these 
patients will require non-cardiac surgery. Ventricular assist 
devices provide mechanical support for a failing heart either 
as a bridge to transplant or now as a long-term support if 
transplant is not available. These devices can add a signifi-
cant technical challenge to abdominal surgery. The power 
supply and drive lines crossing the abdomen can potentially 
be damaged during an operation. The use of preoperative or 
intraoperative imaging may aid in locating these devices and 
increase patient safety.
Methods: We describe a laparoscopic cholecystectomy in a 
patient supported with a Heartmate® II Left Ventricular 
Assist Device. Our use of fluoroscopic guidance in port 
placement is also described. A literature search was per-
formed to assess the frequency of laparoscopic procedures 
performed on patients with similar ventricular assist devices, 
and complications associated with the device and other 
comorbidities.
Results: Laparoscopic cholecystectomy was performed 
without significant intraoperative hemodynamic changes. 
The use of imaging, such as fluoroscopy, can identify the 
locations of the ventricular assist device and its associated 
drive wires to insure they are not damaged intraoperatively.
Conclusion: Laparoscopic cholecystectomy can be per-
formed safely on patients with ventricular assist devices. 
Complications due to damage to the device can be avoided 
with the assistance of fluoroscopy to identify the implanted 
abdominal portions of the ventricular assist device. Each 
laparoscopic procedure performed on these patients presents 
the surgeon with unique obstacles in which careful operative 
planning and intraoperative monitoring are essential.
AMPULLARY PANCREATIC TYPE 
CANCER METASTATIC TO THE ANAL 
CANAL: A UNIQUE CASE
F. Ejtehadi1, N. A. Chatzizacharias1, R. Brais2 and A. Jah1
1Department Of HPB And Transplant Surgery, Cambridge, 
Cambridgeshire UK; 2Department Of Histopathology, 
Cambridge, Cambridgeshire UK
Tumours of the ampulla of Vater account for less than 1% of 
all gastrointestinal malignancies. The most common histo-
logical origin of these tumours is either intestinal or pancrea-
tobiliary. We present for the first time a case of periampullary 
pancreatic type adenocarcinoma that metastasised to the anal 
canal. The patient was a 79 year old female, who had a Whip-
ple’s procedure for a poorly differentiated pancreatic type 
adenocarcinoma arising from the ampulla of Vater (stage 
T4N1M0, AJCC stage III). Less than a month postopera-
tively, the patient experienced symptoms of perianal pain, 
exacerbated after defecation. Examination under anesthesia 
confirmed an anal fissure with an associated mass. Biopsy of 
the mass and immunohistochemical staining demonstrated a 
pancreaticobilary phenotype: CK7/CK17/MUC1 positive 
and CK20/CDX2/MUC2 negative, identical to the ampullary 
cancer. The patient underwent two cycles of palliative radio-
therapy and was discharged with full palliative support. In 
conclusion, specific immunohistochemical staining can be 
utilised in the diagnosis of atypical presentations of meta-
static ampullary adenocarcinoma.
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HYBRID LAPAROSCOPIC-ROBOTIC 
PANCREATICODUODENECTOMY AS AN 
INSTRUCTIONAL VIDEO
K. M. El-Hayek, S. Chalikonda and R. Walsh
Cleveland Clinic, Cleveland Heights, OH, USA
Purpose: This video serves as an instructional tool demon-
strating critical anatomy and concepts of a hybrid laparo-
scopic-robotic pylorus preserving pancreaticoduodenectomy.
Methods: The patient is a 63 year old female (BMI 
33 kg/m2) with an incidentally detected 4 × 3 cm 
intrapapillary mucinous neoplasm (IPMN) of the head 
of the pancreas. Subsequent endoscopic ultrasound and fine 
needle aspiration revealed atypical cells and serum values 
consistent with IPMN. Due to risk of malignancy, she 
was offered hybrid laparoscopic-robotic pylorus preserving 
pancreaticoduodenectomy.
Results: Operative conduct proceeded with the patient 
placed supine and arms tucked at her side. A 5 trocar tech-
nique with a Nathanson liver retractor in the epigastrium was 
used. The video highlights operative concepts including 
laparoscopic specimen resection with robotic assisted recon-
struction. Operative time was 7 hours, and blood loss was 
estimated to be 250 cc. Pathology was consistent with low-
grade IPMN with negative margins and no positive lymph 
nodes. She was discharged on post-operative day 6 and was 
without complaint at one month follow-up.
Conclusion: This video shows feasibility and excellent 
short-term results of a hybrid laparoscopic-robotic pylorus 
preserving pancreaticoduodenectomy and can be used as an 
instructional tool.
SAFETY AND EFFICACY OF  
LIGASURE USAGE IN 
PANCREATICODUODENECTOMIES: A 
RETROSPECTIVE EXPERIENCE
O. S. Eng1, J. Goswami2, D. Moore3, C. Chen3, 
C. Gannon4, D. August5 and D. R. Carpizo5
1Division Of General Surgery, New Brunswick, NJ, USA; 
2Department Of Surgery, Pittsburgh, PA, USA; 3Department 
Of Biostatistics, New Brunswick, NJ, USA; 4Advanced 
Surgical Associates Of New Jersey, Pennington, NJ, USA; 
5Division Of Surgical Oncology, New Brunswick, NJ, USA
Introduction: Use of the LigaSureTM device has increased 
in major abdominal surgery over recent years to include 
pancreaticoduodenectomies (PD). Our aim was to evaluate 
the safety and efficacy of LigaSure usage in PD in compari-
son to established dissection techniques.
Methods: 148 patients who underwent PD from July 2007 
to May 2012 at a single tertiary hepatobiliary center were 
identified from a retrospective database. Two groups were 
recognized: those in which the LigaSure device was used (N 
= 114), and those it was not (N = 34). Uncinate margin posi-
tivity rate, estimated blood loss, operative time, and periop-
erative outcomes were compared.
Results: The associated chart illustrates LigaSure use in PD 
at our institution over time. Technical intraoperative compli-
cations directly due to LigaSure use occurred in 4/114 
patients (3.5%), three involving the superior mesenteric vein, 
and one involving the portal vein. Vascular intraoperative 
complications occurred in 13 LigaSure patients (11.4%) and 
7 in non-LigaSure (NL) patients (20.6%) (p = 0.17). Unci-
nate margin positivity for pancreatic adenocarcinoma was 
20.3% and 25.0% in the LigaSure and NL patients respec-
tively (p = 0.69). Mean estimated blood losses were 926 ml 
and 1163 ml (p = 0.28), and mean operative times were 416 
minutes and 493 minutes, (p < 0.01) in LigaSure and NL 
patients, respectively. Mean lengths of stay in days were 12.1 
for LigaSure patients and 15.6 for NL patients (p = 0.19). 
Postoperative Clavien-Dindo complication grades at 90 days 
were 1.9 in LigaSure patients and 1.7 in NL patients (p = 
0.59).
Conclusion: Ligasure usage is safe, effective, and 
is associated with decreased operative time in 
pancreaticoduodenectomies.
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INCIDENCE OF POST-OPERATIVE 
INFECTIOUS COMPLICATIONS IN 
COMPLEX HEPATOBILIARY SURGERY 
UTILIZING PREOPERATIVE BROAD 
SPECTRUM ANTIBIOTIC AND 
ANTIFUNGAL COVERAGE IN 
CONJUNCTION WITH 
INTRAOPERATIVE CULTURES
A. H. Fathi, K. Siegel and C. Siegel
Case Western Reserve University, Cleveland Heights, Ohio, 
USA
Purpose: We evaluated the incidence of postoperative mor-
bidity and mortality in relation to the institution of routine 
use of broad spectrum antibacterial and antifungal agents 
with the use of routine intraoperative cultures. As opposed 
to the standard 24 hour course of therapy, antibiotics were 
continued until the cultures were 72 hours old and then either 
adjusted as appropriate or discontinued.
Methods: This a retrospective review. Patients from 2006 
to 2011 undergoing complex hepatobiliary surgery involving 
pancreatic head resection, complex bile duct reconstruction 
or combined liver and bile duct resection were included in 
the study. Patients with intraoperative cultures who received 
broad spectrum antibacterial and antifungal coverage were 
compared with a cohort undergoing similar surgery but 
receiving a standard regimen of antibiotics recommended for 
general surgery cases.
Result: Culture results and perioperative data of 163 
patients, undergoing complex hepatobiliary procedures 
between 2006 to 2011 were reviewed. Mortality, wound 
infection rates, length of stay, and anastomotic leaks were 
compared between two cohorts of patients.
Conclusion: In this study we compared regimens of pre-
operative antibiotics on post operative outcomes in complex 
hepatobiliary surgery. The role of antifungal coverage and 
the benefit of intraoperative cultures to be discussed.
CHOLECYSTECTOMY IN OLDER 
PATIENTS: WHAT ARE THE RISKS?
H. Ferdosi1, B. Wu1, T. Buddensick1, A. Sautter1, 
H. Shaukat1, G. Sulkowski1, D. M. Narducci1, R. Faugue1, 
M. Siddique1, F. Kamangar2, G. Kowdley1 and 
S. C. Cunningham1
1Saint Agnes Hospital, Baltimore, MD, USA; 2Morgan 
State University, Baltimore, MD, USA
Background: Cholecystectomy is commonly performed in 
both older and younger individuals. Advanced age may 
increase complications.
Methods: A retrospective chart review of 2573 patients who 
underwent cholecystectomy from 2001 to 2011 was per-
formed. Statistical analyses included two-tailed t tests and 
χ2 tests.
Results: The mean age in the groups were 43 and 75 years. 
The female/male ratio was higher among younger patients 
(P = < 0.0001). Most cholecystectomies were performed 
electively in younger (67%) but emergently in older patients 
(55.5%; P = < 0.0001), 16% of whom had ASA scores of III 
or IV (vs < 10% among younger patients). Older patients 
more frequently had severe comorbidities, such as heart, 
lung, and kidney insufficiency (P = < 0.0001 for all). Mean 
operative time was 95 minutes for younger and 102 minutes 
for older patients (P = 0.2). Mean length of postoperative stay 
was 29 hours in younger and 78 hours in the older patients 
(P = < 0.0001). Mean blood loss was 62 mL in younger and 
102 mL in older patients (P = < 0.0001). Final pathology was 
more likely cholesterosis in younger patients (26% vs 11.5%, 
respectively; P = < 0.0001), but more likely cholecystitis (all 
types) in older patients (P = < 0.0001). Same-day discharge 
was possible in 41% of older patients and 56% of younger 
patients after laparoscopic cholecystectomy (P = < 0.0001). 
Conversion rate was 1.9% in younger and 5% in older 
patients (P = < 0.0001). Postoperative complications occurred 
in 4.6% of the younger and 12% of older patients (P = < 
0.0001).
Conclusion: Laparoscoic cholecystectomy in older patients 
is associated with higher risks, likely due to worse physio-
logical status, mandating greater care in these patients.
PREDICTING GANGRENOUS 
CHOLECYSTITIS: WHO SHOULD 
OPERATE?
B. Wu1, H. Ferdosi1, T. Buddensick1, A. Sautter1, 
H. Shaukat1, R. Faugue1, M. Siddique1, F. Kamangar2, 
D. M. Narducci1, G. N. Sulkowski1, G. Kowdley1 and 
S. C. Cunningham1
1Saint Agnes Hospital, Baltimore, MD, USA; 2Morgan 
State University, Baltimore, MD, USA
While routine cholecystitis is common, often treated by 
general surgeons, gangrenous cholecystitis (GC) is less 
common but more challenging.
Methods: We retrospectively assessed risk of gangrene, and 
consequences thereof, in cases of cholecystitis over 10 years.
Results: Among 2529 patients undergoing cholecystec-
tomy, 887 had a preoperative diagnosis of acute cholecystitis, 
and 642 chronic; GC occurred in 167. The average age was 
53 years; 74% female. Patients with GC were > 5-fold as 
likely to be male (3.4% vs 0.6%), and 3-fold as likely to be 
> 65 years old (8.0% vs 2.7%). Variables relevant to chole-
cystitis were analyzed, including race, age, gender, heart rate, 
white blood cell (WBC) counts and gallbladder wall thick-
ness. In unadjusted analyses the following variables were 
significantly associated with GC: age > 45 years, male 
gender, heart rate (HR) > 90, WBC > 13 and gallbladder wall 
thickening (GBWT), whereas race was not. In adjusted anal-
yses those variables significantly associated with GC were 
age (OR = 6.8; 95% CI: 2.3–20.5), gender (OR = 2.4; 95% 
CI: 1.3–4.6), WBC (OR = 4.8; 95% CI: 2.4–9.5), and GBWT 
(OR = 2.4; 95% CI: 1.1–5.4), but not HR (OR = 1.7; 95% 
CI: 0.8–3.6). A simple scoring system, with 2 points for age 
and WBC, and 1 point for gender, HR, and GBWT, signifi-
cantly predicted GC: a score of 0 gave a 1% probability of 
GC and 7 a 76% probability. Patients with GC had signifi-
cantly more complications (18.1% vs 6.4%), EBL > 500 
(8.9% vs 1.5%), and more frequent conversion to open chole-
cystectomy (18.9% vs 2.3%).
Conclusion: When GC is predicted to be likely, considera-
tion for referral to an HPB surgeon should be considered.
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RIGHT POSTERIOR SECTORECTOMY IS 
PREFERRED OVER RIGHT 
HEPATECTOMY FOR POSTERIOR 
LESIONS: A DUAL-INSTITUTION STUDY
S. B. Fisher1, P. J. Kneuertz2, R. M. Dodson2, S. H. Patel1, 
C. A. Staley1, S. K. Maithel1, T. M. Pawlik2 and 
D. A. Kooby1
1The Winship Cancer Institute, Emory University, Atlanta, 
GA, USA; 2The Sidney Kimmel Comprehensive Cancer 
Center, The Johns Hopkins University, Baltimore, MD, 
USA
Purpose: In the management of posterior right liver lesions, 
right posterior sectorectomy (RPS) preserves liver volume 
but requires longer parenchymal transection compared with 
right hepatectomy (RH). Advantages of one approach over 
the other are undefined.
Methods: Databases at two institutions were reviewed for 
all patients undergoing RPS or RH between 1/2000–8/2012. 
Primary outcomes were perioperative complications and 
60-day mortality.
Results: Patients undergoing RPS (n = 100) and RH (n = 
480) were similar in age, sex, race, comorbidities, preopera-
tive albumin and bilirubin, and had similar operative indica-
tions and MELD scores (7.8 RPS vs 7.7 RH, p = 0.49). 
Comparing RPS to RH, there were no significant differences 
in mean EBL (697 vs 713 ml, p = 0.90), transfusion rates 
(19.2 vs 17.1%, p = 0.72), margin-positive resection rates 
(9.2% vs 11.6%, p = 0.70), minor or major complication 
rates (Clavien I/II, 27% vs 26.7%, p = 1.0; Clavien III–V, 
15% for both, p = 1.0), bile leak (3% vs 4%, p = 1.0), or 
length of stay (7.5 vs 8.3 days, p = 0.36), respectively. Post-
operative hepatic insufficiency (HI), defined as postoperative 
bilirubin ≥7 mg/dl or ascites, occurred less frequently after 
RPS (1% vs 9.2% RH, p = 0.01). Operation type remained 
an independent determinant of postoperative HI after con-
trolling for preoperative risk factors (Table). Overall 60-day-
mortality was 2.6% (n = 15), all of whom were in the RH 
cohort.
Conclusion: Despite similar blood loss and overall morbid-
ity, right posterior sectorectomy is associated with less 
hepatic insufficiency and no postoperative deaths compared 
with right hepatectomy. Right posterior sectorectomy is 
parenchymal-sparing and should be considered when techni-
cally feasible and oncologically sound for patients with 
disease of the right posterior sector.
DYSPLASIA AT THE SURGICAL MARGIN 
PREDICTS RECURRENCE FOLLOWING 
RESECTION OF NON-INVASIVE IPMN
T. L. Frankel1, J. LaFemina2, M. D’Angelica1, 
R. P. DeMatteo1, Y. Fong1, T. P. Kingham1, 
W. R. Jarnagin1 and P. J. Allen1
1Memorial Sloan-Kettering Cancer Center, New York, NY, 
USA; 2University Of Massachusetts Memorial Medical 
Center, Worcester, MA, USA
The significance of positive margins in resected non-invasive 
pancreatic intraductal papillary mucinous neoplasms (IPMN) 
remains controversial. We sought to determine recurrence 
rates when dysplasia was present at the final surgical margin. 
A prospectively maintained database was used to identify 
patients undergoing resection of non-invasive IPMN. Patho-
logic, perioperative and recurrence data were collected. 
Between November 2001 and June 2010, 192 patients under-
went pancreatectomy for non-invasive IPMN. Eighty-six 
patients (45%) had ductal dysplasia at the final surgical 
margin with IPMN or Pancreatic Intraepithelial Neoplasia 
(PanIN) discovered in 38 (20%) and 54 (28%) patients, 
respectively. During the follow-up period, 40 (21%) patients 
recurred with 31 developing radiographic evidence of new 
cysts, 5 undergoing re-resection of IPMN and 4 diagnosed 
with pancreatic cancer within the remnant. On univariate 
analysis, pathologic features of the primary lesion including 
grade, size and location (branch vs main vs mixed) were 
unrelated to recurrence. In patients with ductal dysplasia at 
the margin, 31% developed recurrent disease vs. 13% in 
those without dysplasia (p = 0.004). On multivariate analy-
sis, margin dysplasia was associated with a 3-fold increased 
risk of recurrence (p = 0.003). A higher degree of dysplasia 
did not correlate with increased recurrence rate and no rela-
tionship between dysplasia and development of pancreatic 
cancer was found. In this study, dysplasia at the resection 
margin following pancreatectomy for IPMN was associated 
with an increased rate of recurrence in the remnant gland. 
While this finding may warrant closer follow up, it does not 
appear to identify a gland at higher risk for the subsequent 
development of invasive disease.
CYTOLOGIC ATYPIA AND CANCER-
ASSOCIATED MUTATIONAL CHANGES 
IN CYTOCENTRIFUGATION 
SUPERNATANT FLUID
L. Freed1, B. Corcoran1, J. Bleicher1, V. Stearns1, 
S. Jackson1, E. Ellsworth1 and S. Finkelstein1,2
1RedPath Integrated Pathology, Pittsburgh, PA, USA; 
2Department Of Pathology, Drexel University, 
Philadelphia, PA, USA
Background: Mutational profiling of DNA from fine needle 
aspirates (FNA) of pancreatic solid masses can provide addi-
tional, second-line, information as to presence of cancer-
associated molecular changes. Here, we provide a clinical 
review of DNA within otherwise discarded supernatant fluid 
that was obtained after cytocentrifugation of FNA speci-
mens, which were being prepared for cytology. We estab-
lished a correlation between cancer-associated molecular 
changes in supernatant fluid and the level of atypia present 
in corresponding cytology specimens.
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Methods: The free DNA contained in cytology supernatant 
fluid of 129 pancreatic mass specimens underwent molecular 
analysis. For each specimen, 2 mL of supernatant fluid was 
used for DNA extraction. The fluid was tested for KRAS 
mutations and 16 LOH (loss of heterozygosity) mutations.
Results: Of the initial 129 pancreatic mass specimens, 32 
supernatant specimens tested positive for either KRAS or 
LOH mutations. There was a statistically significant differ-
ence between the mean quantity of DNA present in superna-
tant samples without mutations (8.8 ng/μL) compared to 
those with mutations (16.4 ng/μL) (p-value = 0.01). Further-
more, there were more mutations in samples with increas-
ingly severe atypia relative to those with less severe atypia 
(Table 1).
Conclusions: The higher abundance of mutated DNA in 
more severe cases of atypia may provide additional informa-
tion for diagnosis of pancreatic masses when cytology is 
indeterminate.
HISTOPATHOLOGICAL ANALYSIS OF 
NONFUNCTIONING PANCREATIC 
NEUROENDOCRINE TUMORS
M. Furukouri, K. Watanabe, T. Einama, K. Imai,  
H. Furukawa and M. Taniguchi
Division Of Gastroenterologic And General Surgery, 
Asahikawa Medical Univ, Asahikawa, Hokkaido, Japan
Background and aim: Nonfunctioning pancreatic neuroen-
docrine tumors (non-functioning pNET) are rare disease. All 
cases are adaptation of resection, even in a small tumor, due 
to high malignant potential. Lymphadenectomy is recom-
mended, if malignancy is strongly suspected. However, it is 
still controversial, because diagnostic criteria does not exist. 
The aim of this study is to analyze the histopathological 
findings and study the adaptation of lymphadenectomy in 
nonfunctioning pNET.
Object: The subject was 7 cases of nonfunctioning pNET 
who underwent pancreatectomy between 04/96 and 09/12. 
Surgical procedure, histopathological findings, and progno-
sis were examined.
Result: Nonfunctioning pNET account for 2.3% of all pan-
creatic tumors (7/310). CT scan incidentally detected all 
tumors and showed no evidence of lymph node metastasis 
and distant metastases. The median diameter of a tumor was 
10 mm (6 to 32 mm). Three cases underwent distal pancrea-
tectomy, two cases pylorus-preserving pancreatoduodenec-
tomy, and the others partial pancreatectomy, and subtotal 
stomach-preserving pancreatoduodenectomy. Lymphadenec-
tomy was performed in one case. Regarding with histopatho-
logical findings, four cases showed NET-G1, and one case, 
whose tumor was 22 mm in diameter, demonstrated NEC. 
Six cases had no lymph node metastasis, and one tumor, 
32 mm in diameter, invaded to regional lymph node directly. 
All tumor less than 10 mm in diameter showed no malignant 
change and lymph node metastasis. All cases are alive with 
no recurrence for 14 to 196 months.
Conclusion: Lymphadenectomy can be omitted for tumor 
less than 10 mm in diameter and neither lymph node metas-
tasis nor distant metastases are suspected.
PKI-587 AND SORAFENIB ADDITIVELY 
INHIBIT PROLIFERATION OF LIVER 
CANCER STEM CELLS AND HCC CELL 
LINES
R. Gedaly1, P. Angulo2, J. Hundley1, M. F. Daily1, 
M. Shah1, R. Galuppo1, C. Chen1 and B. M. Evers3
1Department Of Surgery, University Of Kentucky, 
Lexington, KY, USA; 2Department Of Internal Medicine, 
University Of Kentucky, Lexington, KY, USA; 3Markey 
Cancer Center, University Of Kentucky, Lexington, KY, 
USA
Background: The purpose of this study is to evaluate PI3K/
mTOR dual inhibitor PKI-587 and multi-kinase inhibitor 
sorafenib in single agents or in combination on inhibition of 
liver cancer stem cells (LCSC) and HCC cell lines Huh7 and 
PLC.
Methods: The liver cancer stem cells (CD133+, CD44+) are 
from CelProgen. Drug induced inhibition of cell proliferation 
was assayed by 3H-thymidine incorporation and by MTT 
assay.
Results: We found LCSC were more resistant to PKI-587 
inhibition with PKI-587 IC50 (concentration to cause 50% 
inhibition) at 105 nM as compared to Huh7 (IC50 45 nM) 
and PLC (IC50 16.4 nM). The LCSC are more resistant to 
sorafenib than Huh7 but less resistant to sorafenib than PLC. 
The sorafenib IC50 to LCSC, Huh7 and PLC are 5.7, 3.9 and 
9.6 μM respectively. Sorafenib at 5 μM and PKI-587 at 0.1 
μM as single agents significantly inhibited LCSC prolifera-
tion (p < 0.001). Drug combination caused more additive 
inhibition in LCSC than mono-drug therapy (p < 0.002). 
Similarly, drug combination caused additive and significant 
inhibition than mono-therapy in Huh7.
Conclusion: Sorafenib and PKI-587 in combination can 
cause additive inhibition in LCSC and in HCC cell lines. 
This combination therapy may have clinical significance in 
future HCC treatment.
TARGETING BETA-CATENIN 
SIGNALING PATHWAY IN LIVER 
CANCER STEM CELLS AND IN HCC 
CELL LINES WITH FH 535
R. Gedaly1, P. Angulo2, J. Hundley1, M. F. Daily1, 
M. Shah1, R. Galuppo1, C. Chen1, X. Zhang3, 
K. A. Esser3 and B. M. Evers4
1Department Of Surgery, University Of Kentucky, 
Lexington, KY, USA; 2Department Of Internal Medicine, 
University Of Kentucky, Lexington, KY, USA; 3Department 
Of Physiology, University Of Kentucky, Lexington, KY, 
USA; 4Markey Cancer Center, University Of Kentucky, 
Lexington, KY, USA
Background: The purpose of this study is to determine how 
FH535, an inhibitor of β-catenin/TCF activity, inhibits pro-
liferation of liver cancer stem cells (LCSC) and HCC cell 
lines.
Methods: FH535 induced inhibition of LCSC (CD133+, 
CD44+) and HCC cell lines proliferation was assayed by 
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3H-thymidine incorporation. FH535 on inhibition of 
β-catenin/TCF activity was assayed by dual luciferase 
reporter assay by sequential measurement of firefly and 
Renilla luciferase activities after co-transfection of the cells 
with TOPFlash and p-RL plasmids. TCF/LEF mutant plasmid 
(FOPFlash) was used as a negative control.
Results: FH535 inhibited 3H-thymidine incorporation sig-
nificantly in LCSC with 50% inhibition concentration (IC50) 
of 15.4 μM when the cells were cultured in DMEM+10% 
FBS. When the LCSC were cultured in DMEM+1% FBS, 
the FH535 IC50 was 5.1 μM. FH535 inhibited HCC cell line 
Huh7 and PLC proliferation with IC50 of 10.9 and 9.3 μM 
respectively when the cells were cultured in DMEM+10% 
FBS. FH535 at 1 μM and 5 μM significantly inhibited 
β-catenin/TCF reporter gene of the TOPFlash plasmid trans-
fected in LCSC, Huh7 and PLC. In comparison, FH535 is 
much more potent inhibitor than a tankyrase inhibitor 
XAV939 in β-catenin signaling pathway.
Conclusion: β-catenin signaling pathway is the most diffi-
cult to treat in hepatocellular carcinoma. Our study indicated 
that FH535 significantly inhibited beta-catenin pathway in 
LCSC and HCC cells. FH535 has a potential therapeutic 
application in future HCC treatment.
FIVE AND TEN YEAR OVERALL 
SURVIVAL IN PATIENTS UNDERGOING 
RADIOFREQUENCY ABLATION FOR 
PRIMARY AND METASTATIC HEPATIC 
MALIGNANCIES
B. J. Golas, J. W. Marsh, J. C. Mejia, T. C. Gamblin,  
D. A. Geller and A. Tsung
UPMC Liver Cancer Center, University Of Pittsburgh, 
Pittsburgh, PA, USA
Introduction: We sought to determine whether long-term 
overall survival is attainable in patients undergoing radiofre-
quency ablation (RFA) as part of their treatment regimen for 
primary or metastatic hepatic malignancies.
Methods: All patients who underwent RFA of a hepatic 
malignancy at a specialized Liver Center between 1999 and 
2007 were retrospectively reviewed. Survival data were 
obtained through medical record review and a query of the 
Social Security Death Index.
Results: Of the 224 patients included in the analysis, 216 
(96%) had biopsy-proven disease, while the remainder had 
radiographic and/or biochemical evidence of hepatic malig-
nancy. Oncologic diagnoses included hepatocellular carci-
noma (HCC) in 32%, metastatic colorectal cancer in 59%, 
and metastatic neuroendocrine cancer in 9%. Multifocal 
disease was present in 67% (150/224) of patients. 46% 
(104/224) underwent liver resection and concomitant RFA of 
one (59%) or two or more (41%) liver tumors considered 
unresectable. 5-year overall survival was 30% (67/224), 
including 60% (12/20) for neuroendocrine cancer, 31% 
(22/71) for HCC, and 25% (33/133) for colorectal cancer. 
Overall 10-year survival was 11% (6/53), including 50% 
(1/2) for neuroendocrine cancer, 13% for HCC (2/15), and 
8% (3/36) for colorectal cancer.
Conclusions: The use of RFA as a treatment option for 
hepatic malignancy imparts 5- and 10-year overall survivals 
of 30% and 11%, respectively. This study provides convinc-
ing data that long-term survival is possible with RFA 
treatment, especially when combined with hepatic resection 
for multi-focal tumors deemed unresectable. Selective appli-
cation of this modality has the potential to extend patient 
survival in the appropriate setting.
MINIMALLY INVASIVE RESECTION  
OF COLORECTAL CANCER  
LIVER METASTASES SHORTENS  
THE INTERVAL TO INITIATION  
OF ADJUVANT SYSTEMIC 
CHEMOTHERAPY: A CASE-CONTROL 
STUDY
B. J. Golas1, S. Li1, S. K. Reddy1, J. Steel1, J. C. Mejia1, 
J. F. Pingpank2, J. W. Marsh1, D. L. Bartlett2, 
D. A. Geller1 and A. Tsung1
1UPMC Liver Cancer Center, Starzl Transplant Institute, 
Pittsburgh, PA, USA; 2University Of Pittsburgh Medical 
Center, Pittsburgh, PA, USA
Introduction: We sought to determine whether patients 
undergoing minimally invasive resection (MIR) for colorec-
tal liver metastases experience a shorter interval to initiation 
of adjuvant systemic chemotherapy than patients undergoing 
open resection (OR).
Methods: We matched 29 patients undergoing MIR for 
hepatic colorectal metastases with 29 controls undergoing 
OR based on demographics, comorbidities, performance 
status, and extent of resection.
Results: There were no statistically significant differences 
in age, comorbidities, performance status, or extent of partial 
hepatectomy between MIR and OR. Length of hospital stay 
(6.3 vs. 4.2 days, p < 0.05) and post-operative morbidity 
(41% vs. 17%, p = < 0.05) were higher for OR than MIR. 
More MIR patients (79%) initiated adjuvant systemic chem-
otherapy than OR patients (52%). For patients receiving 
adjuvant chemotherapy, the median interval from date of 
surgery to initial dose of systemic chemotherapy was shorter 
with MIR (43 days) than OR [(56 days), p < 0.05]. There 
was not a statistically significant association between com-
plications and likelihood of receiving adjuvant treatment in 
either group. Complication rates were 36% for OR patients 
who did not receive adjuvant treatment compared to 27% for 
those that did (p = 0.21) and 33% among MIR patients who 
did not receive adjuvant treatment compared to 13% for 
those that did (p = 0.12).
Conclusion: Patients undergoing MIR of colorectal metas-
tases experience significantly shorter length of stay, lower 
morbidity, and exhibit a shorter interval to initiation of adju-
vant systemic chemotherapy than OR patients. For both MIR 
and OR, complications do not significantly impact initiation 
of systemic chemotherapy.
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COMPARED TO A CONVENTIONAL 
OPEN APPROACH,  
LAPAROSCOPIC ASSISTED 
PANCREATICODUODENECTOMY  
MAY OFFER PATIENTS BETTER 
PERFORMANCE STATUS AND PHYSICAL 
HEALTH IN THE FIRST 6 MONTHS 
AFTER SURGERY
J. A. Graham, A. B. Chin, A. Rubenstein, J. A. Nusbuam, 
J. Smirniotopoulos, R. Kayser and L. B. Johnson
Dept. Of Surgery, Georgetown University Hospital, 
Washington, DC, USA
Introduction: Laparoscopic assisted pancreaticoduodenec-
tomy (LAPD) offers an alternative approach to surgical 
resection of the pancreatic head and duodenum. More impor-
tantly, practitioners of LAPD have looked to introduce the 
marked benefits of generalized laparoscopy on to patients 
requiring this treatment. Here we provide an assessment of 
the patient’s quality of life (QOL) after a conventional open 
pancreaticoduodectomy (OPD) as compared to a LAPD.
Methods: A combined cohort of patients that underwent an 
OPD or LAPD between August 2010 and June 2012 (n = 69) 
were blindly queried. The SF-36 questionnaire was used to 
generate a mental component summary (MCS) and physical 
component (PCS). The Karnofsky scale was used to gauge 
performance status. The response rate for patients in the OPD 
and LAPD was 65% (n = 21) and 67.5% (n = 25) respec-
tively. Comparisons between the OPD and LAPD groups 
were performed in < 6 mos., 6 mos.–1 yr, and +1 yr 
intervals.
Results: In the first 6mos. after a LAPD, patients had a 
better QOL centered on functional status (PCS 44.79, 
Karnofsky 86.67%) as compared to those who had an OPD 
(PCS 33.21, Karnofsky 60%) (Table 1). Of note, this differ-
ence in PCS and the Karnofsky score was mitigated after 
6mos. There was no difference in the mental health status of 
the patients in either group at any time interval. Complica-
tions rates were 19%(OPD) and 12%(LAPD).
Conclusion: LAPD may offer patients improved perform-
ance status as compared to OPD in the peri-operative period 
( < 6 mos.). Ultimately, earlier return of physical health could 
allow for quicker commencement of chemotherapy.
EARLY PREDICTOR OF OUTCOME 
AFTER PANCREATICODUODENECTOMY 
WITH POSTOPERATIVE PANCREATIC 
FISTULA RISK CALCULATOR
J. A. Graham , R. Kayser, J. Smirniotopoulos,  
J. A. Nusbaum and L. B. Johnson
Department Of Surgery, Washington, DC, USA
Introduction: We have devised a risk calculator that deter-
mines the probability of a post-operative pancreatic fistula 
(POPF) after a pancreaticoduodenectomy during the early 
peri-operative period.
Methods: Retrospective analysis of 146 patients who had 
undergone a pancreaticoduodenectomy by one surgeon 
(LBJ) during September 2007 to June 2012 yielded 34% of 
patients with a POPF. Binary logistic regression was per-
formed to assess the probability of a POPF based on the 
quantitative variables age, body mass index (BMI), pancre-
atic duct size and post-operative day 2 JP amylase levels 
(IU/L).
Results: The aforementioned variables were significant in 
predicting the probability of a POPF; age (odds ratio = 1.035, 
95% CI is 1.002–1.068, p = 0.037), BMI (odds ratio = 1.108, 
95% CI is 1.016–1.208, p = 0.02), post-operative day 2 JP 
amylase level (odds ratio = 1.000155, 95% CI is 1.000055–
1.000255, p = 0.002) and pancreatic duct size (odds ratio = 
2.536, 95% CI is 1.104–5.825, p = 0.025). Overall this 
model, which is based on beta coefficients from these predic-
tive covariates, is statistically significant (likelihood ratio: 
chi-square 41.696; df 4; p < 0.001) and had a goodness of fit 
(Homer and Lemeshow Test: chi square 7.815; df 8; p = 
0.452). Importantly, we demonstrated that a probability 
cut-off value of 36% offers an optimal balance of 72% sen-
sitivity and 81.3% specificity (Table 1).
Conclusions: Often the determination of a POPF relegates 
the patient to lengthy hospital stays as the JP amylase level 
and volume are assessed at 5–7 post-operative days. Using 
an early risk calculator, the clinician may be empowered to 
make management decisions in a more expedient manner 
with the aforementioned covariates.
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MULTI-INSTITUTION ANALYSIS OF 
SURVIVAL AFTER HEPATECTOMY FOR 
FIBROLAMELLAR CARCINOMA
R. T. Groeschl1, R. K. Wong1, C. H. Pilgrim1, 
M. Bloomston2, M. E. Lidsky3, B. M. Clary3, 
R. C. Martin4, J. F. Buell5, G. Belli6 and T. Gamblin1
1Medical College Of Wisconsin, Milwaukee, WI, USA; 
2Ohio State University, Columbus, OH, USA; 3Duke 
University, Durham, NC, USA; 4University Of Louisville, 
Louisville, KY, USA; 5Tulane University, New Orleans, LA, 
USA; 6Loreto Nuovo Hospital, Napoli, Italy
Background: Fibrolamellar carcinoma (FLC) presents in 
young, otherwise-healthy individuals. This study examined 
recurrence and survival characteristics after surgical resec-
tion for FLC by utilizing an international multi-institutional 
database.
Methods: Consecutive patients undergoing hepatectomy 
for FLC from 6 institutions (1993–2010) were reviewed ret-
rospectively. Survival was studied with Cox proportional 
hazards models.
Results: Thirty-five patients (13 female, 37%) were included 
(median age: 32 years). No patient had underlying cirrhosis, 
and only 1 had elevated α-fetoprotein ( > 200 ng/mL). 
Symptoms were present in 27 patients (77%). Lesions were 
solitary in 26 patients (69%), and median size was 7.5 cm. 
R0 resection was achieved in all curative-intent operations 
(n = 30), and palliative operations were performed for 5 
patients. Crude 30-day morbidity and mortality rates were 
22% and 3%, respectively. Overall survival rates at 3 and 5 
years were 77% and 62%. Recurrence occurred in 15 patients 
(43%), of whom 4 underwent subsequent resection. Recur-
rence-free 3 and 5-year survival rates were 54% and 45%. 
Follow up beyond 5 years was available for 38% of our 
patients, and there were no recurrences or cancer-related 
deaths more than 4 years after surgery. No patient with ext-
rahepatic disease lived beyond 3 years, and this was the only 
factor that independently predicted overall (HR: 5.58, 95% 
CI: 1.38–22.55, p = 0.016) and recurrence-free survival (HR: 
5.64, 95% CI: 1.48–21.49, p = 0.011) in multivariable 
models.
Conclusions: Aside from those with extrahepatic disease, 
patients with surgically amenable FLC had encouraging 
long-term survival. In our study population, recurrence-free 
survival to 4 years suggests possible freedom from disease 
thereafter.
VIRAL STATUS AT THE TIME OF  
LIVER TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA: A 
PREDICTOR OF LONG-TERM SURVIVAL 
IN THE MODERN ERA
R. T. Groeschl, C. H. Pilgrim, J. C. Hong and T. Gamblin
Medical College Of Wisconsin, Milwaukee, WI, USA
Background: The impact of pre-transplant hepatitis B 
(HBV) and/or hepatitis C (HCV) infection for patients with 
hepatocellular carcinoma (HCC) is not well-described. We 
hypothesized that viral status was an independent predictor 
of retransplantation rates, graft survival (GS), and overall 
survival (OS) in patients undergoing transplantation for 
HCC.
Methods: Patients with HCC were identified from the 
Organ Procurement and Transplantation Network database 
(2005–2012), and categorized by viral status: B−/C−, B+/C-, 
B−/C+, B+/C+. Factors associated with retransplantation, 
GS, and OS were identified with logistic regression and Cox 
regression models.
Results: Of 7,742 patients transplanted for HCC, 7060 had 
known HBV and HCV status. B+/C− patients had the highest 
5-year GS and OS (both log-rank tests: p < 0.001). In mul-
tivariable analysis, B−/C+ patients were more likely to 
undergo repeat transplantation compared to B+/C− patients 
(Table 1). B−/C+ patients also had poorer GS and OS as 
compared to both B−/C− and B+/C− patients (Table 1). Other 
independent predictors of poorer OS included older age, 
higher Model for End Stage Liver Disease score, African-
American race, and diabetes. Body mass index, gender, and 
presence or absence or cirrhosis had no significant impact on 
retransplantation rates, GS, or OS in these analyses. The few 
B+/C+ patients (n = 169) showed trends toward fewer 
retransplantations, prolonged GS, and prolonged OS com-
pared to B−/C+ patients.
Conclusion: In the era of modern selection criteria, viral 
status is an independent predictor of outcome following liver 
transplantation for HCC. Both B−/C− and B+/C− patients 
have superior GS and OS compared to B−/C+ patients.
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SURGICAL PORTO-SYSTEMIC SHUNTS 
IN THE ERA OF TIPS AND LIVER 
TRANSPLANTATION ARE STILL 
RELEVANT
I. Gur, B. Diggs and S. L. Orloff
OHSU, Portland, OR, USA
Surgical portosystemic shunts (PSS) are a time-proven 
modality for treating portal hypertension (PHTN). During 
the past 2 decades, in the era of transplantation and TIPS, 
there has been a decline in frequency of PSS, despite their 
superior patency.
Objectives: To evaluate our change in practice, short-, long-
term outcomes of surgical PSS pre/post MELD introduction.
Methods: Retrospective analysis of 47 patients undergoing 
PSS from 1996–2011 in a single University Hospital.
Results: Six subgroups were identified. Cirrhosis: Alcoholic 
(17%), HCV (11%), NASH/other (23%); Budd-Chiari 
(13%), Portal Vein Thrombosis (PVT) (23%) and other 
pathology (13%). Subgroups differ significantly with respect 
to hypercoagulopathy, shunt type, preoperative Child-Pugh, 
MELD and perioperative mortality (table). Sixty-day periop-
erative mortality was 15%. Overall median survival was 70 
months; five-year patency was 92%. Survival of patients 
with PVT fared best and Budd-Chiari fared worse versus 
other subgroups, p = 0.028 (figure), long-term patency dif-
fered insignificantly. Substantial change in referral pattern 
coincided with adoption of MELD in 2002 in relation to 
frequency of cirrhotics versus non-cirrhotics (p = 0.013), 
presence of hypercoagulopathy (p = 0.028), and variceal 
bleeding (p = 0.036). On multivariate analysis, Child-Pugh 
B/C, higher MELD and Budd-Chiari were associated with 
increased perioperative mortality, while mesocaval/splenore-
nal shunts were associated with decreased long term patency 
(P = 0.053).
Conclusion: Although the spectrum of diseases benefitting 
from surgical PSS have changed recently, they continue to 
constitute an important addition to surgical armamentarium 
in treating PHTN. Timely referral, careful patient selection 
and meticulous technique are paramount for successful out-
comes. Certain subgroups continue to benefit from excellent 
long-term patency.
30 Abstracts
© 2013 The Authors
HPB © 2013 Americas Hepato-Pancreato-Biliary Association HPB 2013, 15 (Suppl. 1), 1–87
ECHINOCOCCAL LIVER DISEASE IN 
NEW YORK; AN IMPORTED PROBLEM
L. Gutnik, M. Vivanco, C. Coyle and  
J. Chapochnick Friedmann
Montefiore Medical Center – Albert Einstein College Of 
Medicine, Bronx, NY, USA
Background: Echinococcal disease of the liver is rare in 
North America. New York with its ever growing immigration 
represents a silent endemic area of patient with complicated 
Echinococcal liver disease. The aim of this abstract is to 
share our experience in the surgical management of these 
patients.
Methods: Retrospective review of clinical records of all 
patients surgically treated for Echinococcal liver disease 
between 2009 and 2012. Data presented in a descriptive way.
Results: We have resected 7 patients. Four were males and 
three females. Median age 40 (23–59). The most common 
complaint was abdominal pain. All patients had complicated 
Echinococcal liver disease defined as multilobular disease, 
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communication to bile duct, involvement of major vascular 
structures and/or adjacent organs. All patients underwent 
resection with curative attempt including major liver resec-
tions, cyst unroofing and perycistectomies. They all received 
treatment with Albendazole with or without Praziquantel. 
The median length of postoperative stay was 13 days (7–19). 
There was no mortality. Two patient developed a bile leak 
on post operative day 7 successfully managed endoscopi-
cally, and another patient developed a pulmonary embolism 
on post operative day 33 while at home without conse-
quences. During our follow up period (mean 512 days) no 
patient has evidence of local or distance recurrence.
Conclusions: Complicated Echinoccocal liver disease is a 
challenging entity that requires surgical expertise and a 
multidisciplinary approach together with experts in parasitol-
ogy. Even though infrequent in North America, cities with 
high immigration rates like New York are exposed to these 
very complex patients.
ENDOSCOPIC ULTRASOUND IS A SAFE 
AND EFFECTIVE ALTERNATIVE TO 
PORTAL NODE SAMPLING IN PATIENTS 
ENROLLED THE 
CHOLANGIOCARCINOMA TRANSPLANT 
PROTOCOL
S. I. Hanish1, E. Marchan3, F. Willingham2, J. Landry3, 
J. Kauh4, J. Magliocca1, A. Adams1, J. Spivey2 and 
S. Knechtle1
1Emory University Department Of Surgery, Division Of 
Liver Transplantation, Atlanta, GA, USA; 2Emory 
University Department Of Gastroenterology, Atlanta, GA, 
USA; 3Emory University Department Of Radiation 
Oncology, Atlanta, GA, USA; 4Emory University 
Department Of Medical Oncology, Atlanta, GA, USA
Transplantation for Cholangiocarcinoma (CCA) is accepted 
for unresectable hilar tumors or hilar tumors in patients with 
primary sclerosing cholangitis (PSC). Standard neoadjuvant 
protocol includes oral chemotherapy and external beam 
radiation followed by a pre-transplant listing laparotomy and 
lymph node (LN) sampling. We sought to test the efficacy 
and safety of using endoscopic ultrasound and LN sampling 
as a screening tool prior to listing. Prior to the initiation of 
chemotherapy and radiation, all patients underwent EUS and 
LN sampling. Chemotherapy was given with concomitant 
external beam radiation (XRT) followed by an external beam 
boost. MRI and endoscopic ultrasound was performed with 
LN sampling. 7 men and 5 women were enrolled. Mean age 
was 57.6 years. 9/11 patients went on to OLT. Two patients 
dropped out due to complications of XRT and overall physi-
ologic state. 78% of patients transplanted had pCR on 
explant. Two required a simultaneous pancreatiduodenec-
tomy due to a positive distal bile duct margin. All patients 
had node sampling of the portal and hepatic artery nodes. 0/9 
had positive nodes on initial exploration. Average time from 
XRT to transplant was 3.8 months. Median follow-up is 23 
mos. (6.5–37). 6,12,24 month recurrence free survival is 
100%. Actuarial survival at 6, 12, and 24 months is 100%, 
87.5% and 87.5%. 0/11 have evidence of recurrent disease. 
OLT for CCA remains promising. Pre-transplant EUS is a 
safe intervention with excellent correlation to a formal 
LN dissection without the associated morbidity leading to 
excellent long-term post-OLT survivals and minimal peri-
transplant complications.
DEEP SEQUENCING ANALYSIS OF 
MICROBIAL DNA IN INFECTED 
NECROTIZING PANCREATITIS
E. M. Hanna1, I. H. McKillop1,2, F. K. Bahrani-Mougeot1, 
A. Fodor2, T. Hamp2, J. B. Martinie1, D. Sindram1 and 
D. A. Iannitti1
1Carolinas Medical Center, Charlotte, NC, USA; 2UNC At 
Charlotte, Charlotte, NC, USA
Background: Superinfection of necrotizing pancreatitis 
(NP) is associated with significant morbidity and mortality. 
Standard cultures of peripancreatic fluid may fail to compre-
hensively identify all infecting organisms. We hypothesized 
that employing bacterial DNA sequencing would provide 
more accurate bacteria identification than standard culture 
techniques.
Methods: Peripancreatic fluid from patients with severe NP 
was prospectively collected during operative intervention. 
Samples were sent for standard culture and bacterial DNA 
extraction with 16S-rRNA amplification by PCR. Deep 
sequencing was used to generate consensus sequences and 
bacterial identification performed using Silva databases.
Results: 20 patients with NP were consented, from which 
fluid samples were collected on 14 patients (average age of 
52.6 yrs), with 2 patient mortalities. Using standard cultures 
strains most frequently identified included gram-negative 
rods (E. coli and Klebsiella pneumoniae) and Enterococcus. 
Sequencing data demonstrated significantly greater diversity 
in bacterial flora. Of these, the most striking differences 
included a patient with ERCP-induced pancreatitis for whom 
consensus sequences revealed significant presence of Carno-
bacteriaceae desemzia, and a second patient, with alcohol-
induced pancreatitis who grew Enterococcus by culture 
analysis, yet had Streptococcus and Pseudomonas variants 
identified by consensus sequencing.
Conclusions: Our data demonstrate the presence of a pol-
ymicrobial biome in infected NP that is not readily identifi-
able by standard culture techniques. Given that broad-spectrum 
antibiotics remain the standard of care for NP the possibility 
of antibiotic resistance and/or superinfection exists in the 
setting of incomplete bacterial identification. Technological 
improvements, decreased cost, and increased availability 
will make deep sequencing approach more accessible for 
routine clinical diagnosis.
EFFECT OF ALCOHOL ON 
DEVELOPMENT AND PROGRESSION OF 
SEVERE ACUTE PANCREATITIS (SAP) IN 
EXPERIMENTAL RAT MODELS
E. M. Hanna, I. H. McKillop, K. J. Thompson,  
D. M. Foureau, J. B. Martinie, D. A. Iannitti and D. Sindram
Carolinas Medical Center, Charlotte, NC, USA
Background: Severe acute pancreatitis (SaP) often presents 
in the setting of chronic alcohol abuse. Previous studies 
report rodent models with which to study human disease 
pathology. The aim of this study was to determine the 
effect of chronic alcohol consumption on SaP development 
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and progression using established models of chemically-
induced SaP.
Methods: Male Sprague-Dawley rats (150–200 g) were 
randomized to receive drinking water (DW) or 10/20% (v/v) 
alternate days alcohol-drinking water (A-DW) for 10 Wks. 
Animals were further randomized to SaP-induction via 
L-arginine (5 mg/Kg, i.p.) or caerulein (50 μg/kg, × 2 at 6 Hr 
intervals, weekly (4 Wks)). At completion animals were sac-
rificed, blood and tissue collected.
Results: Both models led to SaP induction as determined 
histologically and by elevated serum amylase/lipase levels. 
Comparing the two models, the caerulein model was charac-
terized by pancreatic cell vacuolization, while the L-arginine 
model exhibited greater interstitial edema. Detailed micro-
scopic analysis demonstrated A-DW animals had significantly 
increased inflammatory cell infiltrate and CD68+-specific 
staining (macrophages) vs. C-DW for both models of SaP. 
Finally, significantly greater mortality occurred in the 
L-Arginine-A-DW model compared to all other models.
Conclusions: Both caerulein and L-arginine induced animal 
models of SaP accurately reflect aspects of the human disease 
state with the L-Arginine model generating a more dramatic 
pathology. The pathology of both models is exacerbated by 
chronic alcohol intake and these models will prove valuable 
in investigating the role of underlying, chronic alcohol inges-
tion on disease pathology and progression.
HEPATIC HEMANGIOMAS: HOW MUCH 
GROWTH IS NORMAL OVER LONG-
TERM FOLLOW-UP?
H. Y. Hasan1, J. L. Hinshaw3, E. J. Borman3, 
A. Gegios2 and E. R. Winslow2
1Medical College Of Wisconsin, Milwaukee, WI, USA; 
2University Of Wisconsin, Madison, WI, USA; 3University 
Of Wisconsin, Madison, WI, USA
Purpose: Relatively few long-term data exist describing the 
natural history of hepatic hemangiomas. The purpose of this 
study was to quantitate the rate of growth of untreated 
hepatic hemangiomas, so that normal boundaries can be 
defined.
Methods: Using the radiology information system, reports 
with the key word ‘hemangioma’ were identified over an 18 
year period. Patients with hepatic hemangiomas ≥1 cm with 
comparable cross sectional imaging ≥1 year apart were 
selected. All lesions were re-measured linearly in three 
dimensions and volumes were calculated using standard 3D 
software.
Results: 164 hemangiomas were identified in 124 patients. 
The mean size of the initial lesions was 3.2 ± 3.1 cm. The 
mean length of follow-up was 3.7 ± 1.9 years. During follow-
up, 39.6% of hemangiomas grew in mean linear dimension 
(by more than 5%) and 27.4% grew by > 5 mm in one dimen-
sion. The annual growth rate was 4 ± 2 mm, and among the 
fraction that grew, the annual growth rate was 19 ± 23 mm. 
By volume, 44% of lesions grew, with an annual growth rate 
of 3 ± 21%. Among those that grew > 5% by volume annu-
ally, the annual growth rate was 17 ± 23%. The fraction that 
grew > 5 mm over follow-up was size dependent (hemangi-
omas 1–2 cm, 20%; 3–5 cm, 27%; ≥6 cm, 62%; p < 0.001). 
The figure depicts the percent annual growth by volume as 
a function of initial hemangioma size.
Conclusions: A sizable fraction of hepatic hemangiomas 
grow over long-term follow-up. The normal growth rate is 4 
± 21 mm per year in linear dimension and 3 ± 21% by 3D 
volume measurements.
A NOVEL THERAPEUTIC (SIGMA-2/
SMAC CONJUGATE) EFFECTIVELY 
TARGETS APOPTOSIS IN PANCREAS 
ADENOCARCINOMA
Y. M. Hashim, D. Spitzer, S. Vangveravong, R. Mach  
and W. Hawkins
Washington University School Of Medicine In St Louis, 
Department Of Surgery, St. Louis, MO, USA
Purpose: Pancreatic cancer is a devastating disease in need 
of new therapies. Here we deliver novel drugs selectively to 
pancreatic cancers using sigma-2 ligands and targeting a 
survival/apoptosis pathway. We have previously shown that 
Sigma-2 receptor is highly expressed in pancreas cancer 
cells, and are rapidly internalized in vivo and in vitro.
Method: We synthesized several novel compounds which 
conjugate a Sigma-2 ligand with a SMAC mimetic or a fluo-
rescent label. We tested these compounds on human pancre-
atic cancer cell lines. We applied escalating concentrations 
of Sigma-2 ligand, SMAC, Sigma-2 ligand/SMAC conju-
gate, and Sigma-2 Ligand plus SMAC. TiterGlo cell viability 
assays were performed 24 hours after treatment. The mecha-
nism of drug action was tested by adding inhibitors of 
apoptosis.
Results: All the sigma-2 ligands were rapidly internalized 
by pancreatic cancer cells. The plateau of internal fluores-
cence intensity was reached in ≤5 minutes. There was sig-
nificant killing activity of the conjugated compound 
compared to control compounds (See Figure). The Sigma-2 
ligand/SMAC conjugate has the best effect because the 
effector portion is brought into the cell by the delivery 
moiety. The pan-caspase inhibitors were capable of attenuat-
ing the response in a dose dependent fashion.
Conclusion: We developed a novel molecular therapeutic 
based on the concept of cancer selective delivery and inhibi-
tion of a survival pathway. This strategy for drug delivery 
has the potential to expand the therapeutic window for con-
ventional agents and can be expanded to other small mole-
cule therapeutics. This platform technology has implications 
for future clinical development.
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DOES LAPAROSCOPIC LIVER 
RESECTION MITIGATE 
COMPLICATIONS
J. F. Buell, A. T. Hauch, E. Kane, B. Saggi, L. Balart, N. 
Shores, E. Kandil and J. Lee
Tulane University, New Orleans, LA, USA
Introduction: Laparoscopic liver resection is now an 
accepted modality for the management of benign and malig-
nant liver tumors. This study evaluates the impact of 
laparoscopic resection on the incidence and severity of post-
operative complications.
Methods: Surgical complications after 572 hepatic resec-
tions (352; 62% laparoscopic and 220; 38% open) were ana-
lyzed using univariate and multivariate analysis to examine 
the impact of demographics on the incidence of complica-
tions and their severity (Clavien-Dindo).
Results: The overall incidence of complications in the series 
was 26% with 19% in the laparoscopic group versus 39% in 
the open group (p < 0.001). Univariate analysis of complica-
tions demonstrated no significant differences for gender or 
race, however advanced age, defined as 65 years or greater 
was significant (53/148; 35% vs. 98/404; 24%: p < 0.001). 
This affect was most notable in the laparoscopic group OR 
2.087 vs. 1.054.
Conclusion: The incidence of complications was higher in 
the open resection group with no clear association with 
gender or race. However, this study identified advanced age 
( > 65 years) as a clear risk factor for post resection complica-
tions. A higher incidence of complications in the laparo-
scopic group was unexpected and warrants further subset 
analysis of tumor type and extent of resection.
LIVER RESECTION FOR  
NON-COLORECTAL, NON-
NEUROENDOCRINE, NON-SARCOMA 
METASTASES: A MULTICENTER STUDY
J. Hawel2, G. Martel1, K. P. Croome2, J. Rekman1, 
D. Quan2, F. K. Balaa1 and R. Hernandez-Alejandro2
1University Of Ottawa, Ottawa, ON, Canada; 2Western 
University Canada, London, ON, Canada
The benefits of liver resection for colorectal, neuroendocrine 
and sarcoma metastases are well described. The role of resec-
tion for non-colorectal, non-neuroendocrine, non-sarcoma 
liver metastases (NCNNNSLM) remains ill defined. This 
study aimed to compare long-term outcomes in patients 
undergoing resection for NCNNNSLM to a cohort of patients 
undergoing resection for colorectal liver metastases (CRLM) 
during the same period. A retrospective analysis was per-
formed at two large centres to identify all patients who 
underwent resection for true hematogenous NCNNNSLM 
between 1990 and 2012. Liver resection was offered on a 
case-by-case basis to patients with stable disease. Survival 
in patients with NCNNNSLM was compared to patients with 
CRLM on Kaplan-Meier curves. We identified 52 patients 
who underwent resection for NCNNNSLM. Overall 5-year 
survival was 58%. Five-year survival was 100% for adrenal 
metastases, 85% for breast metastases, 66% for ocular 
melanoma, 83% for other melanomas, 50% for gastro-
esophageal, 0% for renal cell carcinoma, and 46% for other. 
Overall 5-year survival in our CRLM cohort was 63%. There 
was no significant difference in survival between our 
NCNNNSLM and CRLM cohorts based on Kaplan-Meier 
curves (p = 0.47). Liver resection is an effective option in 
the oncologic management of patients with NCNNNSLM. 
Despite the retrospective nature of our study, we demon-
strated a 5-year survival comparable to that for CRLM in 
carefully selected patients. Further, larger studies are required 
to help identify potential prognostic variables and aid in 
decision-making in this heterogeneous population.
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ANATOMICAL HEPATECTOMY USING 
ICG NAVIGATION SYSTEM
S. Hayami, M. Ueno, S. Yamaguchi, M. Kawai,  
M. Tani and H. Yamaue
Wakayama Medical University Second Department Of 
Surgery, Wakayama, Japan
Purpose: In perfoming hepatectomy for hepatocellular car-
cinoma, anatomical resection is desirable to control intrahe-
patic metastasis or to reduce postoperative complications. 
Recently, near-infrared fluorescence (NIRF) imaging under 
indocyanine green (ICG) injection and contrast enhancement 
intraoperative ultrasonography (CEIOUS) were provided 
and progressed the intraoperative imaging diagnosis. Using 
advantages of these techniques, we aimed to develop a novel 
navigation system for anatomical liver resection.
Patients and methods: Previously, 22 HCC patients under-
went anatomical hepatectomy using this navigation system 
(lobectomy (n = 4), segmentectomy (n = 6), sub-segmentec-
tomy (n = 12)). Navigation of anatomical liver resection was 
performed as follows: 1) under ligation of the glissonian 
pedicle where flows the planned liver resection area, ICG 
was intravenously injected and observed the demarcation 
area using NIRF imaging system (PDE, Hamamatsu Photo-
noics, Japan) (counter perfusion method). 2) Immediately 
after ultrasound-guided injection of ICG to the glissonian 
pedicle where flows the planned liver resection area, NIRF 
image was observed (direct perfusion method).
Results: The planned resection area was detected clearly as 
a non-fluorescent area by the counter perfusion method and 
as a fluorescent area by the direct perfusion method. The 
resection volume was statistically correlated with the esti-
mated volume by 3D-CT volume analysis. There were no 
adverse effects related to our new navigation system.
Conclusion: We demonstrated that the navigation system 
using NIRF imaging is a novel and reliable technique for 
anatomical hepatic paranchyme resection.
ELEVATED HEMOGLOBIN A1C IN THE 
DIAGNOSIS OF PANCREATIC DUCTAL 
ADENOCARCINOMA AND THE 
RELATIONSHIP TO POSTOPERATIVE 
MORBIDITY AND DIABETES
K. C. Hewitt, M. C. Mone, S. J. Mulvihill and C. L. Scaife
University Of Utah, Salt Lake City, UT, USA
Pancreatic ductal adenocarcinoma (PDA) may occur more 
commonly in patients with chronic diabetes (DM), while 
PDA may also cause DM. Nearly 30–40% of newly diag-
nosed PDA patients are previously diagnosed with DM. We 
tested hemoglobin A1c (HgA1c) levels prior to PDA surgery 
to evaluate the real frequency of PDA related glucose intoler-
ance and the association with postoperative morbidity. Uti-
lizing our Clinical Cancer Database, we retrospectively 
identified pancreatic resection patients with PDA, at our aca-
demic referral center from 2008–2012. All patients had 
preoperative HgA1c levels drawn within 6 weeks of surgery. 
With Institutional Review Board approval, charts were 
reviewed for demographics and co-morbidities, HgA1c 
levels and perioperative outcomes. At our institution, an 
HgA1c < 5.7% is normal, 5.7–6.4% is at risk, and > 6.4% is 
diagnostic of diabetes. We reviewed 48 patients, of whom 
23% were previously diagnosed with DM. Of the 37 non-
diabetics, 40.5% had an HgA1c of 5.7–6.4% and 13.5% had 
an HgA1c > 6.4%. There was no difference in length of stay, 
UTI, pancreatic leak and/or organ space infection, or any 
type of infection when patients with an HgA1c of < 5.7 (n = 
18) were compared to ≥5.7% (n = 30). Four cases of non-
diabetics required insulin treatment for glucose intolerance 
postoperatively, all of whom had an unexpected elevated 
HgA1c before surgery. Twenty PDA patients (41.6%) had 
undiagnosed elevated HgA1c levels preoperatively, with 
13.5% having undiagnosed DM. Increased HgA1c levels are 
not associated with increased postoperative morbidity, but 
may help predict those patients who require postoperative 
glucose control.
PROGNOSTIC FACTORS AFTER 
HEPATECTOMY FOR INTRAHEPATIC 
CHOLANGIOCARCINOMA: RELEVANCE 
OF LYMPH NODE DISSECTION
T. Hibi, O. Itano, T. Fujimura, M. Shinoda, M. Kitago,  
H. Yagi, Y. Abe, M. Tanabe and Y. Kitagawa
Department Of Surgery, Keio University School Of 
Medicine, Shinjuku-ku, Tokyo Japan
Background: The prognosis of intrahepatic cholangiocarci-
noma (ICC) with lymph node metastasis is dismal. The role 
of regional lymph node dissection has yet to be defined.
Methods: A retrospective cohort analysis was conducted on 
a total of 45 consecutive patients who underwent macro-
scopic curative resection (R0/R1) for ICC. In principle, 
lymph nodes in the hepatic hilum and around the head of the 
pancreas were systematically removed. For tumors located 
in the left liver, lymphadenectomy was added along the 
lesser curvature of the stomach. Prognostic impact of clin-
icopathological factors and lymph node dissection was 
analyzed.
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Results: All patients underwent anatomical liver resection 
(37 major). Combined resection of the portal vein or the 
hepatic artery was performed in 14 patients. Metastatic 
lymph nodes were found in 15 patients. The 5-year overall 
and disease-free survivals were 36% and 32%, respectively. 
Cox multivariate analysis revealed the number of metastatic 
lymph nodes ≥ 5 [hazard ratio (HR) 5.1, 95% confidence 
interval (CI) 1.5–16.8] and serosal invasion (HR 5.3, 95% 
CI 1.8–15.5) as independent negative indicators of overall 
survival. Positive nodes ≥ 5 (HR 7.0, 95% CI 2.0–25.5) and 
tumor location in the left liver (HR 3.1 95% CI 1.1–8.5) were 
significant predictors of diminished disease-free survival.
Conclusion: Regional lymphadenectomy for ICC may 
improve survival if the metastatic nodes are less than 5. 
Lymphatic pathways of the liver are complex and the extent 
of lymph node dissection should be determined based on 
tumor location. New staging system including the number of 
positive nodes is warranted.
INDICATION OF SURGICAL RESECTION 
FOR BRANCH DUCT TYPE IPMN
S. Hirono, M. Tani, M. Kawai, K. Okada, M. Miyazawa, 
A. Shimizu, Y. Kitahata, M. Ueno, S. Hayami and  
H. Yamaue
Wakayama Medical University, Wakayama, Japan
Introduction: The indications for resection of the branch 
duct type IPMN have been controversial. Therefore, in this 
study, we identified predictors of malignancy to determine 
indications for surgery for the patients with branch duct type 
IPMN.
Methods: We retrospectively analyzed the clinicopathologi-
cal factors of 148 patients who underwent resection for 
branch duct type IPMN at Wakayama Medical University 
Hospital from 1999 to 2011, to identify predictors of the 
malignant behavior of this neoplasm. The cutoff values of 
tumor size, main pancreatic duct (MPD) size, mural nodule 
size, and carcinoembryonic antigen (CEA) level in the pan-
creatic juice obtained during preoperative endoscopic 
retrograde pancreatography (ERP) were analyzed using 
receiver-operator characteristic curves.
Results: We found 6 significant predictors for malignancy 
in the branch duct type IPMN in a univariate analysis; jaun-
dice, MPD size > 5 mm, mural nodule size > 5 mm, elevated 
serum CA19–9 level, positive cytology in the pancreatic 
juice, and CEA level in the pancreatic juice > 30 ng/ml. In a 
multivariate analysis, a mural nodule size > 5 mm and a CEA 
level in the pancreatic juice > 30 ng/ml were independent 
factors associated with malignancy. When the combination 
of a mural nodule size > 5 mm and a CEA level in the 
pancreatic juice > 30 ng/ml is used, the positive predictive 
value was 100%, and the negative predictive value was 
96.6%.
Conclusion: We identified two useful predictive factors for 
malignancy in branch duct type IPMN; a mural nodule size 
> 5 mm and a CEA level in the pancreatic juice obtained by 
preoperative ERP > 30 ng/ml.
ROBOTIC ASSISTED SURGERY FOR 
PANCREATIC NEUROENDOCRINE 
TUMORS
M. E. Hogg1, M. Daoaudi1, B. A. Boone1, H. M. Choudry1, 
K. K. Lee1, W. Marsh1, J. F. Pingpank1, M. T. Stang1, 
A. Tsung1, A. J. Moser2, D. L. Bartlett1, H. J. Zeh1 and 
A. H. Zureikat1
1University Of Pittsburgh Medical Center, Pittsburgh, PA, 
USA; 2Beth Isreal Deaconess Medical Center – Harvard 
Medical School, Boston, MA, USA
Introduction: Robotic-assisted (RA) surgery allows for 
complex pancreatic resections and reconstructions to be per-
formed through a minimally invasive approach. We hypoth-
esized that RA resection of neuroendocrine tumors of the 
pancreas (PanNET) would be safe and feasible with accept-
able morbidity and mortality.
Methods: A retrospective review was performed of all RA 
resections of PanNET from a prospectively maintained data-
base of RA pancreatic resections between June 2008 and 
June 2012. Intra-operative and 90 day post-operative out-
comes were analyzed.
Results: Forty-four patients (23 male), with a median age 
of 57 (range 19–83 years), and average BMI of 30 underwent 
RA surgery for PanNET: 36 (82%) nonfunctional and 8 
(18%) functional. RA procedures were pancreaticoduo-
denectomy (RAPD) = 10 (23%), distal pancreatectomy 
(RADP) = 25 (57%), central pancreatectomy (RACP) = 3 
(7%), and pancreatic enucleations (RAPEN) = 6 (14%). No 
patients were converted to open, 4 (9%) required blood trans-
fusion, 2 (5%) patients required re-operation for bleeding, 
and 90 day mortality was zero. Average operating time was 
354 minutes (range 110–848), median blood loss 150 ml 
(range 20–1000), and median length of stay was 7 days 
(range 4–14), with 16 (36%) readmissions. Clinically signifi-
cant pancreatic fistulas (ISGPF B/C) occurred in 8 (18%) 
patients, and major (Clavien III/IV) events occurred in 11 
(25%) patients. See attached table for data breakdown by 
procedure.
Conclusions: Four different robotic-assisted pancreatic pro-
cedures were performed safely without conversions or mor-
tality for PanNET with an acceptable morbidity profile.
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MAJOR HEPATECTOMY FOR 
COLORECTAL LIVER METASTASIS IN 
THE ELDERLY
B. Howe, K. P. Croome, N. Sela and  
R. Hernandez-Alejandro
Western University Canada, London, ON, Canada
The objective of the present study was to evaluate the out-
comes in patients over the age of 70 years that underwent a 
liver resection for CLM at our center compared to patients 
less than 70 years of age. A retrospective analysis of our 
prospectively maintained database was performed. One 
hundred ninety one patients underwent a major hepatic 
resection for CLM. There were 28 (14.7%) that were 70–74 
years old and 26 (13.6%) that were 75–79 years old at time 
of resection. Two (1.0%) were 80 years of age or older. 
Elderly patients had similar tumor size, number of liver 
metastasis, tumor site, and disease stage compared to 
younger patients. Elderly patients were less likely to have 
synchronous lesions. Liver resections for CLM increased 
51% between 2007–2011. More younger individuals ( < 70 
years of age) received peri-operative chemotherapy (89% 
versus 53%; p = 0.0001). Ninety day mortality rate was not 
significantly different for patients greater than 70 years of 
age (2%) compared to those younger than 70 (0.8%) (p = 
0.49). Mortality at one year was also not significantly dif-
ferent for patients greater than 70 years of age (8.1%) com-
pared to those younger than 70 (2.9%) (p = 0.47). 
Perioperative morbidity was similar in the elderly group 
compared to the younger population, although there was a 
trend towards higher morbidity in the elderly (17.5% versus 
11.7%; p = 0.27).
Conclusion: Well-selected elderly patients (≥70 years of 
age) have similar outcomes for hepatic resection for CLM 
compared to younger patients ( < 70 years of age) in our 
centre.
MANAGEMENT OF MEDIASTINAL 
PANCREATIC PSEUDOCYSTS: A CASE 
REPORT AND REVIEW OF THE 
LITERATURE
D. V. Hughes, R. L. Harmon, J. P. Arnoletti, W. S. Eubanks 
and S. G. De La Fuente
Florida Hospital Orlando, Orlando, FL, USA
Background: Pancreatic pseudocysts are a common com-
plication of pancreatitis. Typically pancreatic pseudocysts 
localize to the abdomen but these lesions can also extend 
beyond the boundaries of the peritoneal cavity. We report a 
patient with a mediastinal pancreatic pseudocyst while pro-
viding a review of the literature on the subject.
Methods: PubMed search from 1969 to 2012 was per-
formed identifying studies on pancreatic mediastinal pseu-
docysts published in English.
Results: A 60 year old man with a history of chronic pan-
creatitis presented with a 10 day history of dyspnea, abdomi-
nal pain, and chest pain. CT scan imaging of the chest and 
abdomen revealed a large pancreatic pseudocyst extending 
beyond the gastroesophageal junction into the posterior 
mediastinum. Biochemical analysis of the pleural fluid fol-
lowing chest tube insertion confirmed elevated amylase and 
lipase levels. Endoscopic retrograde cholangio-pancreatog-
raphy (ERCP) with sphincterotomy and pancreatic duct 
stenting resulted in resolution of the fluid collection and 
gradual improvement of symptoms. At 10 week follow up 
the patient had no residual symptoms and ERCP demon-
strated no pancreatic leakage into the mediastinum. Table 1 
shows prior case reports, including different approaches to 
management.
Conclusions: Mediastinal pancreatic pseudocysts are rare 
complications of severe pancreatitis. An endoscopic approach 
with sphincterotomy and pancreatic duct stenting can result 
in adequate pseudocyst drainage and resolution of symptoms 
without the added morbidity of surgical intervention.
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EFFECT OF EXTERNAL BEAM 
RADIOTHERAPY ON SURVIVAL IN 
SURGICALLY RESECTED 
GALLBLADDER ADENOCARCINOMA – A 
PROPENSITY SCORE MATCHED SEER 
ANALYSIS
O. Hyder, T. Sachs, S. Mayo, J. Herman and T. M. Pawlik
Johns Hopkins Hospital, Baltimore, MD, USA
Background: While surgical resection is the mainstay of 
treatment for gallbladder cancer (GBC), National Compre-
hensive Cancer Network (NCCN) guidelines recommend 
that external beam radiotherapy (XRT) be considered in the 
adjuvant setting. We sought to define the utilization, as well 
as effect, of adjuvant XRT on long-term survival among a 
population-based cohort of patients having undergone cura-
tive-intent resection.
Methods: Using the Surveillance, Epidemiology, and End 
Results (SEER) database 5011 patients with GBC who 
underwent surgical resection between 1998–2009 were iden-
tified. Data on demographics, tumor characteristics, and 
receipt of XRT were collected. The impact of XRT on sur-
vival was analyzed using propensity-score matching by com-
paring patients who received surgery+XRT with patients 
who received surgery only.
Results: Median age was 72 years and most patients were 
female (73%); 66% patients had intermediate- to poorly-
differentiated tumors and 19% had lymph node metastasis. 
SEER historic staging classified the disease as ‘localized’ in 
the majority (62%). Overall, 899 patients (18%) received 
XRT while 4112 patients did not. Patients who were younger 
(OR = 6.00), as well as those with tumor extension beyond 
the serosa (OR = 1.46), intermediate- to poorly-differentia-
tion (OR = 1.51), and lymph node metastasis (OR = 2.39) 
were more likely to have received XRT (all P < 0.05). Median 
and 1-year survival were 17 months and 60%, respectively. 
Despite having more advanced tumors, after adjusting for 
these risk factors in the propensity-matched multivariate 
model, XRT was independently associated with 1-year (HR 
= 0.45; P < 0.001), but not 5-year (HR = 1.07; P = 0.43) 
survival (Figure).
Conclusion: Less than 20% of patients with GBC receive 
XRT following curative intent surgery. Utilization of adju-
vant XRT was associated with a short-term survival benefit 
but the benefit dissipated over time.
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POST-TREATMENT SURVEILLANCE OF 
PATIENTS WITH HEPATOCELLULAR 
CARCINOMA: DOES INTENSITY OF 
FOLLOW-UP IMAGING IMPACT 
OUTCOMES
O. Hyder, H. Nathan, D. Cosgrove, K. Hirose,  
C. Wolfgang, J. Geschwind, M. Choti, J. Herman,  
I. Kamel and T. Pawlik
Johns Hopkins Hospital, Baltimore, MD, USA
Background: Little is known about surveillance practices 
after treatment of hepatocellular carcinoma (HCC). We 
sought to define population-based patterns of surveillance 
and investigate if intensity of surveillance impacted outcome.
Methods: We queried the Surveillance, Epidemiology, and 
End Results (SEER)-linked Medicare database for patients 
with HCC diagnosed between 1991–2007 who underwent 
liver-directed therapy. Frequency of post-treatment abdomi-
nal CT or MRI was recorded and analyzed relative to second-
ary interventions and long-term survival.
Results: 2076 patients with HCC were identified. Treatment 
consisted of liver resection (38%), ablation (41%), transplan-
tation (6%), and intra-arterial therapy (IAT) (16%). CT 
(80%) was utilized more than MRI (27%). More frequent 
imaging was obtained in post-treatment year-1 (2.1 scans/
year) vs. year-5 (0.8 scans/year) (P = 0.02); 36% of alive 
patients had no imaging after 2-years. Surveillance frequency 
correlated with procedure type (total number of scans/5-
years: resection, 4.2; ablation, 4.6; transplantation, 4.1; IAT, 
3.2; P = 0.04), as well as younger age at diagnosis, tumor 
size < 5 cm, and solitary tumor (all P < 0.05). The proportion 
of patients undergoing a secondary procedure for recurrence 
did not differ by intensity of surveillance imaging (3–4 
scans/year: 10% vs. 2 scans/year: 8% vs. 1 scan/year: 7%) 
(P = 0.12). Median time to secondary procedure (3–4 scans/
year: 149 days vs. 2 scans/year: 126 days vs. 1 scan/year: 
166 days) (P = 0.76) and survival (3–4 scans/year: 62.8 
months vs. 2 scans/year: 64.5 months vs. 1 scan/year: 57.1 
months) (P = 0.80) did not differ by intensity of surveillance 
imaging.
Conclusion: Marked heterogeneity exists in how often sur-
veillance imaging is obtained following treatment of HCC. 
Intensity of imaging does not affect time to second procedure 
or median survival. National HCC surveillance guidelines 
should be re-examined.
RISK ASSESSMENT OF PANCREATIC 
FISTULA AFTER 
PANCTRATICODUODENECTOMY BY 
MEASURING OF PURE PANCREATIC 
JUICE AMYLASE LEVEL
K. Imai, M. Furukori, K. Watanabe, T. Einama,  
M. Taniguchi and H. Furukawa
Division Of Gastroenterologic And General Surgery 
Asahikawa Medical University, Asahikawa, Hokkaido, 
Japan
Background and aim: ‘Soft pancreas’ is one of the impor-
tant predictive factors for clinically relevant pancreatic 
fistula (PF) after panctraticoduodenectomy. However, it 
lacks objectivity due to depending on surgeon’s palpation. 
The aim of this study is to quantify the hardness of pancreatic 
parenchyma by measuring of pure pancreatic juice amylase 
(p-AMY) level, and establish the new risk index by using 
this parameter.
Method: The data of 11 patients who had undergone pan-
creaticoduodenectomy between March and August 2012 
were retrospectively analyzed. Risk index assumed that 
Drain amylase level on post operative day (POD) 1×Drain 
fluid volume on POD 1 × (Drain amylase level on POD 
1×pure pancreatic juice amylase level).
Result: According to ISGPF criteria, the overall rate of pan-
creatic fistula was 45.4% (5/11), grade A was 36.4% (4/11), 
and grade B was 9.1% (1/11). Seven patients were judged as 
Soft pancreas by palpation, and p-AMY level was 429279 ± 
358297 IU/L (mean ± SD). Four patients judged as Hard 
pancreas, and p-AMY level was 5012 ± 6428 IU/L (p = 
0.0460). The p-AMY level of PF (+) cases (n = 5) was 
554450 ± 347334 IU/L, and that of PF (−) was 44900 ± 
97080 IU/L (p = 0.0073). There was significant correlation 
between p-AMP level and PF grade (R2 = 0.569, p = 0.0180). 
The risk index in soft pancreas group was 398.5 ± 1021.2, 
and that in hard pancreas group was 10.2 ± 18.8 (p = 0.4765). 
The risk index in PF (+) group was 557.8 ± 1205.6, and that 
in PF (−) group was 7.0 ± 15.4 (p = 0.2871).
Conclusion: The measurement of p-AMY level can digitize 
the hardness of pancreatic parenchyma. The risk index using 
these parameters could evaluate the risk of PF.
OPTIMAL SURGICAL STRATEGY FOR 
ADVANCED GALLBLADDER 
CARCINOMA: SINGLE-CENTER 
ANALYSIS OF LONG-TERM SURVIVORS
O. Itano, M. Tanaka, R. Nishiyama, M. Tanabe,  
M. Shinoda, M. Kitago, Y. Abe, T. Hibi, H. Yagi and  
Y. Kitagawa
Department Of Surgery, Keio University, School Of 
Medicine, Tokyo, Japan
Purpose: The purpose of this study was to clarify the 
optimal surgical strategy for advanced gallbladder carcinoma 
(pT2 or more).
Methods: We retrospectively analyzed the clinicopatho-
logic outcomes of 63 patients who underwent resection with 
curative intent for advanced gallbladder cancer in our institu-
tion from 1990 to 2010.
Results: The 5-year survival rate was 59% and the DFS was 
35 months. The significant poor prognostic factors (P < 0.05) 
by univariate analysis were tumor invasion of the serosa or 
more,, positive or narrow (≤5 mm) surgical margins in the 
liver parenchyma, hepatic hilum, or other excision edge, 
lymph node metastasis, and perineural/vascular invasion. 
Cox Multivariate analysis revealed lymph node metastasis 
(P = 0.01) and depth of invasion (P = 0.032) as independent 
negative predictors of survival. There were 19 long-term 
survivors (>5 years) whose lymph node metastasis was 
limited to the cystic duct or the pericholedochal area. The 
most common pattern of recurrence was distant metastasis. 
In cases with no tumor invasion to the liver parenchyma or 
the hepatic hilum, no perineural invasion, or node negative 
disease, adding resection of the liver bed/S4a+S5 hepatec-
tomy and/or extrahepatic bile duct resection had no impact 
on 5-year overall patient survival.
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Conclusion: Meticulous surgical planning to achieve R0 
resection is paramount for long-term survival in advanced 
gallbladder carcinoma. Prophylactic hepatectomy and extra-
hepatic bile duct resection have limited value to improve 
outcomes.
DOES TRAVEL DISTANCE INFLUENCE 
LENGTH OF STAY IN ELECTIVE 
PANCREATIC SURGERY?
K. L. Jackson1, R. E. Glasgow1, M. C. Mone1, 
S. J. Mulvihill1, X. Sheng2 and C. L. Scaife1
1Department Of Surgery, Salt Lake City, UT, USA; 
2Department Of Pediatrics, Salt Lake City, UT, USA
Purpose: Length of stay (LOS) following elective surgery 
is being reported as a quality measure in surgical outcome 
registries, such as the National Surgical Quality Improve-
ment Program (NSQIP). Regional centers with large geo-
graphic catchment areas care for patients traveling significant 
distances. We examined the effect of travel distance on LOS 
in pancreatic surgery patients.
Methods: NSQIP data on 243 elective pancreatic surgery 
patients from January 2005 to October 2011 were reviewed. 
Demographics, surgical variables, and distance traveled were 
analyzed relative to LOS. The LOS was log-transformed in 
general linear models to achieve normality.
Results: Of the 243 patients: 53% were male, the mean age 
was 60.6 ± 14 years, the mean travel distance was 203 ± 319 
miles (range 3–3,006), and the mean LOS was 10.5 ± 7 days 
(range 1–46). Univariate analysis showed a relationship 
between log-transformed LOS and distance traveled (p = 
0.053). Other significant variables related to LOS were: age 
(p = 0.002), relative value unit (RVU) intensity of service 
(p < 0.001), and preoperative American Society of Anesthe-
siology (ASA) class (p = 0.005). These variables were incor-
porated in a general linear model (Table), showing that for 
every 100 more miles traveled, there is an associated 2% 
increase in the LOS (p = 0.031). At 500 more miles travel 
distance, LOS increases by 10.5%.
Conclusions: In a model that controlled for significant vari-
ables, increased travel distance from home to the hospital 
was independently associated with an increase in LOS. 
Based on these results, if LOS is a reportable quality measure 
in pancreatic surgery patients, travel distance should be 
accounted for in risk adjustment model calculations.
AUTOTRANSPLANTATION OF POSITIVE 
CULTURE ISLET PRODUCT: IS DIRTY 
ALWAYS BAD?
C. Johnson, K. Morgan, S. Owczarski, H. Wang,  
J. Fried and D. Adams
Medical University Of South Carolina – Department Of 
Surgery, Charleston, SC, USA
Background: In selected patients, total pancreatectomy 
with islet autotransplantation (TPIAT) effectively relieves 
pain from chronic pancreatitis, while ameliorating the brittle 
diabetes of the apancreatic state. Patients often undergo mul-
tiple endoscopic and surgical interventions prior to TPIAT, 
increasing risk for pancreas colonization with enteric micro-
organisms. Little is known regarding the safety of transplant-
ing islet cells with microbial contamination.
Methods: A prospectively collected database of 80 patients 
undergoing TPIAT was retrospectively reviewed. Specifi-
cally, microbiological results from islet product were evalu-
ated. Electronic medical records were reviewed for 
postoperative infectious complications and the associated 
organisms.
Results: 35 patients (43.7%) had a positive pre-transplant 
islet cell gram stain or islet cell culture from their islet prep 
solution. 33 of the 35 patients (94.3%) were given antibiotics 
prophylactically post-transplant for a positive islet gram 
stain or culture. Twenty patients receiving gram stain or 
culture positive islets (57.1%) developed postoperative 
infectious complications, but only 4 patients (11.4%) devel-
oped infections with the organism cultured from their 
pre-transplant islet product. These 4 patients were treated 
early with antibiotics for their positive islet cultures. 31 
patients (88.6%) with positive pre-transplant gram stains or 
cultures did not develop infections related to their islet cell 
culture.
Conclusion: Islet transplant solutions are frequently culture 
positive, presumably due to prior pancreas intervention. 
Invasive infections correlating with pre-transplant islet cul-
tures do occasionally occur. Microbial contamination of islet 
preparations, however, should not preclude autotransplanta-
tion. The benefit of antibiotic prophylaxis in the setting of a 
positive islet culture is unknown.
A CT-BASED METHOD OF PREDICTING 
PANCREATIC FISTULA BEFORE 
PANCREATECTOMY
W. Johnston, J. Shen, C. Mathews, M. Cassera, S. Cho,  
C. Hammill, R. Wolf, P. Hansen and P. Newell
Providence Portland Medical Center, Portland, OR, USA
Background: Soft pancreatic texture is considered a risk 
factor for developing fistulas after pancreatectomy. Estimat-
ing resection margin density preoperatively may identify 
patients at increased risk of postoperative fistula.
Methods: All patients undergoing distal pancreatectomy 
from 2007–2012 were reviewed. Tissue density at the 
planned pancreatic resection margin was measured in Houns-
field Units (HU) using unenhanced preoperative CT images. 
Histologic slides from resected specimens were scored for 
fibrosis and fat infiltration at the resection margin using 
standardized scales. Patients with clinically significant pan-
creatic fistula (International Study Group of Pancreatic 
Fistula grade B or C) were identified.
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Results: Of the 44 patients identified for the study, 9 (20%) 
developed a clinically significant fistula. Fistulas occurred in 
31% of patients with HU < 25 versus 16% with HU > 25 (p 
= 0.24). Elevated fat infiltration (FI score 3–4) was associ-
ated with fistula in 29% of cases versus 15% in patients with 
fat scores 0–2 (p = 0.22). Fibrosis score of 2–3 was associ-
ated with fistula in 9% of patients versus 24% with low 
fibrosis scores 0–1 (p = 0.27). HU at the planned resection 
margin correlated with degree of fat infiltration (p = 0.001) 
but not with degree of fibrosis (p = 0.13).
Conclusions: Preoperative CT scans can reliably predict 
degree of fat infiltration at the planned pancreatic resection 
margin. Although HU, fibrosis and fat infiltration did not 
predict pancreatic fistula in this review, an association is 
suggested. A larger multi-institutional study may demon-
strate a stronger correlation between preoperative gland 
density measurement and development of post-operative 
fistulas.
THE COST OF FUTILITY: MEASURING 
THE ECONOMIC IMPACT OF 
PERCUTANEOUS CHOLECYSTOSTOMY 
IN MORIBUND PATIENTS
S. D. Kachare1,2, D. J. Suttle1, B. D. Carr1, N. A. Vohra1,2, 
T. J. Fitzgerald2 and E. E. Zervos1,2
1East Carolina University Brody School Of Medicine, 
Greenville, NC, USA; 2Vidant Medical Center, Greenville, 
NC, USA
Purpose: Percutaneous cholecystostomy (PC) may tempo-
rize reversible life threatening conditions in some patients 
while postponing inevitable death in others. Often regarded 
as a ‘no harm’ alternative to certain operative mortality, the 
economic implications of PC in moribund patients are rarely 
considered.
Methods: Moribund patients (pre-procedural predicted 
mortality > 90%) undergoing PC at an academic medical 
center were retrospectively identified in a prospective data-
base consisting of 216 patients. The UHC database was used 
to determine expected and observed costs. Logistic regres-
sion was applied to identify significant contributing factors 
to increased costs.
Results: Seventeen (7.9%) patients undergoing PC were 
identified as moribund. Median survival following PC was 
12 days (range: 2–22 d). Expected mean costs for these 
patients ($27,551, 95% CI: $17,568–$37,534) were signifi-
cantly lower (p = 0.0009) than actual mean cost ($60,436, 
95% CI: $42,072–$78,801). Post procedural factors signifi-
cantly contributing to the observed variance ($32,885, 95% 
CI: $15,660–$50,111) included: need for mechanical ventila-
tion (71%), increased hospital (19 days) and ICU (10 days) 
length stay and age > 80.
Conclusion: Factors justifying refusal to operate on patients 
with acute cholecystitis should similarly be considered for 
PC as the economic impact of such intervention in moribund 
patients is significant.
THE IMPACT OF SURGICAL MARGIN 
STATUS ON OUTCOME AFTER HEPATIC 
RESECTION FOR COLORECTAL 
METASTASIS
S. Kaihara, K. Inoguchi and R. Hosotani
Kobe City Medical Menter General Hospital, Kobe, 
Hyogo, Japan
Objective: To evaluate the impact of surgical margin status 
on site of recurrence after hepatic resection for colorectal 
metastasis.
Methods: Total of 105 tumors were resected in 54 hepatic 
resections from 2008 to 2011. Our operation procedure is 
dissection the liver parenchyma with CUSA and coagulation 
of the cutting surface with VIO system, which produces 
8 mm of additional margin from the resected liver surface.
Results: Intraoperative tumor exposure on the cutting 
surface was observed in 9 tumors of 7 cases and pathological 
margin status was all cancer positive. Microvascular inva-
sion was positive in 11 tumors of 11 cases. At a median 
follow up of 25 months, 28 cases (51.8%) developed recur-
rence of whom 15 cases (27.8%) were intrahepatic metasta-
sis. Resected tumor number and existence of microvascular 
invasion had a significant relationship to the intrahepatic 
recurrence (P = 0.0002 and P = 0.0006); however, intraopera-
tive tumor exposure and pathological margin status were not 
associated with it. Three cases had recurrence at surgical 
margin, but their entire tumor was no intraoperative tumor 
exposure, pathological margin negative, and no microvascu-
lar invasion. Four of the 7 cases with positive intraoperative 
tumor exposure and pathological margin positive tumors 
showed recurrence but were neither at surgical margin nor 
peritoneal dissemination. Two patients died with the tumor 
recurrence and remaining were alive with medial follow up 
of 26.7 months.
Conclusions: The rate of recurrence at the surgical margin 
was low and positive margin was not associated with an 
increased risk of recurrence at the surgical margin or perito-
neal dissemination.
INTRADUCTAL PAPILLARY NEOPLASM 
OF THE BILE DUCT
A. Kamyab and M. J. Jacobs
Providence Hospital And Medical Centers, Southfield,  
MI, USA
Introduction: Intraductal papillary neoplasm of the bile 
duct (IPNB) is a rare bile duct cancer. It is a recognized 
precursor of invasive carcinoma, and is believed to be a 
counterpart to pancreatic intraductal papillary mucinous neo-
plasms. Despite an increase in reported cases, the pathogen-
esis and prognosis are not well defined. Case report: A 65 
year old male with abdominal pain was found on radio-
graphic imaging of the abdomen to have a cystic mass that 
appeared adherent to the liver and invading into the anterior 
abdominal musculature. He underwent surgical resection, 
and pathologic evaluation revealed a non-invasive mucinous 
epithelial neoplasm with high-grade dysplasia lining a cyst, 
consistent with intraductal papillary mucinous neoplasm of 
the bile duct.
Discussion: IPNB is a newly proposed entity characterized 
by bile ducts filled with a noninvasive papillary neoplasm. It 
has recently been added to the WHO classification. Since the 
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similarities and differences between IPNB and IPMN have 
not been fully clarified, the diagnostic and treatment algo-
rithm for IPNB remains to be established. Since it is however 
recognized as a premalignant lesion for the development 
of cholangiocarcinoma, surgical resection has been 
recommended.
Conclusion: Intraductal papillary neoplasm of the bile duct 
is an uncommon type of bile duct neoplasm with a potential 
for malignant transformation. Surgical resection with wide 
margins is the treatment of choice, however more studies are 
needed to assess the natural history of these tumors.
LAPAROSCOPIC CYSTOGASTROSTOMY
A. Kamyab and M. J. Jacobs
Providence Hospital And Medical Centers, Southfield, MI, 
USA
Introduction: Pancreatic pseudocysts (PPs) are one of the 
known sequelae of pancreatitis. Traditional indications for 
intervention include symptomatic, large (>6 cm), or persist-
ent (>6 weeks) pseudocysts. With advancements in mini-
mally invasive techniques, laparoscopic cystogastrostomy 
has become a viable alternative to open internal drainage of 
PPs.
Methods: The laparoscopic cystogastrostomy was per-
formed with the patient in a supine position, using 3 trocars. 
A stapler was fired between the posterior wall of the stomach 
and the pseudocyst, thereby completing the cystogastros-
tomy. A transgastric laparoscopic necrosectomy was per-
formed, and the anterior gastrotomy was closed 
intracorporeally.
Results: A 33 year old male underwent a laparoscopic 
cystogastrostomy for a large symptomatic PP. OR time was 
86 minutes, with an estimated blood loss of 10 mL. There 
were no intraoperative or postoperative complications, and 
the patient was discharged on postoperative day five.
Conclusion: Treatment options for PPs include percutane-
ous, endoscopic, and surgical procedures. Open internal 
drainage has been the standard of care for cysts not located 
in the head of the pancreas, but with advancements in mini-
mally invasive procedures, laparoscopic cystogastrostomy 
has become an attractive alternative. Our experience sug-
gests that laparoscopic cystogastrostomy is feasible and safe, 
and should be considered a viable alternative to endoscopic 
or open cystogastrostomy for the management of PPs.
CLAVIEN COMPLICATIONS OF 
LAPAROSCOPIC VS. OPEN LIVER 
RESECTION: A RETROSPECTIVE 
REVIEW
E. Kane, A. Hauch, J. F. Buell, J. Lee, B. Saggi, L. Balart, 
N. Shores and E. Kandil
Tulane University, New Orleans, LA, USA
Introduction: Laparoscopic hepatic resection has been 
described as a safe and effective means of liver resection for 
benign and malignant tumors. The purpose of this study was 
to examine the incidence and severity of post-operative 
complications.
Methods: Surgical complications were examined in 572 
hepatic resections (352; 62% laparoscopic and 220, 38% 
open) using the Clavien-Dindo Classification and compared 
using student t-test, chi square, and multivariate analysis.
Results: Between ‘00 and ‘12, 572 patients underwent liver 
resection. 151 experienced post-operative complications 
(26.4%). A higher incidence was observed in the open group 
[laparoscopic (18.8%) versus open (38.6%) procedures]. 
Severity of complications, as measured by the Clavien-
Dindo score (0–5), also showed a significant difference 
between the two groups.
Conclusion: Laparoscopic resection carries a lower rate of 
complication than open resection despite similar patient 
disease characteristics such as cirrhosis. This, however, can 
be attributed to the increased complexity of open resections 
not performed laparoscopically.
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CLINICO-PATHOLOGICAL FACTORS 
ASSOCIATED WITH PROGNOSIS IN 
PRIMARY INTRA-HEPATIC 
CHOLANGIOCARCINOMA: A SINGLE 
CENTER EXPERIENCE
Z. S. Kanji2, N. Devaud1, S. Gallinger1 and S. P. Cleary1
1Department of General Surgery, University Health 
Network, Toronto, ON, Canada; 2Department of General 
Surgery, Vancouver, BC, Canada
Introduction: Primary Intrahepatic Cholangiocarcinoma 
(pICC) is an uncommon malignancy with increasing inci-
dence in North America. To date, studies have shown con-
flicting results regarding prognostic factors associated with 
disease.
Methods: A single center retrospective review of surgically 
resected pICC cases at Toronto General Hospital between 
January 2001 and December 2011 was performed. Clinico-
pathological factors were examined using uni-variate and 
multi-variate models. The impact of these variables on 
overall (OS) and disease free survival (DFS) served as the 
primary and secondary objectives.
Results: 59 pICC cases underwent successful resection with 
curative intent. The median age of diagnosis was 62.9 years 
(range: 32.7–85.7) and the average 1, 3 and 5 year OS was 
83.1%, 61.9% and 38.5% respectively. The median DFS was 
15.5 months (range: 2.3–133.9). Factors on uni-variate anal-
ysis adversely affecting OS included the presence of HCV 
(p = 0.008), the need for pre-op embolization (p = 0.0001), 
multiple primary lesions (p = 0.012), portal vein (PV) inva-
sion (p = 0.011), lymph node (LN) involvement (p = 0.017), 
advanced clinical stage (p = 0.0001) and the presence of 
vascular invasion (p = 0.017). Factors associated with a 
shorter DFS included the need for pre-op embolization (p = 
0.003), multiple primary lesions (p = 0.0001), PV invasion 
(p = 0.007), advanced clinical stage (p = 0.005), vascular 
invasion (p = 0.038) and perineural invasion (p = 0.028). 
Advanced clinical stage (p = 0.003) and multiple primary 
lesions (p = 0.002) remained significant for OS and DFS 
respectively following multi-variate analysis.
Conclusions: Stage and multiple primary lesions are the 
greatest determinants of prognosis in pICC. LN involvement 
on OS and DFS remains controversial and future prospective 
studies are required prior to routine lymphadenectomy.
THE IMPACT OF PYLORUS-RESECTING 
PANCREATICODUODENECTOMY-THE 
SHORT AND LONG TERM OUTCOMES 
IN A PROSPECTIVE RANDOMIZED 
CONTROLLED TRIAL
M. Kawai, M. Tani, S. Hirono, K. Okada, M. Miyazawa, 
A. Shimizu, Y. Kitahata, M. Ueno, S. Hayami and  
H. Yamaue
Second Department Of Surgery, Wakayama Medical 
University, Wakayama, Japan
Objective: We conducted this study to confirm the hypoth-
esis that pylorus-resecting pancreatoduodenectomy (PrPD) 
reduces the incidence of delayed gastric emptying (DGE) 
compared to pylorus-preserving pancreatoduodenectomy 
(PpPD).
Methods: Between October 2005 and March 2009, at 
Wakayama Medical University Hospital (WMUH), 130 
patients with pancreatic or periampullary lesions were rand-
omized to preservation of the pylorus ring (PpPD) or to 
resection of the pylorus ring (PrPD). In PpPD, the proximal 
duodenum was divided 3–4 cm distal to the pylorus ring. In 
PrPD, the stomach was divided just adjacent the pylorus ring 
and the nearly total stomach more than 95% was preserved. 
This RCT was registered at Clinical Trials.Gov NCT00639314.
Results: The incidence of DGE was 4.5% in PrPD and 
17.2% in PpPD, a significant difference. DGE was classified 
into three categories proposed by the International Study 
Group of Pancreatic Surgery. The proposed clinical grading 
classified 11 cases of DGE in PpPD into grades A (n = 6), B 
(n = 5), and C (n = 0), and one case in PrPD into each of the 
three grades. PrPD had comparable outcomes compared to 
PpPD in the assessment at 1, 3, and 6 months after surgery-
concerning to quality of life by FACT-Ga questionnaire. 
Moreover, there were no significant differences regarding to 
the postoperative body weight loss, nutritional status during 
a 6-month follow-up between PrPD and PpPD.
Conclusion: This study clarified that PrPD can lead to a 
significant reduction in the incidence of DGE compared with 
PpPD. The patients enrolled in this study follow carefully 
concerning to long term outcomes for 2 year 
postoperatively.
BILIARY ACCESS IN PATIENTS WITH  
A ROUX-EN-Y GASTRIC BYPASS:  
WHOM AND HOW
A. Khithani1,2, S. Conjeevaram1, M. Silberstein1, 
R. Santopietro1, L. Maffucci1 and M. Rangraj1
1Sound Shore Medical Center, New York Medical College, 
New Rochelle, NY, USA; 2Metropolitan Hospital Center, 
New York Medical College, NY, USA
Background: The RYGB anatomy poses particular chal-
lenges for biliary access. Laparoscopic assisted ERCP 
(LAERCP) has been applied in the diagnosis and treatment 
of biliopancreatic conditions in RYGB patients. The objec-
tive of this study was to evaluate our experience with biliary 
access after cholecystectomy with RYGB.
Methods: Records of patients with RYGB who underwent 
a remote cholecystectomy and biliary access were reviewed. 
Perioperative factors including morbidity, hospital stay and 
need for additional procedure were analysed.
Results: Three patients with RYGB underwent biliary 
access with interventional cholangiography. Indications for 
the procedure were choledocholithiasis (n = 2) and cystic 
duct leak (n = 1). Two patients underwent LAERCP preceded 
by an negative intraoperative chololangiography. All the 
patients had a Roux limb length greater than 150 cm. In 
patients with choledocholithiasis, a laparo-endoscopic access 
was obtained and an anterior gastrotomy over the gastric 
remnant was done. A sideviewing duodenoscope was 
advanced into the bilio-pancreatic limb through the gastrot-
omy on the gastric remnant, and a sphincterotomy with stone 
retrieval was performed. The patient with cystic duct leak 
underwent PTC and stenting across the cystic duct-CBD 
junction after MRCP showed no biliary leak. There were no 
major postoperative complications with LAERCP, whereas 
the patient with biliary leak required stent exchange due to 
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stent migration. The mean hospital stay was 5 days with 
LAERCP and 8 days with biliary leak.
Conclusion: LAERCP is a safe and efficacious approach for 
biliary access with RYGB. Though LAERCP patients did 
better, the authors feel that the approach should be deter-
mined on a case-by case basis.
OUTCOMES OF LIVER RESECTION 
VERSUS OPERATIVE BILIARY 
DRAINAGE FOR RECURRENT 
PYOGENIC CHOLANGITIS IS 
OPERATIVE BILIARY DRAINAGE STILL 
RELEVANT IN THE MODERN ERA?
Y. Koh, A. Chok, A. Chiow, L. Lee and S. Tan
Changi General Hospital, Singapore, Singapore
Recurrent pyogenic cholangitis is a disease prevalent in East 
Asia. It is characterised by the presence of intrahepatic 
calculi and recurring cholangitis with or without biliary stric-
tures; ectatic dilated biliary ducts, liver abscesses or liver 
atrophy The aims of treatment are directed at removal of the 
intrahepatic calculi with adequate biliary drainage, and 
resection of the diseased biliary tract where possible. It is 
however known that resection of the diseased biliary tract is 
not always indicated or feasible. In cases of less severe 
disease, operative biliary drainage is an attractive treatment 
option. This is especially so in the setting of underlying liver 
cirrhosis, chronic hepatitis, and extensive RPC involving 
bilateral liver lobes. This article presents the experience at 
our institution and evaluates the outcomes in the surgical 
treatment of recurrent pyogenic cholangitis. It is a retrospec-
tive review of a prospectively maintained database of patients 
with recurrent pyogenic cholangitis for the period of January 
2002 to December 2011. There were 51 patients who under-
went surgical treatment. 30 patients underwent operative 
biliary drainage only and 21 patients underwent hepatectomy 
with or without biliary drainage. Initial treatment failure was 
defined as residual stones after the procedure, persistence or 
progression of cholangitis or liver abscesses within the same 
hospital admission. Long term failure was defined as the 
recurrence of stones, cholangitis or liver abscesses during the 
follow up period. There were no statistically significant 
initial or long term failures between the initial and long term 
failure rates between the 2 treatment groups.
SURGICAL INTERVENTION FOR 
INTRADUCTAL HEPATOCELLULAR 
CARCINOMAS CAUSING JAUNDICE 
SECONDARY TO BILIARY 
OBSTRUCTION
Y. Koh1, S. Lee1,2, A. Chok1 and A. Chung1
1Department Of General Surgery Singapore General 
Hospital, SG, Singapore; 2Department Of Surgical 
Oncology National Cancer Centre, SG, Singapore
Hepatocellular Icteric hepatocellular carcinoma (HCC) was 
first described by Lin et al in 1975. It is known that intra-
luminal biliary obstruction may occur by one of three 
mechanisms: hemobilia caused by bleeding from the 
tumour, migration of tumor debris that has separated from 
the primary growth, or continuous retrograde growth along 
the biliary tree. This is a different pathological process 
from jaundice due to a background of advanced chronic 
disease. As it is known those patients with advanced 
chronic liver disease have poorer surgical outcomes or are 
not fit for surgical intervention. Historically, the prognosis 
of icteric type HCC has been reported to be poor. 
However, various retrospective case series have concluded 
that overall survival of these patients was similar to that of 
HCC patients with no jaundice, and that good palliation 
and occasional cure were possible with proper treatment. It 
is thus important to identify this group of patients as surgi-
cal intervention can still provide these patients a reasona-
ble survival. This is a retrospective review of the surgical 
outcomes of the patients with intraductal hepatocellular 
carcinomas causing biliary obstruction at our institution. 
Five patients were identified from our database of surgi-
cally resected hepatocellular carcinomas, their ages ranged 
from 51 to 78 years. In this study, we describe the clinical 
presentation, surgical approach, pathological characteris-
tics, recurrence free and long term survival of this group of 
patients. We conclude that surgical intervention is a viable 
treatment option that can offer reasonable palliation and 
survival in these patients.
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PANCREAS AND LIVER SURGERY IN 
JEHOVAH’S WITNESSES: FEASIBLE  
AND SAFE
I. T. Konstantinidis, P. J. Allen, M. I. D’Angelica,  
R. P. DeMatteo, Y. Fong, T. Kingham and W. R. Jarnagin
Memorial Sloan-Kettering Cancer Center 
HepatoPancreatoBiliary Surgery Department, New York, 
NY, USA
Background: Jehovah’s Witness (JW) patients undergoing 
liver or pancreas surgery represent a challenging ethical and 
medical problem, with few reports regarding optimal 
management.
Aim: To review the perioperative outcome of JW patients 
submitted to hepatic or pancreatic resection.
Materials and methods: Clinicopathologic data of JW 
patients who underwent a hepatectomy or pancreatectomy 
between March 1996–July 2011.
Results: Clinicopathologic data of 24 patients and 25 resec-
tions were included. The median age was 56.5 years (range 
28–75), and 19 patients were females. Fifteen hepatectomies 
(6 segmentectomy or bisegmentectomy, 9 hemi-hepatectomy 
or extended hepatectomy) and 10 pancreatectomies (6 pan-
creaticoduodenectomy, 4 distal pancreatectomy/splenec-
tomy) were reviewed; additional organs were resected in 5 
patients (2 gastrectomy, 1 colectomy, 1 nephrectomy, 1 
adrenalectomy, 1 salpingoophorectomy). Median estimated 
blood loss (EBL) for the hepatectomies was 400 ml (range 
100–1500 ml) and for the pancreatectomies 400 ml (range 
100–1800 ml). Six patients received preoperative erythro-
poietin. Hemodilution was used in 7 patients. Two patients 
had cell saver generated auto-transfusions. The median pre-
operative hemoglobin was 12.5g/dl (range: 9.6–14.4 g/dl) 
and the median postoperative hemoglobin was 10.4g/dl 
(range: 9–12.4g/dl). In-hospital mortality was 0%. One 
patient required re-exploration for decreasing hemoglobin 
and refusal of blood; 5 other patients developed complica-
tions (4 wound infection/breakdown, 1 urinary tract infec-
tion, 1 ascites). Median hospital stay was 7 days (range 
4–23 d).
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Conclusion: Pancreatic and liver resection can be done 
safely in JW patients who refuse blood products, using a 
variety of blood conservation techniques to help spare red 
cell mass.
PANCREATIC NEUROENDOCRINE 
TUMORS: TUMOR SIZE, RADIOLOGIC 
FEATURES, AND ASSOCIATED HIGH 
RISK FACTORS
S. L. Koonce, J. A. Stauffer, D. L. Eck and H. J. Asbun
Mayo Clinic Florida, Jacksonville, FL, USA
Background: Optimal management for small pancreatic 
neuroendocrine tumors (PNET) is controversial. We aimed 
to determine if an association existed between the size of 
PNET and the presence of high-risk tumor characteristics in 
resected patients. Furthermore, we evaluated the correlation 
between estimates of tumor size with preoperative imaging 
and tumor size at resection.
Methods: A retrospective review of surgery for PNET at our 
institution was performed. Evaluated association between 
tumor size and related factors using Pearson correlation 
coefficient.
Results: Between 1996 and 2012, 86 patients underwent 91 
operations for PNET. There were 38 (45%) males and 48 
(55%) females. Twenty-one (24%) patients had functional 
tumors, 9 (10%) familial (MEN) tumors. On preoperative 
endoscopic ultrasound and cross sectional imaging median 
tumor size was 1.7 cm (range 0–10.5). The median final 
pathologic size of the tumors was 1.8 cm (range 0.5–11). 
Pathologic size correlated with preoperative imaging size on 
all imaging modalities (r = 0.86, EUS; 0.80 MRI; 0.93 CT; 
all p < 0.001). High risk features of positive locoregional 
lymph nodes, distant metastasis, and poorly differentiated 
tumors were present in 0/10 tumors < 1 cm, 1/28 tumors 
1–1.5 cm, 4/10 tumors 1.51–2 cm, and 21/40 tumors > 2 cm 
respectively. Tumor size was significantly associated with 
the presence of high-risk features and recurrence (p < 0.0001; 
p = 0.0013).
Conclusions: High-risk features of PNET are associated 
with increasing tumor size. Preoperative imaging accurately 
predicts final pathological size of tumors. More aggressive 
surgery should be considered with increasing tumor size 
keeping in mind that even small size PNET may display 
aggressive features warranting resection.
THE NEW STAPLING TECHNIQUE 
REINFORCED WITH THE ABSORBABLE 
SHEET FOR THE DISTAL 
PANCREATECTOMY
I. Koyama, K. Okamoto, K. Okada, M. Aikawa,  
Y. Watanabe and M. Miyazawa
Saitama Medical University International Medical Center, 
Hidaka-shi, Saitama, Japan
The pancreatic fistula developed frequently after distal pan-
createctomy even using the stapler. The existing staple height 
is too low for the pancreatic tissue to be closed safely without 
the development of pancreatic fistula. To solve this problem, 
we developed a new method using the PROXIMATE Reload-
able Linear Staplers TLH™ which is designed for staple 
height being adjustable to compensate for various tissue 
thicknesses and the absorbable sheet for reinforcement of the 
staple.
Method: After covering the entire circumference of the pan-
creatic tissue with the absorbable sheet which is made of 
polyglycolic acid, the PROXIMATE Reloadable Linear 
Stapler TLH™(Ethicon-End Corp.) is applied over the sheet 
after release of the safety lock, and approximated the jaws 
of the stapler to the level of staple height of over 2.5–3 mm 
and not to crush the tissue. The main pancreatic duct was not 
identified intensionally.
Results: We applied this method to 51 patients who under-
went the distal pancreatectomy for the pancreatic tumor from 
April in 2007 until February in 2012. The mean operating 
time was 167.0 min., and the mean blood loss was 81.4 ml. 
The median postoperative hospital stay was 9 days. The 
pancreatic fistula of grade A was developed in 4 out of 51 
patients, and Grade B fistula in 1 of 51 patients. None of the 
patients developed the pancreatic fistula of Grade C.
Conclusion: The modified use of the existing stapler 
combined with the absorbable sheet for reinforcement 
resulted in the low incidence of pancreatic fistula after distal 
pancreatectomy.
LAPAROSCOPIC TRANSGASTRIC 
DEBRIDEMENT OF WALLED-OFF 
PANCREATIC NECROSIS: A NEW 
THERAPEUTIC OPTION FOR PATIENTS 
WITH NECROTIZING PANCREATITIS
S. Kulkarni, L. Matsuoka, A. Bogart, R. Selby and  
D. Parekh
Keck School Of Medicine, University Of Southern 
California, Los Angeles, Los Angeles, CA, USA
Background: Laparoscopic transgastric debridement of 
walled off pancreatic necrosis (WON) is a new treatment 
option for patients requiring pancreatic debridement for 
necrotizing pancreatitis. While the reported experience with 
surgical transgastric pancreatic debridement in the literature 
is limited, the much lower incidence of postoperative 
pancreatic fistulae warrants further evaluation of this 
technique.
Method: Retrospective analysis.
Results: Eight patients underwent laparoscopic transgastric 
debridement with a cyst-gastrostomy for clinically sympto-
matic WON from June 1, 2006 to July 31, 2012. The mean 
patient age was 48.7 (48.7 ± 14.13) and the median American 
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Society of Anesthesiologist score was 3. The most common 
etiology for pancreatitis was gallstones and the median time 
from attack of pancreatitis to definitive surgical management 
was 60 days (range 38–300). Median operative time was 240 
minutes (range 85–327) with 100 cc (range 20–150) of blood 
loss. In 3 patients necrosis was found infected and in 5 
patients it was sterile as determined by the intraoperative 
culture of necrotic material. The overall morbidity was 
12.5% and the mortality was 0%. The incidence of postop-
erative pancreatic fistula was 0%. 7 patients (87.5%) were 
symptom free during a median follow up of 12 months.
Conclusion: In selected patients with clinically sympto-
matic WON, laparoscopic transgastric pancreatic debride-
ment appears to be a safe procedure with a low morbidity 
and mortality. The low incidence of postoperative pancreatic 
fistulae warrants further evaluation of this technique.
OPERATIVE MANAGEMENT OF 
NECROTIZING PANCREATITIS AT A 
SINGLE INSTITUTION
K. J. Lafaro1, G. Tran1, D. Fernando2, D. J. Vajgrt2, 
L. K. Findeiss2, A. N. Demirjian1 and D. K. Imagawa1
1University Of California, Irvine Medical Center, Division 
Of Hepatobiliary And Pancreas Surgery, Orange, CA, 
USA; 2University Of California, Irvine Medical Center, 
Division Of Interventional Radiology, Orange, CA, USA
Purpose: To analyze the operative management of necrotiz-
ing pancreatitis at a single tertiary care academic institution 
over a 5-year period.
Methods: This is a retrospective analysis of 29 patients 
treated operatively from our institution, a high-volume, 
multidisciplinary hepato-pancreato-biliary center. All 
patients were confirmed to have necrotizing pancreatitis by 
CT scan.
Results: 29 patients were included for analysis. Patient ages 
ranged from 23 to 81 years of age and there were 23 males 
and 15 females. All causes of necrotizing pancreatitis were 
included. Drainage by the interventional radiology service 
was utilized in all but 4 patients (25/29–86%). Time from 
diagnosis to surgical intervention ranged from 1 to 622 days. 
20 of 29 patients who had surgical intervention were delayed 
at least 21 days. Of these patients, 15 had a single operative 
procedure, while the remaining 5 needed only two proce-
dures. None of these patients required more than 2 opera-
tions. 9 patients required more immediate intervention 
ranging between 1 and 11 days from diagnosis. These 
patients required an average of 2.9 (range 1 to 9) procedures, 
as compared to 1.25 procedures per patient who was able to 
be delayed 21 days or longer. There were no operative or 
peri-operative mortalities.
Conclusions: Necrotizing pancreatitis is a difficult manage-
ment dilemma. Recent data suggests that delayed surgical 
intervention, when necessary is preferred. Our data supports 
this conclusion in that delayed intervention led to fewer 
operative procedures. Percutaneous drainage can be an effec-
tive bridge to delay operative intervention.
THE IMPACT OF UNDERLYING VIRAL 
DISEASE ON OUTCOMES AFTER LIVER 
RESECTION FOR HEPATOCELLULAR 
CARCINOMA: THE RESULTS FROM A 
NORTH AMERICAN CENTRE
J. Lee1, P. T. Kim1, S. Fung2, S. Gallinger1, 
I. McGilvray1, C. Moulton1, A. C. Wei1, P. D. Greig1 and 
S. P. Cleary1
1University Of Toronto, Department Of General Surgery, 
Toronto, ON, Canada; 2University Of Toronto, Division Of 
General Internal Medicine, Toronto, ON, Canada
Background: Hepatitis B (HBV) and hepatitis C (HCV) are 
risk factors for hepatocellular carcinoma (HCC). The char-
acteristics of tumours arising from HBV and HCV often 
differ. The impacts these differences have on patient out-
comes after liver resection are not fully understood. This 
study was conducted to determine if the outcomes after liver 
resection for HCC are influenced by the underlying liver 
disease.
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Patients and methods: A retrospective review was per-
formed at a high volume center. Of 386 liver resections for 
HCC performed between July 1992 and April 2011, 181 
patients had HBV and 74 patients had HCV. The following 
patients were excluded from the study: HBV/HCV co-infec-
tions (N = 20) and non-HBV/HCV (N = 94). Patient, tumor 
characteristics, post-operative and oncologic outcomes were 
compared between patients with HBV and HCV.
Results: The patients with HBV had better overall survival 
than patients with HCV (68 vs. 59 months, P = 0.03); 
however, there was no difference in recurrence-free survival 
between the groups (44 vs. 45 months, P = 0.1). The factors 
predictive of overall survival based on multivariate analyses 
included: vascular invasion (P = 0.0001, HR = 3.4), Child-
Pugh Score (P = 0.0001, HR = 4.8), and underlying liver 
disease (P = 0.01, HR = 1.9). Vascular invasion (P < 0.0001, 
HR = 2.277) and multifocal ( > 1) tumour (P = 0.001, HR = 
2.086) were predictive of recurrence-free survival.
Conclusions: Overall survival but not recurrence-free sur-
vival after liver resection for HCC is better in patients with 
HBV than HCV. This survival advantage for HBV patients 
may be due to the nature and the treatment of their 
recurrence.
RE-RECURRENT NON-ALCOHOLIC 
STEATOHEPATITIS AFTER RE-DO 
LIVER TRANSPLANTATION
V. Leow1, V. G. Agopian2, C. R. Lassman3, 
R. W. Busuttil4 and D. G. Farmer5
1Dumont-UCLA Multivisceral Transplant Center, David 
Geffen School Of Medicine, LA, CA, USA; 2Dumont-UCLA 
Multivisceral Transplant Center, David Geffen School Of 
Medicine, LA, CA, USA; 3UCLA Department Of Pathology 
And Laboratory Medicine, David Geffen School Of 
Medicine, LA, CA, USA; 4Dumont-UCLA Multivisceral 
Transplant Center, David Geffen School Of Medicine, LA, 
CA, USA; 5Dumont-UCLA Multivisceral Transplant Center, 
David Geffen School Of Medicine, LA, CA, USA
Background: The treatment of non-alcoholic steatohepati-
tis (NASH) in pre- and post-liver transplantation (LT) 
remains a challenge. Although the recurrence of NASH after 
LT has been well described, there is paucity of data on liver 
retransplantation for recurrent NASH. Case report: We 
present here a 29 year-old African-American female with 
NASH who required retransplantation of the liver due to 
recurrent NASH, and subsequently developed re-recurrent 
fatty infiltration in her second allograft. Her past medical 
history was remarkable for diabetes, hypertension, and a 
roux-en-Y gastric bypass. After undergoing LT in January 
2005, she developed several episodes of acute cellular rejec-
tion and multiple biopsies showing significant steatohepatitis 
involving the majority of her allograft. She underwent 
retransplantation in May of 2010 due to severe recurrent 
nonalcoholic steatohepatitis and chronic rejection. Post-
operatively, her liver functions remained normal, however 
post-operative serial CT imaging revealed significant exten-
sive fatty liver infiltrations of her second allograft.
Discussion: The rate of recurrent steatohepatitis after LT 
ranges between 4% and 33%. Post LT immunosuppressive 
medications including steroids and calcineurin inhibitors are 
thought to contribute to insulin resistance and the develop-
ment of recurrent NASH after LT.
Conclusion: We describe a case of retransplantation of the 
liver for recurrent steatohepatitis, complicated by re-recur-
rent fatty infiltration. Further studies are required to delineate 
interventions that may ameliorate the development of post 
LT recurrent NASH.
A NOVEL PROCEDURE FOR MANAGING 
EXCLUDED SEGMENTAL 
POSTOPERATIVE BILE DUCT LEAK
D. J. Lerner1, B. C. Wible1, P. Chesis4, C. Gooden2, 
S. Pelletier3 and H. B. Randall2
1University Of Missouri – Kansas City Diagnostic And 
Interventional Radiology, Kansas City, MS, USA; 2St. 
Lukes Hospital, Kansas City, MS, USA; 3University Of 
Michigan Health Systems, Ann Arbor, MI, USA; 4SSM St. 
Joseph Health Center, St. Charles, MS, USA
Objective: Explore novel approach for managing excluded 
segmental postoperative bile duct leak (ESBDL).
Background: Current primary treatment for ESBDL is 
resection of the involved segment; duct sclerosis with ethanol 
has also been described. We present a case of ESBDL embol-
ized with Onyx (ev3, Irvine, CA).
Method: A 54 year old female was diagnosed with recurrent 
bile leak status-post laparoscopic left-trisegmental resection 
of a giant hemangioma. The post-operative course was com-
plicated by persistent bile leak and intra-abdominal infec-
tions despite common bile duct stent placement and 
exploratory laparotomy. A percutaneous cholangiogram dis-
played post-surgical biliary anatomy without leak; however, 
several right hepatic lobe bile ducts failed to fill. Forceful 
injection of contrast through the existing percutaneous intra-
abdominal abscess drain demonstrated contrast reflux into 
variant bile ducts of segments 6, 7 and residual of 8, signify-
ing extensive ESBDL. Failing conservative management, 
and with further surgical resection contraindicated due to 
limited hepatic reserve, two serial procedures were per-
formed in Interventional Radiology in which the affected bile 
ducts were percutaneously accessed and embolized. Onyx 
was utilized as the embolic agent because its radiodense 
properties allow easy radiographic visualization while its 
non-adhesive properties allowed slow, careful casting of the 
entire variant duct. There were no complications. Six-month 
imaging showed progressive atrophy of ESBDL affected 
parenchyma with accompanied hypertrophy of non-involved 
hepatic parenchyma. Nine months after embolization the 
patient is doing well with cessation of bilious drainage.
Conclusion: Percutaneous Onyx embolization of ESBDL 
may be a viable consideration for patients unable to undergo 
further surgical resection.
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ENDOSCOPIC DRAINAGE IS A SAFE AND 
EFFECTIVE INITIAL MANAGEMENT OF 
SELECTED PANCREATIC PSEUDOCYSTS
C. Luu, J. Velasquez, B. E. Stabile and B. Lee
Harbor-UCLA Medical Center, Torrance, CA, USA
Objectives: To determine the primary and overall success 
rates and morbidity and mortality rates of endoscopic drain-
age of pancreatic pseudocysts (PP).
Methods: A retrospective study of 27 patients with a soli-
tary and symptomatic PP who received endoscopic drainage 
as initial treatment between 2008 and 2012 was performed. 
Data on patient demographics, interventions, and outcomes 
were analyzed.
Results: 29 endoscopic drainage procedures were per-
formed as the initial management of PP. Mean size of the PP 
was 10.9 cm (range 2–22 cm). Endoscopic ultrasound (EUS) 
guidance was used to place 18 transgastric and 7 transduo-
denal stents. 2 PP required endoscopic debridement prior to 
stent placement. 4 pancreatic duct stents were placed when 
a connection to the main pancreatic duct was visualized; 2 
of the pancreatic stents were placed in conjunction with a 
transenteric stent. Primary success of drainage was achieved 
in 28 procedures (97%). 7 patients (26%) had recurrence of 
their PP. 3 were managed successfully with repeat endo-
scopic drainage for an overall endoscopic drainage success 
rate of 85%. 2 of the remaining 4 patients underwent surgical 
drainage, and 2 underwent CT-guided percutaneous catheter 
drainage. Only one procedural related complication was 
recorded which was an injury to the duodenal mucosa which 
was treated conservatively. There were no mortalities.
Conclusion: Endoscopic drainage is an effective and safe 
treatment for symptomatic PP with an 85% overall success 
rate and minimal morbidity and mortality. Failure of this 
modality does not preclude success of salvage therapies for 
recurrent PP.
OUTCOME DATA FROM MUTATIONAL 
PROFILING OF PANCREATIC CYST 
FLUIDS
M. J. Lybik1, D. B. Mallat2, A. Lybik1, B. Corcoran3, 
E. Ellsworth3, S. Jackson3, A. Terry3 and S. D. Finkelstein3,4
1Northside Gastroenterology Endoscopy Center, 
Indianapolis, IN, USA; 2Premier Gastroenterology Of 
Texas, Dallas, TX, USA; 3RedPath Integrated Pathology, 
Pittsburgh, PA, USA; 4Department Of Pathology, Drexel 
University, Philadelphia, PA, USA
Background: First-line testing (imaging, cytology, CEA) 
alone is often inadequate to determine the malignant poten-
tial of pancreatic cysts. Second-line testing, such as muta-
tional profiling, may help to indentify malignant potential. 
Using a retrospective analysis of patient outcome informa-
tion we evaluated the performance characteristics of com-
mercially available mutational profiling testing (RedPath 
Integrated Pathology, Pittsburgh, PA).
Methods: Benign and malignant outcome information was 
obtainable for 121 patients who had previous RedPath muta-
tional profiling of their pancreatic cyst fluid. Malignant diag-
noses were assessed by surgical pathology, positive cytology, 
and/or clinical cancer treatment. Benign outcomes were 
defined as surgical pathology with no malignancy or 2 years 
without disease progression. Patients with less than 2 years 
follow-up were excluded from the analysis. All previous 
mutational profiling was performed according to standard 
RedPath processes. Biological behavior was assigned based 
on four distinct categories: benign, statistically indolent low 
(SI-Low), statistically indolent high (SI-High), and aggres-
sive. Diagnoses of Benign and SI-Low were treated as nega-
tive for malignancy (benign), while SI-High and Aggressive 
were treated as positive for malignancy (malignant).
Results: Table 1 shows integrated mutational profiling 
results versus patient outcome for 121 cyst fluids. Mutational 
profiling sensitivity and specificity for malignancy in cyst 
fluids were 85% and 95%, respectively. Overall accuracy 
was 93%.
Conclusions: Integrated molecular testing of pancreatic 
cyst fluids using mutational profiling can be used as a sec-
ond-line test with high overall accuracy for the malignant 
potential of pancreatic cysts.
THREE-DIMENSIONAL (3-D) CT FOR 
VIRTUAL SIMULATION/SURGICAL 
PLANNING OF PANCREATIC 
NEUROENDOCRINE TUMORS – 
ENUCLEATION VS. RESECTION
A. V. Maker and V. K. Maker
University Of Illinois At Chicago, Department Of Surgery, 
Division Of Surgical Oncology, Chicago, IL, USA
Pancreatic neuroendocrine tumors (NETs) can be difficult to 
localize and preoperative determination of enucleation vs. 
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resection is often difficult for any but the most peripheral 
lesions. We have begun utilizing 3-D CT technology to 
augment the preoperative workup and to simulate surgery in 
NETs. As a proof of concept, we applied this technology to 
patients with non-functioning NETs to determine resectabil-
ity and the potential for enucleation. Using a 3-D workstation 
attached to the server in our office, images are efficiently 
constructed and manipulated real-time. 3-D images that visu-
alize the pancreatic duct and both the portal-venous and 
arterial structures are created to aid in operative planning. 
These images identify areas where tumor biopsy or enuclea-
tion would be maladvised. As a simulation tool, the 3-D 
reconstructions allow the surgeon to see the tumor from the 
skin to the pancreas with visceral organ transparency aiding 
in laparoscopic port placement. For resection planning, the 
ability to rotate and visualize the tumors in 3D space along 
with the pancreatic duct and vasculature aids in determina-
tion of pancreaticoduodenectomy/central/distal resection vs. 
enucleation. Simulating the laparoscopic camera, the abdom-
inal cavity can be examined for metastases with the ability 
to rotate the tumor in all directions, thereby providing a 
virtual exploration of the tumor and surrounding lymph 
nodes. These points will be demonstrated with 3-D dynamic 
images/videos from NETs in the head, neck, body, and tail. 
Corresponding laparoscopic and pathologic images from the 
same patients will illustrate the utility of this technology for 
HPB surgeons managing NETs.
IMAGE GUIDED PARENCHYMAL 
TRANSECTION REDUCES BLOOD LOSS 
DURING THE FIRST YEAR OF SOLO 
HPB PRACTICE
J. Mandell and K. Lowe
Akron General Medical Center, Akron, OH, USA
Hepatobiliary surgeons who attempt to develop new HPB 
practices face complex and high risk operations, sometimes 
with limited support from more experienced surgeons. 
Recently available image processing software coupled with 
intraoperative instrument tracking technology allows 3 – 
dimensional awareness during parenchymal transection. At 
our non – university tertiary referral center, during the first 
ten months of solo HPB practice after fellowship, 6 major 
hepatic resections were performed. Two of these were per-
formed without the benefit of image guidance in which EBL 
was 1000 cc and 7500 cc. Four major resections were 
performed using image guidance. Blood loss was 200 cc and 
300 cc for lesions which could be approached anteriorly, 
without mobilization of both hemi-livers, allowing real-time 
image tracking during transection of liver parenchyma. Two 
patients had lesions in segments 6 and 7 requiring significant 
medial rotation of the liver relative to pre-operative imaging, 
thus preventing image guidance during parenchymal transec-
tion. EBL for these two patients was 1000 cc and 2000 cc. 
Recently developed real-time image guidance during liver 
transection may reduce blood loss during liver resections in 
which an anterior approach is possible and may be particu-
larly useful for surgeons new to HPB practice.
COMPARISON OF TECHNIQUES FOR 
VOLUMETRIC ANALYSIS OF THE 
FUTURE LIVER REMNANT: 
IMPLICATIONS FOR MAJOR HEPATIC 
RESECTIONS
G. Martel, R. Huang, A. Belblidia, M. Dagenais,  
R. Lapointe and F. Vandenbroucke-Menu
HPB Surgery And Liver Transplantation Unit, Hopital 
Saint-Luc, Universite De Montreal, Montreal, QC Canada
Introduction: The objective of this work was to evaluate 
the accuracy and variability of methods used to estimate liver 
remnant volumes prior to major hepatic surgery.
Methods: A cohort of patients who underwent major liver 
resection for colorectal liver metastases (2004–2011) was 
reviewed retrospectively. Volumetric data on the future liver 
remnant (FLR), total liver volume (TLV), FLR/TLV, and 
tumor volume were generated prospectively on liver CT 
scans or MRI prior to surgery. Data derived from measure-
ments were compared for accuracy to 6 formulae-based tech-
niques available in the literature. A difference of ± 5% in 
standardized FLR (sFLR) between techniques was consid-
ered clinically-meaningful.
Results: A total of 54 patients (63% males) were reviewed. 
The mean BMI was 27.1. All patients underwent major liver 
resection (3–4 segments 66%, 5–6 segments 34%). On initial 
preoperative CT scans, the mean measured TLV was 1738 
cc ± 375, yielding a mean sFLR of 41.8% ± 15.4. Mean TLV 
obtained from formulae was 1339–1685 cc (mean difference 
range 53–399 cc). Mean sFLR obtained from formulae was 
41.5–52.0% (mean difference range −10.2–0.29%). Four of 
six formulae yielded a significant sFLR mean difference 
(p < 0.05) of at least −2.0%. For all formulae, the variability 
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of sFLR mean differences was significant, such that 32– 
67% of individual patients had differences with measured 
sFLR of at least ± 5%.
Conclusion: Significant variation exists between methods 
of volumetric analysis, leading to potentially clinically-sig-
nificant measurement differences for individual patients. 
Individual centers should consider whether local standardi-
zation of volumetric techniques is warranted.
USING IMAGE-GUIDANCE AND 3-D 
MODELS FOR NEEDLE PLACEMENT 
DURING IRE-NANOKNIFE SURGERIES
R. C. Martin1, J. D. Stefansic2, B. W. Neese2 and 
P. Dumpuri2
1University Of Louisville, KY, Louisville, KY, USA; 
2Pathfinder Therapeutics, Nashville, TN, USA
Background: Tumors located near vasculature, airways or 
vulnerable tissues have always been difficult to treat. The 
NanoKnife system (marketed by AngioDynamics) has been 
successfully employed at University of Louisville to treat 
such tumors. When multiple monopolar probes are used for 
treatment, the relative distances between the probes have to 
be accurate in order to prevent reverse electroporation or 
excessive electroporation that could damage the sensitive 
structures and healthy tissue surrounding the lesions. Current 
state of the art techniques limit the surgeon to measuring the 
inter-needle distances using 2D ultrasound images. These 
factors necessitate 3D models and image-guidance using 3D 
models.
Methods: Explorer is a ‘GPS’ device for the surgeon that 
fuses pre-operative diagnostic images, three-dimensional 
models of the organ and vessels constructed from pre-oper-
ative images, and intra-operative ultrasound images of real 
time needle positions. Using principles of image registration, 
this device allows for needle positions that are identified on 
2D ultrasound images to 3D models thereby allowing for the 
distances to be measured in 3D space. Figure 1 depicts the 
workflow used for measuring 3D inter-needle distances using 
Explorer.
Results: Four needles were used to treat a patient with pan-
creatic cancer and inter-needle distances were measured for 
three of those needles. Table 1 compares the distances meas-
ured in 3D using Explorer system to the 2D distances meas-
ured intra-operative ultrasound. Albeit in one patient these 
results are encouraging and we believe that 3D image-guided 
systems can be used to guide and assist IRE surgeries.
PREDICTORS OF OUTCOMES IN LIVER 
TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA IN 
THE MELD ERA
A. Mathur2, A. M. Makris3, J. Arrobas4, K. Bruner4, 
A. Imperatore4, M. Christian4, E. S. Franco1, N. Kemmer1, 
G. W. Neff1 and A. E. Alsina1
1Tampa General Medical Group, Tampa, FL, USA; 
2Department Of Surgery, University Of South Florida, 
Morsani College Of Medicine, Tampa, FL, USA; 3College 
Of Public Health, University Of South Florida, Tampa, FL, 
USA; 4Office Of Clinical Research, Tampa General 
Hospital, Tampa, FL, USA
We aimed to identify factors associated with survival and 
recurrence post LTx for HCC in the MELD era.
Methods: Between Feb 2002 and July 2011, excluding inci-
dental tumors (n = 45), 135 HCC LTx were included, with 
median follow up of 60 mo. Kaplan-Meier (KM), logistic 
regression, Cox, and Fisher’s test were used. Early deaths 
< 60 days were excluded from recurrences, to avoid bias of 
under reporting.
Results: Median waiting time was 30 days. 13% developed 
recurrent HCC. Loco-regional therapy (LRT) was used in 
68% of LTx, with no impact in survival. Patient survival by 
KM at 1, 3, 5 yrs was: 85%, 74%, 63%, respectively. Factors 
associated with higher recurrence or survival included: 1) 
Females, (36% recurrence, p < 0.02); 2) Radiologic, total 
tumor burden (worse survival, p < 0.02, dropping when 
largest tumor reached 4 cm); 3) Path stage (patient survival): 
Stage A (1 yr, 88%; 3 yr, 79%; 5 yr, 71%) vs Stage B: (1 yr, 
80%; 3 yr, 64%; 5 yr, 51%), (p < 0.04); 4) Presence of > 1 
tumor at path stage, which increased the hazard ratio of death 
by 14% (p < 0.04); 5) Microvascular invasion was rare (4%), 
but present in 6/16 (37%) recurrent vs (1.2%) non-recurrent 
(p < 0.0001). AFP and waiting time did not affect survival.
Conclusion: Waiting time has little impact on survival and 
is a poor parameter for recurrence. Intense use of LRT and 
its timing related to LTx appear to be more important. Stage 
remains a strong predictor. Efforts should be directed at post 
LTx therapies.
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SURVIVAL AND CANCER RECURRENCE 
IN LIVER TRANSPLANTATION FOR 
HEPATOCELLULAR CARCINOMA IN 
THE LAST DECADE: IS THERE 
PROGRESS?
A. Mathur2, A. M. Makris3, J. Arrobas4, K. Bruner4, 
A. Imperatore4, M. Christian4, G. Neff1, E. Franco1,2, 
N. Kemmer1 and A. E. Alsina1,2
1Tampa General Medical Group, Tampa, FL, USA; 
2Department Of Surgery, University Of South Florida 
Morsani College Of Medicine, Tampa, FL, USA; 3College 
Of Public Health, University Of South Florida, Tampa, FL, 
USA; 4Office Of Clinical Research, Tampa General 
Hospital, Tampa, FL, USA
Hepatocellular carcinoma (HCC) is a burgeoning health 
problem in US and is increasing as an indication for liver 
transplantation (LTx). We hypothesized that recurrence rates 
and outcomes with LTx have improved.
Methods: From 1997–June 2011, 208 LTx for HCC were 
performed. Analysis was stratified in 4 groups (Gp): Pre 
MELD era (n = 28), and MELD era [ Gp 1 (2002–2005, n = 
53), Gp 2 (2006–2008, n = 63), and Gp 3 (2009 to 2011, n 
= 62)], with median follow up of 6.6, 4.7, 3.1, and 2.0 yrs, 
respectively. Kaplan-Meier (KM), Cox, Accelerated failure 
time, and Akaike (AIC) models were used.
Results: Gp 3 had largest fraction of LTx for HCC (22%). 
PreMELD era patients had higher recurrence rates (28%) vs. 
Groups 1,2, and 3 (9%) (p = 0.04), but recurrence of HCC 
have not changed in last decade (Gp 1, 2, and 3 = 8.3%, 11%, 
and 8.3%, respectively). Three year patient survival was: 
PreMELD = 71%, Gp 1 = 70%, Gp 2 = 72%, and Gp 3 = 
82%, although none of the models proved survival was 
improved. When adjusted for pathologic stage, the year of 
entry into LTx predicted survival (p < 0.0001).
Conclusions: Recurrences following HCC LTx are uncom-
mon and unchanged over last decade. Survival is encourag-
ing, with best results during the past 4 years. HCC recurrence 
and survival continue to promote application of LTx for 
HCC, although LTx center aggressive and wide application 
of HCC LTx may mitigate further improvements. Three 
factors that should improve survival will be discussed.
THE EFFECT OF INTRA-OPERATIVE 
STENTING ON BILIARY 
COMPLICATIONS FOLLOWING 
ORTHOTOPIC LIVER 
TRANSPLANTATION
A. K. Mathur, S. N. Nadig and T. H. Welling
University Of Michigan, Ann Arbor, MI, USA
Background: Biliary complications are among the leading 
source of surgical morbidity following liver transplantation. 
We attempted to identify the effect of prophylactic stent 
placement during orthotopic liver transplantation on subse-
quent post-transplant morbidity.
Methods: We performed a single-center retrospective study 
using the records of liver transplant recipients over an 8 year 
period. Recipient and donor covariates were collected to 
determine the risk of biliary complications. Multivariate 
regression models were performed to estimate the effect of 
operative biliary stent placement on post-operative morbidity 
following liver transplantation.
Results: Overall, 434 deceased donor liver transplant recipi-
ents were analyzed. 87.1% of recipients had a duct-to-duct 
biliary anastomosis. 30.7% had biliary stents placed at opera-
tion. The overall biliary complication rate was 37.3% (n = 
162). Biliary complications included 77 leaks and 85 stric-
tures. Stenting was associated with a 30% lower risk of 
biliary complications (HR 0.70, p < 0.05), and was associ-
ated with a 46% decreased risk of needing ERCP (OR 0.54, 
p = 0.01).
Conclusions: Intra-operative biliary stenting significantly 
reduces the risk of post-liver transplant leaks and strictures, 
as well as subsequent utilization of invasive procedures. To 
date, this is largest study analyzing intra-operative biliary 
stenting in orthotopic liver transplantation.
PREDICTORS OF INITIATION AND 
COMPLETION OF ADJUVANT THERAPY 
AFTER SURGICAL RESECTION FOR 
PANCREATIC ADENOCARCINOMA
L. M. Mazer1, C. M. Vollmer2, M. P. Callery1 and 
T. S. Kent1
1Department Of Surgery Beth Israel Deaconess Medical 
Center, Boston, MA, USA; 2HUP Dept Of Surgery, 
Philadelphia, PA, USA
Purpose: Most patients undergoing resection of pancreatic 
ductal adenocarcinoma (PDAC) are referred for adjuvant 
therapy to gain the best chance of long-term survival. This 
study investigates factors associated with timely initiation, 
and successful completion of adjuvant therapy after 
resection.
Methods: Patients undergoing PDAC resection with cura-
tive intent (2001–2011) with documented medical oncology 
courses were included. Patient and tumor factors were com-
pared between patients who had timely vs delayed initiation 
and between those who completed chemoradiation vs termi-
nated prematurely.
Results: Of 116 patients with resected PDAC, 93 (80%) 
were prescribed adjuvant therapy, of which 97% initiated 
treatment at a mean interval of 58 days postoperatively 
(range 20–245). Postoperative complications were the most 
common reason for delaying initiation beyond 6 weeks. 
There was a trend toward higher complication rate in patients 
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not prescribed adjuvant therapy but complications were not 
association with successful completion of adjuvant therapy 
once started. 40% of patients completed the prescribed 
course; 11% terminated due to side effects and 28% due to 
disease progression/death. Patients who terminated therapy 
early had a higher POSSUM score (21 vs. 19, p = 0.0463). 
Patients initiating adjuvant therapy later, were more likely to 
complete the regimen (Table). Completing the adjuvant 
course is associated with significantly longer survival (41 vs 
30 months, p 0.0011).
Conclusions: Postoperative complications may limit timely 
initiation of adjuvant therapy after PDAC resection. However, 
later initiation of adjuvant therapy is associated with comple-
tion of the course. Recommendations for best timing to allow 
the highest likelihood of completion warrant further 
investigation.
INDICATIONS AND OUTCOMES OF 
PANCREAS SURGERY AFTER LIVER 
TRANSPLANTATION
J. C. Mejia1, J. W. Marsh1, J. Steel1, B. J. Golas1, 
A. Humar2, H. Zeh3, D. A. Geller1 and A. Tsung1
1Division Of Hepatobiliary And Pancreatic Surgery, 
Pittsburgh, PA, USA; 2Thomas E. Starzl Transplantation 
Institute, Pittsburgh, PA, USA; 3UPMC Cancer Pavilion, 
Pittsburgh, PA, USA
Introduction: Previous orthotopic liver transplantation can 
make undertaking any pancreas surgery uniquely challeng-
ing. In this report we review our experience with this complex 
presentation.
Methods: Retrospective review of a transplant and hepato-
pancreatobiliary surgery database.
Results: From 7–1-1991 to 2–28–2009, there were 3,546 
liver transplants performed in 3,196 patients at our institu-
tion. Eighteen (0.01%) patients over this time period required 
pancreas surgery after transplantation of an allograft that 
included the liver. The most frequent indications for liver 
transplant in this sub-group of patients were: alcohol (n = 6), 
cryptogenic (n = 2) and hepatitis C virus (n = 2). Pancreas 
surgeries included pancreaticoduodenectomy (n = 5), distal 
pancreatectomy (n = 7) and pancreas necrosectomy (n = 4) 
with a median estimated blood loss of 500 ml (IQR 850). 
Pathology results revealed malignant lesions in 6 patients 
(adenocarcinoma = 4, cholangiocarcinoma = 1, and neuroen-
docrine tumor = 1) and pre-malignant lesions in 2 patients. 
The 30 days post-operative morbidity rate was 77.8%. The 
majority of these complications were Clavien grading 1–3. 
The 3 months, 1 and 2 year survival following pancreas 
surgery was 78%, 48% and 24% respectively. The median 
survival for patients with malignant pathology was 21 
months and 95% CI = 0–48 months (18 months for adeno-
carcinoma, 26 months for cholangiocarcinoma, and 91 
months for neuroendocrine tumor).
Conclusion: The need for pancreas surgery following liver 
transplantation is an uncommon occurrence. Our 30 day 
morbidity, estimated blood loss and 3 month mortality 
suggest that with adequate experience undertaking this type 
of surgery is feasible, however with guarded 1 and 2 year 
survivals.
COMBINED ORTHOTOPIC LIVER 
TRANSPLANT WITH 
PANCREATICODUODENECTOMY
M. G. Mesleh, J. A. Stauffer, H. J. Asbun and  
J. H. Nguyen
Mayo Clinic Florida, Jacksonville, FL, USA
Pancreaticoduodenectomy (PD) is occasionally indicated in 
unique clinical scenarios. We aim to discuss the technical 
aspects and clinical outcomes of patients who undergo PD 
in combination with orthotopic liver transplantation (OLT). 
A retrospective review of all patients who underwent OLT 
from 1998 to present at our institution was performed. We 
analyzed 8 patients who underwent PD combined with OLT. 
Seven were Whipple resections and 1 underwent total pan-
createctomy. Indications for pancreatic resection included 
cholangiocarcinoma (n = 6), periampullary adenocarcinoma 
(n = 1), and pancreatic adenocarcinoma (n = 1). Indications 
for OLT were primary sclerosing cholangitis (n = 6), alco-
holic cirrhosis (n = 1), and hilar cholangiocarcinoma (n = 
1). Mean operative time was 439 min (175–625 min), and 
mean anhepatic time was 48 min (34–81 min). Three 
patients had both specimens removed en bloc, 4 underwent 
OLT followed by PD, and 1 underwent PD followed by 
OLT. There were 2 patients which had pancreatic fistulas 
that resolved with conservative management. Graft survival 
at 1 year was 75%. One patient required retransplation at 29 
months, due to allograft failure secondary to portal vein 
occlusion. Mean overall survival was 32 months, ranging 
from 1 to 63 months. Five patients died of tumor recurrence, 
2 patients died of transplant complications, and 1 patient is 
still alive at 3 years. There are technical aspects to perform-
ing pancreaticoduodenectomy combined with OLT which 
are unique. Recurrence of malignant disease appears to be 
the main factor limiting survival, and morbidity is expect-
edly high. However, good outcomes can be achieved, and 
when indicated, the combined resection should be 
performed.
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TECHNIQUE OF LAPAROSCOPIC 
CHOLEDOCHODUODENOSTOMY
M. G. Mesleh, H. J. Asbun and J. A. Stauffer
Mayo Clinic Florida, Jacksonville, FL, USA
We present a video describing the technique of laparoscopic 
choledochoduodenostomy. We illustrate a step-by-step 
reproducible method to create this anastomosis. The patient 
has primary common bile duct stones, and had undergone 
multiple endoscopic interventions to clear her CBD, however 
they continued to recur. The anastomosis was performed 
laparoscopically in a running 4-quadrant diamond configura-
tion, using a 4–0 absorbable braided suture. She tolerated the 
procedure well and was discharged home on the first post-
operative day with normal LFTs.
ASSESSING THE IMPACT OF FISTULAS 
AFTER PANCREATICODUODENECTOMY 
USING THE POSTOPERATIVE 
MORBIDITY INDEX (PMI)
B. C. Miller1, J. D. Christein2, M. P. Callery3, J. A. Drebin1, 
T. S. Kent3, W. B. Pratt3 and C. M. Vollmer1
1Department Of Surgery, Hospital Of The University Of 
Pennsylvania, University Of Pennsylvania, Philadelphia, 
PA, USA; 2Department Of Surgery, University Of Alabama 
At Birmingham School Of Medicine, Birmingham, AL, 
USA; 3Department Of Surgery, Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, MA, 
USA
Background: PMI is a quantitative utility measure of com-
plication severity created through a process of severity 
weighting. The Fistula Risk Score (FRS) is a validated model 
which strongly predicts whether a patient will develop a 
postoperative pancreatic fistula (POPF). These novel tools 
allow for the ISGPF grading system to be further 
discriminated.
Methods: From 2001–2012, 885 pancreaticoduodenecto-
mies were performed at three institutions. POPFs, when they 
occurred, were categorized by ISGPF standards. PMI scores 
were calculated based on the modified Accordion severity 
grading system for complications. FRS scores were assigned 
according to the relative influence of four recognized factors 
(small duct size, soft pancreas texture, high-risk pathology, 
and increased blood loss) for developing a clinically relevant 
POPF (CR-POPF).
Results: 192 patients (21.7%) developed any POPF, of 
which 45% were clinically relevant. The PMI differed sig-
nificantly between the various ISGPF grades and patients 
with no complications or non-fistulous complications (p < 
0.001). Overall, 60% of POPFs contributed the highest 
Accordion grade to the PMI calculation. However, this con-
tribution rose to 80.5% in CR-POPFs (Table). Additionally, 
for all patients, the FRS correlated strongly with the PMI 
(Figure: R2 = 0.71, p = 0.001).
Conclusion: This data establishes quantitative benchmarks 
for various grades of fistula, reinforcing the ISGPF grades 
that were developed qualitatively around the concept of clini-
cal severity. While biochemical POPFs are often superseded 
by more severe complications, CR-POPFs usually reflect the 
patient’s highest Accordion score. The strong correlation 
between FRS and PMI substantiates this predictive tool, 
indicating that risk factors for fistula greatly contribute to 
overall morbidity in pancreaticoduodenectomies.
DENDRITIC CELLS ADENOVIRALLY-
TRANSDUCED WITH FULL-LENGTH 
MESOTHELIN CDNA ELICIT 
MESOTHELIN-SPECIFIC 
CYTOTOXICITY AGAINST PANCREATIC 
CANCER CELL LINES IN VITRO
M. Miyazawa, M. Iwahashi, T. Ojima, M. Tani, M. Kawai, 
S. Hirono, K. Okada, A. Shimizu, Y. Kitahata and  
H. Yamaue
Second Department Of Surgery, Wakayama Medical 
University School Of Medicine, Wakayama, Japan
Mesothelin (MSLN) is an attractive candidate as a molecular 
target for pancreatic cancer immunotherapy. The purpose of 
this study was to demonstrate that cytotoxic T lymphocytes 
(CTLs) generated from peripheral blood mononuclear cells 
(PBMCs) by stimulation with genetically-modified dendritic 
cells (DCs) expressing MSLN could produce specific anti-
tumor immunity against pancreatic cancer cells endog-
enously expressing MSLN. MSLN-specific CTLs were 
generated from PBMCs of healthy donors by in vitro stimu-
lation with DCs adenovirally-transduced with the full-length 
MSLN gene (DC-AxCAMSLN). The cytotoxic activity was 
tested using a 4-hour 51Cr-release assay. The pancreatic 
cancer cell lines (PK1, CfPAC1, AsPC1), a lymphoblastoid 
cell lines (LCL) transduced with the MSLN gene, and LCL 
pulsed with MSLN-epitope peptides were used as target 
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cells. MSLN-specific CTLs induced by in vitro stimulation 
with DC-AxCAMSLN killed pancreatic cancer cell lines 
expressing MSLN in an HLA-restricted fashion. These CTLs 
also showed cytotoxic activity against autologous LCL 
pulsed with multiple MSLN-derived epitope peptides. In 
addition, CD8+ T cells, as well as CD4+ T cells, sorted from 
these CTLs showed significant production of interferon-γ 
when stimulated with DC-AxCAMSLN. The in vitro stimu-
lation of PBMCs with DCs transduced with the full-length 
MSLN gene elicited a potent MSLN-specific cytotoxic activ-
ity against pancreatic cancer cell lines endogenously express-
ing MSLN by recognizing multiple MSLN epitopes and 
activating both CD8+ T cells and CD4+ helper T cells. These 
results therefore suggest the potential of developing future 
clinical applications of the vaccines using genetically modi-
fied DCs expressing MSLN.
ELEVATED RISK OF BILE LEAK 
FOLLOWING HEPATIC RESECTION 
AMONG PATIENTS EXPOSED TO 
BEVACIZUMAB
B. D. Nath1, S. Tizio1, L. Mazer1, T. S. Kent1, A. J. Moser1, 
S. R. Johnson2 and D. W. Hanto1
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 
2St. Elizabeth’s Medical Center, Brighton, MA, USA
Background: Bile leaks are a major complication after 
hepatic resection with significant morbidity and mortality. 
This study aimed to identify risk factors for bile leaks after 
hepatic resection.
Methods: A retrospective review was conducted of patients 
undergoing hepatic resection over an eight-year study period 
at a single institution. Clinical variables (preoperative and 
intraoperative factors) were assessed for association with 
development of bile leaks.
Results: 297 cases of hepatic resection were identified. 
Operations were categorized into major (right/left hepatic 
lobectomy, or resection of four or more segments) and non-
major resections. 66 (22%) patients developed bile leaks. 
Intraoperative blood loss, use of hepatic inflow occlusion, 
total inflow occlusion time, and dissection method were 
similar between bile leak and control groups. In univariate 
analysis, bile leaks were significantly associated with major 
hepatic resection (OR: 3.14, 1.78–5.55, p < 0.01), malignant 
diagnosis (OR: 7.23, 3.77–13.89, P < 0.01), and bevacizu-
mab exposure (OR: 3.17, 1.2–8.4, p < 0.02). Among patients 
with a malignant diagnosis, 48 (24%) had received preopera-
tive chemotherapy including 18 (8.4%) who had received 
bevacizumab. In a multivariate logistic regression, major 
hepatic resection and bevacizumab conferred increased risk 
of postoperative bile leak (Table 1.).
Conclusions: Operation for malignancy or preoperative 
exposure to the anti-angiogenesis drug bevacizumab con-
ferred an elevated risk for postoperative bile leak, regardless 
of dissection method or pringle time. Patients with exposure 
to bevacizumab should be advised of possible elevated risk 
of bile leak following hepatic resection. Future studies may 
clarify the mechanism of this association.
THE EFFECT OF CHEMOTHERAPY ON 
THE SHORT TERM OUTCOME OF LIVER 
RESECTION – A COMPARISON OF NO 
CHEMOTHERAPY VERSUS 
CONVENTIONAL CHEMOTHERAPY 
VERSUS BIOLOGICAL AGENTS
G. C. Ndlovu, S. iosifidou, G. E. Bond-Smith and  
R. R. Hutchins
Barts And The London HPB Unit, London, England, 
United Kingdom
Chemotherapy can induce steatosis/steatohepatitis. Oxalipla-
tin/irinotecan/5FU cause hepatic injury. Little is known of 
the liver effects of biologicals. Case series from the literature 
quote similar incidence of morbidity related to liver surgery 
after chemotherapeutic agents. Although not a primary end 
point, the EORTC intergroup trial demonstrated increased 
morbidity in liver surgery after folfox4 (25%v16%). We 
evaluated the effect on liver resection of pre-operative no 
chemotherapy (N), conventional chemotherapy (C) or bio-
logical agents (B). The study group were hepatic resections 
by single surgeon (RH) for colorectal liver metastases. 226 
liver resections performed; N = 89 C = 97 B = 40. Median 
age was 62 (30–88). M : F 135 : 91. Neoadjuvant chemo-
therapy administration was accepted as chemotherapy given 
within 3 months of operation. Washout of 4 weeks was used 
before attempting surgery. Liver function pre-operatively 
was normal in all patients as measured by serum albumin 
levels, platelets and INR. Surgical morbidity was 32% with 
a 60 day mortality of 2.2% Morbidity from each group was 
32.5% (N), 27.8% (C) and 40% (B). Biliary complications 
occurred in 2.2%, 5.1% and 12.5% respectively. The table 
shows the differences in major resections, blood loss, mor-
bidity, biliary morbidity, transfusion requirements and length 
of stay for each of the treatment groups. Liver parenchyma 
was assessed using the pathologist’s report. Conventional 
and biological agents do not affect overall morbidity, mortal-
ity, blood loss or transfusion of liver resection. Unexplained 
by size of resection alone, biological agents may increase the 
risk of biliary complications.
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THE VALIDATION OF A 
CLASSIFICATION SYSTEM FOR 
BILIARY COMPLICATIONS FOLLOWING 
ORTHOTOPIC LIVER 
TRANSPLANTATION (OLT)
A. Neville, M. Boutros and J. Barkun
McGill University Health Centre, Montreal, QC, Canada
Introduction: The estimated incidence of biliary complica-
tions after liver transplantation (OLT) ranges from 10–40% 
but the absence of a standardized classification hinders 
proper documentation. We propose a structured classification 
for biliary complications following choledocho-choledochal 
anastomosis (CCA) at non living-related OLT. It is based on 
3 major components and anatomic location: strictures (intra-
hepatic, common hepatic or anastomotic), leaks (anasto-
motic, non-anastomotic) and filling defects. This previously 
validated classification has not yet been validated.
Methods: OLT recipients from the McGill University 
Health Centre between 2004–2010 were eligible for the 
study. The classification was validated by analysis of subse-
quent clinical outcomes (including diagnostic studies, surgi-
cal revision of anastomosis, retransplantation, number of 
post-transplant hospital admissions, the total number of hos-
pital admission days and graft and patient survival).
Results: A total of 189 patients, including 76 patients with 
biliary complications, were included. The components of the 
proposed classification showed a strong relationship with 
clinical outcomes. The relationship between the ‘stricture’ 
components of the classification and days of hospital 
readmission provide an appropriate illustration of this rela-
tionship. The median number of post-transplant hospital 
readmission days in patients without complications versus 
those with anastomotic strictures, common duct strictures 
and intrahepatic strictures were 1, 25, 42 and 47 respectively 
(p < 0.01).
Conclusions: The proposed classification of biliary compli-
cations shows good construct validity. The significant differ-
ence in clinical outcomes between different classification 
components demonstrates the appropriateness of the chosen 
components. The classification components reflect the rela-
tive severity of the different complications, further support-
ing validity.
HEPATECTOMY FOR BENIGN 
PATHOLOGY IN 112 PATIENTS AT A 
SINGLE TERTIARY CARE INSTITUTION
S. D. Nichols1, C. R. Schmidt1, E. W. Martin1, 
P. Muscarella2, W. S. Melvin2, E. C. Ellison2 and 
M. Bloomston1
1The Ohio State University, Wexner Medical Center, 
Columbus, OH, USA; 2The Ohio State University, Wexner 
Medical Center, Columbus, OH, USA
Background: While typically safe, morbidity associated 
with hepatectomy is offset by the promise of improved sur-
vival in properly selected patients with cancer. However, 
liver resection for benign causes is often approached with 
great trepidation, even when symptoms are present. We 
sought to review our experience with hepatectomy for benign 
diseases.
Methods: After Institutional Review Board Approval, we 
reviewed the records of all patients at a single institution who 
underwent hepatectomy for benign diseases between 1996 
and 2012.
Results: We identified 112 patients who underwent 114 
hepatectomies for benign pathology, with one patient under-
going three partial hepatectomies on separate admissions. 
Most patients were women (82.3%) and the average age was 
48.6 years (range 17–79). Simultaneous or remote non-
hepatic cancer diagnoses were present in 16.1% of patients. 
Most hepatectomies were for neoplasms (78.6%) with a 
mean diameter of 5.9 cm, and the most common neoplasms 
were hemangiomas and focal nodular hyperplasia, account-
ing for 26.5% and 20.5%, respectively. The majority were 
single lesions with 5 patients (4.3%) having multiple tumors 
resected. Of the 22.2% of hepatectomies for non-neoplastic 
indications, most were for necrosis or infection. Major resec-
tion (i.e. ≥3 segments) was uncommon (14.0%); whereas 
wedge resection, segmentectomy, and bisegmentectomy 
accounted for 44.7%, 13.2%, and 19.3%, respectively. Two 
(1.8%) deaths occurred following hepatectomy.
Conclusions: As expected, the most common benign tumor 
resected at our institution was hemangioma. These resections 
tended to be non-anatomic wedge resections. Hepatectomy 
for a benign indication is safe even when major anatomic 
resection is necessary and should be considered in patients 
with worrisome lesions.
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OPTIMAL ABLATION VOLUMES ARE 
ACHIEVED AT SUB-MAXIMAL POWER 
SETTINGS IN A 2.45 GHZ MICROWAVE 
ABLATION SYSTEM
D. J. Niemeyer, K. A. Simo, M. McMillan, E. M. Hanna,  
J. H. Swet, D. Sindram, J. B. Martinie, I. H. McKillop and 
D. A. Iannitti
Carolinas Medical Center, Charlotte, NC, USA
Background: Local ablative therapies, including micro-
wave ablation (MWA), are common treatment modalities for 
in situ tumor destruction. Commercial MWA systems employ 
either 915 MHz or 2.45 GHz frequencies. Newer, 2.45 GHz 
systems are gaining prominence due to shorter application 
times to produce equivalent ablations compared to 915 MHz 
system(s). As new systems become available, accurate 
guidelines regarding system settings and ablation volumes 
(AbVs) are required. We sought to determine optimal power 
and time to AbV ratios for a new 1.8 mm/2.45 GHz antenna 
at settings ≤180 watts (W) using ex-vivo tissue models.
Methods: A 1.8 mm/2.45 GHz antenna MWA system 
(Accu2i, Microsulis, UK) was employed to perform abla-
tions in bovine liver, porcine muscle, and porcine kidney 
ex-vivo. Whole tissues were pre-warmed (350C) and multi-
ple ablations performed at power settings of 60, 100, 140, or 
180 W over 2, 4, or 6 min time intervals. Post-ablation 
tissues were dissected, AbVs calculated, and correlations to 
power and time settings made.
Results: Significant increases in AbV were measured 
between each of the time points for a constant power setting 
in all 3-tissue types. Increasing power settings led to signifi-
cant increases AbV at power settings ≤140 W. However, no 
significant differences in AbV were obtained by increasing 
the power setting above 140 W.
Conclusions: Optimal efficiency for MWA using a new 
1.8 mm/2.45 GHz is achieved at settings of 140 W for 
6 mins in ex vivo tissue (liver, kidney and muscle). No addi-
tional benefit was measured by increasing power settings 
(180 W) in these tissues.
A SIMPLE SYSTEM FOR VIDEO OF 
OPEN SURGICAL CASES
N. N. Nissen, V. G. Menon, J. A. Williams and G. Berci
Cedars-Sinai Medical Center, Los Angeles, CA, USA
This video demonstrates a simple system we have developed 
to allow continuous video display of open surgical cases, 
similar to that of laparoscopic surgery. The system utilizes a 
mechanical arm that is part of a standard laparoscopic camera 
holder system, coupled with a prototype camera basket, that 
allows a standard high definition laparoscopic video camera 
to be mounted above the surgical field. The mechanical arm 
and basket allow the camera to be positioned in a nonobtru-
sive manner that is also easily adjustable. This, in turn, allow 
the surgical procedure to proceed without the need for 
outside camera or video equipment to be brought to the 
operative field. The system essentially provided continuous 
video display of the operation on monitors placed at the 
patient’s shoulder level, just as would occur during a laparo-
scopic case. In addition, the camera can be moved close to 
the operative field and can be used as an adjunct to perform 
microsurgery. The benefits of video display of open surgery 
cases are numerous, including improved educational 
opportunities, improved OR communication, and improved 
documentation of both routine and unique cases. In addition, 
surgeon fatigue can be lessened when working off the video 
monitor for select phases of surgery. Finally, we have used 
this system successfully when performing microsurgical 
aspects of pancreaticoduodenectomy, bile duct repair and 
liver transplantation.
ENUCLEATION OF HEPATIC 
NEUROENDOCRINE TUMOR 
METASTASES
N. N. Nissen and V. G. Menon
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Neuroendocrine tumors represent a unique type of hepatic 
metastasis. These tumors tend to be well encapsulated and 
are often associated with a favorable prognosis due both to 
the often indolent biological behavior and also to the expand-
ing number of treatments available for these patients. Many 
of these patients will require repeated hepatic interventions 
over a period of several decades, which can include resec-
tion, ablation and hepatic arterial therapy. Enucleation of 
neuroendocrine tumor metastases is a technique that is not 
often employed but that holds great potential. The benefits 
of enucleation include the preservation of maximal hepatic 
parenchyma, as well as the low likelihood that underlying 
vascular or biliary structure will be compromised. This video 
presents 5 cases demonstrating the unique application of 
enucleation to patients with NET metastases. Patient selec-
tion, surgical techniques and management of complications 
are discussed as well.
HIGH-RISK CENTRAL 
PANCREATECTOMY MANAGED  
WITH DUAL PANCREATIC-ENTERIC 
ANASTOMOSIS
N. N. Nissen and V. G. Menon
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Central pancreatic resection is utilized in low-grade mid-
pancreatic pathology in an attempt to preserve maximal pan-
creatic parenchyma. One of the drawbacks of central 
pancreatectomy is the increased rate of pancreatic fistula, 
presumably due to the potential leak from both the pancreatic 
transection line and the distal pancreatic anastomosis. In 
cases involving complex proximal pathology such as a 
dilated proximal pancreatic duct or lesions that extend into 
the head of the pancreas, the leak risk from the proximal 
gland may be exceedingly high. In these cases, the leak rate 
from the proximal pancreas may be lessened by creating a 
proximal pancreatico-enteric anastomosis in addition to the 
standard distal pancreatico-enteric anastomosis. Our pre-
ferred approach in these cases is to place both the proximal 
and distal pancreatic anastomosis on the same defunctional-
ized jejunal limb (Figure), but these anastomoses can also be 
separated into separate pancreaticogastrostomy and pancrea-
ticojejunostomy. The choice of pancreatic anastomosis varies 
for both the proximal and distal gland, and is dependent on 
the nature of disease, pancreatic duct dilatation and pancre-
atic parenchyma. If a proximal ampullary obstruction is sus-
pected or the proximal PD is dilated, a durable duct-to-mucosa 
anastomosis to the proximal gland is favored. If the PD is 
not dilated, we use an intussuscepting technique with sutures 
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placed through the full thickness of the stump of the proximal 
gland to add to the stump closure while simultaneously pro-
viding stump drainage. Several illustrative cases are shown.
LAPAROSCOPIC VISUALIZATION OF 
LESIONS AT THE HEPATIC DOME 
USING NOVEL TELESCOPES: 
VARIABLE-DIRECTION-OF-VIEW 
TELESCOPE AND DEFLECTABLE 
TELESCOPE
N. N. Nissen and V. G. Menon
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Visualization and treatment of tumors at the dome of the liver 
can be challenging to the surgeon because of obstruction 
imposed by the lungs, diaphragm and costal margins. Even 
with full mobilization of the right lobe, multiple ports and 
directional approaches are necessary to adequately inspect 
and treat tumors in these areas. Failure to appreciate vital 
structures can lead to aborted attempts at surgery or unin-
tended injury to diaphragm or other structures. Development 
of new telescopes has improved the access to these difficult 
areas. The first device used for these cases is a commercially 
available telescope (Endocameleon, Storz Endoscopy) with 
a variable field of view. This HD telescope has an adjustment 
dial near the optical mount that allows the user to vary the 
field from 0 to 120 degrees, allowing inspection of the entire 
right hemidiaphragm and dome of the liver from a single 
10 mm port site. We have used this device to facilitate micro-
wave ablation or resection of lesions at the dome of the liver 
(segment 7/8). The second device that is useful in these 
scenarios is a 10 mm HD telescope with a zero degree optic 
but a deflectable tip that allows for functional field of view 
of 0 to 100 degrees (Endoeye Flex, Olympus). Using this 
device, the optical tip is flexed much like a standard endo-
scope to vary the field of view, again allowing the surgeon 
to view the diaphragm and all of the dome of the liver from 
a single access point.
TECHNIQUES FOR ENUCLEATION OF 
PANCREATIC MASSES
N. N. Nissen, V. G. Menon, V. C. Puri and A. Annamalai
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Background: Benign and low-grade pancreatic lesions such 
as cystic neoplasms and certain neuroendocrine tumors may 
be amenable to encleation, thereby preserving maximal pan-
creatic parenchyma. This technique is, however, accompa-
nied by a high rate of pancreatic leak. Several measures can 
be employed to lessen the likelihood or severity of pancreatic 
leak when performing pancreatic enucleation.
Technique: Enucleation is most applicable in expansive 
lesions that create a small degree of parenchymal atrophy 
which creates a plane around the tumor. The primary method 
used to separate the tumor from surrounding parenchyma is 
blunt dissection. Cautery or thermal sealing devices are 
avoided to lessen the liklihood of pancreatic duct injury. In 
lesions deep in the parenchyma, needle localization can be 
used to lead the surgeon on the right tract through paren-
chyma until the lesion of interest is exposed. The NET most 
amenable to this technique is insulinoma, which often has a 
characteristic texture and color and can be easily distin-
guished from parenchyma once overlying tissue is opened 
(Figure). In the case of IPMN, microscopy is used to identify 
small ducts connecting the cystic lesion to the main pancre-
atic duct (Figure). Deep resection beds are covered with 
Roux-en-Y pancreaticojejunostomy, and shallow resection 
beds coated with sealing agents such as BioGlue or with 
omentum. If the main PD is skeletonized, ERCP with PD 
stenting is performed immediately after surgery to lessen the 
likelihood of main PD blowout.
DISCORDANCE BETWEEN 
CONVENTIONAL AND DETAILED 
LYMPH NODE ANALYSIS IN RESECTED 
BILIARY CARCINOMA AT OR ABOVE 
THE CYSTIC DUCT: ARE WE 
UNDERSTAGING PATIENTS?
L. M. Ocuin1, P. Bagci2, S. B. Fisher1, S. H. Patel1, 
D. A. Kooby1, C. A. Staley1, N. Adsay2 and S. K. Maithel1
1Department Of Surgery, Atlanta, GA, USA; 2Department 
Of Pathology, Atlanta, GA, USA
Purpose: Analysis of portal lymph node (LN) metastases 
following resection of biliary carcinomas at or above the 
cystic duct (BC) is used to select patients for adjuvant 
therapy, but no standard guidelines exist. LN yield is typi-
cally low. Some consider a minimum of 7 LNs necessary for 
accurate staging. We hypothesized that conventional patho-
logic LN analysis may understage patients.
Methods: We identified 38 patients who underwent resec-
tion of BC from 2000–2008 with no evidence of LN 
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metastases. Each LN (n = 187) was re-reviewed in detail for 
occult metastases (OM) using 2-micron re-cut immunohisto-
chemistry staining for pancytokeratin (modified Weaver pro-
tocol). Primary outcome was discordance in LN positivity. 
Secondary outcome was survival.
Results: 5 of 38 patients with negative LNs on conventional 
analysis had OM on detailed examination (13%). Mean sur-
vival of patients with OM was reduced (19 mos vs. 30 mos). 
There was no association between OM and T-stage, grade, 
margin status, satellite lesions, and perineural or lymphovas-
cular invasion. The median number of LNs retrieved was 3. 
One of 27 patients with < 7 LNs retrieved had OM (4%), 
compared with 4 of 11 patients with > 7 LNs removed (36%; 
p = 0.03). In this latter cohort of well-staged patients, OM 
were associated with reduced median survival (9 mos vs. 
41 mos; p = 0.03; Figure).
Conclusions: There is discordance between conventional 
and detailed LN analysis in resected biliary carcinoma. 
Detailed evaluation and higher LN yield resulted in greater 
likelihood of detecting occult metastases. The presence of 
occult metastases is associated with decreased survival. Con-
ventional LN analysis may understage patients with resect-
able biliary carcinoma.
BODY MASS INDEX (BMI): DOES IT 
MAKE A DIFFERENCE IN 
PANCREATICODUODENECTOMY 
OUTCOME?
H. Osman, A. Thomas and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX, USA
Objective: The impact of obesity on pancreaticoduodenec-
tomy (PD) has been an area of controversy. The aim of this 
study is to evaluate the effect of BMI on the outcome of PD.
Method: All patients who underwent PD for periampullary 
carcinoma between September 2005 and May 2012 have 
been identified retrospectively in our database. Patients were 
categorized based on their preoperative BMI into normal 
weight group (BMI < 25) and overweight/obese group (BMI 
≥ 25). Outcomes of PD were compared.
Results: 162 patients have been identified, 73 patients had 
normal weight and 89 patients were overweight/obese. The 
average BMI was 21.7 ± 2.47 and 29.5 ± 3.53 in the normal 
and overweight/obese groups respectively. The median esti-
mated blood loss (EBL) was 300 ml in the normal weight 
group and 450 ml in the overweight/obese group (p = 0.008). 
More overweight/obese patients required intensive care unit 
(ICU) admission (p = 0.044), but there was no difference in 
overall length of hospital stay (p = 0.896). The average 
operative time was 209 minutes for the normal weight group 
and 221 minutes for the overweight/obese group (p = 0.163). 
There was no difference in resection margin positivity (p = 
0.554), regional lymph node positivity (p = 0.683), or number 
of lymph node retrieved (p = 0.525).
Conclusion: PD is technically challenging in overweight/
obese patients as evidenced by the significant increase in 
EBL and the need for ICU admission. Despite this, over-
weight/obese patients have comparable postoperative course 
and tumor oncological characteristics to normal weight 
patients when PD is performed by an experienced HPB 
surgeon.
HEPATO-PANCREATO-BILIARY (HPB) 
SURGERY FELLOWS: WHAT IS AFTER 
FELLOWSHIP? A SINGLE FELLOWSHIP 
EXPERIENCE
H. Osman and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX, USA
Background: The importance of HPB fellowship training 
is well documented. Our program is a one year HPB/foregut 
fellowship that serves as a bridge between surgical oncology 
and transplant training. Fellows are widely exposed to both 
benign and malignant HPB and foregut conditions. The fel-
lowship started in 2006 and is currently training its 7th 
fellow. The aim of the study is to evaluate the practice of the 
fellowship graduates.
Method: A questionnaire was sent to all six graduates. Five 
graduates responded. The responses were then analyzed.
Results: The practice of the graduates was described as 
HPB/surgical oncology by two graduates, HPB/general 
surgery by another two, and HPB/foregut by one graduate. 
Two graduates are in private practice, and three are enrolled 
in a hybrid of academic and private practice. All graduates 
are actively involved in surgical education. During the past 
year, one graduate performed > 100 HPB cases, another 
performed 50–100 cases, and three performed 20–50 cases. 
Benign HPB conditions constitute 31–50% of the HPB prac-
tice for two graduates, 10–30% for two graduates, and < 10% 
for one. The percentage of foregut cases was 20–49% for one 
graduate and < 20% for the others. The strongest competitors 
were tertiary referral centers and surgical oncologists. The 
most common referral sources were gastroenterologists, 
oncologists, and other surgeons. All graduates have adequate 
logistic support for their HPB practice.
Conclusion: This fellowship module prepares graduates for 
a successful career in HPB. Exposure to both benign and 
malignant disease is an important element for success.
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INTRAOPERATIVE ESTIMATED BLOOD 
LOSS PREDICTS NEED FOR ICU CARE: 
A SINGLE CENTER EXPERIENCE
H. Osman, A. Thomas and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX, USA
Objective: Estimated blood loss (EBL) has been identified 
as an indicator for worse outcome in gastrointestinal surgery. 
The effect of blood loss volume on outcome of pancreati-
coduodenectomy (PD) has not been studied. With the imple-
mentation of multidisciplinary team, our routine is to admit 
PD patients to a floor with a dedicated nursing staff. The aim 
of this study is to evaluate EBL as a predictor for ICU 
admission.
Method: All patients who underwent PD between Septem-
ber 2005 and May 2012 have been identified retrospectively 
in our database. Patients are divided into two groups based 
on their need for ICU admission after PD. EBL was then 
compared.
Results: 253 patients were identified. The average and 
median EBL were 585 ml and 500 ml for patients who 
required ICU versus 350 ml and 300 ml for patients who did 
not require ICU admission respectively (p < 0.05).
Conclusion: Patients with low EBL do not require ICU 
admission after PD when a multidisciplinary team and dedi-
cated nursing staff are implemented. High EBL may be used 
as an indicator for ICU admission.
NOT ALL NODES ARE THE SAME: 
NODAL STATIONS VARIABILITY IN 
PANCREATICODUODENECTOMY (PD) 
AND ROLE IN DECISION MAKING
H. Osman, A. Thomas and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX, USA
Objective: Presence of positive lymph node carries worse 
prognosis in patients with periampullary carcinoma. A previ-
ous paper by the author precluded the use of intraoperative 
nodal sampling of superior pancreatic node (SPN/station 8) 
and lateral common bile duct node (CBDN/station 12) as 
predictors for overall lymph node status in the specimen. The 
aim of this study is to evaluate the prognostic value for these 
lymph node stations.
Method: 88 patients who underwent PD for periampullary 
carcinoma between September 2005 and December 2009 
were identified retrospectively in our database. We routinely 
harvest the SPN and CBDN and process them separately for 
pathological examination. The patients were divided into two 
groups based on their SPN and/or CBDN status. The margin 
status was then compared. 63 patients with positive regional 
lymph nodes were divided into 2 groups based on their SPN/
CBDN status, and the 2 year survival rate was compared.
Results: The SPN and/or CBDN were positive in 13 patients 
and negative in 75 patients. No correlation was found 
between SPN and/or CBDN positivity and resection margin 
status (p = 0.099) with 0.538 positive predictive value. 
23.1% of SPN and/or CBDN positive group were alive at 2 
years versus 49.3% in the negative group but no statistical 
significance was reached.
Conclusion: The presence of positive SPN/CBDN is an 
independent factor that carries a trend towards decreased two 
year survival. Despite this, involvement of these lymph node 
stations should not preclude PD with curative intent.
THE NEED FOR JEJUNAL FEED OR TPN 
AFTER PANCREATICODUODENECTOMY 
(PD): IS IT PREDICTABLE?
H. Osman, A. Thomas and D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX, USA
Objective: When oral intake is unfeasible after pancreati-
coduodenectomy (PD), the ideal route of nutritional support 
is controversial. Some surgeons practice jejunal feeding 
while others prefer total parenteral nutrition (TPN) and avoid 
routine placement of jejunal feeding tube. The aim of this 
study is to determine if the need for jejunal feed or TPN after 
PD can be predicted based on preoperative and intraoperative 
parameters, which may allow for a more selective approach 
in placing jejunal feeding tube at the time of PD.
Method: 274 patients who underwent PD in our institution 
between September 2005 and May 2012 have been identified 
retrospectively in our database. Our routine is to place a 
gastro-jejunostomy tube at the time of surgery. Jejunal feed 
is used when oral intake cannot be attained or is inadequate. 
TPN is used as second line. Patients were divided into two 
groups based on the administration of jejunal feed during 
their hospital stay following PD. Preoperative and intraop-
erative parameters were compared.
Results: There was no difference in comorbid conditions 
between the 2 groups; diabetes mellitus, congestive heart 
failure, or cerebrovascular accident. There was no difference 
in age (p = 0.818), albumin level (p = 0.772), BMI (p = 
0.428), or bilirubin level (p = 0.145). No difference was 
found between pylorus preserving PD versus standard PD 
(p = 0.493) or in estimated blood loss (p = 0.346).
Conclusion: The use of jejunal tube feeding or TPN depends 
on surgeon/institution preference and practice. The need for 
either one is unpredictable.
60 Abstracts
© 2013 The Authors
HPB © 2013 Americas Hepato-Pancreato-Biliary Association HPB 2013, 15 (Suppl. 1), 1–87
TOTAL PANCREATO DUODENECTOMY 
WITH PORTACAVAL SHUNT FOR THE 
TREATMENT OF A PANCREATIC 
NEUROENDOCRINE TUMOR WITH 
PORTAL HYPERTENSION
M. Palavecino, P. Pellegrini, G. Arbues, P. Perez Mesa  
and J. Pekolj
Hospital Italiano De Buenos Aires, Buenos Aires, 
Argentina
Background: Well differentiated neuroendocrine tumors 
(NET) are associated with long term survival. Aggressive 
resections are indicated in those patients with good perform-
ance status. Portal hypertension is a relative contraindication 
for pancreatic resections. The aim of this report is to present 
a case where a portacaval shunt was performed prior to a 
total pancreato duodenectomy for the treatment of a pancre-
atic NET.
Methods: a 66-year-old male patient with a NET in the head 
and body of the pancreas with liver metastases, is presented. 
FNA of the tumor demonstrated a well-differentiated NET 
(Ki67 < 2%). MR and CT Scan showed a tumor in the head 
and body of the pancreas, with portal invasion, collateral 
circulation and multiple liver metastases.
Results: prior to resection, a end-to-end shunt was per-
formed between a colic vein and the vena cava. A cadaveric 
iliac vein was used as a graft. Once the collateral circulation 
decreased, the total pancreato duodenectomy with splenec-
tomy was safely performed. The portal vein was resected and 
it was reconstructed with a cadaveric vein graft. An accessory 
right posterior artery was also replaced with a cadaveric artery 
graft. The patient was discharged at day 10 with no postopera-
tive complications. Liver transplantation will be considered 
if there is no evidence of progression within 6 months.
Conclusion: a portacaval shunt can be safely performed and 
it is useful to increase resection rate in patients with pancre-
atic NET and portal hypertension.
ANTECOLIC VS. RETROCOLIC GASTRO/
DUODENOJEJUNOSTOMY AND 
DELAYED GASTRIC EMPTYING (DGE) 
AFTER PANCREATICODUODENECTOMY
A. D. Parmar1,4, K. M. Sheffield1, G. M. Vargas1, 
H. A. Pitt2, E. M. Kilbane2, B. L. Hall3 and T. S. Riall1
1University Of Texas Medical Branch, Galveston, TX, USA; 
2Indiana University School Of Medicine, Indianapolis, IN, 
USA; 3Washington University School Of Medicine, St. 
Louis, MO, USA; 4University Of California San Francisco-
East Bay, Oakland, CA, USA
Objective: To evaluate the effect of antecolic vs. retrocolic 
gastro- (GJ) or duodenojejunostomy (DJ) on DGE after pan-
creaticoduodenectomy (PD) using a multi-institutional 
dataset.
Methods: During the initial 3 months of the American 
College of Surgeons-National Surgical Quality Improvement 
Program (ACS-NSQIP) Pancreatectomy Demonstration 
Project, data were prospectively collected on 358 patients 
undergoing pancreaticoduodenectomy (PD). Data on the 
position of the GJ/DJ in 265 patients and the effect on DGE 
were evaluated in bivariate and multivariate models.
Results: In 265 patients who underwent pancreaticoduo-
denectomy or total pancreatectomy, 167 (67%) underwent 
antecolic and 88 (33%) retrocolic GJ/DJ. In bivariate analy-
sis, DGE occurred in 16% of patients undergoing antecolic 
reconstruction and 25% of those undergoing retrocolic 
reconstruction (p = 0.08). Retrocolic reconstruction was 
associated with decreased use of preoperative biliary stents 
and intraoperative drains and higher rates of pylorus-preser-
vation, deep surgical site infection, and postoperative percu-
taneous drain placement. Pancreatic fistula and organ space 
surgical site infection (SSI) were similar between the two 
groups (Table). In a multivariate model controlling for 
pylorus-preservation, stent, organ space SSI, deep SSI, intra-
operative drains, and postoperative sepsis, patients undergo-
ing retrocolic anastomoses were 2.2 times more likely to 
experience DGE (CI = 1.06 to 4.5).
Conclusion: Our data demonstrate that retrocolic GJ/DJ is 
an independent predictor of DGE after PD, consistent with 
previous single institution retrospective studies and prospec-
tive, randomized trials. The multi-institutional nature of the 
study includes both high and low volume centers and pro-
vides further evidence of the ‘real-world’ effectiveness of 
antecolic reconstruction in prevention of this costly problem.
ISLET AUTOTRANSPLANTATION AFTER 
PANCREATECTOMY IN DIABETICS: IS 
IT WORTH IT?
A. Patel and K. Morgan
Medical University Of South Carolina, Charleston, SC, 
USA
In patients with debilitating pain from chronic pancreatitis, 
pancreatectomy with islet autotransplantation (IAT) can 
effect pain relief while ameliorating the brittle diabetes of 
the apancreatic state. IAT in patients who are diabetic preop-
eratively is controversial and outcomes have not been well 
examined. A prospectively collected database of patients 
undergoing TP-IAT over a 40 month period was reviewed. 
Patient demographics, insulin use, opiate use, laboratory 
values, and quality of life (QOL-SF12) scores were exam-
ined. IRB approval was obtained. 95 patients total underwent 
IAT over the study period. 18 patients were diabetic prior to 
IAT, 12 insulin requiring; 4 on oral hypoglycemic(s); and 2 
diet controlled. Mean islet harvest was 2,701 IEQ/kg, with 
mean 93.6% viability. At 6 months and one year, 15% and 
9% of patients were insulin independent, while the others 
were insulin requiring (compared to 27% and 25% at 6 
months and one year in nondiabetic group). In the insulin 
requiring group, mean daily insulin was 39.9U and 42.9U at 
6 months and one year (+2.9U at 6 months and +5.9 at 1 
year). All had hypoglycemic awareness. Physical and mental 
health QOL scores preoperatively averaged 29.2 and 37. At 
6 months and one year they were P-QOL 32.3 and 34.8 and 
MH-QOL 38.7 and 37.4. Diabetic patients often demonstrate 
islet function after IAT with minimal increase in exogenous 
insulin requirements and may receive associated benefits of 
C-peptide. TP-IAT improves QOL in patients with diabetes 
and debilitating pain from chronic pancreatitis. Longer term 
follow up is needed.
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RIGHT TRISECTONECTOMY WITH 
ANTERIOR APPROACH AND HANGING 
MANEUVER
J. Pekolj, L. Yazde, S. Rochet, G. Del Valle and  
E. De Santibanes
HPB Surgery And Liver Transplant Unit. Hospital Italiano 
De Buenos Aires, Buenos Aires, Argentina
Introduction: Surgical treatment of big right liver tumors 
presents a technical challenge. In order to prevent manipula-
tion of the tumor and liver remnant compression, the anterior 
approach has been described. This consist in section the right 
vascular pedicle, liver parenchyma and hepatic veins before 
liver mobilization. The last maneuver is the mobilization of 
right liver lobe. In order to make simpler the parenchymal 
transection and avoid injury to the inferior vena cava, 
Belghiti described the liver hanging maneuver. Material: we 
present the case of a 24 yo male with a huge tumor (30 cm) 
in segments 5,6,7,8 and 4. Intraoperative ultrasound shows 
indemnity of segments 1, 2 and 3.
Results: Right hepatic artery, right portal vein and bile duct 
are tight and cut. Segment 1 portal branches are tight and cut 
in order to expose anterior face of inferior vena cava. Hepatic 
veins and the plane between retrohepatic vena cava and liver 
are dissected. A Nelaton catheter is inserted and used to hang 
the liver during transection. Hepatic resection is achieved 
using intermittent Pringle maneuver. Intraoperative cholan-
giogram and hydraulic test are performed. Postoperative 
course was uneventful.
Conclusion: the combination of anterior approach and 
hanging maneuver made simpler and safer the resections of 
big right tumors.
SAFETY AND ADVANTAGES OF 
COMBINED RESECTION AND 
MICROWAVE ABLATION IN PATIENTS 
WITH BILOBAR HEPATIC 
MALIGNANCIES
P. Philips, R. W. Farmer, S. C. Schiffman,  
K. M. McMasters, C. R. Scoggins, G. Callender  
and M. C. Robert
University Of Louisville, Department Of Surgery, Division 
Of Surgical Oncology, Louisville, KY, USA
Background: Multimodality approach, including interstitial 
ablative technologies have significantly improved outcomes 
for hepatic malignancies. Microwave ablation is often used 
in isolation or subsequently after resections. Potential ben-
efits and pitfalls from combined resection and ablation 
therapy in patients with complex and extensive bilobar 
hepatic disease have not been well defined.
Methods: Review of a 2012 Hepato-Pancreatico-Biliary 
Patients database was performed with multi-focal bilobar 
disease that underwent microwave ablation with resection, 
microwave alone or resection alone were included. They 
were propensity-matched for resection type and disease-
burden from 2004–2010.
Results: 230 patients (75% metastatic, 55% Colorectal and 
13% Hepatocellular carcinoma) were treated with micro-
wave alone (Group A, n = 84), combination ablation and 
resection (Group B, n = 72) and resection alone (Group C, n 
= 72). The types of resections (major 55.5% vs. 66.6%, p = 
0.3), operative times (p = 0.8), blood loss (p = 0.1) and 
hospital-stay (p = 0.8), readmission rates (p = 0.9), complica-
tions (p = 0.7) and high-grade complications (p = 0.8) were 
not significantly different in Group B compared to resection 
alone (Group C), but were lower in microwave only group. 
Median follow-up for the cohort was 30 months, with OS 
was similar between the three groups (29, 26 and 28 months). 
Disease free survival was lower in Group B (13.2, 12.7 and 
20 months). Patients with colorectal metastasis showed 
similar results as the whole cohort except for higher overall 
survival rates (29,29 and 31 months).
Conclusion: The use of microwave ablation in addition to 
surgical resection did not significantly impact the morbidities 
or short-term outcomes. In combination with systemic and 
other local-regional forms of therapy, combined resection 
and ablation can give similar results, making a strong case 
for concurrent ablation and resection versus subsequent two 
staged resections.
62 Abstracts
© 2013 The Authors
HPB © 2013 Americas Hepato-Pancreato-Biliary Association HPB 2013, 15 (Suppl. 1), 1–87
PANCREATODUODENECTOMY IN 
AMERICA: DO PRACTICE PATTERNS 
VARY?
S. C. Pitt1, T. S. Riall2, M. E. Kilbane3, B. L. Hall1 and 
H. A. Pitt3
1Washington University In St. Louis, St. Louis, MO, USA; 
2University Of Texas Medical Branch, Galveston, TX, USA; 
3Indiana University, Indianapolis, IN, USA
Purpose: The aim of this study was to delineate the practice 
patterns of surgeons performing pancreatoduodenectomy 
(PD) in the United States.
Methods: During the initial three months of the American 
College of Surgeons-National Surgical Quality Improvement 
Program (ACS-NSQIP) Pancreatectomy Demonstration 
Project, data were prospectively collected on 523 patients, 
343 (66%) of whom underwent PD. Patient characteristics, 
comorbidities, laboratory data, operative factors, and out-
comes were consistent with recent reports of PD in the U.S.
Results: Preoperatively, half of PD patients (48%) were jaun-
diced by physical exam or bilirubin level, and 79% of this 
group had a biliary stent placed (94% endoscopically). The use 
of neoadjuvant chemotherapy (10%) or radiation (4%) was 
uncommon. Sixty percent of PDs were classic as opposed to 
pylorus-preserving procedures, and a minimally invasive 
approach was undertaken in 3% of cases. Venous resection was 
performed in 17% of PDs, while arterial resection was carried 
out in 4%. Pancreatic anastomoses were most commonly pan-
creaticojejunostomy duct-to-mucosa (74%) followed by 
invagination (24%); pancreaticogastrostomy was rarely uti-
lized (2%). Gastro- and duodenojejunostomies were antecolic 
65% of the time. Drains were employed in 86% of patients, 
and postoperative day (POD) 1 drain amylase was measured 
after 29% of cases. In addition, the percentages of drains 
removed by POD 3 and 7 were 4% and 48%, respectively.
Conclusion: This early analysis of the ACS-NSQIP Pan-
createctomy Demonstration Project suggests that considera-
ble variation exists in the practice patterns of surgeons 
performing pancreatoduodenectomy in America. Evaluating 
and reducing variations in surgical technique and drain man-
agement may improve postoperative outcomes.
3-D ADVANCED IMAGING FOR 
DETAILED DELINEATION OF LIVER 
SEGMENTAL ANATOMY IN PRE-
SURGICAL PLANNING
S. Rahmanuddin, Y. Genyk, H. Anoushiravan, D. Tahour, 
S. Cen, G. Whang, V. Duddalwar and S. Palmer
Keck Medical Center, University Of Southern California, 
Los Angeles, CA, USA
Background: The purpose of this study is to compare 2D 
vs. 3D method for measuring liver segmental volumes-prior 
to transplant surgery. We analyzed the livers of 29 patients 
prior to liver transplant surgery. Multi-phase CT and MR 
images of the abdomen with intravenous contrast were trans-
ferred into two different imaging workstations. Vitrea 
(version 4.1 version 4.1.8.0 Vital Images, MI USA) used for 
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2D and AZE (version 3.2 2 AZE of America, CA, USA) used 
for 3D liver volume measurement. 3D measurement were 
obtained, using the semi-threshold method. Portal and 
hepatic veins were extracted from CT images using the semi-
automated threshold method. If required, the images were 
edited with the manual tool on specific slices and analyzed 
in surgical simulation mode for total liver volume measure-
ment. Left and right lobes of the liver were separated from 
the cutting mode tool using the middle hepatic vein. Portal 
and hepatic vascular anatomy were defined for surgical plan-
ning, displayed in the live transparent view. For the 2D 
measurement, liver margins were outlined with software 
enabled free hand tool on alternate sections, edited manually 
and total liver, right and left lobe volumes were measured. 
The paired t-test was used to compare the mean liver volumes 
between 2D and 3D. Pearson correlation, and Intraclass cor-
relation (ICC2, 1) was used to examine the agreement 
between 2D and 3D and The Bland & Altman plot was used 
to display the pattern of discrepancies.
HEPATIC ISCHEMIC 
PRECONDITIONING INCREASES 
PORTAL BLOOD FLOW IN 
EXPERIMENTAL LIVER ISCHEMIA/
REPERFUSION INJURY IN RATS
E. Ramos Figueira1,2, J. A. Rocha Filho1,3, M. Nakatani4, 
E. R. Tatebe5, V. Oliveira Andre6, M. F. Souza Buto5, 
F. F. Galvao1,7, E. Chaib1,7, C. Lanchotte1, I. Cecconello2 
and L. C. D’ Albuquerque1,7
1Laboratory Of Medical Investigations – LIM37, University 
Of SAo Paulo School Of Medicine, Sao Paulo, SP, Brazil; 
2Discipline Of Digestive Surgery, Department Of 
Gastroenterology, HC-FMUSP, Sao Paulo, SP, Brazil; 
3Discipline Of Anestesiology, University Of Sao Paulo 
School Of Medicine, Sao Paulo, SP, Brazil; 4Scientific 
Initiation FAPESP 2011/09434–8, University Of Sao Paulo 
School Of Medicine, Sao Paulo, SP, Brazil; 5Scientific 
Initiation, University Of Sao Paulo School Of Medicine, 
Sao Paulo, SP, Brazil; 6Scientific Initiation FAPESP 
2011/08759–0, University Of Sao Paulo School Of 
Medicine, Sao Paulo, SP Brazil; 7Discipline Of Liver And 
Gastrointestinal Transplant, Department Of 
Gastroenterology, HC-FMUSP, Sao Paulo, SP, Brazil
Background: The microcirculatory dysfunction after liver 
ischemia/reperfusion injury may cause a disturbance in liver 
macro hemodynamic. We aimed to evaluate the hemody-
namic of portal venous system after experimental warm liver 
IR injury.
Methods: Fifty-six Wistar rats were divided into 4 groups: 
Sham; Resection Control (RC): rats submitted to resection 
of right and caudate liver lobes; Ischemia (IR): rats subjected 
to 60 min of warm liver ischemia of left and median lobes, 
followed by resection of non-ischemic lobes at reperfusion; 
Ischemic Preconditioning (IPC): rats were submitted to IPC 
for 10 min and 10 min of reperfusion, followed by 60 min 
of ischemia. Four and 12 h after reperfusion mean arterial 
pressure (MAP), mean portal venous flow (MPF) and mean 
portal venous pressure (MPP) were registered. At the end, 
blood was collected for AST and ALT, glucose, lactate, pH 
and potassium analysis.
Results: AST and ALT were increased in IR and ICP com-
pared to RC and sham groups at 4 h, but they were decreased 
in ICP at 12 h. MPF was decreased in ICP compared to RC 
at 4, but it was increase in ICP compared to IR at 12 h. MPP 
was decreased in ICP and IR groups at 4 h. Glucose was 
decreased in ICP and IR. Lactate was decreased in ICP com-
pared to IR at 12 h.
Conclusion: This warm liver ischemia/reperfusion model 
shows a 2 to 3-fold reduction of mean portal flow after 
60 min of ischemia. The ischemic preconditioning 
restores part of portal flow, leading to better metabolic per-
formance, demonstrated by lower lactate levels. (FAPESP 
2011/05214–3).
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SURGICAL TREATMENT OF BENIGN 
BILIOPANCREATIC DISEASES IN 
PATIENTS OVER 60 YEARS
E. Ramos Figueira1, T. Bacchella1, J. A. Rocha Filho2, 
C. N. Carneiro3, A. R. Assalin4, M. R. Ciongoli3, 
R. Jureidini1 and I. Cecconello1
1Discipline Of Digestive Surgery, Department Of 
Gastroenterology, Hospital Das Clinicas FMUSP, Sao 
Paulo, SP, Brazil; 2Discipline Of Anesthesiology, University 
Of Sao Paulo School Of Medicine, Sao Paulo, SP, Brazil; 
3Scientific Initiation, University Of Sao Paulo School Of 
Medicine, Sao Paulo, SP, Brazil; 4Scientific Initiation 
FAPESP 2011/22470–3, University Of Sao Paulo School 
Of Medicine, Sao Paulo, SP, Brazil
Background: Biliopancreatic surgery in elderly patients 
maybe associated with additional surgical risk. We aimed to 
evaluate clinical characteristics and early outcome of patients 
over 60 years with benign biliopancreatic diseases submitted 
to surgery.
Methods: We retrospectively evaluated 69 patients submit-
ted to biliopancreatic surgery at our Institution in 2010 and 
2011. We analyzed age, sex, diagnosis, comorbidities, BMI, 
ASA classification, cardiovascular risk, symptoms, surgical 
procedure, postoperative complications, mortality.
Results: There were 47 (68%) female, median age was 65 
yo (60–87) and BMI, 27.9 ± 5.3. Forty-two patients (61%) 
were ASA II, and 28 (41%) presented intermediate cardio-
vascular risk. Diagnosis was cholelithiasis in 59 (85.5%), 
bile duct stricture in 5 (7.2%), and other in 5 (7.2%), gall-
bladder polyp, pseudocyst of pancreas, intrahepatic lithiasis 
and coledochal cyst. The main comorbidity was high blood 
pressure in 76%. Surgical procedures were laparoscopic 
cholecystectomy (75.0%), open cholecystectomy (7.2%), 
biliodigestive anastomosis (14.4%), choledocotomy with 
drainage (1.7%) and cystic-enteric anastomosis (1.7%). 
Median length-of-stay was 2 (1–78). There Postoperative 
complications were 10% with one case of pneumonia and 
one sepsis. There was no postoperative mortality. The char-
acteristics of patients diagnosed with cholelithiasis were 
summarized in the table.
Conclusions: The main surgery in our series was cholecys-
tectomy. Although this is a safe procedure, showing no mor-
tality in this study, patients over 60 yo deserves careful 
preoperative evaluation. The number of comorbidities and 
the increased cardiovascular risk may influence in the 8 to 
10% rate of postoperative morbidity.
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SURGICAL TREATMENT OF 
PANCREATIC NEUROENDOCRINE 
TUMORS: CLINICOPATHOLOGIC 
FEATURES
E. Ramos Figueira1, T. Bacchella1, J. A. Rocha Filho2, 
A. V. Fernandes3, J. Okubo3, R. Jureidini1, U. Ribeiro1 
and I. Cecconello1
1Discipline Of Digestive Surgery, Department Of 
Gastroenterology, Hospital Das Clinicas FMUSP, Sao 
Paulo, SP, Brazil; 2Discipline Of Anesthesiology, University 
Of Sao Paulo School Of Medicine, Sao Paulo, SP, Brazil; 
3Scientific Initiation, University Of Sao Paulo School Of 
Medicine, Sao Paulo, SP, Brazil
Background: Pancreatic neuroendocrine tumors (PNET) 
are rare neoplasms with heterogeneous presentation due to 
its various subtypes. The association between tumor size and 
survival is still controversial. We aimed to evaluate the clin-
icopathologic features of patients that underwent pancreatic 
resection of neuroendocrine tumors.
Methods: We retrospectively evaluated 30 patients with 
diagnosis of pancreatic neuroendocrine tumor that under-
went pancreatic resection at our Institution. Patients with 
distant metastasis were not included. We analyze age, sex, 
clinical diagnosis, surgical procedure, histology, tumor size, 
lymph node metastasis, and follow-up time.
Results: There were 16 (53%) women and 14 (47%) men 
with median age of 42 yo (20–79). Diagnosis was nonfunc-
tional PNET in 25% (7) of cases, insulinoma in 50% (16), 
gastrinoma in 9% (3), glucagonoma in 9% (3) and somatasti-
noma in 6% (1). Surgical procedure was duodenopancreate-
ctomy in 27% (8), distal pancreatectomies in 30% (9), 
enucleation in 27% (8 insulinomas), and other pancreatic 
resections in 16% (5). 27% of PNET were well differentiated 
and 73% were carcinomas. The median tumor size was 2.0 
(0.6–7.0) cm and the median follow-up time was 4.7 (0.03–
11.9) years. The table shows characteristics by diagnosis.
Conclusions: Nonfunctional PNET is associated with 
bigger tumor size and shorter follow-up time than insulinoma 
and other functional PNET.
CLOSER PROXIMITY TO THE 
TRANSPLANT CENTER IS ASSOCIATED 
WITH BETTER PHYSICAL HEALTH-
RELATED QUALITY OF LIFE AFTER 
LIVER TRANSPLANTATION
L. D. Redhage1, K. Harms1, D. E. Moore1, C. W. Pinson1 
and I. D. Feurer1,2
1Vanderbilt University Transplant Center, Nashville, TN, 
USA; 2Vanderbilt University Medical Center, Nashville, TN, 
USA
The distance between liver transplant candidates’ permanent 
residence and a transplant center has been associated with 
higher risk of wait-list mortality. The purpose of this study 
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is to test whether there is a relationship between distance and 
health-related quality of life (HRQOL) before and after liver 
transplantation. Distances from patients’ home address to the 
transplant center were determined based on zip codes and the 
most direct driving route. Longitudinal HRQOL was meas-
ured using the SF-36 Health Survey and a rolling enrollment 
process. Multivariate mixed effects models that controlled 
for time in relation to transplant, HCV infection status, age, 
sex, and race examined the relationship between distance and 
physical and mental HRQOL before and after liver transplan-
tation. Summary data are reported as mean ± SD. A total of 
706 adult liver transplant recipients (33% female, 91% Cau-
casian, 45% HCV positive, age at transplant 53 ± 10 years) 
completed 2847 HRQOL assessments (781 pre- and 2066 
post-transplant). Distance averaged 179 ± 223 miles (range: 
0 to 2261) and follow-up time at the last HRQOL assessment 
averaged 48 ± 50 months (range: 0.4 to 229). Pre-transplant 
physical and mental HRQOL scores were lower (both p < 
0.001) as time to transplantation was reduced. After control-
ling for model covariates, increased distance to the transplant 
center was associated with decreased post-transplant physi-
cal HRQOL (p < 0.001). Distance was not related to pre-
transplant physical HRQOL or to pre- or post-transplant 
mental HRQOL (all p ≥ 0.489). These data demonstrate that 
living further from the transplant center is associated with 
worse physical health-related quality of life after liver 
transplantation.
ASSOCIATION OF CONGENITAL 
PORTOSYSTEMIC SHUNT (CEPS)  
WITH HEPATOMA
A. Rege, P. Suhocki, C. Berg, D. Sudan and K. Ravindra
Duke University Medical Center, Durham, NC, USA
Background: CEPS is a rare condition which occurs 
without portal hypertension and is associated with anomalies 
(polysplenia, cardiac defects, GI & skeletal malformations). 
Presentations include encephalopathy and development of 
hepatic lesions such as FNH, adenoma, hepatoma etc.
Methods: We report an unusual patient with Type II CEPS 
developing a hepatoma, without underlying liver disease.
Results: A 37 year male presented with abdominal pain. 
Imaging revealed a 10.8 × 8.5 cm hypervascular right lobe 
liver mass. Incidentally a small but patent portal vein and a 
large splenorenal shunt was seen (Fig. 1). Left lobe liver 
biopsy showed moderate to severe hepatocellular iron. 
Tumor markers were normal. Hereditary hemochromatosis 
was ruled out. At surgery, there was no evidence of portal 
hypertension, the hepatic artery was large and the portal vein 
was atretic but patent. A right hepatectomy was performed 
without incident. Since there was no prior encephalopathy, 
the splenorenal shunt was left alone. Postoperatively liver 
functions normalized in 3 weeks. Pathology revealed a mod-
erately differentiated hepatocellular cancer without macrov-
ascular or extrahepatic nodal disease.
Conclusions: CEPS is an anomaly that can rarely lead to 
the development of liver tumors. We report the successful 
resection of a hepatoma developing in young man with Type 
II CEPS. Long term follow up of these patients for the pos-
sible development of encephalopathy of pulmonary hyper-
tension has been recommended.
SERUM IGFBP2 AND MSLN AS 
DIAGNOSTIC AND PROGNOSTIC 
BIOMARKERS FOR PANCREATIC 
ADENOCARCINOMA
R. C. Repko1, Z. W. Kendrick1, M. A. Firpo1,4, 
C. L. Scaife1,4, D. G. Adler2,4, K. M. Boucher3,4 and 
S. J. Mulvihill1,4
1Department Of Surgery, Salt Lake City, UT, USA; 
2Division Of Gastroenterology And Hepatology, Salt Lake 
City, UT, USA; 3Department Of Oncological Sciences, Salt 
Lake City, UT, USA; 4Huntsman Cancer Institute, Salt Lake 
City, UT, USA
Early diagnosis and establishing prognosis through biomar-
kers is a focus in research of pancreatic ductal adenocarci-
noma (PDAC). Insulin-like growth factor binding protein 2 
(IGFBP2) and mesothelin (MSLN) were identified as 
potentially valuable biomarkers from a compendium of 
secreted proteins that are routinely over expressed in 
PDAC. Both proteins have shown potential as serum 
biomarkers in other cancer types, but have not been previ-
ously studied in serum of patients with PDAC. IGFBP2 
and MSLN levels were quantified in sera by using com-
mercial ELISA kits in a cohort of 84 PDAC patients, 84 
healthy control subjects (CON), and 40 chronic pancreatitis 
(ChPT) patients. Linear regression models related IGFBP2 
and MSLN to gender, age, stage, class, treatment, and sur-
vival. Serum levels of IGFBP2 and MSLN were signifi-
cantly elevated in PDAC subjects relative to ChPT patients 
(P = 0.0007 and P = 0.014 respectively) and healthy 
control subjects (P = 0.0265 and P < 0.0001 respectively). 
Serum levels of both proteins were significantly related to 
age (P = 0.0017 and P = 0.00029 respectively). Both 
IGFPB2 and MSLN were diagnostic for PDAC in age 
adjusted models when compared to all control subjects as a 
single group (P = 0.032 and P = 0.002 respectively). 
MSLN yielded 17% sensitivity at 95% specificity and 
IGFBP2 yielded 22% sensitivity at 95% specificity. Serum 
levels of neither protein were significantly related to sur-
vival in our cohort. Serum IGFBP2 and MSLN are weak 
diagnostic classifiers individually, but may be useful in a 
diagnostic biomarker panel.
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FINANCIAL IMPLICATIONS OF 
COMMON BILE DUCT INJURIES 
DURING CHOLECYSTECTOMY: 
ANALYSIS OF THE NATIONWIDE 
INPATIENT SAMPLE OVER A  
10-YEAR PERIOD
T. Rogers1, S. Varadarajulu2, R. Hawes2, S. Eubanks1, 
P. Arnoletti1 and S. G. De La Fuente1
1Florida Hospital, Division Of Surgical Oncology, 
Orlando, FL, USA; 2Florida Hospital, Division Of 
Gastroenterology, Orlando, FL, USA
Background: Common bile duct (CBD) injuries are a 
serious complication of cholecystectomy and a frequent 
cause of litigation against surgeons. To date, there is no avail-
able data regarding the financial implications related to these 
injuries. In this study, we investigated overall hospital 
charges in patients that suffered a common bile duct injury 
during both open and laparoscopic cholecystectomy over a 
decade-long period.
Methods: A retrospective reviewed of the Nationwide Inpa-
tient Sample for all patients with the principal diagnosis at 
discharge of a CBD injury (ICD-9 868.0–868.1) was per-
formed. The study period extended from 2001 to 2010. Hos-
pital charges are defined in the database as the amount the 
hospital charged for the entire hospital stay without including 
professional fees.
Results: A total of 46,769 discharged patients were found 
to have sustained a CBD injury during the 10 year study 
period with an annual mean of 4,677 patients, corresponding 
to 1.18% of both open and laparoscopic cholecystectomy 
cases performed. The mean length of stay for patients that 
sustained a CBD injury was 5.8 days with an average in-
patient mortality rate of 6.35% annually. This resulted in 
mean hospital charges of $215.8 million annually. In the year 
2010, hospital charges were $357.5 million or 25.5% higher 
than the previous year.
Conclusions: Injuries to the CBD are associated with pro-
longed hospital stay and elevated mortality rates. These 
injures impose a heavy financial burden on hospitals and 
insurance companies and charges appear to be on the rise.
IMPACT OF PERIOPERATIVE 
BEVACIZUMAB ON SURVIVAL IN 
PATIENTS WITH RESECTED 
COLORECTAL LIVER METASTASES: AN 
ANALYSIS OF LIVERMETSURVEY
Z. Rong1, G. Martel1, F. Vandenbroucke-Menu1, 
R. Adam2 and R. Lapointe1
1HPB Surgery And Liver Transplantation Unit, Hopital 
Saint-Luc, Universite De Montreal, Montreal, QC, 
Canada; 2Hepatobiliary Center, Hopital Paul Brousse, 
Villejuif, Cedex, France
Background: Perioperative chemotherapy and hepatic 
resection are recommended for the management of colorectal 
liver metastases (CRLMs). This work examined the impact 
of perioperative bevacizumab on survival in patients with 
resected CRLMs.
Methods: A multicenter retrospective cohort of patients 
with resected CRLMs was analyzed from the LiverMetSur-
vey International Registry. Patients who received periopera-
tive FOLFOX (group A) were compared to those who 
received FOLFOX and bevacizumab (group B).
Results: In total, 501 patients were compared (A, n = 384; 
B, n = 117). Group A was older (67.2 vs. 61 yrs, p < 0.01), 
had more rectal cancers (31 vs. 19%, p < 0.01), and lower 
CEA levels at diagnosis (121.8 vs. 140.7 ng/mL, p = 0.03). 
No difference was observed regarding gender, primary tumor 
stage, or number and size of metastases. Infectious postop-
erative complications were more frequent in group B (5 vs. 
14%, p < 0.01). The use of perioperative bevacizumab did 
not influence the 3-year overall survival (OS) (76.4 vs. 
79.8%, p = 0.33), and had no effect on 3-year disease-free 
survival (DFS) (7.4 vs. 7.9%, p = 0.08). At multivariate 
analysis, OS was inversely associated with the absence of 
clinical response or progression after postoperative chemo-
therapy (p = 0.05). Similarly, DFS was associated with 
primary tumor lymph node positivity (p = 0.01), synchronous 
presentation (p = 0.02), and the absence of response after 
postoperative chemotherapy (p = 0.03).
Conclusions: While bevacizumab may be important to 
increase tumor response rate, its perioperative addition to 
standard chemotherapy does not appear to be associated with 
improved OS or DFS in patients with resected CRLMs.
EXTENDED NEOADJUVANT 
CHEMOTHERAPY FOR BORDERLINE 
RESECTABLE PANCREATIC CANCER 
DEMONSTRATES PROMISING 
POSTOPERATIVE OUTCOMES AND 
SURVIVAL
J. B. Rose1, F. Rocha1, A. Alseidi1, T. Biehl1, R. Moonka1, 
J. Ryan1, B. Lin2, V. Picozzi2 and S. Helton1
1Virginia Mason Medical Center – Department Of Surgery, 
Seattle, WA, USA; 2Virginia Mason Medical Center – 
Department Of Hematology/Oncology, Seattle, WA, USA
Introduction: The optimal duration of neoadjuvant chemo-
therapy for patients with borderline resectable pancreatic 
cancer has yet to be established. Herein we report the surgi-
cal outcomes of a 6 month regimen of gemcitabine and 
docetaxel prior to resection.
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Methods: All patients between 2008–2012 with borderline 
resectable pancreatic cancer by the AHPBA/SSO criteria 
offered neoadjuvant chemotherapy at our institution were 
enrolled in the study. Medically fit patients who completed 
6 months of chemotherapy and had no radiographic signs of 
progression were offered an operation for curative intent.
Results: 57 patients with borderline resectable pancreatic 
cancer started neoadjuvant therapy. 21 (37%) patients had 
progression of disease, chemotherapy toxicity, or medical 
comorbidities that precluded operation. 36 (63%) patients 
completed neoadjuvant therapy and underwent an attempt at 
resection. 7 (12%) were found to have incurable disease 
intraoperatively while 29 (51%) patients had a subsequent 
pancreatectomy. All resections were R0 with 10 (35%) 
requiring en bloc venous resections. There were no postop-
erative deaths at 90 days and 21% of patients had complica-
tions resulting in a 30 day readmission rate of 8%. The 
median overall survival of all 57 patients was 33 months and 
25 of 29 (86%) of the resected patients are alive with a 
median follow-up of 21 months.
Conclusion: Neoadjuvant chemotherapy for 6 months with 
gemcitabine and docetaxel is well tolerated, selects a subset 
of patients for curative surgery with low postoperative mor-
bidity, and is associated with favorable survival.
POSTERIOR SMA FIRST APPROACH 
FOR RESECTION OF LOCALLY 
ADVANCED PANCREATIC CANCER
J. Rose, F. Rocha, A. Alseidi, T. Biehl and S. Helton
Virginia Mason Medical Center, Seattle, WA, USA
Patients with locally advanced pancreatic cancer commonly 
require enblock resection of the SMV, PV and/or splenic vein 
with venous reconstruction. Dissection and separation of the 
pancreatic head from the SMA first prior to resection of the 
enblcok pancreas with SMV/portal vein has been shown to 
be safe, reduce blood loss and result in shorter portal vein 
clamp times. This video will illustrate the technique of using 
the posterior, ‘SMA artery first’ approach using a bipolar 
sealing device in patients with locally advanced pancreatic 
cancer.
CORRECTION OF PRE-OPERATIVE 
ANEMIA WITHOUT BLOOD PRODUCTS 
MAY REDUCE THE NEED TO 
TRANSFUSE PATIENTS AFTER A 
PANCREATICODUODENECTOMY
A. J. Rubinstein , C. Devulapalli, J. A. Graham,  
A. B. Parker and L. B. Johnson
Georgetown University Hospital, Washington, DC, USA
Introduction: In a pancreaticoduodenectomy (PD) a sig-
nificant amount of blood loss may be encountered. As such, 
performing a PD on a patient that refuses transfusions is 
considered a relative contraindication to this operation. 
However, at our institution we have a devised protocol 
through our Bloodless Medicine Group that may offset the 
need for transfusions in the perioperative period.
Methods: We have performed PDs on 3 Jehovah’s Witness 
patients after extensive counseling. We performed our 
first PD on a patient with pancreatic duct ectasia without 
pre-operative hemoglobin (Hb) management as the pre-oper-
ative Hb was above our threshold for treatment (12.5 g/dL). 
We subsequently performed PDs on 2 more patients with Hb 
< 12.5 g/dL with pancreatic adenocarcinoma. In these 2 
patients, anemia management consisted of 3 weekly doses of 
both epoietin alfa (40,000 units/dose) and intravenous ferric 
gluconate (250 mg).
Results: Pre-operative anemia management resulted in a 
16–34% increase in Hb prior to the PD (table 1). More 
importantly, there were no transfusions of blood products 
performed on these patients in the peri-operative period. 
Mean estimated blood loss was 425 ml, length-of-stay 8.6 
days and there were no complications.
Conclusion: Transfusions have long been known to cause 
immunosuppression in patients that may result in decreased 
survival following resection for cancer. While the patients 
involved in this study had a religious predilection not to 
receive blood products, we feel that this management can be 
extended to all patients undergoing a PD and facilitate longer 
survival.
ROBOTIC-ASSISTED RIGHT HEPATIC 
RESECTION, EXTRAHEPATIC  
VEIN LIGATION
M. S. Sabbaghian, D. L. Bartlett and A. Tsung
University Of Pittsburgh Medical Center, Pittsburgh,  
PA, USA
Purpose: Robotic-assistance offers several advantages for 
certain surgical procedures. Its use has been and is being 
investigated for its application in liver resection. This video 
demonstrates robotic-assistance for right hepatic resection 
with laparoscopic technique used to isolate and ligate the 
right hepatic vein in an extra-hepatic manner.
Method: The Da Vinci Surgical System was used in com-
bination with laparoscopy to isolate and resect the right 
hepatic lobe in a patient with colorectal cancer metastatic to 
the liver.
Results/conclusion: Robotic-assisted right hepatic resec-
tion can be safely achieved. Laparoscopy is helpful for extra-
parenchymal isolation/ligation of the right hepatic vein when 
this is important.
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PROGRESSION AND MANAGEMENT OF 
ADVANCED DUODENAL POLYPOSIS IN 
PATIENTS WITH FAMILIAL 
ADENOMATOUS POLYPOSIS
P. Serrano, D. Kim, R. Grant, G. May, P. Kortan, T. Berk, 
H. Al-Ali and S. Gallinger
University Of Toronto, Toronto, ON, Canada
Purpose: To describe the natural history of advanced duo-
denal polyposis in patients with familial adenomatous poly-
posis (FAP) and to evaluate the outcomes of endoscopic 
surveillance, endoscopic intervention and surgery.
Methods: Retrospective review of 94 patients with FAP and 
advanced duodenal adenomatosis followed from 1982–2012 
with side-viewing endoscopy. The appearance of the duode-
num was classified as Stage 1–5.
Results: Patients had a median of 9 endoscopies (range = 
2–25) over an 11-year median (range = 1–26). First endos-
copy was performed at median age 35-years (range = 19–67), 
11-years after colectomy. Median age at diagnosis of Stage-
3-disease (adenoma 2.1–10 mm) was 41-years and Stage-4-
disease (adenoma > 10 mm) was 45-years. There was a 47% 
risk of progression from Stage-3 to 4 by 5 years. The risk of 
progression from advanced duodenal polyposis to cancer 
was 4.9% by 5 years. Larger polyp size was associated with 
the presence of high-grade dysplasia (HGD) (p < 0.001). 
Duodenal cancer developed in 9 (9.6%) patients at median 
age 57-years (range = 51–66), 1.7-years (range = 1–13) after 
being diagnosed with HGD. There were 47 (50%) patients 
that underwent endoscopic polypectomies with 9 endoscopic 
ampullectomies. Twenty patients underwent resection of 
periampullary neoplasms at median age 51-years (range = 
29–71), including 9 (43%) pancreaticoduodenectomies, 8 
(38%) open polypectomies/ampullectomies and 3 (14%) seg-
mental duodenal resections. There were 16 (17%) deaths in 
the cohort, 3 of which were attributed to duodenal/ampullary 
cancer.
Conclusions: Most advanced duodenal adenomas progress 
to worse stages; however, the rate of progression to carci-
noma is slow. Aggressive endoscopic and surgical interven-
tion, especially in the presence of large polyps and HGD is 
recommended to prevent cancer deaths.
IPMN TYPE BUT NOT GRADE  
OF DYSPLASIA IS ASSOCIATED  
WITH SMOKING
K. M. Shaffer1, M. R. Barron1, E. C. Sturm1, C. Schmidt1, 
M. A. Al-Haddad2, J. M. Dewitt2, J. A. Waters1 and 
C. M. Schmidt1
1Indiana University School Of Medicine Department Of 
Surgery, Indianapolis, IN, USA; 2Indiana University School 
Of Medicine Department Of Gastroenterology, 
Indianapolis, IN, USA
Smoking has been strongly associated with pancreatic aden-
ocarcinoma. The influence of smoking on IPMN, a group at 
significant risk for pancreatic adenocarcinoma, however, is 
unclear. We hypothesized that smoking history increases the 
incidence of malignant (high grade and invasive) IPMN. 360 
patients underwent resection for IPMN at an academic 
medical center (1992–2012). Of these, 264 had adequate data 
on smoking history for analysis of clinical, pathologic, and 
demographic parameters. Heavy smokers were defined as 
> 25 cigarettes/day. Of 264 patients, 142 (54%) were 
smokers. The frequency of main-duct IPMN was higher in 
smokers versus nonsmokers, 60% versus 48% (p = 0.045), 
respectively. This association was more pronounced in 
females (65% vs 45%, p = 0.03) but insignificant in males 
(p = 0.57). Contrarily, there was no difference in the corre-
sponding rate of malignant IPMN. Among smokers, 34% had 
malignant IPMN compared to 34% in non-smokers (p = 
0.99). In heavy smokers, Invasive IPMN was present in 2 of 
22 (9%) compared to 27 of 122 (22%) non-smokers (p = 
0.14). In addition, there was no significant difference in 
tumor size, lymph nodes, differentiation, or stage of invasive 
IPMN between smokers and non-smokers. Despite the 
increased frequency of main duct IPMN in smokers, in 
patients undergoing resection for IPMN, smoking does not 
appear to be positively associated with the incidence of 
IPMN malignancy or pathologic stage of adenocarcinoma. 
IPMN dysplasia may be influenced differently by environ-
mental risk factors commonly associated with pancreatic 
adenocarcinoma.
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COMPARISON OF MICROWAVE 
ABLATION AND TRANSCATHETER 
ARTERIAL CHEMOEMBOLIZATION IN 
THE TREATMENT OF 
HEPATOCELLULAR CARCINOMA
L. A. Shirley, J. C. Henry, L. Malhotra,  
P. M. Bloomston and C. R. Schmidt
The Ohio State University Medical Center, Columbus, OH, 
USA
Purpose: Patients with cirrhosis and early stage HCC may 
not be candidates for surgical resection due to liver dysfunc-
tion or portal hypertension. Two common alternative thera-
pies are transcatheter arterial chemoembolization (TACE) 
and microwave ablation (MWA). We compared outcomes 
between HCC patients within Milan criteria after initial treat-
ment with TACE or MWA.
Methods: The records of 58 patients diagnosed with HCC 
within Milan criteria and treated initially with either TACE 
or MWA were reviewed. Pre-treatment factors, perioperative 
outcomes and survival were compared between the groups.
Results: There were 36 patients within Milan criteria treated 
with MWA and 22 treated with TACE. Pre-treatment AFP 
levels were higher in the TACE group (Table). Treatment 
with MWA was associated with progression-free survival 
(PFS) of 17.1 months compared to 8.9 months after TACE 
(p = 0.56). Disease-specific survival (DSS) was higher in the 
MWA group (median not reached) than the TACE group 
(32.0 months, p = 0.047, Graph). Local recurrence rate at one 
year after MWA was 13.8%. Patients treated with MWA 
spent slightly less time in the hospital and showed a trend to 
fewer complications. Nine (15.5%) patients in this cohort 
went on to receive liver transplantation after MWA or TACE.
Conclusions: Treatment with either MWA or TACE for 
patients with cirrhosis and unresectable HCC within Milan 
criteria is generally safe and initially effective, but recurrence 
of HCC and eventual death due to HCC or cirrhosis is 
common. These therapies should be a bridge to liver trans-
plantation for all appropriate candidates until better systemic 
therapies increase cure rates.
ALTERED LYSOPHOSPHATIDIC ACID 
RECEPTOR EXPRESSION DURING 
HEPATIC REGENERATION
K. A. Simo, E. M. Hanna, K. J. Thompson,  
D. J. Niemeyer, A. L. Eheim, E. Sokolov, D. Sindram,  
D. A. Iannitti and I. H. McKillop
Carolinas Medical Center, Charlotte, NC, USA
Introduction: Following partial hepatectomy (PHx) liver 
regeneration requires ordered G-protein signaling. The spe-
cific G-protein coupled receptors (GPCRs) that regulate 
regeneration remain to be elucidated. We hypothesized that 
lysophosphatidic acid receptors (LPARs), including the 
newly described LPAR6, may be involved in regulating 
hepatic regeneration.
Methods: Two-thirds PHx were performed (C57Bl/6 mice). 
Analysis of regeneration and LPAR1–6 mRNA (qRT-PCR) 
and protein (Western blot/immunohistochemistry; IHC) was 
performed.
Results: PHx resulted in mean resected liver weight of 57 
± 2.0% vs. control (C; no PHx). 96 Hrs post-PHhx livers 
were 94 ± 4.9% of C. LPAR2, 4 and 5 were not detected in 
C or regenerating liver (RgL). LPAR1 and 3 mRNA was 
detected at (relatively) low levels in C, while LPAR6 mRNA 
was readily detectable. Following PHx LPAR 1, 3 and 6 
mRNAs were significantly elevated (4–6 fold-LPAR1 and 3; 
20–25 fold-LPAR6), maximal increases being detected 
24 Hrs post-PHx correlating with changes in Gi/Gs-protein 
expression. Protein analysis of LPAR6 demonstrated signifi-
cantly elevated expression (6–8 fold, RgL vs C), maximum 
expression occurring 12–24 Hrs after changes in mRNA. 
LPAR6 protein in RgL was localized to hepatocytes in the 
absence of zonal distribution.
Conclusion: Our data demonstrate the newly identified 
LPAR6 is expressed in the liver. Furthermore, PHx leads to 
significantly increased LPAR1, 3 and 6-expression in RgL, 
the most pronounced differences being measured for LPAR6. 
These data provide important insight into the regulation of 
hepatic regeneration and, based on our previous studies, may 
have equally important implications during hepatocyte trans-
formation and tumor growth.
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ROBOTIC TRANSGASTRIC 
CYSTGASTROSTOMY AND PANCREATIC 
DEBRIDEMENT
K. A. Simo, R. Z. Swan, D. Sindram, D. A. Iannitti  
and J. B. Martinie
Carolinas Medical Center, Charlotte, NC, USA
Introduction: Walled-off pancreatic necrosis (WOPN), 
abscess and pseudocyst formation can be associated with 
significant morbidity and mortality. Percutaneous and endo-
scopic procedures may be effective in selected cases; 
however, if these approaches fail, surgical drainage is indi-
cated and can be performed in a minimally invasive fashion 
via a robotic approach.
Methods: We present our approach to WOPN in the lesser 
sac utilizing a robotic transgastric technique to perform a 
cystgastrostomy and debridement of pancreatic necrosis.
Results: A 75 year old male presents with a history of acute 
necrotizing pancreatitis secondary to gallbladder cholestero-
losis presents with a large lobulated WOPN (15.3 cm × 
7.9 cm and 4.9 cm × 4.6 cm). He remained asymptomatic 4 
months after initial presentation but the WOPN continued to 
increase in size. The patient undergoes a robotic transgastric 
cystgastrostomy and pancreatic debridement. The abdomen 
is insufflated and a camera port and 3 working ports are 
placed. After docking the robot, an anterior gastrotomy is 
made, the position of the WOPN confirmed with intraopera-
tive laparoscopic ultrasound, and a longitudinal posterior 
gastrotomy is made. Debridement of pancreatic necrosis and 
reinforcement of the posterior wall cystgastrostomy wall is 
performed with the robotic instruments entirely within the 
stomach. The anterior gastrostomy is closed, followed by 
laparoscopic port removal and port sites closure. The patient 
tolerated the procedure well and was discharged on postop-
erative day two.
Conclusion: Robotic transgastric cystgastrostomy and pan-
creatic debridement of WOPN with its ease of intracorporeal 
suturing offers another minimally invasive alternative to a 
technically challenging problem.
LAPAROSCOPIC MICROWAVE 
ABLATION OF LIVER TUMORS USING 
3D GUIDANCE SYSTEM IN HUMANS
D. Sindram, K. A. Simo, R. Z. Swan, D. J. Niemeyer,  
S. B. Lee, I. H. McKillop, D. A. Iannitti and J. B. Martinie
Carolinas Medical Center, Charlotte, NC, USA
Introduction: Accurate antenna placement is essential to 
achieve effective microwave ablation (MWA) and avoid 
recurrence. Laparoscopic targeting can be particularly chal-
lenging for liver tumors due to the needle trajectory as it 
passes through the abdominal wall into the liver. Previous 
infrared three-dimensional (3D) guidance systems were 
limited due to ‘line of sight’ interference in the operating 
room. To counter this, a new magnetic guidance system has 
been developed with sensors embedded in the MWA 
antenna. The aim of this study was to perform laparoscopic 
magnetic guidance and tumor ablation in a prospective clin-
ical trial.
Methods: Ten patients undergoing laparoscopic MWA of 
liver tumors were consented for enrollment. 3D lesion target-
ing was performed using an InnerOptic AIM™ guidance 
system that, coupled with a laparoscopic ultrasound trans-
ducer, tracks antenna position and orientation in real time 
with the exact physical relationship being represented on a 
stereoscopic monitor. The intersection of antenna trajectory 
and ultrasound image thus allows tumor targeting prior to 
antenna insertion through abdominal wall.
Results: A total of 36 ablations were performed on 28 
lesions. Median number of lesions per patient was 2. Median 
lesion diameter was 18 mm. Mean time to target acquisition 
was 4 minutes with a first attempt success rate of 92.9%. 
There were no intraoperative or immediate postoperative 
complications.
Conclusion: The AIM™ guidance system is an effective 
adjunct for laparoscopic ablation providing high efficiency 
for first attempt lesion acquisition and overcoming line of 
site interference associated with previously employed 
systems.
DISTINCTIVE LYSOPHOSPHATIDIC 
ACID RECEPTOR EXPRESSION IN 
HEPATOCELLULAR CARCINOMA
N. J. Skill, J. Wu and M. A. Maluccio
Indiana University, Indianapolis, IN, USA
Previous studies show lysophosphatidic acid (LPA) variant 
profile is unique to patients with HCC. Manifesting as an 
increase in arachidonyl-LPA and a reduction in linoleoyl-
LPA. This study focuses on LPA signaling in HCC to promote 
new biomarkers and pathways to target.
Methods: LPA receptor abundance in normal liver (OLT-
fascial closure biopsy), HEPC liver, HCC tumor and matched 
HEPC infected adjacent liver was quantified by qPCR. In 
vitro LPA variant affect on LPA receptor expression was 
examined using Hep3B and CL48 cells using qPCR to quan-
tify LPA receptor and TNFα expression.
Results: LPA3 receptor expression was significantly 
increased in HCC tumors when compared to normal, HEPC 
and adjacent tissue (P = 0.049). LPA3 : LPA1 ratio increased 
from 0.45 ± 0.08 to 1.04 ± 0.23 (P = 0.05). LPA3 and LPA2 
gene expressions were significantly greater in HEP3B cells 
when compared to CL48 cells ( > 4fold). Hep3B LPA recep-
tor and TNFα gene expressions were upregulated by ara-
chidonoyl-LPA but not linoleoyl-LPA. In contrast CL48 LPA 
receptor and TNFα expressions were downregulated by 
linoleolyl-LPA but not arachidonoyl-LPA.
Conclusion: Distinctive LPA receptor expression in HCC 
tumors, contemporaneous with changes in LPA variant 
metabolism and differences in LPA variant biological affect 
on hepatic cells, provides a unique LPA signaling back-
ground in HCC that can be utilized for diagnostic and thera-
peutic ends. While LPA1 and LPA3 have overlapping 
signaling components LPA3 does have unique secondary 
signaling cascades that can be targeted to abrogate tumor 
emergence and growth. Future experiments will focus on 
LPA receptor subtype affinity to individual LPA variants 
associated with HCC.
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THE CONTRIBUTION OF FOUNDER 
BRCA-PATHWAY GERMLINE 
MUTATIONS TO PANCREAS  
CANCER SUSCEPTIBILITY
A. Smith1,2, A. Hall1,2, A. Volenik1,2, H. Rothenmund1,2, 
G. Chong3, A. Omeroglu1, P. Metrakos1, W. Foulkes1 and 
G. Zogopoulos1,2
1The McGill University Health Centre, Montreal, QC, 
Canada; 2The Goodman Cancer Research Centre, McGill 
University, Montreal, QC, Canada; 3Molecular Pathology 
Unit, Department Of Pathology, Jewish General Hospital, 
Montreal, QC, Canada
The BRCA-pathway genes (BRCA1, BRCA2, PALB2) 
account for a small fraction of hereditary pancreas cancer 
(PC), but may have a significant role in the French-Canadian 
(FC), Ashkenazi Jewish (AJ) and Eastern-European (EE) 
ethnicities where founder mutations in these genes occur. 
Therefore, in a clinic-based study, we are evaluating the 
contribution of founder BRCA-pathway mutations to PC 
susceptibility. To date, we have identified 22 FC, 8 AJ, and 
4 EE affected probands for testing. Testing for founder 
BRCA mutations (19 FC, 4 AJ, 12 EE) was performed using 
PCR/bead-based fluorescent detection (Luminex 200) and 
sequencing was used to test for the FC PALB2:c.2323C > T 
mutation. Two probands tested positive. First, a 60 year-old 
FC female with locally advanced PC, a personal history of 
breast cancer and a family history of PC, was found to carry 
the PALB2:c.2323C > T mutation. We also tested and found 
the proband’s mother, who had a PC diagnosis, to carry the 
mutation. Second, a 47 year-old FC male with metastatic PC 
and a family history of breast cancer, was found to carry the 
BRCA2:c.3170_3174delAGAAA mutation. Both patients 
were treated with platinum-based chemotherapy but demon-
strated different responses to treatment, with the BRCA2, but 
not the PALB2, mutation carrier showing a marked response 
to treatment. We report a PC kindred with a PALB2 mutation 
and disease segregation, strengthening the evidence for 
PALB2 as a PC susceptibility gene. Our data suggest that 
BRCA-pathway founder mutations contribute significantly 
to PC susceptibility and, that BRCA and PALB2 mutation 
carriers have different treatment responses.
WHEN THE OUTFLOW SLOWS: 
TECHNICAL AND DIAGNOSTIC 
CONSIDERATIONS FOR THE HEPATIC 
VENOUS ANASTAMOSIS IN PEDIATRIC 
LIVER TRANSPLANTATION
J. Sommovilla1, M. M. Doyle1,2, N. Vachharajani1, 
N. Saad1, M. Nadler2, Y. P. Turmelle1,2, A. Weymann1,2, 
W. C. Chapman1,2 and J. A. Lowell1,2
1Washington University, St. Louis, MO, USA; 2ST Louis 
Children’s Hospital, St. Louis, MO, USA
Problem: Hepatic venous outflow obstruction (HVOO) 
creates significant diagnostic and management dilemmas in 
the pediatric liver transplant population, particularly in tech-
nical variant grafts (TVG – split or reduced size), which are 
predisposed by size, position, and growth.
Methods: 134 liver transplants (70 TVGs) were performed 
in 124 patients between 1993 and 2011 at a single institution. 
The series was divided into two cohorts, by technique imple-
mented for caval anastomosis. Group 1, consisting of 95 
transplants (41 TVGs) utilized a continuous running anasto-
mosis. Group 2 (39 transplants, 29 TVGs), implemented a 
triangulated anastomosis. All transplants were reviewed for 
demographics, presentation, diagnosis, interventions, and 
outcome.
Results: The overall incidence of HVOO was 7/134 trans-
plants (5.2%). Six occurred in TVGs. In TVGs, Group 1 
incidence was 5/41 (12.2%) compared to 1/29 (3.45%; p = 
0.2, odds ratio 3.89) in Group 2. All patients presented with 
ascites and only two with abnormal liver function. Liver 
doppler was employed in all patients, with only three sug-
gesting HVOO. All patients underwent venogram with meas-
urement of pressure gradients. Venogram timing ranged from 
41 to 254 days post-transplant (median = 83 days). All 
patients with HVOO underwent venoplasty at diagnosis, 
requiring between 1 and 6 venoplasties, eventually resolving 
HVOO in all.
Discussion: HVOO incidence has improved since adopting 
the triangulated anastomotic technique. Ultrasound is not 
adequately sensitive to exclude HVOO, particularly in 
patients with persistent ascites > 3 months post-transplanta-
tion. Venogram should be performed in these patients, and 
venoplasty has been highly successful in treatment of HVOO.
OPERATIVE COMPLICATIONS 
ASSOCIATED WITH NON-THERAPEUTIC 
LAPAROTOMY IN PATIENTS WITH 
UNRESECTABLE PANCREATIC CANCER
P. M. Spanheimer, A. R. Cyr, J. R. Howe and J. J. Mezhir
University Of Iowa Hospitals And Clinics, Iowa City,  
Iowa, USA
Objective: To evaluate complications associated with non-
therapeutic laparotomy in patients with unresectable pancre-
atic cancer.
Methods: A retrospective chart review was performed to 
evaluate patients with pancreatic cancer taken to the operat-
ing room with curative intent that did not undergo pancrea-
tectomy. Complications were graded, and comparisons were 
made between patients who had a laparoscopy or laparotomy 
and were closed and those who had laparotomy plus a pro-
cedure (e.g., double bypass).
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Results: From 10/1997–8/2012, 56 patients were explored 
with curative intent. Preoperative endoscopic procedures 
were performed in 48 patients (85.7%). Pancreatectomy was 
aborted for M1 disease (n = 29, 51.8%) or local unresectabil-
ity/vascular invasion (n = 27, 48.2%). There were 51 patients 
who had a laparotomy, and of those 36 (70.6%) had an addi-
tional procedure performed. There were 20 patients (38.5%) 
who had either a diagnostic laparoscopy only (n = 5) or who 
had a laparotomy with no additional procedure performed (n 
= 15). Postoperative complications occurred in 23 patients 
(41.1%) (see Table below). There was 1 death within 30 days 
from the time of surgery (mortality rate = 1.8%). Patients 
who had a laparotomy plus an additional procedure per-
formed had significantly more overall complications and 
severe (grade 2/3) complications. Both groups had a similar 
rate of postoperative invasive procedures, treatment with 
palliative therapy, and overall survival.
Conclusions: In this study, patients with unresectable pan-
creatic cancer treated with palliative procedures had a high 
rate of complications and frequently required postoperative 
invasive interventions. Consideration for closure in select 
patients with unresectable pancreatic cancer amenable to 
endoscopic palliation following laparotomy may be 
justified.
TRANSECTION OF THE NECK  
OF THE PANCREAS: PANCREATIC  
DUCT ISOLATION
J. A. Stauffer, M. G. Mesleh and H. J. Asbun
Mayo Clinic, Jacksonville, FL, USA
Background: Pancreatic fistula (PF) rates after pancreati-
coduodenectomy (PD) remain problematic. We describe our 
technique of transection of the pancreas. Description: This 
technique is used during open and laparoscopic PD with a 
short video demonstrating this technique. An ultrasound 
coagulation device is used to perform the pancreas parenchy-
mal transection from caudal to cranial. The device is acti-
vated and slowly compressed into the tissue to allow for full 
sealing of the vessels and small ducts. As the dissection 
progresses, there is a subtle increase in vascularity indicating 
the proximity to the main pancreatic duct (MPD). The MPD 
can generally be identified and isolated with the use of blunt 
dissection or coagulation of surrounding structures as dem-
onstrated in the video. Once the MPD is identified, the duct 
is transected with cold scissors leaving a 1–2 mm stump 
protruding out of the remnant pancreatic surface. Ultrasound 
coagulation is used to transect the remainder of the paren-
chyma. A duct to mucosa anastomosis to the jejunal limb is 
used to create the pancreaticojejunostomy.
Results: From May 2009 to May 2012, 101 patients under-
went PD via an open (42) or lap (59) approach. Overall PF 
rate was 15% with grades of A, B, and C in 5%, 7%, and 3% 
respectively.
Conclusion: PF after PD is very difficult to prevent but the 
authors feel that this method of pancreatic parenchymal 
transection may result in sealed side branches at the cut 
margin surface of the pancreas while allowing for an undam-
aged MPD for use in a duct to mucosa reconstruction 
technique.
MATCHED COMPARISON BETWEEN 
ROBOTIC AND LAPAROSCOPIC MAJOR 
LIVER RESECTIONS IN PATIENTS WITH 
BENIGN AND MALIGNANT LIVER 
LESIONS
D. C. Sukato1, S. Tohme2, S. Reddy2, J. W. Marsh2, 
D. Geller2, D. Bartlett4 and A. Tsung2
1University Of Pittsburgh School Of Medicine, Pittsburgh, 
PA, USA; 2Division Of Hepatobiliary And Pancreatic 
Surgery, University Of Pittsburgh Medical Center, 
Pittsburgh, PA, USA; 4Division Of Surgical Oncology, 
University Of Pittsburgh Medical Center, Pittsburgh, PA, 
USA
Background: The utilization of robotics in major hepatobil-
iary resections has been increasing due to the current limita-
tions of laparoscopy. However, few studies have investigated 
the advantages and disadvantages of robotic-assisted 
approaches over laparoscopic surgeries. Therefore, the aim 
of this study is to compare the surgical outcomes of robotic 
and laparoscopic major hepatectomies associated with 
benign and malignant liver lesions.
Methods: A retrospective study was performed on 63 Uni-
versity of Pittsburgh Medical Center patients who underwent 
either a robotic (n = 21) or laparoscopic (n = 43) major 
hepatectomy between 2005 and 2012. Resections involving 
three or more segments are classified as major. Patients were 
individually matched in a 1:2 robotic to laparoscopic ratio 
based on, in order of priority, cirrhosis, steatohepatitis, ASA, 
diagnosis, BMI, age, and gender.
Results: Demographics, tumor, and other pre-operative 
parameters were similar. Additionally, there is no significant 
difference in EBL, OR time, complication rate, LOS, and 
90-days mortality (Table 1). Robotic liver resections had a 
longer in/out room time (452 vs. 331 minutes) and greater 
post-operative ICU admission rate (24% vs. 5%) compared 
to the laparoscopic group (p < 0.05). However, the robotic 
surgeries allowed for an increased rate of major resections 
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to be performed in a purely minimally invasive manner (62% 
vs. 26%, p = 0.004).
Conclusions: Major robotic hepatic resections are compa-
rable to major laparoscopic resections in terms of many 
intra-operative and post-operative variables. The robotic 
approach also allows for more major hepatectomies to be 
completed in a purely minimally invasive fashion over the 
laparoscopic cases.
PRIMARY CHOLEDOCHORRHAPHY IS 
ASSOCIATED WITH REDUCED 
COMPLICATIONS COMPARED TO 
T-TUBE DRAINAGE AFTER 
CHOLEDOCHOTOMY: A META-
ANALYSIS AND A SYSTEMATIC REVIEW
P. B. Sukharamwala, S. Parikh, H. Safi, N. Parikh,  
J. Smith, A. Ghani and P. DeVito
Northside Medical Center/Northeast Ohio Medical 
University, Youngstown, OH, USA
Background: Between 6 to 12% of people with cholelithi-
asis also have choledocholithiasis. Primary Bile duct closure 
and T-tube drainage are two options available for closure of 
choledochotomy after Common bile duct exploration. The 
aim of this meta-analysis was to analyze the outcomes of 
primary choledochorrhaphy versus T-tube drainage after 
common bile duct exploration for choledocholithiasis.
Methods: A systematic literature search was conducted 
using Embase, MEDLINE, Cochrane and PubMed databases 
on all randomized controlled trials (RCT) published between 
January 1980 and September 2012 reporting perioperative 
outcomes after primary choledochorrhaphy versus T-tube 
drainage after common bile duct exploration.
Results: Eight RCT were included comprising of 619 
patients. Primary choledochorrhapy was found to reduce the 
length of stay (weighted mean difference 95% confidence 
interval (CI), −1.09 [−1.59 to −0.60]; p < 0.0001), overall 
complications (odds ratio (OR) 95% CI, 0.47 [0.28, 0.80]; 
p = 0.005) and positive bile culture (OR 95% CI, 0.22 [0.10, 
0.45]; p < 0.0001) compared to T tube drainage. Whereas no 
significant differences were found in retained bile duct stones 
(OR 95% CI, 0.60 [0.23, 1.57]; p = 0.30), mortality (OR 95% 
CI, 0.44 [0.10, 1.81]; p = 0.25), biliary leak (OR 95% CI, 
0.58 [0.23, 1.42]; p = 0.23) and subhepatic collection (OR 
95% CI, 1.06 [0.30, 3.68]; p = 0.93).
Conclusion: Primary choledochorrhaphy should be the 
method of choice after choledochotomy for common bile 
duct exploration as it is associated with reduced length of 
stay and overall complications compared to T tube 
drainage.
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THERE IS NO SIGNIFICANT 
DIFFERENCE IN PERIOPERATIVE 
OUTCOMES AFTER 
PANCREATICOGASTROSTOMY VS 
PANCREATICOJEJUNOSTOMY FOR 
RECONSTRUCTION FOLLOWING 
PACREATICODUDENECTOMY: A META-
ANALYSIS AND SYSTEMATIC REVIEW
P. Sukharamwala, H. Safi, S. Parikh, P. DeVito, G. Bogen, 
N. Parikh and A. Ghani
Northside Medical Center/Northeast Ohio Medical 
University, Youngstown, Ohio, USA
Background: Pancreaticogastrostomy and pancreaticojeju-
nostomy are both options for reconstruction following pan-
creaticoduodenectomy. The aim of this meta-analysis is to 
analyze the overall patient benefit in utilizing pancreati-
cogastrostomy (PG) versus pancreaticojejunostomy (PJ).
Methods: A systematic literature search was conducted 
using Embase, MEDLINE, Cochrane and PubMed databases 
on all randomized controlled trials (RCT) published between 
January 1992 and September 2012 reporting perioperative 
outcomes of pancreaticogastrostomy and pancreaticojeju-
nostomy. The primary end-point was the incidence of Post-
operative pancreatic fistula. Secondary outcomes examined 
were the incidence of perioperative mortality, delayed gastric 
emptying, biliary leak, fluid collection, and overall 
complications.
Results: Five trials involving 669 patients were included in 
the meta analysis. No statistical significant difference was 
noted in the incidence of POPF (OR 0.7 (0.45, 1.10) 95% CI 
p = 0.13), delayed gastric emptying (OR 0.77 (0.47, 1.26) 
95% CI p = 0.29), perioperative mortality (OR 1.07 (0.43, 
2.66) 95% CI p = 0.88), overall complications (OR 0.79 
(0.56, 1.12) 95% CI p = 0.18) and biliary leak (OR (0.22, 
1.35) 95% CI p = 0.19). However the incidence of Fluid 
collection was less after PG compared to PJ (OR 0.51 (0.31, 
0.83) 95% CI p = 0.006).
Conclusions: Since there is no significant difference in peri-
operative outcomes of performing pancreaticogastrostomy 
versus pancreaticojejunostomy following pancreaticoduo-
denectomy, performing either of the technique for recon-
struction should be the surgeons preference.
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PROGNOSTIC LIMITATIONS OF THE 
CLINICAL RISK SCORE: A 
CONDITIONAL SURVIVAL ANALYSIS IN 
PATIENTS WITH COLORECTAL LIVER 
METASTASIS
M. Tan, J. M. Butte, M. Gonen, Y. Fong, P. J. Allen,  
T. Kingham, R. P. DeMatteo, W. R. Jarnagin and  
M. I. D’Angelica
Memorial Sloan-Kettering Cancer Center, New York, NY, 
USA
Background: This study analyzes the prognostic capability 
of the clinical risk score as survival time increases after 
margin-negative resection of colorectal liver metastasis.
Methods: Retrospective review of a prospectively main-
tained database of patients who underwent R0 resection 
of colorectal liver metastases from 1994 to 2004 at a 
single institution. Post-operative deaths were excluded. 
Disease-specific survival (DSS) was calculated from the 
time of initial hepatectomy using the Kaplan-Meier 
method.
Results: 808 consecutive patients were identified. Median 
follow-up for survivors was 87 months, with a 5-year DSS 
of 67%. The probability of further survival increased as sur-
vival time increased. For patients who were already 1 or 
3-year survivors, the conditional probability of surviving an 
additional 5 years was 64% and 68%, respectively. For 
3-year survivors (n = 589), DSS was no longer significantly 
different between patients with a low (0–2) or high (3–5) 
clinical risk score (p = 0.19). On multivariate analysis, only 
perineural invasion in the primary tumor predicted worse 
DSS after 3 years of survival (hazard ratio 1.5, 95% CI 
1.0–2.0, p = 0.045). Similarly, for those patients who 
remained disease-free at 3 years (n = 342), low or high clini-
cal risk score did not predict subsequent disease recurrence 
(p = 0.06).
Conclusion: After 3 years of survival, conventional base-
line clinicopathologic variables have limited ability to predict 
future survival. These data suggest the value of long-term 
post-operative surveillance regardless of the level of risk on 
initial presentation.
THE ANALYSIS OF FACTORS UPON 
VOLUMETRICAL AND FUNCTIONAL 
LIVER REGENERATION AFTER LIVER 
RESECTION
M. Taniguchi, K. Watanabe, T. Einama, K. Imai and  
H. Furukawa
Division Of Gastroenterologic And General Surgery, 
Asahikawa Medical University, Asahikawa, Hokkaido 
Japan
Background and aim: In living donor liver transplantation, 
liver regeneration is reported to be related with portal hyper-
tension, donor age, and graft volume. However, the factors 
upon liver regeneration in liver surgery are still unknown, 
because they are influenced by various perioperative factors. 
The aim of this study is to analyze the factors upon volu-
metrical and functional liver regeneration after liver resec-
tion. Patients and method The subject was 50 cases with liver 
resection (more than sectionectomy) between 01/11 and 
08/12. The age, indocyanine green-clearance (ICG R15), 
steatosis, fibrosis, portal hypertension, hepatic blood flow in 
hepatic accumulation ofTc-99m-GSA (GSA flow), and esti-
mated remnant liver volume were calculated as pre-operative 
factors. The liver and spleen volume, GSA flow and liver 
function test on 28 days after resection (28POD) were ana-
lyzed by pre-operative factors.
Results: There was the positive correlation between ICG 
R15 and GSA flow (p = 0.0381). The GSA flow on 28POD 
was significantly higher in the group of low ICG R15. 
Neither remnant liver volume nor liver function test after 
liver resection was influenced by ICG R15. The GSA flow 
and the value of PT-INR on 28POD were significantly higher 
in the group of low grade of liver fibrosis (p = 0.0298 and 
0.0445 respectively). However, remnant liver volume rate 
was not influenced by the grade of liver fibrosis. Other pre-
operative factors did not influence upon post-operative 
factors.
Conclusion: The hepatic blood flow in hepatic accumula-
tion of Tc-99m-GSA was reflected remnant liver function as 
an index of functional liver regeneration. The grade of liver 
fibrosis influenced upon the liver regeneration.
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LAPAROSCOPIC RADIOFREQUENCY 
ABLATION OF LIVER METASTASES 
FROM BREAST CANCER
Y. Tasci, E. Aksoy, H. Moore, H. E. Taskin, S. Aliyev,  
O. Agcaoglu, A. Siperstein and E. Berber
Cleveland Clinic, Cleveland, OH, USA
Background: There is controversy about the role of loco-
regional therapies for patients with liver metastases from 
breast cancer (LMBC). The aim of this study is to analyze 
the survival after laparoscopic radiofrequency ablation 
(LRFA) of LMBC, with a comparison to patients receiving 
systemic therapy (ST) alone.
Methods: Within 15 years, 24 patients underwent LRFA for 
LMBC who had failed or had incomplete response to ST. 
These were compared to 32 patients with LMBC who were 
matched by tumor size and number, but treated with ST 
alone. Clinical parameters and overall survival were com-
pared using t-test, chi square and Kaplan-Meier analysis.
Results: The groups were similar regarding hormone recep-
tor status and chemotherapy exposure. For the LRFA vs ST 
group, the dominant tumor size and number of tumors per 
patient was 3.7 ± 0.4 vs 2.4 ± 0.4 cm, and 2.6 ± 0.4 vs 3.3 
± 0.4, respectively (p = NS). At a median follow-up of 20 
months in LRFA group, 42% of patients developed local liver 
recurrence, 63% new liver and 38% extra-hepatic disease. 
The overall survival after diagnosis of liver metastasis was 
47 months in the LRFA and 9 months in the ST alone group 
(p = 0.0001). The 5-year survival after diagnosis of liver 
metastasis was 29% in the LRFA group, and zero in the ST 
alone group.
Conclusion: To our knowledge, this is the first study com-
paring RFA to ST alone for LMBC. Our results show that 
the survival after LRFA plus ST was better than that after ST 
alone.
TREATMENT SEQUENCING STRATEGY 
FOR HEPATIC EPITHELIOID 
HEMANGIOENDOTHELIOMA
R. M. Thomas1, M. J. Truty2, E. Choi3, S. A. Curley1, 
J. Vauthey1, E. K. Abdalla4 and T. A. Aloia1
1The University Of Texas MD Anderson Cancer Center, 
Houston, TX, USA; 2Mayo Clinic, Rochester, MN, USA; 
3The University Of Chicago, Chicago, IL, USA; 4University 
Medical Center, Achrafieh, Beirut, Lebanon
Introduction: Hepatic epithelioid hemangioendothelioma 
(HEHE) is a disease with variable biology that lies interme-
diate between hemangioma and angiosarcoma. This study 
aimed to develop a treatment strategy as current regimens 
vary due to the rarity of the disease.
Methods: A retrospective analysis was performed for all 
patients treated for HEHE at a single institution from 1988–
2011. Clinicopathologic data and treatment regimens were 
correlated to tumor progression and survival data.
Results: Fifty patients with a median follow-up from diag-
nosis of 46.5 mo (range 1–322 mo) were evaluated. There 
was no difference in median overall survival (OS) for unilo-
bar vs. bilobar hepatic disease (55 mo vs. not reached) nor 
absence or presence of metastatic disease at diagnosis 
(124 mo vs. not reached), respectively. The mean time to 
progression of disease was longer for patients initially treated 
surgically (80.4 mo) vs. initially observed or treated 
non-surgically (29.8 and 22 mo, respectively; p = 0.03). 
Although there was no difference in median OS based on 
initial treatment regimen of observation, non-surgical, or sur-
gical treatment (not reached vs. 91 mo vs. 124 mo, respec-
tively), median OS for patients who received any systemic 
chemotherapy at any time was shorter than for those who did 
not (48 mo vs. not reached, respectively; p = 0.02).
Conclusion: HEHE tends to have an indolent clinical course 
with a small subset of patients having a more aggressive 
behavior that predicts poor outcome regardless of treatment 
strategy. These data suggest that patients should initially be 
observed to determine their biologic phenotype, reserving 
surgery for those patients with stable disease over time.
MICRO-RNA PROFILING IN A MOUSE 
MODEL OF OBESITY-PROMOTED HCC
K. J. Thompson, N. M. Steurewald, D. J. Neimeyer,  
D. A. Iannitti, I. H. McKillop and D. Sindram
Carolinas Medical Center, Charlotte, NC, USA
Hepatocellular carcinoma (HCC) is an increasingly diag-
nosed cancer in the USA and a huge global health burden. 
Risk factors include chronic ethanol consumption and viral 
hepatitis infection. Obesity is emerging as a risk factor, par-
ticularly in developed nations. MicroRNAs (miRNAs) are 
implicated in the pathology of cancers, including HCC, and 
have potential as therapeutic and diagnostic targets. The 
purpose of this study was to characterize miRNA expression 
in models of obesity- and EtOH-promoted HCC in the pres-
ence of the liver tumor promoter diethylnitrosamine (DEN).
Methods: Male C57BL/6 mice were injected with either 
vehicle (100 mL sterile olive oil) or DEN (5 mg/kg) at 25 d 
and randomized to 10% kcal% fat diet (CD) or 60% kcal% 
fat diet (HFD) at 5 wks of age. At 35 wks mice were weaned 
to either 10%/20% ethanol (EtOH) in drinking water (alter-
nating days) or maintained on drinking water (H2O) alone. 
Mice were maintained on respective diets until 42 wks, and 
then sacrificed. Livers were excised, examined for gross liver 
tumors and processed for histological and miRNA analysis.
Results: HFD H2O DEN treatment resulted in markedly 
increased tumor incidence (89% vs. 30% CD H2O DEN) and 
larger tumors (8/9). EtOH consumption had no effect on 
tumor incidence or size. Analysis of miRNAs revealed many 
significantly dysregulated miRNAs, including 34 and 17 
between HFD H2O DEN and HFD EtOH DEN paired tumor 
and non-tumor liver respectively.
Conclusion: MicroRNAs are dysregulated in obesity-pro-
moted HCC and further validation in human obese patients 
may generate markers for patients at risk for HCC.
METFORMIN DOES NOT INCREASE 
SURVIVAL FOR PATIENTS WITH 
DIABETES WHO UNDERGO 
PANCREATICODUODENECTOMY FOR 
PANCREATIC ADENOCARCINOMA
P. Toomey, S. Ross, A. Joseph, A. Teta, H. Paul,  
K. Luberice, K. Cohen and A. Rosemurgy
Florida Hospital Tampa, Tampa, FL, USA
Introduction: Recent studies denote that patients with pan-
creatic adenocarcinoma and diabetes treated with metformin 
have increased survival, especially when compared to 
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patients using sulfonylureas and/or insulin. These studies 
may be skewed because a majority of patients studied have 
had unresectable or metastatic pancreatic cancer. This study 
was undertaken to determine if metformin use is associated 
with increased survival for patients undergoing pancreati-
coduodenectomy for pancreatic adenocarcinoma.
Methods: Patients who underwent pancreaticoduodenec-
tomy for pancreatic adenocarcinoma from 1991–2012 were 
studied. Survival was evaluated by Kaplan-Meier analysis. 
Median data are presented.
Results: 413 patients underwent pancreaticoduodenectomy 
for pancreatic adenocarcinoma. 132 (32%) patients had dia-
betes: 35 (27%) patients were diet-controlled, 18 (14%) were 
treated with metformin alone, 24 (18%) were treated with 
metformin in addition to sulfonylureas/insulin, and 55 (42%) 
were treated with sulfonylureas/insulin alone. Patients 
treated with metformin did not have improved survival com-
pared to patients with diabetes not treated with metformin (p 
= 0.65) or patients treated with sulfonylureas/insulin (p = 
0.24). Diabetes and the use of sulfonylureas/insulin also did 
not correlate with survival.
Conclusion: Preexisting diabetes does not impact survival 
after pancreaticoduodenectomy for patients with pancreatic 
adenocarcinoma. Furthermore, for patients with preexisting 
diabetes, metformin does not increase survival for patients 
who undergo pancreaticoduodenectomy for pancreatic ade-
nocarcinoma. As well, sulfonylureas and/or insulin do not 
impact survival. The salutary impact of metformin is lost 
when patients undergo pancreaticoduodenectomy for pancre-
atic adenocarcinoma. Factors beyond diabetes and diabetes 
medication, including metformin, continue to be overriding 
predictors of survival for patients with resectable pancreatic 
adenocarcinoma.
NONTHERAPEUTIC LAPAROTOMY 
INCIDENCE IS NOT  
AFFECTED BY VOLUME OF 
PANCREATICODUODENECTOMY FOR 
PANCREATIC ADENOCARCINOMA
P. Toomey1, S. Ross1, C. Childs2, K. Patel1, K. Luberice1 
and A. Rosemurgy1
1Southeastern Center For Digestive Disorder And 
Pancreatic Cancer, Florida Hospital Tampa, Tampa, FL, 
USA; 2Morsani College Of Medicine, Tampa, FL, USA
Introduction: Nontherapeutic laparotomy for pancreatic 
adenocarcinoma is detrimental to patients by delaying 
medical treatment, increasing cost, and unnecessarily 
increasing morbidity/mortality. This study was undertaken to 
evaluate whether surgeon volume of pancreaticoduodenec-
tomy for pancreatic adenocarcinoma impacted the incidence 
of nontherapeutic laparotomy.
Methods: Patients undergoing exploration for pancreati-
coduodenectomy for pancreatic adenocarcinoma from 
2003–2012 were evaluated. Patients who underwent pan-
creaticoduodenectomy for other pathologies were excluded. 
Survival was calculated using Kaplan-Meier analysis. Asso-
ciation between surgeon volume and incidence of nonthera-
peutic laparotomy was assessed using Fisher’s exact test. 
Median data are presented.
Results: 443 patients with proven pancreatic adenocarci-
noma underwent exploration for pancreaticoduodenectomy 
by 8 surgeons; 329 (74%) patients underwent pancreaticodu-
odenectomy and 114 (26%) patients underwent nontherapeu-
tic laparotomy. Two surgeons undertook 85% of operations. 
Surgeon volume did not impact incidence of nontherapeutic 
laparotomy (p = 0.26). 77 (68%) patients had metastatic 
pancreatic cancer at the time of exploration, while 37 (32%) 
patients had locally advanced unresectable pancreatic cancer; 
these patients had survivals of 4.8 and 6.3 months, respec-
tively (p = 0.70).
Conclusion: A high proportion of patients, 1 in 4 at our 
institution, undergoing intended pancreaticoduodenectomy 
for pancreatic adenocarcinoma will ultimately undergo a 
nontherapeutic laparotomy with particularly short survival. 
Surgeon volume of pancreaticoduodenectomy for pancreatic 
adenocarcinoma does not influence the incidence of non-
therapeutic laparotomy. These superfluous nontherapeutic 
explorations can hopefully be minimized; limitations of 
current imaging technology may be overcome by using diag-
nostic laparoscopy, which should always be considered prior 
to undertaking pancreaticoduodenectomy for patients with 
pancreatic adenocarcinoma.
PATIENTS WITHOUT INSULIN-
DEPENDENT DIABETES OR 
HYPERLIPIDEMIA HAVE INCREASED 
SURVIVAL AFTER 
PANCREATICODUODENECTOMY FOR 
PANCREATIC ADENOCARCINOMA
P. Toomey, S. Ross, A. Joseph, A. Teta, K. Luberice,  
K. Cohen and A. Rosemurgy
Southeastern Center For Digestive Disorders And 
Pancreatic Cancer, Tampa, FL, USA
Introduction: The impact of preexisting insulin dependent 
diabetes mellitus (IDDM) and/or hyperlipidemia on survival 
after pancreaticoduodenectomy for pancreatic adenocarci-
noma is uncertain. We undertook this study to investigate the 
impact of diabetes and hyperlipidemia on survival after 
resection of pancreatic adenocarcinoma.
Methods: All patients who underwent pancreaticoduo-
denectomy for pancreatic adenocarcinoma from 1991–2012 
were evaluated. Survival was determined by Kaplan-Meier 
analysis. Median data are presented.
Results: A total of 413 patients underwent pancreaticoduo-
denectomy for pancreatic adenocarcinoma. Patients with 
IDDM and/or hyperlipidemia had a survival of 13 months, 
while patients without either comorbidity had a significantly 
improved survival of 20 months (p = 0.04). The impact of 
IDDM and/or hyperlipidemia on survival was independent 
from T-stage, N-stage, AJCC stage, margin status, or other 
comorbidities.
Conclusion: Long-term survival after pancreaticoduo-
denectomy for pancreatic adenocarcinoma can be achieved. 
Historically, cancer stage and margin status have been the 
overwhelming influences that dictate survival. However, 
IDDM and HLD have an independent predictive influence 
on survival after pancreaticoduodenectomy for pancreatic 
adenocarcinoma.
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CLINICAL AND FINANCIAL 
CONSIDERATIONS OF ESTABLISHING A 
HEPATOBILIARY CENTER DURING AN 
ECONOMIC CRISIS
G. Tsoulfas, E. Kastanias, A. Toolias, S. Kalamaras and  
G. Marakis
First Department of Surgery, Aristotle University of 
Thessaloniki, Greece
Objectives: In today’s society a complete evaluation of the 
management of hepatobiliary (HB) malignancies must take 
financial cost into consideration. Our goal is to analyze the 
clinical and financial data of managing primary or metastatic 
HB malignancies in a coordinated way.
Methods: A retrospective review of the files of a University 
Surgical Department within a period of 30 months revealed 
34 patients operated upon for primary or metastatic HB 
malignancies. Patients were divided into 3 groups by type of 
resection to evaluate the financial impact: major hepatic 
resection (Group 1), combined colorectal resection and hepa-
tectomy (Group 2), palliative procedure (Group 3). Demo-
graphic, clinical and financial data were analyzed.
Results: Of the 34 patients, 19 were operated for liver meta-
static disease, 11 for hepatocellular carcinoma (HCC) and 4 
for cholangiocarcinoma. Seventeen patients had undergone 
neoadjuvant chemotherapy, 3 preoperative hepatic artery 
chemoembolization, and 4 portal vein embolization. 26 
patients underwent an R0 resection and there were 4 deaths 
(none in the perioperative period). The data for the separate 
groups are presented in the Table. Group 1 patients had the 
highest cost because of the instruments required, but the 
shortest LOS (statistically significant) because of our fast-
track protocol.
Conclusion: Despite the limited number of cases, we 
believe that the coordinated management of primary and 
metastatic HB malignancies can lead to satisfactory results, 
in a financially sensible manner.
DISTINCT PREDICTORS OF PRE- 
VERSUS POST-DISCHARGE VENOUS 
THROMBOEMBOLISM AFTER 
HEPATECTOMY: ANALYSIS OF  
7,621 NSQIP PATIENTS
C. D. Tzeng, S. A. Curley, J. N. Vauthey and T. A. Aloia
The University Of Texas MD Anderson Cancer Center, 
Houston, TX, USA
Background: Hepatectomy patients are now known to be 
at significant risk for venous thromboembolism (VTE), but 
previous studies have not differentiated pre- vs. post-dis-
charge events. This study was designed to evaluate the 
timing, rate, and predictors of pre- (‘early’) vs. post-dis-
charge (‘late’) VTE.
Methods: All elective hepatectomies were identified in the 
2005–10 ACS-NSQIP participant use file. Perioperative 
factors associated with 30-day rates of early and late VTE 
were analyzed.
Results: The 7,621 total patients underwent 4,553 (59.7%) 
partial; 802 (10.5%) left; 1,494 (19.6%) right; and 772 
(10.1%) extended hepatectomies. Overall event rates 
included: deep venous thrombosis (DVT – 1.9%), pulmonary 
embolus (PE – 1.2%), and VTE (2.8%). Of these events, 
27.5% of DVT, 33.0% of PE, and 28.6% of VTE were post-
discharge. Median postoperative length of stay was 6 days. 
For late VTE, median presentation was postoperative day 14. 
Multivariate analysis determined that early VTE was associ-
ated with the following preoperative, intraoperative, and 
postoperative risk factors: age ≥ 75 (odds ratio, OR – 1.92, 
p = 0.007), male (OR 1.87, p = 0.002), intraoperative transfu-
sion (OR – 2.49, p < 0.001), operative time > 240 min (OR 
– 2.28, p < 0.001), organ space infection (OSI) (OR – 2.60, 
p < 0.001), and return to operating room (ROR) (OR – 3.25, 
p < 0.001). Late VTE was associated with only intraoperative 
and postoperative factors: operative time > 240 min (OR – 
2.35, p = 0.008), OSI (OR – 3.78, p < 0.001), and ROR (OR 
– 2.84, p = 0.011).
Conclusions: Approximately 30% of post-hepatectomy 
VTE occur post-discharge. These late VTE events occur in 
patients with clearly identifiable intraoperative and postop-
erative risk factors, providing a rationale for selective use of 
post-discharge VTE chemoprophylaxis after hepatectomy in 
high-risk patients.
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PREDICTING THE RISKS OF VENOUS 
THROMBOEMBOLISM VERSUS POST-
PANCREATECTOMY HEMORRHAGE: 
ANALYSIS OF 13,771 NSQIP PATIENTS
C. D. Tzeng, M. H. Katz, J. E. Lee, J. B. Fleming,  
P. W. Pisters, J. N. Vauthey and T. A. Aloia
The University Of Texas MD Anderson Cancer Center, 
Houston, TX, USA
Background: The fear of post-pancreatectomy hemorrhage 
can prevent surgeons from prescribing chemoprophylaxis for 
venous thromboembolism (VTE). This study was designed 
to analyze the incidence of and risk factors for postoperative 
VTE vs. postoperative bleeding complications in relation to 
extent of pancreatectomy.
Methods: All elective pancreatectomies were identified in 
the 2005–10 ACS-NSQIP participant use file. Factors associ-
ated with 30-day rates of VTE, post-pancreatectomy hemor-
rhage (PPH, defined as bleeding/transfusion > 4 units within 
72 hrs), and return to operating room (ROR), were 
analyzed.
Results: Pancreaticoduodenectomies (PD) and distal pan-
createctomies (DP) numbered 9,140 (66.4%) and 4,631 
(33.6%) of 13,771 pancreatectomies, respectively. Overall 
event rates included: deep venous thrombosis (2.16%), pul-
monary embolus (1.21%), VTE (3.1%), PPH (1.07%), 
ROR+PPH (0.65%). PD and DP had similar rates of VTE 
(3.0% vs. 3.3%), PPH (1.1% vs. 1.0%), and ROR+PPH 
(0.7% vs. 0.5%) (all p > 0.05). For both PD/DP, VTE rates 
exceeded PPH and ROR+PPH (2.8–6.6 times, p < 0.001). 
Multivariate analysis identified risk factors for VTE: preop-
erative hematocrit < 39 (odds ratio [OR] – 1.46, p = 0.003), 
age ≥ 70 (OR – 1.47, p = 0.002), BMI ≥ 30 (OR – 1.47, p = 
0.003), bleeding disorder (OR – 1.93, p = 0.010), preopera-
tive sepsis (OR – 1.98, p = 0.008), disseminated cancer (OR 
– 2.12, p = 0.001), operative time ≥ 360 min (OR – 1.30, p 
= 0.048), postoperative organ space infection (OR – 1.72, p 
= 0.001), ventilator dependence > 48 hrs (OR – 3.55, p < 
0.001). Patients with VTE suffered a 30-day mortality rate 
of 7.0% (vs. 2.5% non-VTE, p < 0.001).
Conclusions: PPH and ROR+PPH are rare events after both 
PD and DP. VTE rates outnumber major bleeding complica-
tions and provide a modifiable risk factor for post-pancrea-
tectomy mortality. The fear of PPH should not prevent 
routine postoperative VTE chemoprophylaxis in patients 
undergoing pancreatectomy.
PREDICTORS OF MORBIDITY AND 
MORTALITY AFTER HEPATECTOMY IN 
ELDERLY PATIENTS: ANALYSIS OF 7,621 
NSQIP PATIENTS
C. D. Tzeng, S. A. Curley, J. N. Vauthey and T. A. Aloia
The University Of Texas MD Anderson Cancer Center, 
Houston, TX, USA
Background: Increasingly, surgeons are performing hepa-
tectomies on older patients. This study was designed to 
analyze the incidence of and risk factors for post-hepatec-
tomy morbidity and mortality in this growing cohort.
Methods: All elective hepatectomies were evaluated in the 
2005–10 ACS-NSQIP participant use file. Perioperative 
factors associated with 30-day rates of morbidity/mortality 
were compared in patients ≥75 vs. <75-years old.
Results: Elderly patients accounted for 894 (11.7%) of 
7,621 hepatectomies. Compared to patients < 75, elderly 
patients had more comorbidities including diabetes, smoking, 
alcoholism, dyspnea, poor performance status, stroke, lung/
cardiovascular disease, lower albumin, elevated creatinine, 
thrombocytopenia, and higher anesthesia risk score (all 
p < 0.05). They received more partial/left hepatectomies 
(p = 0.013) and shorter operative times (median 204 min vs. 
223 min, p < 0.001). Elderly patients suffered a higher rate 
of severe complications (23.9% vs. 18.4%, p < 0.001, includ-
ing organ failure/sepsis, re-operations, organ space infec-
tions, venous thromboembolisms) and postoperative 
mortality (4.8% vs. 2.0%, p < 0.001). Severe complications 
resulted in 20.1% mortality in elderly vs. 10.8% in non-
elderly patients (p < 0.001). Multivariate analysis identified 
these risk factors for severe complications: lung disease 
(odds ratio, OR – 3.12, p = 0.002), intraoperative transfusion 
(OR – 2.43, p < 0.001), concurrent intra-abdominal operation 
(OR – 2.24, p = 0.003), and operative time > 240 min (OR 
– 2.76, p < 0.001). Independent factors associated with mor-
tality included albumin < 4g/dL (OR – 2.85, p = 0.017), 
intraoperative transfusion (OR – 2.37, p = 0.047), and opera-
tive time > 240 min (OR – 4.02, p = 0.003).
Conclusions: With less physiologic reserve, elderly patients 
who develop severe complications are at much greater risk 
of post-hepatectomy death. The cumulative effect of multiple 
risk factors in elderly patients indicates that to improve out-
comes, surgeons should balance preoperative comorbidities 
with magnitude of hepatectomy.
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SERUM CA 19–9 REPRESENTS A 
MARKER OF RESPONSE TO 
NEOADJUVANT THERAPY IN PATIENTS 
WITH BORDERLINE RESECTABLE 
PANCREATIC CANCER
C. D. Tzeng1, J. B. Fleming1, J. E. Lee1, P. W. Pisters1, 
T. A. Aloia1, J. N. Vauthey1, R. A. Wolff2, 
G. Varadhachary2, C. H. Crane3 and M. H. Katz1
1The University Of Texas MD Anderson Cancer Center, 
Houston, TX, USA; 2The University Of Texas MD Anderson 
Cancer Center, Houston, TX, USA; 3The University Of 
Texas MD Anderson Cancer Center, Houston, TX, USA
Background: We previously showed that radiographic 
change cannot be used as an indicator of treatment response 
to neoadjuvant therapy (NT) in patients with borderline 
resectable pancreatic adenocarcinoma (PDAC), and that the 
role of serial CA 19–9 measurements in patients with ana-
tomically resectable PDAC treated with NT is limited. We 
sought to determine the relationship between CA 19–9 levels 
and outcome in patients with borderline resectable PDAC 
treated with NT.
Methods: We evaluated all patients with borderline resect-
able PDAC, with CA 19–9 level ≥40U/ml and bilirubin 
≤2 mg/dL, who initiated NT at our institution (2001–2010). 
We evaluated the association between pre- and post-NT CA 
19–9, resection, and overall survival (OS).
Results: We identified 141 eligible patients. CA 19–9 
declined with NT in 116 (median −72%, range 0.3–99%) and 
increased in 25 (median +112%, range 2–564%). After com-
pleting NT, 83/141 (59%) patients underwent resection. As 
predictors of resection following NT, the positive predictive 
value of a decline in CA 19–9 and the negative predictive 
value of an increase were 69% and 88%, respectively. A 
decline in CA 19–9 was associated with longer median OS 
(14 vs. 8 months, p = 0.002) among unresected but not 
resected patients. CA 19–9 normalization (post-NT < 40U/
ml) was associated with a longer median OS among both 
unresected (15 vs. 11 months, p = 0.030) and resected 
patients (38 vs. 26 months, p = 0.001).
Conclusions: Serum CA 19–9 represents a dynamic preop-
erative marker of tumor biology and response to NT and 
provides useful prognostic information in patients with bor-
derline resectable PDAC.
NATIONAL TRENDS OF PANCREATIC 
CYSTIC LESIONS OVER AN 18-YEAR 
PERIOD
E. Vega1, S. Varadarajulu2, R. Hawes2, S. Eubanks1, 
P. Arnoletti1 and S. G. De La Fuente1
1Florida Hospital, Division Of Surgical Oncology, 
Orlando, FL, USA; 2Florida Hospital, Division Of 
Gastroenterology, Orlando, FL, USA
Background: Pancreatic cystic lesions are being increas-
ingly recognized on imaging studies obtained for unrelated 
reasons. Currently, there is a lack of data regarding the finan-
cial implications of these incidentally found lesions. In this 
study, we determined national trends in diagnosis, length of 
stay (LOS), overall charges, and in-patient mortality associ-
ated with the surgical treatment of pancreatic cystic lesions 
over an 18-year period.
Methods: The Nationwide Inpatient Sample database was 
queried to identify patients with pancreatic cystic lesions 
(ICD-9 577.2) discharged from 1993–2010. Hospital charges 
are defined as the amount the hospital charged for the entire 
hospital stay without including professional fees.
Results: A total of 109,069 patients were identified in the 
studied period. There has been as steady increase in the 
number of patients diagnosed with pancreatic cystic lesions, 
with 4,887 hospital discharges back in 1993 to almost dou-
bling to 8,420 in 2010, p < 0.001. The mean overall hospital 
charges per patient for the entire cohort were found to be 
$41,149, with a significant increment noticed over time 
($30,572 ± 1,843 in 1993 vs. $66,667 ± 4,318 in 2010, 
p < 0.001) (Table). The in-hospital death rate was 2.44% of 
all admissions in 1993 but went down to 0.84% in 2010, 
p < 0.01). More than 72% of all patients during this time 
were discharged home after a median LOS of 7 days.
Conclusions: The increasingly recognition of pancreatic 
cystic lesions has significantly implications in costs and 
health care resources utilization. Development of manage-
ment guidelines is crucial to overcome some of the financial 
burdens associated with these lesions.
RECOVERY OF HEPATIC FUNCTION 
AFTER GIANT HEPATIC ARTERY 
ANEURYSMECTOMY WITHOUT 
REVASCULARIZATION
E. Vega1, L. T. Chin2 and G. Vedula2
1Florida Hospital General Surgery Residency, 
Orlando, FL, USA; 2Florida Hospital Transplant Center, 
Orlando, FL, USA
Hepatic artery aneurysms are rare, but can cause significant 
morbidity and mortality. They carry the highest risk of 
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rupture of all visceral aneurysms and a 40% mortality. The 
incidence has increased over the last 20 years. Therapy has 
evolved with endovascular techniques improving. Open sur-
gical intervention may in many cases still be the best option. 
We present a patient in whom resection of a hepatic artery 
aneurysm was done without collateralization or vascular 
reconstruction. This aneurysm did not lend itself to endovas-
cular repair, given anatomical constraints. During open 
repair, it became evident that the hepatic arteries had throm-
bosed and occluded from the common hepatic artery to the 
bifurcation of the right and left hepatic arteries. No collater-
als where noted. The common bile duct was also eroded into 
and obstructed with thrombus. Given the condition of the 
liver, and the complex reconstruction that would be neces-
sary, it was decided to allow the liver to declare whether it 
would recover on portal blood flow alone. Fortunately for 
our patient, portal flow and oxygenation was sufficient for 
hepatic recovery. He underwent biliary reconstruction with 
roux-en-y hepatico-jejunostomy and continued to do well 
two months post-operatively. This case demonstrates how 
complex the management of hepatic artery aneurysms can 
be. Ligation of the common hepatic artery has been described, 
but arterial reconstruction is advised when no collateraliza-
tion is seen. Our patient, in whom no reconstruction was 
done and no collaterals noted, had sufficient portal flow for 
return of hepatic function.
BILIARY PERITONITIS DUE TO 
GASTRIC WALL PERFORATION AND 
LIVER PENETRATION AFTER 
SWALLOWING OF FOREIGN BODY
L. M. Veltchev1,2
1State Hospital, Biala Slatina, Vratza, Bulgaria; 2Privat 
Hospital ‘Clement Drevon’, Dijon, Bourgundy, France
Swallowing of foreign body is incidental and usually ends 
up with extraction by natural opening per vias naturalis. In 
small number of cases, when the body has sharp edges, 
complications after wall perforation of gastrointestinal tract 
and most dangerous secondary complications due to penetra-
tion and injury of life supporting organs such as liver, portal 
vein and aorta might be observed. A 52 years old female 
presented in emergency room of a district hospital with three 
days continuous pain in upper abdomen, vomiting and weak-
ness, fever to 38°C. Previous laboratory test confirmed 
inflammation. Abdominal US and upper endoscopy find no 
etiology. A control abdominal CT scan showed linear 52 mm 
foreign body that perforated pyloric wall and penetrated the 
liver. We performed diagnostic laparoscopy and found sharp 
chicken bone that perforated the pyloric wall and penetrated 
liver segment 5 causing fissure and bile leak. After extraction 
of the foreign body by trocar a 10 mm, we performed suture 
of the pyloric wall with a single resorbale suture Vicryl 2/0. 
Small, sharp bone parts may be swollen with food and cause 
symptoms of discomfort or provoke major gastrointestinal 
complications requesting surgical procedure. Review of the 
problem finds that fish or chicken bones are the most frequent 
etiology. Only its location between mouth and D2 duodenum 
and colorectal segment permitted to use endoscope for 
extraction. Double organ perforation with secondary major 
complications such as biliary leak, peritonitis, vascular 
injury or mechanical bowel obstruction needs emergency 
laparoscopy or laparotomy for dissolving the problem.
RADICAL SURGERY OF LIVER TUMORS 
INVOLVING HEPATIC VENOUS 
OUTFLOW WITH AND WITHOUT 
HIPOTHERMIC PROTECTION
E. Vicente, Y. Quijano, B. Ielpo, H. Duran, E. Diaz,  
I. Fabra, R. Puga, C. Oliva, R. Caruso, V. Ferri, J. Plaza, 
B. Alvarez and S. Olivares
Sanchinarro University Hospital, Madrid, Spain
Surgical resection of recurrent liver tumors involving the 
hepatic venous outflow is a challenging technique for most 
of the surgeons. However, it is well known that it provides 
to the patients the best chance of cure. In some cases is 
required an hepatic vein reconstruction in order to achieve 
an adequate surgical resection. High vascular reconstruction 
outflow determines the excellent result of this technique. In 
fact, a suboptimal outflow can compromise the function of 
the liver remnant. The recent progressive development 
acquired in liver donor transplantation has been used suc-
cessfully for vascular resection and reconstruction of tumors 
involving the hepatic venous outflow. In this video we 
present two cases with combined liver and vascular resection 
of the extra hepatic venous outflow for intrahepatic cholan-
giocarcinoma and recurrent colorectal liver metastases with 
and without hypothermic protection, respectively.
INTRAHEPATIC INTRADUCTAL 
PAPILAR MUCINOUS NEOPLASIA OF 
THE BILE DUCTS; A CASE SERIES OF 
THIS UNFREQUENT ENTITY
M. Vivanco, L. Gutnik, B. Wengerter, M. Kinkhabwala,  
S. Bellemare and J. Chapochnick Friedmann
Montefiore Medical Center – Albert Einstein College Of 
Medicine, Bronx, NY, USA
Introduction: Intraductal papillary mucinous neoplasm of 
the bile ducts (IPMN-B) can be classified based on his-
topathological differentiation, anatomic location and onco-
logical degeneration. Intrahepatic IPMN-B (iIPMN-B) has 
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been rarely reported in the literature. This study reports a 
series of three patients.
Methods: Retrospective review of clinical records of 
patients with iIPMN-B. Data is being presented in a descrip-
tive way. A literature review was performed using PubMed.
Results: Between August 2007 and July 2012 three patients 
were diagnosed with an iIPMN-B. Two patients underwent 
a liver resection for an intrahepatic mass in the left lobe with 
adjacent bile duct dilatation seen on cross sectional images. 
The pathology of the specimen confirmed iIPMN-B. Both 
were females with ages of 16 and 72 respectively. They 
presented with abdominal pain. On histology one patient had 
intestinal differentiation and the other gastric differentiation 
both with moderate dysplasia. After a mean follow up of 3.8 
years they continue to be disease free. The third patient was 
a 75 years old male with primary sclerosis cholangitis and 
abdominal pain. Images showed an intrahepatic mass in the 
right lobe with adjacent bile duct dilatation. He was not a 
candidate for liver resection. Endoscopic biopsy confirmed 
the presence of iIPMN-B with intestinal differentiation and 
moderate dysplasia. He died three months later secondary to 
liver failure.
Conclusions: iIPMN-B should be considered in the differ-
ential diagnosis of an intrahepatic mass with associated bile 
duct dilatation. Given their significant risk of harboring inva-
sive carcinoma resection should be the preferable mode of 
treatment.
FAILURE TO FOLLOW EVIDENCE-
BASED, BEST-PRACTICE GUIDELINES 
IN THE TREATMENT OF SEVERE 
PANCREATITIS
A. Vlada, B. Schmit, J. Trevino, K. Behrns and  
S. J. Hughes
University Of Florida, Gainesville, FL, USA
Introduction: Evidence-based guidelines for the treatment 
of severe pancreatitis have been established. We hypothe-
sized that deviation from these guidelines frequently occurs.
Methods: Under IRB approval, we performed a retrospec-
tive review of the outside medical records of patients with 
severe pancreatitis transferred to our institution (2005–
current). Severe pancreatitis was defined using the Atlanta 
Classification criteria. Outside medical records were 
reviewed with respect to evidence-based, published guide-
lines defining appropriate use of imaging, antibiotics, and 
nutritional support.
Results: A total of 538 patients meeting inclusion criteria 
were identified. A random sample of 40 patients transferred 
from 23 different hospitals was selected. Sixty-five percent of 
these patients were male, and the mean age was 54. The 
average Ranson’s criteria score upon admission was 3.4. 
Thirty-two (70%) of the patients were imaged upon admis-
sion, but only 10 (25%) of the patients were appropriately 
imaged to assess for the presence of necrosis or other compli-
cations (computerized tomography with intravenous contrast). 
Broad-spectrum antibiotics were initiated and continued in the 
absence of culture data or image-confirmed necrosis in 12 
(35%) of the patients. Twenty-two (55%) of the patients met 
guidelines for initiation of nutritional support prior to transfer. 
TPN was administered to 15 (68.2%) patients and only 3 
(13.6%) of these patients received enteric feeding. Any nutri-
tional support was lacking in 4 (18.2%) of the patients.
Conclusions: Adherence to best-practice guidelines regard-
ing imaging, nutritional support and antibiotics in the treat-
ment of severe pancreatitis is poor. Consistent application of 
current knowledge could improve outcomes in these patients.
ADULT CHOLEDOCHAL CYST:  
A SINGLE CENTRE EXPERIENCE  
IN MANAGEMENT
F. Vyas, P. Joseph, R. Sanghi and V. Sitaram
Christian Medical College, Vellore, Tamil Nadu, India
Choledochal cyst is congenital cystic dilatation of intra or 
extrahepatic biliary tree. They are increasingly reported in 
adults. We present our experience in managing adult choledo-
chal cysts over an 8 year period from March 2004 to March 
2012.
Methodology: Retrospective analysis of prospectively main-
tained database was done.
Results: There were 201 patients (61 males, 140 females). 
The mean age was 36.8 years (14–71 years). Abdominal pain 
(n = 114) and recurrent cholangitis (n = 35) were the com-
monest presentations. In 3 patients, cyst was detected inci-
dentally. Rare presentations included rupture (n = 2) and 1 
each with hemobilia, discharging sinus and left hepatic artery 
pseudoaneurysm. The most common procedures performed 
prior to presentation were ERCP, cholecystectomy and 
biliary enteric bypass. There were 142 type I, 51 type IV A, 
1 type IV B, 4 type V and 3 distal remnants of choledochal 
cysts. Complete excision with biliary enteric anastomosis 
and radiological access loop was the most common proce-
dure performed. Additional procedures (Frey’s procedure, 
radical cholecystectomy, hepatectomy, cholangioscopy and 
hepatolithotomy) were performed when necessary. Seven 
patients had co-existent malignancy (cholangiocarcinoma – 
2, carcinoma gall bladder – 4, squamous cell carcinoma in 
distal remnant – 1). One patient had biliary papillomatosis 
and one had high grade biliary dysplasia. Most common 
complications were bile leak (n = 25) and intra abdominal 
haemorrhage (n = 5). There were 5 deaths. Follow up ranged 
from 3–84 months.
Conclusion: Choledochal cyst should be considered as dif-
ferential diagnosis in patients with biliary symptoms or 
recurrent pancreatitis with biliary dilatation. Misdiagnosis 
increases the incidence of suboptimal surgical therapy.
DIFFERENCES IN HOSPITAL CHARGES 
AND LENGTH OF STAYS IN PATIENTS 
UNDERGOING OPEN VERSUS 
LAPAROSCOPIC RADIOFREQUENCY 
ABLATION
L. Watkins1, S. Varadarajuli2, R. Hawes2, S. Eubanks1, 
P. Arnoletti1 and S. G. De La Fuente1
1Florida Hospital, Division Of Surgical Oncology, 
Orlando, FL, USA; 2Florida Hospital, Division Of 
Gastroenterology, Orlando, FL, USA
Background: In this study, we investigated overall hospital 
charges and length of stay (LOS) in patients that underwent 
open (Op) versus laparoscopic (Lap) RFA using a large 
nationwide database.
Methods: The Nationwide Inpatient Sample for the years 
2006–2010, was used for the current retrospective study. The 
cohort analyzed included patients that were discharged from 
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the hospital after undergoing Op (ICD-9 50.23) versus Lap 
(ICD-9 50.21) RFA of liver lesions. Hospital charges in the 
database are defined as the amount the hospital charged for 
the entire hospital stay without including professional fees.
Results: A total of 3,708 hospital discharges were included 
in the Lap group while 3,031 were assigned to the Op RFA 
cohort during the 5-year study period, p = 0.44. The mean 
LOS was significantly shorter in the Lap RFA group (Lap 
RFA 3.32 days ± 0.32 vs. Op RFA 6.82 days ± 0.5, p < 0.001). 
In addition, mean overall total hospital charges were higher 
in those treated with Op RFA compared to the Lap RAF 
patients (Op RFA $75,491 ± $8,554 vs. Lap RFA $47,183 ± 
$5,637, p < 0.005). Private insurance plans were the major 
payers in the Op RFA group, while Medicare was the most 
frequent payer in the Lap RFA group, but these differences 
were not significant.
Conclusions: Analysis of the largest all-payer health care 
database shows that Lap RFA techniques are associated with 
shorter hospital stays and lower overall hospital charges 
compare to Op RFA techniques. These findings should be 
taken into account in the era of limited financial resources.
PERCUTANEOUS TRANSHEPATIC 
BILIARY DRAINAGE: FIRST CHOICE OR 
SECOND CHOICE FOR PREOPERATIVE 
BILIARY DRAINAGE OF HILAR 
CHOLANGIOCARCINOMA?
J. K. Wiggers, J. J. Kloek, E. A. Rauws, K. P. Van Lienden, 
O. R. Busch, D. J. Gouma and T. M. Van Gulik
Academic Medical Centre, Amsterdam, Noord-Holland, 
Netherlands
Most patients undergoing preoperative biliary drainage for 
hilar cholangiocarcinoma (HCCA) have previously been 
treated with endoscopic biliary drainage (EBD) on referral, 
while percutaneous transhepatic biliary drainage (PTBD) is 
used to treat cholangitis or overcome technical difficulties.
Objective: To test the hypothesis that previous EBD predis-
poses infection-naïve patients for post-PTBD infectious 
complications. Furthermore, we assessed risk factors for 
failure of EBD, defined as the need for subsequent PTBD.
Methods: This study included 163 patients undergoing 
preoperative biliary drainage for HCCA between 2001–2012. 
Sixteen patients initially underwent PTBD. 147 patients ini-
tially underwent EBD, of which 54 required subsequent 
PTBD. Infection naïve PTBD patients with- and without 
post-PTBD cholangitis were compared in regard with previ-
ous EBD procedures, demographics, pre-PTBD bilirubin 
level, and tumor grade (Bismuth-Corlette (BC) Type I/II/III 
versus IV). In patients treated with EBD the need for subse-
quent PTBD procedures was analyzed, considering demo-
graphics, pre-EBD bilirubin level, and tumor grade.
Results: Of 39 patients who were infection naïve at PTBD, 
11 patients developed post-PTBD cholangitis, and previous 
EBD was the only significant risk factor in univariate analy-
sis (10/23 versus 1/16 patients; p = 0.01). Risk factors for 
failure of EBD were BC Type 4 tumors, which more often 
required conversion to PTBD (13/22 patients) than Type I/
II/III tumors (42/126 patients; p = 0.03).
Conclusion: Used as escape procedure after failed EBD, the 
incidence of post-PTBD cholangitis is significantly increased. 
Especially in BC Type 4 tumors, often requiring complex 
biliary drainage, patients potentially benefit from direct 
referral to a specialized centre and PTBD as first choice.
PRIMARY HEPATIC 
LEIOMYOSARCOMA: SHOULD  
AN INTERNATIONAL DATABASE  
BE ESTABLISHED FOR BETTER 
STANDARD OF CARE?
R. Wijaya, L. Lee, S. Tan and S. Tan
Changi General Hospital, Singapore, Singapore
Primary adult hepatic sarcoma is a rare tumor, with hepatic 
leiomyosarcoma an even rarer occurrence. Only two of the 
thirty primary adult hepatic adult sarcomas treated in a terti-
ary American cancer centre over a fourteen-year period were 
leiomyosarcoma. We present a case report and a review of 
literature. A forty-three year old lady presented with a large 
heterogeneous hepatic mass and underwent a right hepatec-
tomy. Final histology revealed leiomyosarcoma with clear 
margins of surgical resection. She developed local recurrence 
and disseminated disease within three months of surgical 
resection and is receiving palliative radiotherapy and chemo-
therapy. Primary hepatic leiomyosarcoma is characterized by 
delayed diagnosis and poor prognosis. Patients often present 
with non-specific symptoms and serological markers. This 
coupled with the controversial issue of pre-operative histo-
logical diagnosis in hepatic tumors; make this condition a 
challenge for early diagnosis. Surgical resection with adju-
vant chemotherapy forms the cornerstone of management. 
Age, size of lesion and negative surgical resection margins 
are associated with improved survival. Standards of care for 
primary hepatic leiomyosarcoma are difficult to establish due 
to paucity of cases. We propose to consolidate an interna-
tional database of cases to better define standard treatment 
regimes. This has to be undertaken to improve outcomes in 
the management of this rare hepatic tumor.
NATIONALLY PLACED HIGH-RISK 
LIVER ALLOGRAFTS ARE A COST-
EFFECTIVE MECHANISM OF 
INCREASING PATIENT ACCESS AND 
DECREASING WAIT LIST MORTALITY
P. Witkowski1, J. Byam1, A. Desai2, H. Te2, A. Arohnson2, 
M. Millis1 and J. Renz1
1University Of Chicago, Chicago, IL, USA; 2University Of 
Chicago, Chicago, IL, USA
High-risk liver allografts are frequently allocated nationally 
to patients who may not be competitive for local organ allo-
cation. We performed a retrospective review of 36 initial, 
adult liver transplant (OLT) recipients from 01/09 through 
03/12 excluding status 1A and exception prioritization. This 
included 16 locally-allocated allografts (LCL) and 20 nation-
ally-placed liver allografts (NPA). Groups were compared 
for demographic data, wait-time, listing MELD, pre-OLT 
hospital admissions (ADM), procurement cost, hospital stay, 
allograft type, donor risk index (DRI), delayed graft function 
(DGF), and patient/allograft survival. There was no differ-
ence in demographics or listing MELD. At OLT, NPA recipi-
ents had a significantly lower MELD and wait-time but had 
required increased ADM and accrued higher pre-transplant 
costs than LCL. NPA allografts demonstrated significantly 
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higher DRI, DGF, and requirement for additional surgery 
post-OLT; however, patient and allograft 3 mo, 6 mo, and 
12 mo survival exceeded DRI predictions and was not dif-
ferent from LCL. NPA recipients required longer hospitaliza-
tion and accrued increased OLT costs resulting from increased 
procurement costs. NPA utilization doubled transplant activ-
ity and yielded the largest decrease in wait-list mortality 
observed in our region.
Conclusions: NPA liver allografts are associated with 
increased DGF and post-transplant complications but dem-
onstrate patient/allograft survival comparable to local, 
MELD-allocated allografts. NPA allografts effectively 
increase transplant center activity and can significantly 
decrease wait-list mortality by affording an opportunity for 
transplantation of individuals who are underserved by our 
current allocation scheme. Transplantation of NPA allografts 
costs more, but the difference is fractional compared to the 
continuing costs of waiting for OLT.
PANCREATIC NEUROENDOCRINE 
TUMORS: HYPOENHANCEMENT ON 
ARTERIAL PHASE COMPUTED 
TOMOGRAPHY PREDICTS BIOLOGIC 
AGGRESSIVENESS
D. J. Worhunsky, J. A. Norton, B. C. Visser, P. D. Poullos 
and G. A. Poultsides
Stanford University Medical Center, Stanford, CA, USA
Purpose: Contrary to pancreatic adenocarcinoma, pancre-
atic neuroendocrine tumors (PNET) are commonly hyperen-
hancing on arterial phase computed tomography (APCT). 
However, a subset of these tumors can be hypoenhancing. 
The prognostic significance of the CT appearance of these 
tumors remains unclear.
Methods: From 2001 to 2012, 146 patients with well-dif-
ferentiated PNET underwent surgical resection. Synchronous 
liver metastases, if present, were typically addressed with 
curative intent. The degree of tumor enhancement on APCT 
was recorded and correlated with clinicopathologic variables 
and overall survival.
Results: APCT images were available for re-review in 118 
patients (81%). Of those, the majority had hyperenhancing 
tumors (n = 80, 68%), 12 (10%) isoenhancing (including 
cases where no mass was visualized), and 26 (22%) hypoen-
hancing. Among the three groups, no significant difference 
was noted for age, gender, multifocality, location in the pan-
creas, calcifications, functionality, or margin status (Table). 
However, hypoenhancing PNETs were larger, more com-
monly intermediate grade, and with higher rates of lymph 
node and synchronous liver metastases (Table). Hypoen-
hancing PNETs were also associated with significantly worse 
overall survival after resection as opposed to isoenhancing 
and hyperenhancing tumors (5-year, 54% vs. 89% vs. 93%, 
Figure). On multivariate analysis of factors available preop-
eratively, only hypoenhancement (HR 2.32, P = 0.02) but not 
size (P = 0.90), presence of synchronous liver metastases 
(P = 0.54) or functionality (P = 0.88), was independently 
associated with decreased survival.
Conclusions: Hypoenhancement on APCT is noted in 22% 
of well-differentiated PNETs and is an independent predictor 
of poor outcome. This information can inform preoperative 
decision making in the multidisciplinary treatment of these 
neoplasms.
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IMPROVED MORTALITY IN ACUTE 
PANCREATITIS ASSOCIATED WITH 
EARLY PANCREATIC DEBRIDEMENT 
– ANALYSIS OF 3,617 PATIENTS 
UTILIZING THE NATIONWIDE 
INPATIENT SAMPLE
B. A. Wormer, R. Z. Swan, K. B. Williams, J. F. Bradley, 
A. L. Walters, J. B. Martinie and B. T. Heniford
Carolinas Medical Center, Charlotte, NC, USA
Introduction: The objective of this study was to perform 
a national review of etiologies and outcomes of patients 
with acute pancreatitis (AP) who undergo pancreatic debri-
dement (PD).
Methods: The Nationwide Inpatient Sample (NIS) was used 
to identify adult patients with a diagnosis of AP between 
1998 and 2010 using ICD-9-CM coding. Patients with a 
diagnosis of chronic pancreatitis or pancreatic neoplasm 
were excluded. Patients undergoing PD during their admis-
sion were identified and stratified based on etiology: biliary 
(BI), alcoholic (AL), idiopathic (ID), and other (OT) origins.
Results: 726,575 patients were identified with AP, of which 
3,617 (0.5%) underwent PD. More men underwent PD than 
non-PD (62% v. 49%; p < 0.0001), they were older (54.3 ± 
16 v. 53.6 ± 18 yrs; p < 0.0001) and had higher in-hospital 
mortality (17% v. 3%; p < 0.0001); However, Charlson 
Comorbidity index (CCI) (1.3 v. 1.2; p = 0.1744) was similar. 
PD was associated with a significant length of stay (LOS), 
longest in AL etiology compared to BI and ID (45.1 v. 38.8 
v. 38.6 days; p < 0.0167). AL etiology was associated with 
younger men and less postoperative bowel complications 
compared to BI and ID (p < 0.0167) (Table 1). Shorter mean 
days to PD were noted in those that survived compared to 
those that died (9.6 ± 14 v. 14.5 ± 17 days; p < 0.0001). Of 
all AP patients that died, the PD patients lived longer than 
the non-PD patients (39.1 ± 35 v. 13.0 ± 19 days; p < 0.0001).
Conclusion: Patients undergoing PD for AP have a high 
mortality and long hospitalization despite the etiology of 
their pancreatitis. However, patients undergoing early PD 
were more likely to survive than those undergoing delayed 
surgical treatment.
LAPAROSCOPIC VENTRAL HERNIA 
REPAIR IN THE CIRRHOTIC PATIENT, A 
SAFE ALTERNATIVE
B. A. Wormer, P. D. Colavita, J. F. Bradley,  
K. B. Williams, A. L. Walters, V. A. Augenstein  
and B. T. Heniford
Carolinas Medical Center, Charlotte, NC, USA
Introduction: The objective of this study was to perform a 
national review of the outcomes of laparoscopic (LVHR) 
versus open ventral hernia repair (OVHR) in cirrhotic 
patients.
Methods: The National Inpatient Sample, which captures 
approximately 20% of all US inpatient admissions, was 
queried for adults undergoing LVHR or OVHR from 1/2009–
12/2010 using ICD-9-CM coding. Patients were grouped 
based on a diagnosis of cirrhosis, with (PORT) or without 
(CIRR) signs of portal hypertension.
Results: 25,368 patients underwent OVHR, 150 (0.6%) had 
CIRR and 123 (0.5%) had PORT. 9,419 patients underwent 
LVHR, 49 (0.5%) had CIRR and 27 (0.3%) had PORT. CIRR 
and PORT had equal rates of incarcerated hernias undergoing 
LVHR and OVHR, along with no difference in gender, race, 
or Charlson Comorbidity Index. In CIRR, admissions were 
more commonly elective in LVHR v. OVHR (87.8% v. 
63.3%; p = 0.0013). Length of stay was shorter in CIRR 
undergoing LVHR v. OVHR (4.1 ± 4.4 v. 5.1 ± 4.5 days; 
p = 0.0100). For CIRR and PORT, there was no difference 
in postoperative wound or infectious morbidity, or mortality 
between OVHR and LVHR (P > 0.5). Mortality was higher 
for PORT v. CIRR for OVHR (9.76% v. 1.33%; p = 0.0019), 
but not LVHR (7.41% v. 2.04%; p = 0.2863). Despite repair 
type, mortality was higher in non-elective v. elective setting 
in PORT (14.3% v. 3.0%; p = 0.0187) and all cirrhotics (9.7% 
v. 1.5%; p = 0.0005).
Conclusion: Severity of liver disease influences mortality 
more in OVHR than in LVHR, which is associated with 
decreased LOS in CIRR patients. Elective VHR should be 
considered in cirrhotic patients to improve mortality regard-
less of the repair type.
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NEW SURGICAL STRATEGY FOR 
PATIENTS WITH PANCREATIC BODY/
TAIL CARCINOMA – THE IMPACT OF 
DISTAL PANCREATECTOMY WITH 
EN-BLOC CELIAC AXIS RESECTION-
H. Yamaue, M. Kawai, K. Okada, M. Tani, S. Hirono,  
M. Miyazawa, A. Shimizu, Y. Kitahata and H. Yamaue
Second Department Of Surgery, Wakayama Medical 
University, Wakayama, Japan
Aim: The aim of the present study was to clarify who should 
and who should not undergo DP-CAR in patients with poten-
tially resectable/borderline resectable pancreatic carcinoma.
Methods: Fifty-two consecutive patients with pancreatic 
cancer who underwent distal pancreatectomy, including 36 
standard distal pancreatectomies (standard DP) and 16 
DP-CAR were reviewed retrospectively.
Results: After standard DP, microscopically positive 
margins were identified at the dissection sites around the 
transection-margins of the splenic arteries and were detected 
more frequently in the patients with tumors within 10 mm 
from the root of the splenic artery (14%). After DP-CAR, the 
estimated overall survival rate in patients who were patho-
logically negative for portal venous and artery invasion (n = 
7) was greater than that of the other patients (n = 9) (p = 
0.023; log-rank test). The estimated overall 1- and 2-year 
survival rates after standard DP/DP-CAR were 81/81% and 
52/53%, and the median survival times were 32/25 months, 
respectively, with no significant differences noted between 
the groups. There were no differences in the mortality rates 
and the incidence of each complication between the two 
groups except for delayed gastric emptying.
Conclusions: We have to select carefully the patients for 
whom DP-CAR can be considered as follows: patients with 
tumors located within 10 mm from the root of the splenic 
artery, and the patients with double negative invasion into 
portal venous system and artery on preoperative imaging 
study. To improve their survival, we are performing clinical 
study of preoperative therapy for patients with borderline 
resectable pancreatic body/tail carcinoma.
A STEPWISE APPROACH TO 
RESECTION IN HEPATIC 
ADENOMATOSIS
C. Yazici, D. J. Niemeyer, M. T. Lavelle, D. Iannitti and 
M. W. Russo
Carolinas Medical Center, Charlotte, NC, USA
Background: Hepatic adenomatosis (HA) ( > 10 adenomas) 
is often unresectable and orthotopic liver transplantation 
(OLT) is a consideration. A stepwise approach to achieve 
resectability avoids the long-term sequelae of OLT. Although 
portal vein embolizaiton (PVE) has been used as part of 
management for malignant liver tumors published data are 
scarce on its use in patients with HA.
Methods: We present a 22 year old female treated for HA 
with transarterial bland embolization (TAE), PVE, and right 
hepatectomy.
Results: She presented with abdominal pain and was found 
to have bilateral hepatic adenomatosis. The largest lesions 
were 12.5 cm in the right and 4 cm in the left lobe. Her only 
risk factor was oral contraceptive (OC) use. In consideration 
of right hepatectomy her future liver remnant (FLR) to total 
liver volume (TLV) ratio was 19.7% by CT volumetric analy-
sis. OC was discontinued. She underwent TAE to right lobe 
with 150–250 micron particles (MP) to reduce vascularity of 
largest adenomas. Hypertrophy of FLR was achieved with 
right PVE 2 weeks after TAE with 300–500 MP, 900 MP, 
and microcoils. Left lobe hypertrophy was significant with 
post-PVE CT volumetrics indicating FLR/TLV of 33.1% 
with a FLR of 1002 cc. She had a second TAE followed by 
open right hepatectomy 2 months later. The procedure was 
well tolerated and she was discharged on postoperative day 
6 with total bilirubin of 1.8 and INR of 1.2.
Conclusion: Unresectable HA can be treated using a step-
wise approach including TAE, PVE, and resection. In 
selected cases ablation may also be beneficial.
PREDICTORS OF EARLY POST-
OPERATIVE MORTALITY FOLLOWING 
RIGHT EXTENDED HEPATECTOMY
A. Zhuruk, K. P. Croome, R. Leeper, N. Sela and  
R. Hernadez-Alejandro
Western University Canada, London, ON, Canada
The number of extended hepatectomies (EH) (≥5 segments) 
performed has continued to rise. There is a need to identify 
predictors of early mortality after EH. A retrospective analy-
sis of our prospectively maintained database was performed 
to identify all cases of right extended hepatectomy (REH) 
between the dates of 2005–2011. A Cox univariate regression 
for survival up to 90 days post REH was performed. Varia-
bles investigated included age, BMI, preoperative chemo-
therapy, liver steatosis, operative time, intraoperative blood 
transfusion, bilirubin on post-operative day (POD) 5 and 
INR on POD 5. A total of 36 patients were identified, which 
included 5 patients with benign lesions, 5 cholangiocarcino-
mas and 26 patients with metastatic liver disease. Significant 
predictors for survival post REH were age at the time of 
resection (p = 0.045), number of PRBC transfused (p = 
0.028), steatosis > 30% (p = 0.049), bilirubin on POD 5 
(p = 0.002) and INR on POD 5 (p = 0.003). The rate of post-
operative mortality was significantly higher in those patients 
meeting the ‘50–50’ criteria (60%) compared to those not 
meeting the criteria (6.4%) (p = 0.001). Of all patients under-
going PVE none developed post-resection liver failure (PLF) 
(based on 50–50-criteria) post-operatively compared to 17% 
in patients not undergoing PVE. Advanced age, steatosis and 
number of PRBC transfused predict post-operative survival 
following EH. PVE appears to be protective against PLF and 
should be strongly considered in patients undergoing EH, 
particularly in those patients with advanced age or high like-
lihood of steatosis. The 50–50-criteria is a good predictor of 
early mortality in the population of patients post REH.
